SB 966: Pharmacy benefits.
- Session Year: 2023-2024
- House: Senate
- Latest Version Date: 2024-09-03
Current Status:
Failed
(2024-09-28: In Senate. Consideration of Governor's veto pending.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law, the Knox-Keene Health Care Service Plan Act of 1975 (the Knox-Keene Act), a violation of which is a crime, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care. The Knox-Keene Act requires a pharmacy benefit manager under contract with a health care service plan to, among other things, register with the Department of Managed Health Care. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would additionally require a pharmacy benefit manager, as defined, to apply for a license from the Department of Insurance to operate as a pharmacy benefit manager no later than January 1, 2027. The bill would establish application qualifications and requirements, and would require initial license and renewal fees to be collected into the newly created Pharmacy Benefit Manager Account in the Insurance Fund, to be available to the department for use, upon appropriation by the Legislature, as specified, for costs related to licensing and regulating pharmacy benefit managers.
This bill would require a pharmacy benefit manager to file with the department at specified annual intervals 2 reports, one of which discloses product benefits specific to the purchaser, and the other of which includes information about categories of drugs and the pharmacy benefit managers contracts and revenues. The bill would specify that the contents of the reports are not to be disclosed to the public. The bill would require the department, at specified annual intervals, to prepare 2 reports based on the reports submitted by pharmacy benefit managers, and would require the department to post its reports on the departments internet website.
This bill would impose specified duties on pharmacy benefit managers and requirements for pharmacy benefit manager services and pharmacy benefit manager contracts. The bill would require a pharmacy benefit manager to disclose to the Department of Insurance all types of fees it receives and how the fees are calculated.
The bill would make a violation of the above-specified provisions subject to specified civil penalties. The bill would establish various filing and service requirements when a proceeding is brought for a violation of specified requirements by a pharmacy benefit manager. The bill would create the Pharmacy Benefit Manager Fines and Penalties Account in the General Fund, into which fines and administrative penalties would be deposited.
Existing law requires a health care service plan contract or health insurance policy that provides coverage for outpatient prescription drugs to cover medically necessary prescription drugs and subjects those policies to certain limitations on cost sharing and the placement of drugs on formularies. Existing law limits the maximum amount an enrollee or insured may be required to pay at the point of sale for a covered prescription drug to the lesser of the applicable cost-sharing amount or the retail price, and requires that payment apply to the applicable deductible. Existing law requires a plan or insurer that reports rate information to report specified prescription drug information to the relevant department no later than October 1 of each year.
This bill would prohibit a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage from calculating an enrollees or insureds cost sharing at an amount that exceeds the actual rate paid for the prescription drug, and would require a health care service plan contract to include specified cost-sharing provisions. The bill would require a plan or insurer to include additional information in its annual prescription drug data reporting, including the aggregate amount of rebates received by the pharmacy benefit manager for each drug. By expanding the scope of a crime under the Knox-Keene Act, the bill would impose a state-mandated local program.
This bill would declare that it would not narrow, abrogate, or otherwise alter the authority of the Attorney General to maintain or restore competitive, fair, and honest markets and prosecute state and federal antitrust and unfair competition violations, among other violations, and would declare that the provisions of this bill are severable.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest.
This bill would make legislative findings to that effect.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975 (the Knox-Keene Act), a violation of which is a crime, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care. The Knox-Keene Act requires a pharmacy benefit manager under contract with a health care service plan to, among other things, register with the Department of Managed Health Care. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would additionally require a pharmacy benefit manager, as defined, to apply for and obtain a license from the Department of Insurance to operate as a pharmacy benefit manager no later than January 1, 2027. The bill would establish application qualifications and requirements, and would require initial license and renewal fees to be collected into the newly created Pharmacy Benefit Manager Account in the Insurance Fund, to be available to the department for use, upon appropriation by the Legislature, as specified, for costs related to licensing and regulating pharmacy benefit managers.
This bill would require a pharmacy benefit manager to file with the department at specified annual intervals 2 reports, one of which discloses product benefits specific to the purchaser, and the other of which includes information about categories of drugs and the pharmacy benefit managers contracts and revenues. The bill would specify that the contents of the reports are not to be disclosed to the public. The bill would require the department, at specified annual intervals, to submit 2 reports to the Legislature prepare 2 reports based on the reports submitted by pharmacy benefit managers, and would require the department to post the its reports on the departments internet website.
This bill would impose specified duties on pharmacy benefit managers and requirements for pharmacy benefit manager services and pharmacy benefit manager contracts, including requiring the pharmacy benefit manager to use a passthrough pricing model, in which the payment made by the health care service plan or health insurer client to the pharmacy benefit manager for a covered outpatient drug is equivalent to the payment the pharmacy benefit manager makes to the pharmacy or provider for the drug, and is passed through in its entirety by the health care service plan or health insurer client or the pharmacy benefit manager to the pharmacy or provider, as specified. Commencing January 1, 2026, the bill would require a pharmacy benefit manager to offer a health care service plan or health insurer the option of a non-spread pricing contract. The bill would require a pharmacy benefit manager to disclose to the Department of Insurance all types of pharmacy benefit management fees that it receives, and would require the department to keep that information confidential. The contracts. The bill would require a pharmacy benefit manager to disclose to the Department of Insurance all types of fees it receives and how the fees are calculated.
The bill would make a violation of the above-specified provisions subject to specified civil penalties. The bill would establish various filing and service requirements when a proceeding is brought for a violation of specified requirements by a pharmacy benefit manager. The bill would create the Pharmacy Benefit Manager Fines and Penalties Account in the General Fund, into which fines and administrative penalties would be deposited.
Existing law requires a health care service plan contract or health insurance policy that provides coverage for outpatient prescription drugs to cover medically necessary prescription drugs and subjects those policies to certain limitations on cost sharing and the placement of drugs on formularies. Existing law limits the maximum amount an enrollee or insured may be required to pay at the point of sale for a covered prescription drug to the lesser of the applicable cost-sharing amount or the retail price, and requires that payment apply to the applicable deductible. Existing law requires a plan or insurer that reports rate information to report specified prescription drug information to the relevant department no later than October 1 of each year.
This bill would prohibit a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage from calculating an enrollee enrollees or insureds cost sharing at an amount that exceeds the actual rate paid for the prescription drug, and would require a health care service plan contract to include specified cost-sharing provisions. The bill would require a plan or insurer to include additional information in its annual prescription drug data reporting, including the aggregate amount of rebates received by the pharmacy benefit manager for each drug. By expanding the scope of a crime under the Knox-Keene Act, the bill would impose a state-mandated local program.
This bill would declare that it shall would not narrow, abrogate, or otherwise alter the authority of the Attorney General to maintain or restore competitive, fair, and honest markets and prosecute state and federal antitrust and unfair competition violations, among other violations, and would declare that the provisions of this bill are severable.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest.
This bill would make legislative findings to that effect.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975 (the Knox-Keene Act), a violation of which is a crime, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care. The Knox-Keene Act requires a pharmacy benefit manager under contract with a health care service plan to, among other things, register with the Department of Managed Health Care. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would additionally require a pharmacy benefit manager, as defined, to apply for and obtain a license from the Department of Insurance to operate as a pharmacy benefit manager no later than January 1, 2027. The bill would establish application qualifications and requirements, and would require initial license and renewal fees to be collected into the newly created Pharmacy Benefit Manager Account in the Insurance Fund, to be available to the department for use, upon appropriation by the Legislature, as specified, for costs related to licensing and regulating pharmacy benefit managers.
This bill would require a pharmacy benefit manager to file with the department at specified annual intervals 2 reports, one of which discloses product benefits specific to the purchaser, and the other of which includes information about categories of drugs and the pharmacy benefit managers contracts and revenues. The bill would specify that the contents of the reports are not to be disclosed to the public. The bill would require the department, at specified annual intervals, to submit 2 reports to the Legislature based on the reports submitted by pharmacy benefit managers, and would require the department to post the reports on the departments internet website.
This bill would impose specified duties on pharmacy benefit managers and requirements for pharmacy benefit manager services and pharmacy benefit manager contracts, including requiring the pharmacy benefit manager to use a passthrough pricing model, in which the payment made by the health care service plan or health insurer client to the pharmacy benefit manager for a covered outpatient drug is equivalent to the payment the pharmacy benefit manager makes to the pharmacy or provider for the drug, and is passed through in its entirety by the health care service plan or health insurer client or the pharmacy benefit manager to the pharmacy or provider, as specified. Commencing January 1, 2026, the bill would require a pharmacy benefit manager to offer a health care service plan or health insurer the option of a non-spread pricing contract. The bill would require a pharmacy benefit manager to disclose to the Department of Insurance all types of pharmacy benefit management fees that it receives, and would require the department to keep that information confidential. The bill would make a violation of the above-specified provisions subject to specified civil penalties. The bill would establish various filing and service requirements when a proceeding is brought for a violation of specified requirements by a pharmacy benefit manager. The bill would create the Pharmacy Benefit Manager Fines and Penalties Account in the General Fund, into which fines and administrative penalties would be deposited.
Existing law requires a health care service plan contract or health insurance policy that provides coverage for outpatient prescription drugs to cover medically necessary prescription drugs and subjects those policies to certain limitations on cost sharing and the placement of drugs on formularies. Existing law limits the maximum amount an enrollee or insured may be required to pay at the point of sale for a covered prescription drug to the lesser of the applicable cost-sharing amount or the retail price, and requires that payment apply to the applicable deductible. Existing law requires a plan or insurer that reports rate information to report specified prescription drug information to the relevant department no later than October 1 of each year.
This bill would prohibit a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage from calculating an enrollee or insureds cost sharing at an amount that exceeds the actual rate paid for the prescription drug. The bill, for a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizing spread pricing, would prohibit an amendment or renewal of the contract from authorizing spread pricing. The bill would prohibit a contract between a pharmacy benefit manager and a health care service plan or health insurer that is executed on or after January 1, 2025, from authorizing spread pricing. drug, and would require a health care service plan contract to include specified cost-sharing provisions. The bill would require a plan or insurer to include additional information in its annual prescription drug data reporting, including the aggregate amount of rebates received by the pharmacy benefit manager for each drug. By expanding the scope of a crime under the Knox-Keene Act, the bill would impose a state-mandated local program.
This bill would declare that it shall not narrow, abrogate, or otherwise alter the authority of the Attorney General to maintain or restore competitive competitive, fair, and honest markets and prosecute state and federal antitrust and unfair competition violations, among other violations, and would declare that the provisions of this bill are severable.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest.
This bill would make legislative findings to that effect.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975 (the Knox-Keene Act), a violation of which is a crime, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care. The Knox-Keene Act requires a pharmacy benefit manager under contract with a health care service plan to, among other things, register with the Department of Managed Health Care. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would additionally require a pharmacy benefit manager, as defined, to apply for and obtain a license from the Department of Insurance to operate as a pharmacy benefit manager no later than January 1, 2027. The bill would establish application qualifications and requirements, and would require initial license and renewal fees to be collected into the newly created Pharmacy Benefit Manager Account in the Insurance Fund, to be available to the department for use, upon appropriation by the Legislature, as specified, for costs related to licensing and regulating pharmacy benefit managers.
This bill would require a pharmacy benefit manager to file with the department at specified annual intervals 2 reports, one of which discloses product benefits specific to the purchaser, and the other of which includes information about categories of drugs and the pharmacy benefit managers contracts and revenues. The bill would specify that the contents of the reports are not to be disclosed to the public. The bill would require the department, at specified annual intervals, to submit 2 reports to the Legislature based on the reports submitted by pharmacy benefit managers, and would require the department to post the reports on the departments internet website.
This bill would impose specified duties on pharmacy benefit managers and requirements for pharmacy benefit manager services and pharmacy benefit manager contracts, including requiring the pharmacy benefit manager to use a passthrough pricing model, in which the payment made by the health care service plan or health insurer client to the pharmacy benefit manager for a covered outpatient drug is equivalent to the payment the pharmacy benefit manager makes to the pharmacy or provider for the drug, and is passed through in its entirety by the health care service plan or health insurer client or the pharmacy benefit manager to the pharmacy or provider, as specified. The bill would make a violation of the above-specified provisions subject to specified civil penalties. The bill would establish various filing and service requirements when a proceeding is brought for a violation of specified requirements by a pharmacy benefit manager. The bill would create the Pharmacy Benefit Manager Fines and Penalties Account in the General Fund, into which fines and administrative penalties would be deposited.
Existing law requires a health care service plan contract or health insurance policy that provides coverage for outpatient prescription drugs to cover medically necessary prescription drugs and subjects those policies to certain limitations on cost sharing and the placement of drugs on formularies. Existing law limits the maximum amount an enrollee or insured may be required to pay at the point of sale for a covered prescription drug to the lesser of the applicable cost-sharing amount or the retail price, and requires that payment apply to the applicable deductible. Existing law requires a plan or insurer that reports rate information to report specified prescription drug information to the relevant department no later than October 1 of each year.
This bill would prohibit a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage from calculating an enrollee or insureds cost sharing at an amount that exceeds the actual rate paid for the prescription drug. The bill, for a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizing spread pricing, would prohibit an amendment or renewal of the contract from authorizing spread pricing. The bill would prohibit a contract between a pharmacy benefit manager and a health care service plan or health insurer that is executed on or after January 1, 2025, from authorizing spread pricing. The bill would require a plan or insurer to include additional information in its annual prescription drug data reporting, including the aggregate amount of rebates received by the pharmacy benefit manager for each drug. By expanding the scope of a crime under the Knox-Keene Act, the bill would impose a state-mandated local program.
This bill would declare that it shall not narrow, abrogate, or otherwise alter the authority of the Attorney General to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations, and would declare that the provisions of this bill are severable.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest.
This bill would make legislative findings to that effect.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975 (the Knox-Keene Act), a violation of which is a crime, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care. The Knox-Keene Act requires a pharmacy benefit manager under contract with a health care service plan to, among other things, register with the Department of Managed Health Care. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would additionally require a pharmacy benefit manager, as defined by the bill, defined, to apply for and obtain a license from the Department of Insurance to operate as a pharmacy benefit manager on and after January 1, 2026. no later than January 1, 2027. The bill would establish application qualifications and requirements, and would require initial license and renewal fees to be collected into the newly created Pharmacy Benefit Manager Fund Account in the Insurance Fund, to be available to the department for use, upon appropriation by the Legislature, as specified, for costs related to licensing and regulating pharmacy benefit managers.
This bill would require a pharmacy benefit manager to file with the department at specified annual intervals 2 reports, one of which discloses product benefits specific to the purchaser, and the other of which includes information about categories of drugs and the pharmacy benefit managers contracts and revenues. The bill would specify that the contents of the reports are not to be disclosed to the public. The bill would require the department, at specified annual intervals, to submit 2 reports to the Legislature based on the reports submitted by pharmacy benefit managers, and would require the department to post the reports on the departments internet website.
This bill would impose specified duties on pharmacy benefit managers and requirements for pharmacy benefit manager services and pharmacy benefit manager contracts, including prohibiting a pharmacy benefit manager from deriving income from pharmacy benefit management services, except as specified. requiring the pharmacy benefit manager to use a passthrough pricing model, in which the payment made by the health care service plan or health insurer client to the pharmacy benefit manager for a covered outpatient drug is equivalent to the payment the pharmacy benefit manager makes to the pharmacy or provider for the drug, and is passed through in its entirety by the health care service plan or health insurer client or the pharmacy benefit manager to the pharmacy or provider, as specified. The bill would make a violation of the above-specified provisions subject to specified civil penalties. The bill would create the Pharmacy Benefit Manager Fines and Penalties Fund, Account in the General Fund, into which fines and administrative penalties would be deposited.
Existing law requires a health care service plan contract or health insurance policy that provides coverage for outpatient prescription drugs to cover medically necessary prescription drugs and subjects those policies to certain limitations on cost sharing and the placement of drugs on formularies. Existing law limits the maximum amount an enrollee or insured may be required to pay at the point of sale for a covered prescription drug to the lesser of the applicable cost-sharing amount or the retail price, and requires that payment apply to the applicable deductible. Existing law requires a plan or insurer that reports rate information to report specified prescription drug information to the relevant department no later than October 1 of each year.
This bill would prohibit a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage from calculating an enrollee or insureds cost sharing at an amount that exceeds the actual rate paid for the prescription drug. The bill, for a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizing spread pricing, would prohibit an amendment or renewal of the contract from authorizing spread pricing. The bill would prohibit a contract between a pharmacy benefit manager and a health care service plan or health insurer that is executed on or after January 1, 2025, from authorizing spread pricing. The bill would require a plan or insurer to include additional information in its annual prescription drug data reporting, including the aggregate amount of rebates received by the pharmacy benefit manager for each drug. By expanding the scope of a crime under the Knox-Keene Act, the bill would impose a state-mandated local program.
This bill would declare that it shall not narrow, abrogate, or otherwise alter the authority of the Attorney General to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations, and would declare that the provisions of this bill are severable.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest.
This bill would make legislative findings to that effect.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975 (the Knox-Keene Act), a violation of which is a crime, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care. The Knox-Keene Act requires a pharmacy benefit manager under contract with a health care service plan to, among other things, register with the Department of Managed Health Care. Existing law provides for the regulation of health insurers by the Department of Insurance.
This bill would additionally require a pharmacy benefit manager, as defined by the bill, to apply for and obtain a license from the Department of Insurance to operate as a pharmacy benefit manager. manager on and after January 1, 2026. The bill would establish application qualifications and requirements, and would establish an unspecified fee for initial licensure and renewal. require initial license and renewal fees to be collected into the newly created Pharmacy Benefit Manager Fund to be available to the department for use, upon appropriation by the Legislature, for costs related to licensing and regulating pharmacy benefit managers.
This bill would require a pharmacy benefit manager, on or before April 1, 2027, and annually thereafter, manager to file with the department a report containing specified information. at specified annual intervals 2 reports, one of which discloses product benefits specific to the purchaser, and the other of which includes information about categories of drugs and the pharmacy benefit managers contracts and revenues. The bill would specify that the contents of the report shall not reports are not to be disclosed to the public. The bill would require the department, on or before August 1, 2027, and annually thereafter, at specified annual intervals, to submit a report 2 reports to the Legislature based on the reports submitted by licensees, pharmacy benefit managers, and would require the department to post the report reports on the departments internet website.
This bill would impose specified duties on pharmacy benefit managers and requirements for pharmacy benefit manager services and pharmacy benefit manager contracts, including prohibiting a pharmacy benefit manager from deriving income from pharmacy benefit management services, except as specified. The bill would make a violation of the above-specified provisions subject to specified civil penalties. The bill would create the Pharmacy Benefit Manager Fines and Penalties Fund, into which fines and administrative penalties would be deposited.
Existing law requires a health care service plan contract or health insurance policy that provides coverage for outpatient prescription drugs to cover medically necessary prescription drugs and subjects those policies to certain limitations on cost sharing and the placement of drugs on formularies. Existing law limits the maximum amount an enrollee or insured may be required to pay at the point of sale for a covered prescription drug to the lesser of the applicable cost-sharing amount or the retail price, and requires that payment apply to the applicable deductible. Existing law requires a plan or insurer that reports rate information to report specified prescription drug information to the relevant department no later than October 1 of each year.
This bill would require prohibit a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage to calculate from calculating an enrollee or insureds cost sharing amount, including deductible and coinsurance, based exclusively on its negotiated rate at an amount that exceeds the actual rate paid for the prescription drug. The bill, for a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizing spread pricing, would prohibit an amendment or renewal of the contract from authorizing spread pricing. The bill would prohibit a contract between a pharmacy benefit manager and a health care service plan or health insurer that is executed on or after January 1, 2025, from authorizing spread pricing. The bill would require a plan or insurer to include additional information in its annual prescription drug data reporting, including the aggregate amount of rebates received by the pharmacy benefit manager for each drug. By expanding the scope of a crime under the Knox-Keene Act, the bill would impose a state-mandated local program.
This bill would declare that it shall not narrow, abrogate, or otherwise alter the authority of the Attorney General to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations, and would declare that the provisions of this bill are severable.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest.
This bill would make legislative findings to that effect.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975 (the Knox-Keene Act), a violation of which is a crime, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care. The Knox-Keene Act requires a pharmacy benefit manager under contract with a health care service plan to, among other things, register with the Department of Managed Health Care. Existing law provides for the regulation of health insurers by the Department of Insurance.
Existing law imposes requirements on audits of pharmacy services provided to beneficiaries of a health benefit plan, as specified, and prohibits those audit provisions from being construed to suggest or imply that the Department of Consumer Affairs or the California State Board of Pharmacy has any jurisdiction or authority over those audit provisions.This bill would delete the latter provision relating to the construction and jurisdiction over those provisions by the department and the board.This bill would additionally require a pharmacy benefit manager, as defined by the bill, to apply for and obtain a license from the California State Board of Pharmacy Department of Insurance to operate as a pharmacy benefit manager. The bill would establish application qualifications and requirements, and would establish an unspecified fee for initial licensure and renewal.
This bill would require a pharmacy benefit manager, on or before April 1, 2027, and annually thereafter, to file with the board department a report containing specified information. The bill would specify that the contents of the report shall not be disclosed to the public. The bill would require the board, department, on or before August 1, 2027, and annually thereafter, to submit a report to the Legislature based on the reports submitted by licensees, and would require the board department to post the report on the boards departments internet website.
This bill would impose specified duties on pharmacy benefit managers and requirements for pharmacy benefit manager services and pharmacy benefit manager contracts, including prohibiting a pharmacy benefit manager from deriving income from pharmacy benefit management services, except as specified. The bill would make a violation of the above specified above-specified provisions subject to specified civil penalties.
Existing law requires a health care service plan contract or health insurance policy that provides coverage for outpatient prescription drugs to cover medically necessary prescription drugs and subjects those policies to certain limitations on cost sharing and the placement of drugs on formularies. Existing law limits the maximum amount an enrollee or insured may be required to pay at the point of sale for a covered prescription drug to the lesser of the applicable cost-sharing amount or the retail price, and requires that payment apply to the applicable deductible.
This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage to calculate an enrollee or insureds cost sharing amount, including deductible and coinsurance, based exclusively on its negotiated rate for the prescription drug. The bill, for a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizing spread pricing, would prohibit an amendment or renewal of the contract from authorizing spread pricing. The bill would prohibit a contract between a pharmacy benefit manager and a health care service plan or health insurer that is executed on or after January 1, 2025, from authorizing spread pricing. By expanding the scope of a crime under the Knox-Keene Act, the bill would impose a state-mandated local program.
This bill would declare that it shall not narrow, abrogate, or otherwise alter the authority of the Attorney General to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations, and would declare that the provisions of this bill are severable.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest.
This bill would make legislative findings to that effect.
Existing law, the Pharmacy Law, establishes the California State Board of Pharmacy in the Department of Consumer Affairs to license and regulate the practice of pharmacy. Existing law, the Knox-Keene Health Care Service Plan Act of 1975 (the Knox-Keene Act), a violation of which is a crime, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care. The Knox-Keene Act requires a pharmacy benefit manager under contract with a health care service plan to, among other things, register with the Department of Managed Health Care. Existing law provides for the regulation of health insurers by the Department of Insurance.
Existing law imposes requirements on audits of pharmacy services provided to beneficiaries of a health benefit plan, as specified, and prohibits those audit provisions from being construed to suggest or imply that the Department of Consumer Affairs or the California State Board of Pharmacy has any jurisdiction or authority over those audit provisions.
This bill would delete the latter provision relating to the construction and jurisdiction over those provisions by the department and the board.
This bill would require a pharmacy benefit manager, as defined by the bill, to apply for and obtain a license from the California State Board of Pharmacy to operate as a pharmacy benefit manager. The bill would establish application qualifications and requirements, and would establish an unspecified fee for initial licensure and renewal.
This bill would require a pharmacy benefit manager, on or before April 1, 2027, and annually thereafter, to file with the board a report containing specified information. The bill would specify that the contents of the report shall not be disclosed to the public. The bill would require the board, on or before August 1, 2027, and annually thereafter, to submit a report to the Legislature based on the reports submitted by licensees, and would require the board to post the report on the boards internet website.
This bill would impose specified duties on pharmacy benefit managers and requirements for pharmacy benefit manager services and pharmacy benefit manager contracts, including prohibiting a pharmacy benefit manager from deriving income from pharmacy benefit management services, except as specified. The bill would make a violation of the above specified provisions subject to specified civil penalties.
Existing law requires a health care service plan contract or health insurance policy that provides coverage for outpatient prescription drugs to cover medically necessary prescription drugs and subjects those policies to certain limitations on cost sharing and the placement of drugs on formularies. Existing law limits the maximum amount an enrollee or insured may be required to pay at the point of sale for a covered prescription drug to the lesser of the applicable cost-sharing amount or the retail price, and requires that payment apply to the applicable deductible.
This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage to calculate an enrollee or insureds cost sharing amount, including deductible and coinsurance, based exclusively on its negotiated rate for the prescription drug. The bill, for a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizing spread pricing, would prohibit an amendment or renewal of the contract from authorizing spread pricing. The bill would prohibit a contract between a pharmacy benefit manager and a health care service plan or health insurer that is executed on or after January 1, 2025, from authorizing spread pricing. By expanding the scope of a crime under the Knox-Keene Act, the bill would impose a state-mandated local program.
This bill would declare that it shall not narrow, abrogate, or otherwise alter the authority of the Attorney General to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations, and would declare that the provisions of this bill are severable.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing constitutional provisions require that a statute that limits the right of access to the meetings of public bodies or the writings of public officials and agencies be adopted with findings demonstrating the interest protected by the limitation and the need for protecting that interest.
This bill would make legislative findings to that effect.
A health care service plan contract issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an enrollees cost sharing at an amount that exceeds the actual rate paid for the prescription drug, and shall include cost-sharing provisions consistent with Section 4079 of the Business and Professions Code.
SEC. 2.Section 1367.243 of the Health and Safety Code is amended to read:1367.243.(a)(1)A health care service plan that reports rate information pursuant to Section 1385.03 or 1385.045 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(vi)The aggregate fees that pharmacy benefit managers receive.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health care service plans.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2019, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 1385.045.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 3.Section 1367.2431 is added to the Health and Safety Code, immediately following Section 1367.243, to read:1367.2431.In preparing the report required as set forth in subdivision (b) of Section 1367.243, the department shall ensure that the information regarding rebates is aggregated and does not reveal information specific to individual health care service plans or manufacturers, or reveal any manufacturers individual or aggregated discounted prices for a drug.
SEC. 4.Section 10123.2045 is added to the Insurance Code, immediately following Section 10123.204, to read:10123.2045.A health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an insureds cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
SEC. 5.Section 10123.205 of the Insurance Code is amended to read:10123.205.(a)(1)A health insurer that reports rate information pursuant to Section 10181.3 or 10181.45 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(vi)The aggregate fees that pharmacy benefit managers receive.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health insurers.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2018, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 6.Section 10123.2051 is added to the Insurance Code, immediately following Section 10123.205, to read:10123.2051.In preparing the report required as set forth in subdivision (b) of Section 10123.205, the department shall ensure that the information regarding rebates is aggregated and does not reveal information specific to individual health insurers or manufacturers, or reveal any manufacturers individual or aggregated discounted prices for a drug.
SEC. 7.Division 6 (commencing with Section 17000) is added to the Insurance Code, to read:6.Regulation of Pharmacy Benefit Managers1.General Provisions17000.For purposes of this division, the following definitions apply:
(a)Affiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a pharmacy benefit manager.
(b)Claim means a request for payment for administering, filling, or refilling a drug or for providing a pharmacy service or a medical supply or device to an enrollee or insured.
(c)Contract pharmacy means a pharmacy that contracts directly or through a pharmacy services administration organization with a pharmacy benefit manager.
(d)Drug has the same meaning as defined in Section 4025 of the Business and Professions Code.
(e)Financially viable means that either of the following conditions is met:
(1)The pharmacy benefit manager has received an unqualified opinion from an independent public accountant, as described in Section 260.613(b) of Title 10 of the California Code of Regulations.
(2)If an independent public accountant opinion is not obtained, the pharmacy benefit manager remains solvent after adjusting for goodwill and intangible assets.
(f)Group purchasing organization means a third party or affiliated person employed by, contracted with, or otherwise utilized by a pharmacy benefit manager to negotiate, obtain, or otherwise procure rebates from drug manufacturers or wholesalers.
(g)Health care service plan means an entity licensed pursuant to the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code).
(h)Health insurer means a disability insurer that issues health insurance, as defined in Section 106.
(i)Manufacturer has the same meaning as defined in Section 4033 of the Business and Professions Code.
(j)Nonaffiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, does not control, is not controlled by, and is not under common control with, a pharmacy benefit manager.
(k)Person has the same meaning as defined in Section 4035 of the Business and Professions Code.
(l)Personal representative means an individual who has authority to make a health care decision on behalf of another individual pursuant to Division 4.7 (commencing with Section 4600) of the Probate Code.
(m)Pharmacist has the same meaning as defined in Section 4036 of the Business and Professions Code.
(n)Pharmacist services means products, goods, and services, or any combination of products, goods, and services, provided as a part of the practice of pharmacy.
(o)Pharmacy has the same meaning as defined in Section 4037 of the Business and Professions Code.
(p)Pharmacy benefit management service means all of the following:
(1)Negotiating the price of prescription drugs, including negotiating and contracting for direct or indirect rebates, discounts, or other price concessions.
(2)Managing any aspect of a prescription drug benefit, including, but not limited to, developing or managing a drug formulary, including utilization management or quality assurance programs, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with pharmacies, management of retail, mail order, or specialty pharmacies, controlling the cost of covered prescription drugs, managing or providing data relating to the prescription drug benefit, or the provision of services related thereto.
(3)Performing any administrative, managerial, clinical, pricing, financial, reimbursement, data administration or reporting, or billing service.
(4)Other services as the department may define in regulation.
(q)Pharmacy benefit manager means a person, business, or other entity that, either directly or indirectly, manages the prescription drug coverage, including, but not limited to, the following: clinical or other formulary or preferred drug list development or management; the processing and payment of claims for prescription drugs; the negotiation or administration of rebates, discounts, payment differentials, or other incentives; the inclusion of particular prescription drugs in a particular category or to promote the purchase of particular prescription drugs; the performance of drug utilization review; the processing of drug prior authorization requests; the adjudication of appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. Pharmacy benefit manager does not include any of the following:
(1)A health care service plan that is part of a fully integrated delivery system in which enrollees primarily use pharmacies that are entirely owned and operated by the health care service plan, and the health care service plans enrollees may use any pharmacy in the health care service plans network that has the ability to dispense the medication or provide the services.
(2)An entity providing services pursuant to a contract authorized by Section 4600.2 of the Labor Code.
(3)A health care service plan or its contracted provider, as defined in subdivision (i) of Section 1345 of the Health and Safety Code, performing the services described in this subdivision.
(4)A health insurer.
(5)A city or county that develops or manages drug coverage programs for uninsured patients for which no reimbursement is received.
(6)An entity exclusively providing services to patients covered by Part 418 (commencing with Section 418.1) of Subchapter B of Chapter IV of Title 42 of the Code of Federal Regulations.
(r)Pharmacy services administration organization means an entity that provides contracting and other administrative services relating to prescription drug benefits to pharmacies.
(s)Rebate means a formulary discount or remuneration attributable to the use of prescription drugs that is paid by a manufacturer or third party, directly or indirectly, to a pharmacy benefit manager after a claim has been adjudicated at a pharmacy. Rebate does not include a fee, including a bona fide service fee or administrative fee, that is not a formulary discount or remuneration.
(t)Third party means a person that is not an enrollee, insured, or pharmacy benefit manager.
17004.5.Any activity conducted by a pharmacy benefit manager, as defined in this division, shall be construed as the business of insurance.
17004.7.This division does not apply to a collectively bargained Taft-Hartley self-insured prescription drug plan offered pursuant to the federal Employee Retirement Income Security Act of 1974 (29 U.S.C. Section 1001 et seq.) or to a pharmacy benefit managers provision of pharmacy benefit management services pursuant to that Taft-Hartley plan. To the extent a pharmacy benefit manager is providing services for other health plans or health insurers in addition to a collectively bargained self-insured plan that provides prescription drug plans governed by federal law, the provisions of this division shall continue to apply to the pharmacy benefit manager in its performance of pharmacy benefit management services pursuant to those other health care plans or health insurers.
17005.The department shall adopt regulations necessary to implement this division, including, but not limited to, regulations regarding group purchasing organizations and the use of those organizations.
(a)Until January 1, 2028, necessary regulations for the purpose of implementing this division may be adopted as emergency regulations in accordance with the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The adoption of emergency regulations pursuant to this section shall be deemed to be an emergency and necessary for the immediate preservation of the public peace, health and safety, or general welfare.
(b)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, including subdivisions (e) and (h) of Section 11346.1, an emergency regulation adopted pursuant to this section shall be repealed by operation of law unless the adoption, amendment, or repeal of the regulation is promulgated by the department pursuant to Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code within five years of the initial adoption of the emergency regulation.
(c)A regulation adopted pursuant to this section shall be discussed by the department during at least one public stakeholder meeting before the department adopts the rule or regulation.
17006.(a)The department shall establish procedures for receiving, investigating, tracking, and publicly reporting consumer complaints against pharmacy benefit managers.
(b)The department shall publish on its internet website a record of consumer complaints against a pharmacy benefit manager that have been determined by the department to be justified. Complaint data shall not be published unless it has been provided to the pharmacy benefit manager in accordance with subdivision (c) of Section 12921.1.
2.Licensing17010.(a)The department shall license and regulate pharmacy benefit managers. The department shall have the authority to enforce this division and Chapter 9.5 (commencing with Section 4430) of Division 2 of the Business and Professions Code and Article 3 (commencing with Section 127470) of Chapter 2.5 of Part 2 of Division 107 of the Health and Safety Code.
(b)No later than January 1, 2027, a pharmacy benefit manager that provides services in this state shall apply for a license to operate as a pharmacy benefit manager from the department. A pharmacy benefit manager shall maintain its license in good standing.
(c)An application for a pharmacy benefit manager license shall be submitted in a form and manner determined by the department, and shall be signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the application form and any attachments are correct. The application shall include all of the following:
(1)A nonrefundable application fee in an amount established by the department under Section 17015.
(2)A list of every health care service plan or health insurer on behalf of which the pharmacy benefit manager contracts with a pharmacy or a pharmacy services administration organization to provide health services to individuals covered by the health care service plan or health insurer.
(3)A statement indicating all jurisdictions where the applicant has an application pending or has been registered, licensed, or otherwise certified to transact business as a pharmacy benefit manager.
(4)A statement indicating whether either of the following has occurred:
(A)The pharmacy benefit manager or any individual responsible for the conduct of the affairs of the pharmacy benefit manager has had a pharmacy benefit manager certificate of authority or license denied or revoked for cause in another state.
(B)Any individual responsible for the conduct of the affairs of the pharmacy benefit manager has been convicted of, or has entered a plea of guilty or nolo contendere to a felony without regard to whether adjudication was withheld.
(5)A copy of a power of attorney duly executed by the pharmacy benefit manager if not domiciled in this state, appointing the department, the departments successors in office, and the departments authorized deputies as the attorney of the pharmacy benefit manager in and for this state, on whom process in any legal action or proceeding against the pharmacy benefit manager on a cause of action arising in this state may be served.
(6)The names, addresses, official positions, and professional qualifications of each individual who is responsible for the conduct of the affairs of the pharmacy benefit manager.
(7)A copy of a recent financial statement showing the pharmacy benefit managers assets, liabilities, and sources of financial support that the department determines are sufficient to show that the pharmacy benefit manager is financially viable. If the pharmacy benefit managers financial statements are prepared by an independent public accountant, a copy of the most recent regular financial statement satisfies the requirement to show financial viability unless the department determines that additional or more recent financial information is required for the proper administration of this act.
(8)A document providing the names, addresses, dates of birth, social security numbers, official positions, and professional qualifications of each individual who owns, legally or the information as to each person beneficially, 10 percent or more in equity in the entity interested therein or any person with management or control over the pharmacy benefit manager.
(9)A copy of all basic organizational and governing documents of the pharmacy benefit manager, including, but not limited to, the articles of incorporation, bylaws, articles of association, trade name certificate, and other similar documents and all amendments to those documents.
(10)A description of the pharmacy benefit manager, its services, facilities, and personnel.
(11)A document in which the pharmacy benefit manager confirms that its business practices and each ongoing contract comply with this chapter.
(12)Any other relevant information required by the department.
(d)The individual responsible for the conduct or affairs of the pharmacy benefit manager and any of the organizations partners, members, controlling persons, officers, directors, and managers shall comply with the background check requirements as required by the commissioner.
(e)Within 30 days after a modification of the information or documents submitted pursuant to subdivision (b), a pharmacy benefit manager shall file a notice of the modification with the department.
(f)An applicant for a pharmacy benefit manager license or licensed pharmacy benefit manager shall be subject to Sections 1702 and 1703, Article 6.5 (commencing with Section 790) of Chapter 1 of, and Article 3 (commencing with Section 1631), Article 4 (commencing with Section 1652), Article 6 (commencing with Section 1666), Article 10 (commencing with Section 1708), Article 12 (commencing with Section 1724), and Article 13 (commencing with Section 1737) of Chapter 5 of Part 2 of Division 1, and Article 1 (commencing with Section 12919), Article 3.5 (commencing with Section 12962), and Article 4 (commencing with Section 12970) of Chapter 2 of Division 3, excluding Sections 1634, 1635, 1640, 1642, 1647.5, 1649.5, 1661, 1725, 1725.5, 1726, 1728, 1729.5, 1730.5, 1730.6, 1731, 1732, and 1735.5.
(g)A pharmacy benefit manager shall not operate in this state unless it is licensed pursuant to this division.
(h)This division does not abrogate compliance by a pharmacy benefit manager with any applicable requirements of Chapter 5A (commencing with Section 1759) of Part 2 of Division 1.
(i)A violation of this division constitutes an unfair practice under Article 6.5 (commencing with Section 790) of Chapter 1 of Part 2 of Division 1.
(j)Notwithstanding any other law, the commissioner shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
17015.(a)A pharmacy benefit manager license applicant shall pay the initial application fee as determined by the department. A license shall be renewed every two years, beginning on the last calendar day of the month in which the initial license was issued. The license is nontransferable.
(b)To renew a pharmacy benefit manager license, an applicant shall submit to the department both of the following:
(1)A renewal application in a form and manner determined by the department that is signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the renewal form are correct.
(2)A renewal schedule and fee as determined by the department.
(c)(1)A pharmacy benefit manager license shall expire if a complete renewal filing and fee is not received by the due date established by the department.
(2)The application for renewal of an expired license may be filed after the expiration date and until that same month and day of the next succeeding year. The fee for a renewal application under this subdivision shall be the fee specified in subdivision (d) and a delinquent fee in the amount specified for a one-year period in subdivision (d) for the filing. Each licensee shall be subject to payment of delinquent fees under this section.
(d)An application fee of eleven thousand one hundred sixty dollars ($11,160), and for each year of the two-year license term thereafter, a fee of five thousand sixty dollars ($5,060), for a total renewal fee of ten thousand one hundred twenty dollars ($10,120). The commissioner may increase or decrease fees, and schedule fees and charges as set forth in Section 12978.
17020.Beginning no earlier than January 1, 2026, the fees for a pharmacy benefit manager initial license and renewal application shall be sufficient to fund the departments duties in relation to responsibilities under this chapter, but in no case shall the fee exceed the reasonable regulatory cost to administer the act. Fees received under the act shall be deposited into the Pharmacy Benefit Manager Account, which is hereby created in the Insurance Fund, and shall be subject to an annual appropriation each fiscal year for the support of the Department of Insurance related to the licensing and regulation of pharmacy benefit managers.
3.Licensee Duties17025.(a)On or before July 1, 2028, and on or before each July 1 thereafter, a pharmacy benefit manager shall file with the department a report that contains all of the information required by subdivision (e) of Section 4441 of the Business and Professions Code from the preceding calendar year.
(b)On or before January 1, 2029, and on or before each January 1 thereafter, the department shall prepare a report based on the information received by the department pursuant to subdivision (a) and shall publish the report on its internet website. The report shall contain aggregate data and shall exclude any information that the department determines would cause financial, competitive, or proprietary harm to a pharmacy benefit manager.
(c)On or before July 1, 2027, and on or before each July 1 thereafter, a pharmacy benefit manager shall report to the department all of the following information:
(1)A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. For each drug that falls into the above categories, the pharmacy benefit manager shall report both of the following:
(A)The pharmacy type used to fill the drug prescription, such as integrated, chain, independent, specialty, and mail order pharmacies.
(B)Pricing and rebate information, including the net price paid, the amount of rebate the pharmacy benefit manager receives from the manufacturer, the amount of rebate the pharmacy benefit manager passes to the health care service plan or health insurer, the amount the health care service plan or health insurer pays the pharmacy benefit manager, and the amount the pharmacy benefit manager pays the pharmacy.
(C)For each list in subparagraphs (A) and (B), all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(vi)Deidentified claims level information in electronic format that allows the commissioner to sort and analyze the following information for each claim, whether the claim required prior authorization.
(vii)The amount paid to the pharmacy for each prescription, net of the aggregate amount of fees or other assessments imposed on the pharmacy, including point-of-sale and retroactive charges. These data are confidential pursuant to subdivision (e).
(2)All of the following information in the aggregate:
(A)The purchasers, as described in paragraphs (1) to (4), inclusive, of subdivision (a) of Section 127675 of the Health and Safety Code, with which the pharmacy benefit manager contracts, the scope of services provided to the purchasers, and the number of enrollees, insureds, and plan members served.
(B)Pharmacy benefit manager revenue, including revenue from manufacturers, purchasers, and other revenue.
(C)Pharmacy benefit manager expenses, including payments to pharmacies, claims processing, special programs, administration, and other expenses.
(3)The following regarding group purchasing organizations:
(A)The identity of any group purchasing organization that the pharmacy benefit manager employed, contracted with, utilized, or otherwise has any affiliation with.
(B)A copy of any contract with an identified group purchasing organization.
(C)The aggregate financial benefit derived from the use of the identified group purchasing organizations.
(d)The department shall compile the information reported pursuant to subdivision (c) into a report for the public and Legislature that demonstrates the overall impact of pharmacy benefit managers on drug costs. The data in the report shall be aggregated and shall not reveal information specific to individual purchasers or individual manufacturers, or reveal a manufacturers individual or aggregated discounted prices for a drug.
(1)On or before January 1, 2029, and on or before each January 1 thereafter, the department shall publish the report on its internet website.
(2)The department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(3) The department may consolidate the reports required by this section.
(e)Except for the reports required pursuant to subdivisions (b) and (d), the information submitted to the department pursuant to subdivisions (a) and (c) shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). This section does not prevent disclosure to the Attorney General to investigate, prosecute, or defend any legal claim or cause or action, or to use the reports in any court or proceeding of law.
(f)For purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
17030.(a)A pharmacy benefit manager shall not impose any requirements, conditions, or exclusions that discriminate against a nonaffiliated pharmacy in connection with dispensing drugs.
(b)Discrimination prohibited pursuant to subdivision (a) includes all of the following:
(1)Terms or conditions applied to nonaffiliated pharmacies based on their status as a nonaffiliated pharmacy.
(2)Refusing to contract with, or terminating a contract with, a nonaffiliated pharmacy on the basis that the pharmacy is a nonaffiliated pharmacy or for reasons other than those that apply equally to affiliated pharmacies.
(3)Retaliation against a nonaffiliated pharmacy based on its exercise of any right or remedy under this chapter.
(4)Reimbursing a nonaffiliated pharmacy less for a pharmacy service than the pharmacy benefit manager would reimburse an affiliated pharmacy for the same pharmacy service.
(5)Engaging in any unlawful action against a covered entity, as defined in subdivision (b) of Section 127470 of the Health and Safety Code.
(c)This division does not preclude a pharmacy benefit manager or a purchaser of pharmacy benefit manager services from establishing a network of contracting pharmacies.
17035.A pharmacy benefit manager shall not do any of the following:
(a)Require an enrollee or insured to use only an affiliated pharmacy if there are nonaffiliated pharmacies in the network.
(b)Financially induce an enrollee, insured, or prescriber to transfer a prescription only to an affiliated pharmacy if there are nonaffiliated pharmacies in the network.
(c)Require a nonaffiliated pharmacy to transfer a prescription to an affiliated pharmacy if there are nonaffiliated pharmacies in the network. This subdivision does not prevent a purchaser or pharmacy benefit manager from offering and communicating to enrollees or insureds financial incentives to use a particular pharmacy, such as lower copays, coinsurance, or any other cost sharing for a prescription when the prescription is dispensed.
(d)Unreasonably restrict an enrollee or insured from using a particular contracted pharmacy for the purpose of receiving pharmacist services covered by the enrollees or insureds contract or policy.
(e)Communicate to an enrollee or insured, in any manner, that the enrollee or insured is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other nonaffiliated pharmacies that have the ability to dispense the medication or provide the services and are also in network.
(f)Deny a nonaffiliated contract pharmacy the opportunity to participate in a pharmacy benefit manager network as preferred participation status if the pharmacy is willing to accept the same terms and conditions that the pharmacy benefit manager has established for affiliated pharmacies as a condition of preferred network participation status.
17040.(a)A contract issued, amended, or renewed on or after January 1, 2025, between a nonaffiliated pharmacy and a pharmacy benefit manager shall not prohibit the pharmacy from offering either of the following as an ancillary service of the pharmacy:
(1)The delivery of a prescription drug by mail or common carrier to a patient or personal representative on request of the patient or personal representative if the request is made before the drug is delivered.
(2)The delivery of a prescription to a patient or personal representative by an employee or contractor of the pharmacy.
(b)Except as otherwise provided in a contract described in subdivision (a), the pharmacy shall not charge a pharmacy benefit manager for the delivery service described in subdivision (a). This section does not prohibit the use of remote pharmacies, secure locker systems, or other types of pickup stations if those services are otherwise permitted by law.
(c)Contracts entered into pursuant to this section shall be open for inspection by the department.
17050.(a)The pharmacy benefit manager shall disclose the amount and types of fees it charges for the pharmacy benefit management services to the health insurer or health care service plan.
(b)Pharmacy benefit managers shall transmit 100 percent of all prescription drug manufacturer rebates received to the health care service plan or health insurer if the contractual arrangement delegates the negotiation of rebates to the pharmacy benefit manager, for the sole purpose of offsetting defined cost sharing, deductibles, and coinsurance contributions and reducing premiums of enrollees or insureds.
(c)(1)A pharmacy benefit manager shall disclose to the department all types of fees that it receives, and how the fees are calculated, including all of the following:
(A)Fees for pharmacy benefit management services related to the acquisition cost or any other price metric of a drug.
(B)Fees for pharmacy benefit management services related to the amount of additional savings, additional rebates, or other fees charged, realized or collected by, or generated based on the activity of the pharmacy benefit manager, that is retained by the pharmacy manager.
(C)The amount of premiums, deductibles, or other cost sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.
(2)Compensation arrangements governed by this section shall be open for inspection by the department.
(3)This section does not prevent disclosure to the Attorney General to investigate, prosecute, or defend any legal claim, cause, or action, or to use the reports in any court or proceeding of law.
(4)The department shall compile the information reported pursuant to this section into a report for the public and legislators that demonstrates the impact of fees on drug costs and quantifies the impact of the retention of fees by pharmacy benefit managers. The data in the report shall be aggregated.
(d)A pharmacy benefit manager shall not make or permit any reduction of payment for pharmacist services by a pharmacy benefit manager or a health insurer or health care service plan directly or indirectly to a pharmacy under a reconciliation process to an effective rate of reimbursement, including without limitation generic effective rates, brand effective rates, direct and indirect remuneration fees, or any other reduction or aggregate reduction of payment.
(e)A claim or aggregate of claims for pharmacist services shall not be directly or indirectly retroactively denied or reduced after adjudication of the claim or aggregate of claims unless any of the following have occurred:
(1)The original claim was submitted fraudulently.
(2)The original claim payment was incorrect because the pharmacy or pharmacist had already been paid for the pharmacist services.
(3)The pharmacist services were not properly rendered by the pharmacy or pharmacist.
(f)A pharmacy benefit manager shall not reverse and resubmit the claim of a contract pharmacy under any of the following circumstances:
(1)Without prior written notification to the contract pharmacy.
(2)Without just cause or attempt to first reconcile the claim with the pharmacy.
(3)More than 90 days after the claim was first affirmatively adjudicated.
(g)A pharmacy benefit manager shall not charge a pharmacy or pharmacist a fee to process a claim electronically.
(h)The termination of a contract with a nonaffiliated pharmacy by a pharmacy benefit manager shall not release the pharmacy benefit manager from the obligation to make a payment due to the pharmacy for an affirmatively adjudicated claim unless payments are withheld because of an investigation relating to insurance fraud.
(i)A pharmacy benefit manager shall not retaliate against a pharmacist or pharmacy based on the pharmacists or pharmacys exercise of a right or remedy under this chapter. Prohibited retaliation includes any of the following:
(1)Terminating or refusing to renew a contract with the pharmacist or pharmacy.
(2)Subjecting the pharmacist or pharmacy to increased audits.
(3)Failing to promptly pay the pharmacist or pharmacy money owed by the pharmacy benefit manager to the pharmacist or pharmacy.
17055.(a)Except as permitted under existing law, a pharmacy benefit manager shall not unreasonably obstruct or interfere with a patients right to timely access a prescription drug or device that has been legally prescribed for that patient at a contract pharmacy of their choice.
(b)A pharmacy benefit manager shall not make, disseminate, or cause or permit the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
(c)The department may investigate referrals provided by the California State Board of Pharmacy.
17065.(a)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with manufacturers that do business in California that expressly or implicitly restricts, or implements implicit or express exclusivity for, those manufacturers drugs, medical devices, or other products.
(b)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with pharmacies or pharmacy services administration organizations that do business in California that expressly or implicitly restricts, or imposes implicit or express exclusivity on, nonaffiliated pharmacies ability to contract with employers, health insurers, and health care service plans.
4.Enforcement17070.(a)In addition to any of the grounds to deny a license listed in Section 17010, the department may deny, suspend, or revoke the license of a pharmacy benefit manager if the department finds that any of the following are true:
(1)The pharmacy benefit manager has violated a statute or regulation applicable to the pharmacy benefit manager.
(2)The pharmacy benefit manager has refused to be examined or to produce its accounts, records, and files for examination by the department, or an individual responsible for the conduct of affairs of the pharmacy benefit manager has refused to give information with respect to its affairs or has refused to perform any other legal obligation as to an examination required by the department.
(3)The pharmacy benefit manager has, without just cause, exhibited a pattern or practice of refusing to pay proper claims or perform services arising under its contracts or has, without just cause, caused enrollees or insureds to accept less than the amount due them.
(4)The pharmacy benefit manager is required under this chapter to have a license and fails to continue to meet the qualifications for licensure during its active licensure.
(5)The pharmacy benefit manager failed to file a timely report as required by Section 17025.
(6)The pharmacy benefit manager is not financially viable.
(b)If a hearing is held pursuant to this section, it shall be conducted in accordance with the Administrative Procedure Act (Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code).
17075.(a)The department may examine or audit any books and records of a pharmacy benefit manager pursuant to Article 4 (commencing with Section 729) of Chapter 1 of Part 2 of Division 1 to determine if the pharmacy benefit manager is in compliance with this division. A pharmacy benefit manager shall pay for reasonable expenses for any examinations or audits conducted pursuant to this section. Those payments shall be deposited into the Pharmacy Benefit Manager Account.
(b)The department may produce and disclose publicly an examination report describing any act or omission committed by a pharmacy benefit manager that violates this division.
(c)(1)The department shall establish a retention schedule for all records, books, papers, and other data on file with the department related to the enforcement of this chapter.
(2)The department shall not order the destruction or other disposal of a record, book, paper, or other data that is required to be filed or kept on file with the department during the retention period.
(d)Section 735.5 does not prevent disclosure of information and data acquired during an examination to the Attorney General to investigate, prosecute, or defend any legal claim or cause of action, or to use the information and data in any court or proceeding of law. In any matter arising under this chapter, the department may provide to the Attorney General information related to competition and obtain an opinion from a consultant or consultants with the expertise to assess the competitive impact of the matter.
17080.(a)(1)Notwithstanding Section 4441 of the Business and Professions Code and Article 6.1 (commencing with Section 1385.001) of Chapter 2.2 of Division 2 of the Health and Safety Code, a pharmacy benefit manager shall have a duty and obligation to the health care service plan, the subscriber and enrollee covered by the health care service plan contract, the health insurer, and the policyholder and the insured of the health insurance policy, and shall perform its services with care, skill, prudence, diligence, and professionalism.
(2)A pharmacy benefit manager shall disclose to a health insurer or health care service plan information of clinical efficacy and clinical evidence regarding the inclusion, exclusion, or limitation of prescription drugs in the formulary.
(b)Any pharmacy benefit manager that violates this division shall, in addition to any other penalty provided by law, be liable for restitution to any enrollee or insured harmed by the violation.
(c)If a violation of this section, or Section 17030 or 17035 is alleged and is at issue in any proceeding in the Supreme Court, a state court of appeal, or the appellate division of a superior court, a person filing a brief or petition with the court in that proceeding shall serve, within three days of filing with the court, a copy of the brief or petition on the Attorney General at a service address designated on the Attorney Generals internet website for service of papers under this section, or, if a service address is not designated, at the Attorney Generals office in San Francisco. Upon the Attorney Generals request, a person who has filed any other document, including all or a portion of the appellate record, with the court in addition to a brief or petition shall provide a copy of that document, without charge, to the Attorney General within five days of the request. The time for service may be extended by the Chief Justice of California or presiding justice or judge for good cause shown. No judgment or relief, temporary or permanent, shall be granted or opinion issued until proof of service of the brief or petition on the Attorney General is filed with the court.
(d)This section does not alter or abrogate the departments authority to enforce this division.
17085.(a)Any person that violates this division shall be subject to an injunction and liable for a civil penalty of not less than one thousand dollars ($1,000) or more than seven thousand five hundred dollars ($7,500) for each violation which shall be assessed and recovered in a civil action brought in the name of the people of the State of California by the Attorney General.
(b)(1)A violation of Section 17030 or 17035 is an act of unfair competition within the meaning of Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code. However, this paragraph does not limit any other statutory or common law rights or remedies, including liability pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code).
(2)This subdivision does not alter or abrogate the departments authority to enforce this division.
(c)Notwithstanding any other law, the Attorney General shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this division and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
(d)The remedies or penalties provided by this chapter are cumulative to each other and to the remedies or penalties available under all other laws of this state.
17086.The provisions of this division are severable. If any provision of this division or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
17090.Beginning on or after January 1, 2026, the fines and administrative penalties collected pursuant to this chapter shall be deposited into the Pharmacy Benefit Manager Fines and Penalties Account, which is hereby established in the General Fund.
SEC. 8.The authority of the Attorney General to maintain or restore competitive, fair, and honest markets and prosecute violations of state and federal antitrust, consumer protection, unfair competition, unfair practices, or any other related law shall not be narrowed, abrogated, or otherwise altered by this act.
SEC. 9.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 10.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SEC. 11.The Legislature finds and declares that Section 7 of this act, which adds Sections 17025, 17050, and 17075 to the Insurance Code, imposes a limitation on the publics right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 5 of Article I of the California Constitution. Pursuant to that constitutional provision, the Legislature makes the following findings to demonstrate the interest protected by this limitation and the need for protecting that interest:
In order to protect the confidentiality of information received by state agencies from pharmacy benefit managers, it is necessary that those documents be presumptively confidential, except as otherwise provided by law.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an enrollees cost sharing at an amount that exceeds the actual rate paid for the prescription drug, and shall include cost-sharing provisions consistent with Section 4079 of the Business and Professions Code.
(b)Commencing January 1, 2026, a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) of the Insurance Code shall offer a health care service plan the option of a non-spread pricing contract.SEC. 2.Section 1367.243 of the Health and Safety Code is amended to read:1367.243.(a)(1)A health care service plan that reports rate information pursuant to Section 1385.03 or 1385.045 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(vi)The aggregate income from pharmacy benefit management services fees that pharmacy benefit managers receive.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health care service plans.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2019, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 1385.045.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 3.Section 1367.2431 is added to the Health and Safety Code, immediately following Section 1367.243, to read:1367.2431.In preparing the report required as set forth in subdivision (b) of Section 1367.243, the department shall ensure that the information regarding rebates is aggregated and does not reveal information specific to individual health care service plans or manufacturers, or reveal any manufacturers individual or aggregated discounted prices for a drug.
SEC. 4.Section 10123.2045 is added to the Insurance Code, immediately following Section 10123.204, to read:10123.2045.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an insureds cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
(b)Commencing January 1, 2026, a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) shall offer a health insurer the option of a non-spread pricing contract.SEC. 5.Section 10123.205 of the Insurance Code is amended to read:10123.205.(a)(1)A health insurer that reports rate information pursuant to Section 10181.3 or 10181.45 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(vi)The aggregate income from pharmacy benefit management services fees that pharmacy benefit managers receive.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health insurers.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2018, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 6.Section 10123.2051 is added to the Insurance Code, immediately following Section 10123.205, to read:10123.2051.In preparing the report required as set forth in subdivision (b) of Section 10123.205, the department shall ensure that the information regarding rebates is aggregated and does not reveal information specific to individual health insurers or manufacturers, or reveal any manufacturers individual or aggregated discounted prices for a drug.
SEC. 7.Division 6 (commencing with Section 17000) is added to the Insurance Code, to read:6.Regulation of Pharmacy Benefit Managers1.General Provisions17000.For purposes of this division: division, the following definitions apply:
(a)Affiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a pharmacy benefit manager.
(b)Claim means a request for payment for administering, filling, or refilling a drug or for providing a pharmacy service or a medical supply or device to an enrollee or insured.
(c)Contract pharmacy means a pharmacy that contracts directly or through a pharmacy services administration organization with a pharmacy benefit manager.
(d)Drug has the same meaning as defined in Section 4025 of the Business and Professions Code.
(e)Financially viable means that either of the following conditions is met:
(1)The pharmacy benefit manager has received an unqualified opinion from an independent public accountant, as described in Section 260.613(b) of Title 10 of the California Code of Regulations.
(2)If an independent public accountant opinion is not obtained, the pharmacy benefit manager remains solvent after adjusting for goodwill and intangible assets.
(f)Group purchasing organization means a third party or affiliated person employed by, contracted with, or otherwise utilized by a pharmacy benefits benefit manager to negotiate, obtain, or otherwise procure rebates from drug manufacturers or wholesalers.
(g)Health care service plan means an entity licensed pursuant to the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code).
(h)Health insurer means a disability insurer that issues health insurance, as defined in Section 106.
(i)Manufacturer has the same meaning as defined in Section 4033 of the Business and Professions Code.
(j)Nonaffiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, does not control, is not controlled by, and is not under common control with, a pharmacy benefit manager.
(k)Passthrough pricing model means a payment model used by a pharmacy benefit manager in which the payments made by the health care service plan or health insurer client to the pharmacy benefit manager for the covered outpatient drugs are both of the following:(1)Equivalent to the payments the pharmacy benefit manager makes to a pharmacy or provider for those drugs, including any contracted professional dispensing fee between the pharmacy benefit manager and its network of pharmacies. That dispensing fee would be paid if the health care service plan or health insurer was making the payments directly.(2)Passed through in their entirety by the health care service plan or health insurer client or by the pharmacy benefit manager to the pharmacy or provider that dispenses the drugs, and the payments are made in a manner that is not offset by any reconciliation.(l)(k)Person has the same meaning as defined in Section 4035 of the Business and Professions Code.
(m)(l)Personal representative means an individual who has authority to make a health care decision on behalf of another individual pursuant to Division 4.7 (commencing with Section 4600) of the Probate Code.
(n)(m)Pharmacist has the same meaning as defined in Section 4036 of the Business and Professions Code.
(o)(n)Pharmacist services means products, goods, and services, or any combination of products, goods, and services, provided as a part of the practice of pharmacy.
(p)(o)Pharmacy has the same meaning as defined in Section 4037 of the Business and Professions Code.
(q)Pharmacy benefit management fee means a flat, defined, dollar-amount fee that covers the cost of providing one or more pharmacy benefit management services and that does not exceed the value of the service or services actually performed by the pharmacy benefit manager. The value of the service or services shall be based on the value to the health insurer or health care service plan. A pharmacy benefit management fee may not be based on or contingent upon any of the following:(1)The acquisition cost or any other price metric of a drug.(2)The amount of savings, rebates, or other fees charged, realized, or collected by, or generated based on the activity of, the pharmacy benefit manager, that is retained by the pharmacy benefit manager.(3)The amount of premiums, deductibles, or other cost sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.(r)(p)Pharmacy benefit management service means all of the following:
(1)Negotiating the price of prescription drugs, including negotiating and contracting for direct or indirect rebates, discounts, or other price concessions.
(2)Managing any aspect of a prescription drug benefit, including, but not limited to, developing or managing a drug formulary, including utilization management or quality assurance programs, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with pharmacies, management of retail, mail order, or specialty pharmacies, controlling the cost of covered prescription drugs, managing or providing data relating to the prescription drug benefit, or the provision of services related thereto.
(3)Performing any administrative, managerial, clinical, pricing, financial, reimbursement, data administration or reporting, or billing service.
(4)Other services as the department may define in regulation.
(s)(q)Pharmacy benefit manager means a person, business, or other entity that, either directly or indirectly, manages the prescription drug coverage, including, but not limited to, the following: clinical or other formulary or preferred drug list development or management; the processing and payment of claims for prescription drugs; the negotiation or administration of rebates, discounts, payment differentials, or other incentives; the inclusion of particular prescription drugs in a particular category or to promote the purchase of particular prescription drugs; the performance of drug utilization review; the processing of drug prior authorization requests; the adjudication of appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. Pharmacy benefit manager does not include any of the following:
(1)A health care service plan that is part of a fully integrated delivery system in which enrollees primarily use pharmacies that are entirely owned and operated by the health care service plan, and the health care service plans enrollees may use any pharmacy in the health care service plans network that has the ability to dispense the medication or provide the services.
(2)An entity providing services pursuant to a contract authorized by Section 4600.2 of the Labor Code.
(3)A health care service plan or its contracted provider, as defined in subdivision (i) of Section 1345 of the Health and Safety Code, performing the services described in this subdivision.
(4)A health insurer.
(5)A city or county that develops or manages drug coverage programs for uninsured patients for which no reimbursement is received.
(6)An entity exclusively providing services to patients covered by Part 418 (commencing with Section 418.1) of Subchapter B of Chapter IV of Title 42 of the Code of Federal Regulations.
(t)(r)Pharmacy services administration organization means an entity that provides contracting and other administrative services relating to prescription drug benefits to pharmacies.
(u)(s)Rebate means a formulary discount or remuneration attributable to the use of prescription drugs that is paid by a manufacturer or third party, directly or indirectly, to a pharmacy benefit manager after a claim has been adjudicated at a pharmacy. Rebate does not include a fee, including a bona fide service fee or administrative fee, that is not a formulary discount or remuneration.
(v) Spread pricing means the model of prescription drug pricing in which a pharmacy benefit manager charges a health care service plan or health insurer a contracted price for prescription drugs, and the contracted price for the prescription drugs differs from the amount the pharmacy benefit manager directly or indirectly pays the pharmacist or pharmacy.(w)(t)Third party means a person that is not an enrollee, insured, or pharmacy benefit manager.
17004.5.Any activity conducted by a pharmacy benefit manager, as defined in this division, shall be construed as the business of insurance.
17004.7.This division does not apply to a collectively bargained Taft-Hartley self-insured prescription drug plan offered pursuant to the federal Employee Retirement Income Security Act of 1974 (29 U.S.C. Section 1001 et seq.) or to a pharmacy benefit managers provision of pharmacy benefit management services pursuant to that Taft-Hartley plan. To the extent a pharmacy benefit manager is providing services for other health plans or health insurers in addition to a collectively bargained self-insured plan that provides prescription drug plans governed by federal law, the provisions of this division shall continue to apply to the pharmacy benefit manager in its performance of pharmacy benefit management services pursuant to those other health care plans or health insurers.
17005.The department shall adopt regulations necessary to implement this division, including, but not limited to, regulations regarding group purchasing organizations and the use of those organizations.
(a)Until January 1, 2028, necessary regulations for the purpose of implementing this division may be adopted as emergency regulations in accordance with the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The adoption of emergency regulations pursuant to this section shall be deemed to be an emergency and necessary for the immediate preservation of the public peace, health and safety, or general welfare.
(b)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, including subdivisions (e) and (h) of Section 11346.1, an emergency regulation adopted pursuant to this section shall be repealed by operation of law unless the adoption, amendment, or repeal of the regulation is promulgated by the department pursuant to Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code within five years of the initial adoption of the emergency regulation.
(c)A regulation adopted pursuant to this section shall be discussed by the department during at least one public stakeholder meeting before the department adopts the rule or regulation.
17006.(a)The department shall establish procedures for receiving, investigating, tracking, and publicly reporting consumer complaints against pharmacy benefit managers.
(b)The department shall publish on its internet website a record of consumer complaints against a pharmacy benefit manager that have been determined by the department to be justified. Complaint data shall not be published unless it has been provided to the pharmacy benefit manager in accordance with subdivision (c) of Section 12921.1.
2.Licensing17010.(a)The department shall license and regulate pharmacy benefit managers. The department shall have the authority to enforce this division and Chapter 9.5 (commencing with Section 4430) of Division 2 of the Business and Professions Code and Article 3 (commencing with Section 127470) of Chapter 2.5 of Part 2 of Division 107 of the Health and Safety Code.
(b)No later than January 1, 2027, a pharmacy benefit manager that provides services in this state shall apply for a license to operate as a pharmacy benefit manager from the department. A pharmacy benefit manager shall maintain its license in good standing.
(c)An application for a pharmacy benefit manager license shall be submitted in a form and manner determined by the department, and shall be signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the application form and any attachments are correct. The application shall include all of the following:
(1)A nonrefundable application fee in an amount established by the department under Section 17015.
(2)A list of every health care service plan or health insurer on behalf of which the pharmacy benefit manager contracts with a pharmacy or a pharmacy services administration organization to provide health services to individuals covered by the health care service plan or health insurer.
(3)A statement indicating all jurisdictions where the applicant has an application pending or has been registered, licensed, or otherwise certified to transact business as a pharmacy benefit manager.
(4)A statement indicating whether either of the following has occurred:
(A)The pharmacy benefit manager or any individual responsible for the conduct of the affairs of the pharmacy benefit manager has had a pharmacy benefit manager certificate of authority or license denied or revoked for cause in another state.
(B)Any individual responsible for the conduct of the affairs of the pharmacy benefit manager has been convicted of, or has entered a plea of guilty or nolo contendere to a felony without regard to whether adjudication was withheld.
(5)A copy of a power of attorney duly executed by the pharmacy benefit manager if not domiciled in this state, appointing the department, the departments successors in office, and the departments authorized deputies as the attorney of the pharmacy benefit manager in and for this state, on whom process in any legal action or proceeding against the pharmacy benefit manager on a cause of action arising in this state may be served.
(6)The names, addresses, official positions, and professional qualifications of each individual who is responsible for the conduct of the affairs of the pharmacy benefit manager.
(7)A copy of a recent financial statements statement showing the pharmacy benefit managers assets, liabilities, and sources of financial support that the department determines are sufficient to show that the pharmacy benefit manager is financially viable. If the pharmacy benefit managers financial statements are prepared by an independent accountant public accountant, a copy of the most recent regular financial statement satisfies the requirement to show financial viability unless the department determines that additional or more recent financial information is required for the proper administration of this act.
(8)A document providing the names, addresses, dates of birth, social security numbers, official positions, and professional qualifications of each individual who owns, legally or the information as to each person beneficially, 10 percent or more in equity in the entity interested therein or any person with management or control over the pharmacy benefit manager.
(9)A copy of all basic organizational and governing documents of the pharmacy benefit manager, including, but not limited to, the articles of incorporation, bylaws, articles of association, trade name certificate, and other similar documents and all amendments to those documents.
(10)A description of the pharmacy benefit manager, its services, facilities, and personnel.
(11)A document in which the pharmacy benefit manager confirms that its business practices and each ongoing contract comply with this chapter.
(12)Any other relevant information required by the department.
(d)The individual responsible for the conduct or affairs of the pharmacy benefit manager and any of the organizations partners, members, controlling persons, officers, directors, and managers shall comply with the background check requirements as required by the commissioner.
(e)Within 30 days after a modification of the information or documents submitted pursuant to subdivision (b), a pharmacy benefit manager shall file a notice of the modification with the department.
(f)An applicant for a pharmacy benefit manager license or licensed pharmacy benefit manager shall be subject to Sections 1702 and 1703, Article 6.5 (commencing with Section 790) of Chapter 1 of, and Article 3 (commencing with Section 1631), Article 4 (commencing with Section 1652), Article 6 (commencing with Section 1666), Article 10 (commencing with Section 1708), Article 12 (commencing with Section 1724), and Article 13 (commencing with Section 1737) of Chapter 5 of Part 2 of Division 1, and Article 1 (commencing with Section 12919), Article 3.5 (commencing with Section 12962), and Article 4 (commencing with Section 12970) of Chapter 2 of Division 3, excluding Sections 1634, 1635, 1640, 1642, 1647.5, 1649.5, 1661, 1725, 1725.5, 1726, 1728, 1729.5, 1730.5, 1730.6, 1731, 1732, and 1735.5.
(g)A pharmacy benefit manager shall not operate in this state unless it is licensed pursuant to this division.
(h)This division does not abrogate compliance by a pharmacy benefit manager with any applicable requirements of Chapter 5A (commencing with Section 1759) of Part 2 of Division 1.
(i)A violation of this division constitutes an unfair practice under Article 6.5 (commencing with Section 790) of Chapter 1 of Part 2 of Division 1.
(j)Notwithstanding any other law, the commissioner shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
17015.(a)A pharmacy benefit manager license applicant shall pay the initial application fee as determined by the department. A license shall be renewed every two years, beginning on the last calendar day of the month in which the initial license was issued. The license is nontransferable.
(b)To renew a pharmacy benefit manager license, an applicant shall submit to the department both of the following:
(1)A renewal application in a form and manner determined by the department that is signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the renewal form are correct.
(2)A renewal schedule and fee as determined by the department.
(c)(1)A pharmacy benefit manager license shall expire if a complete renewal filing and fee is not received by the due date established by the department.
(2)The application for renewal of an expired license may be filed after the expiration date and until that same month and day of the next succeeding year. The fee for a renewal application under this subdivision shall be the fee specified in subdivision (d) and a delinquent fee in the amount specified for a one-year period in subdivision (d) for the filing. Each licensee shall be subject to payment of delinquent fees under this section.
(d)An application fee of eleven thousand one hundred sixty dollars ($11,160), and for each year of the two-year license term thereafter, a fee of five thousand sixty dollars ($5,060), for a total renewal fee of ten thousand one hundred twenty dollars ($10,120). The commissioner may increase or decrease fees, and schedule fees and charges as set forth in Section 12978.
17020.Beginning no earlier than January 1, 2026, the fees for a pharmacy benefit manager initial license and renewal application shall be sufficient to fund the departments duties in relation to responsibilities under this chapter, but in no case shall the fee exceed the reasonable regulatory cost to administer the act. Fees received under the act shall be deposited into the Pharmacy Benefit Manager Account, which is hereby created in the Insurance Fund, and shall be subject to an annual appropriation each fiscal year for the support of the Department of Insurance related to the licensing and regulation of pharmacy benefit managers.
3.Licensee Duties17025.(a)On or before July 1, 2028, and on or before each July 1 thereafter, a pharmacy benefit manager shall file with the department a report that contains all of the information required by subdivision (e) of Section 4441 of the Business and Professions Code from the preceding calendar year.
(b)On or before January 1, 2029, and on or before each January 1 thereafter, the department shall prepare a report based on the information received by the department pursuant to subdivision (a) and shall publish the report on its internet website. The report shall contain aggregate data and shall exclude any information that the department determines would cause financial, competitive, or proprietary harm to a pharmacy benefit manager.
(c)On or before July 1, 2027, and on or before each July 1 thereafter, a pharmacy benefit manager shall report to the department all of the following information:
(1)A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. For each drug that falls into the above categories, the pharmacy benefit manager shall report both of the following:
(A)The pharmacy type used to fill the drug prescription, such as integrated, chain, independent, specialty, and mail order pharmacies.
(B)Pricing and rebate information, including the net price paid, the amount of rebate the pharmacy benefit manager receives from the manufacturer, the amount of rebate the pharmacy benefit manager passes to the health care service plan or health insurer, the amount the health care service plan or health insurer pays the pharmacy benefit manager, and the amount the pharmacy benefit manager pays the pharmacy.
(C)For each list in subparagraphs (A) and (B), all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(vi)Deidentified claims level information in electronic format that allows the commissioner to sort and analyze the following information for each claim, whether the claim required prior authorization.
(vii)The amount paid to the pharmacy for each prescription, net of the aggregate amount of fees or other assessments imposed on the pharmacy, including point-of-sale and retroactive charges. These data are confidential pursuant to subdivision (e).
(2)All of the following information in the aggregate:
(A)The purchasers, as described in paragraphs (1) to (4), inclusive, of subdivision (a) of Section 127675 of the Health and Safety Code, with which the pharmacy benefit manager contracts, the scope of services provided to the purchasers, and the number of enrollees, insureds, and plan members served.
(B)Pharmacy benefit manager revenue, including revenue from manufacturers, purchasers, and other revenue.
(C)Pharmacy benefit manager expenses, including payments to pharmacies, claims processing, special programs, administration, and other expenses.
(3)The following regarding group purchasing organizations:
(A)The identity of any group purchasing organization that the pharmacy benefit manager employed, contracted with, utilized, or otherwise has any affiliation with.
(B)A copy of any contract with an identified group purchasing organization.
(C)The aggregate financial benefit derived from the use of the identified group purchasing organizations.
(d)The department shall compile the information reported pursuant to subdivision (c) into a report for the public and Legislature that demonstrates the overall impact of pharmacy benefit managers on drug costs. The data in the report shall be aggregated and shall not reveal information specific to individual purchasers or individual manufacturers, or reveal a manufacturers individual or aggregated discounted prices for a drug.
(1)On or before January 1, 2029, and on or before each January 1 thereafter, the department shall publish the report on its internet website.
(2)The department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(3) The department may consolidate the reports required by this section.
(e)Except for the reports required pursuant to subdivisions (b) and (d), the information submitted to the department pursuant to subdivisions (a) and (c) shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). This section does not prevent disclosure to the Attorney General to investigate, prosecute, or defend any legal claim or cause or action, or to use the reports in any court or proceeding of law.
(f)For purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
17030.(a)A pharmacy benefit manager shall not impose any requirements, conditions, or exclusions that discriminate against a nonaffiliated pharmacy in connection with dispensing drugs.
(b)Discrimination prohibited pursuant to subdivision (a) includes all of the following:
(1)Terms or conditions applied to nonaffiliated pharmacies based on their status as a nonaffiliated pharmacy.
(2)Refusing to contract with with, or terminating a contract with with, a nonaffiliated pharmacy on the basis that the pharmacy is a nonaffiliated pharmacy or for reasons other than those that apply equally to affiliated pharmacies.
(3)Retaliation against a nonaffiliated pharmacy based on its exercise of any right or remedy under this chapter.
(4)Reimbursing a nonaffiliated pharmacy less for a pharmacy service than the pharmacy benefit manager would reimburse an affiliated pharmacy for the same pharmacy service.
(5)Engaging in any unlawful action against a covered entity, as defined in subdivision (b) of Section 127470 of the Health and Safety Code.
(c)This division does not preclude a pharmacy benefit manager or a purchaser of pharmacy benefit manager services from establishing a network of contracting pharmacies.
17035.A pharmacy benefit manager shall not do any of the following:
(a)Require an enrollee or insured to use only an affiliated pharmacy if there are nonaffiliated pharmacies in the network.
(b)Financially induce an enrollee, insured, or prescriber to transfer a prescription only to an affiliated pharmacy if there are nonaffiliated pharmacies in the network.
(c)Require a nonaffiliated pharmacy to transfer a prescription to an affiliated pharmacy if there are nonaffiliated pharmacies in the network. This paragraph subdivision does not prevent a purchaser or pharmacy benefit manager from offering and communicating to enrollees or insureds financial incentives to use a particular pharmacy, such as lower copays, coinsurance, or any other cost sharing for a prescription when the prescription is dispensed.
(d)Unreasonably restrict an enrollee or insured from using a particular contracted pharmacy for the purpose of receiving pharmacist services covered by the enrollees or insureds contract or policy.
(e)Communicate to an enrollee or insured, in any manner, that the enrollee or insured is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other nonaffiliated pharmacies that have the ability to dispense the medication or provide the services and are also in network.
(f)Deny a nonaffiliated contract pharmacy the opportunity to participate in a pharmacy benefit manager network as preferred participation status if the pharmacy is willing to accept the same terms and conditions that the pharmacy benefit manager has established for affiliated pharmacies as a condition of preferred network participation status.
17040.(a)A contract issued, amended, or renewed on or after January 1, 2025, between a nonaffiliated pharmacy and a pharmacy benefit manager shall not prohibit the pharmacy from offering either of the following as an ancillary service of the pharmacy:
(1)The delivery of a prescription drug by mail or common carrier to a patient or personal representative on request of the patient or personal representative if the request is made before the drug is delivered.
(2)The delivery of a prescription to a patient or personal representative by an employee or contractor of the pharmacy.
(b)Except as otherwise provided in a contract described in subdivision (a), the pharmacy shall not charge a pharmacy benefit manager for the delivery service described in subdivision (a). This section does not prohibit the use of remote pharmacies, secure locker systems, or other types of pickup stations if those services are otherwise permitted by law.
(c)Contracts entered into pursuant to this section shall be open for inspection by the department.
17045.A pharmacy benefit manager shall not require more than two accreditations from an independent accrediting organization for pharmacists and pharmacies to dispense specialty drugs and shall make every effort to ensure that enhanced standards are not imposed to dispense specialty drugs beyond those related to the safety and competency necessary to comply with requirements for dispensing specified medications and providing optimal patient care.17050.(a)The pharmacy benefit manager shall disclose the amount and types of fees it charges for the pharmacy benefit management service fees services to the health insurer or health care service plan.
(b)A pharmacy benefit manager shall offer a passthrough pricing model, in addition to other pricing options offered to a health care service plan or health insurer.(c)(b)Pharmacy benefit managers shall pass transmit 100 percent of all prescription drug manufacturer rebates received to the health care service plan or health insurer if the contractual arrangement delegates the negotiation of rebates to the pharmacy benefit manager, for the sole purpose of offsetting defined cost sharing, deductibles, and coinsurance contributions and reducing premiums of enrollees or insureds.
(d)(c)(1)A pharmacy benefit manager shall disclose to the department all types of pharmacy benefit management service fees that it receives, and how the fees are calculated, including all of the following:
(A)Pharmacy Fees for pharmacy benefit management service fees services related to the acquisition cost or any other price metric of a drug.
(B)Pharmacy Fees for pharmacy benefit management service fees services related to the amount of additional savings, additional rebates, or other fees charged, realized or collected by, or generated based on the activity of the pharmacy benefit manager, that is retained by the pharmacy manager.
(C)The amount of premiums, deductibles, or other cost sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.
(2)Compensation arrangements governed by this section shall be open for inspection by the department.
(3)The department shall keep confidential all information it receives pursuant to this subdivision, and the information shall not be subject to disclosure, including disclosure under the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code).(3)This section does not prevent disclosure to the Attorney General to investigate, prosecute, or defend any legal claim, cause, or action, or to use the reports in any court or proceeding of law.
(4)The department shall compile the information reported pursuant to this section into a report for the public and legislators that demonstrates the impact of fees on drug costs and quantifies the impact of the retention of fees by pharmacy benefit managers. The data in the report shall be aggregated.
(e)(d)A pharmacy benefit manager shall not make or permit any reduction of payment for pharmacist services by a pharmacy benefit manager or a health insurer or health care service plan directly or indirectly to a pharmacy under a reconciliation process to an effective rate of reimbursement, including without limitation generic effective rates, brand effective rates, direct and indirect remuneration fees, or any other reduction or aggregate reduction of payment.
(f)(e)A claim or aggregate of claims for pharmacist services shall not be directly or indirectly retroactively denied or reduced after adjudication of the claim or aggregate of claims unless any of the following have occurred:
(1)The original claim was submitted fraudulently.
(2)The original claim payment was incorrect because the pharmacy or pharmacist had already been paid for the pharmacist services.
(3)The pharmacist services were not properly rendered by the pharmacy or pharmacist.
(g)(f)A pharmacy benefit manager shall not reverse and resubmit the claim of a contract pharmacy under any of the following circumstances:
(1)Without prior written notification to the contract pharmacy.
(2)Without just cause or attempt to first reconcile the claim with the pharmacy.
(3)More than 90 days after the claim was first affirmatively adjudicated.
(h)(g)A pharmacy benefit manager shall not charge a pharmacy or pharmacist a fee to process a claim electronically.
(i)(h)The termination of a contract with a nonaffiliated pharmacy by a pharmacy benefit manager shall not release the pharmacy benefit manager from the obligation to make a payment due to the pharmacy for an affirmatively adjudicated claim unless payments are withheld because of an investigation relating to insurance fraud.
(j)(i)A pharmacy benefit manager shall not retaliate against a pharmacist or pharmacy based on the pharmacists or pharmacys exercise of a right or remedy under this chapter. Prohibited retaliation includes any of the following:
(1)Terminating or refusing to renew a contract with the pharmacist or pharmacy.
(2)Subjecting the pharmacist or pharmacy to increased audits.
(3)Failing to promptly pay the pharmacist or pharmacy money owed by the pharmacy benefit manager to the pharmacist or pharmacy.
17055.(a)Except as permitted under existing law, a pharmacy benefit manager shall not unreasonably obstruct or interfere with a patients right to timely access a prescription drug or device that has been legally prescribed for that patient at a contract pharmacy of their choice.
(b)A pharmacy benefit manager shall not make, disseminate, or cause or permit the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
(c)The department may investigate referrals provided by the California State Board of Pharmacy.
17060.Commencing January 1, 2026, a pharmacy benefit manager shall offer a health care service plan or health insurer the option of a non-spread pricing contract.17065.(a)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with manufacturers who that do business in California that expressly or implicitly restrict, restricts, or implements implicit or express exclusivity for, those manufacturers drugs, medical devices, or other products.
(b)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with pharmacies or pharmacy administrative services organizations who services administration organizations that do business in California that expressly or implicitly restrict, or impose restricts, or imposes implicit or express exclusivity on, nonaffiliated pharmacies ability to contract with employers, health insurers, and health care service plans.
4.Enforcement17070.(a)In addition to any of the grounds to deny a license listed in Section 17010, the department may deny, suspend, or revoke the license of a pharmacy benefit manager if the department finds that any of the following are true:
(1)The pharmacy benefit manager has violated a statute or regulation applicable to the pharmacy benefit manager.
(2)The pharmacy benefit manager has refused to be examined or to produce its accounts, records, and files for examination by the department, or an individual responsible for the conduct of affairs of the pharmacy benefit manager has refused to give information with respect to its affairs or has refused to perform any other legal obligation as to an examination required by the department.
(3)The pharmacy benefit manager has, without just cause, exhibited a pattern or practice of refusing to pay proper claims or perform services arising under its contracts or has, without just cause, caused enrollees or insureds to accept less than the amount due them.
(4)The pharmacy benefit manager is required under this chapter to have a license and fails to continue to meet the qualifications for licensure during its active licensure.
(5)The pharmacy benefit manager failed to file a timely report as required by Section 17025.
(6)The pharmacy benefit manager is not financially viable.
(b)If a hearing is held pursuant to this section, it shall be conducted in accordance with the Administrative Procedure Act (Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code).
17075.(a)The department may examine or audit any books and records of a pharmacy benefit manager pursuant to Article 4 (commencing with Section 729) of Chapter 1 of Part 2 of Division 1 to determine if the pharmacy benefit manager is in compliance with this division. A pharmacy benefit manager shall pay for reasonable expenses for any examinations or audits conducted pursuant to this section. Those payments shall be deposited into the Pharmacy Benefit Manager Account.
(b)The department may produce and disclose publicly an examination report describing any act or omission committed by a pharmacy benefit manager that violates this division.
(c)(1)The department shall establish a retention schedule for all records, books, papers, and other data on file with the department related to the enforcement of this chapter.
(2)The department shall not order the destruction or other disposal of a record, book, paper, or other data that is required to be filed or kept on file with the department during the retention period.
(d)Section 735.5 does not prevent disclosure of information and data acquired during an examination to the Attorney General to investigate, prosecute, or defend any legal claim or cause of action, or to use the information and data in any court or proceeding of law. In any matter arising under this chapter, the department may provide to the Attorney General information related to competition and obtain an opinion from a consultant or consultants with the expertise to assess the competitive impact of the matter.
17080.(a)(1)Notwithstanding Section 4441 of the Business and Professions Code and Chapter 2.2 Article 6.1 (commencing with Section 1385.001) of Chapter 2.2 of Division 2 of the Health and Safety Code, a pharmacy benefit manager shall have a duty and obligation to the health care service plan or the health insurer plan, the subscriber and enrollee covered by the health care service plan contract, the health insurer, and the policyholder and the insured of the health insurance policy, and shall perform its services with care, skill, prudence, diligence, and professionalism, and for the best interests of the health care service plan or health insurer. professionalism.
(2)A pharmacy benefit manager shall disclose to a health insurer or health care service plan information of clinical efficacy and clinical evidence regarding the inclusion, exclusion, or limitation of prescription drugs in the formulary.
(b)Any pharmacy benefit manager that violates this division shall, in addition to any other penalty provided by law, be liable for restitution to any enrollee or insured harmed by the violation.
(c)If a violation of this section, or Section 17030, 17035, or 17045 17030 or 17035 is alleged and is at issue in any proceeding in the Supreme Court, a state court of appeal, or the appellate division of a superior court, a person filing a brief or petition with the court in that proceeding shall serve, within three days of filing with the court, a copy of the brief or petition on the Attorney General at a service address designated on the Attorney Generals internet website for service of papers under this section, or, if a service address is not designated, at the Attorney Generals office in San Francisco. Upon the Attorney Generals request, a person who has filed any other document, including all or a portion of the appellate record, with the court in addition to a brief or petition shall provide a copy of that document, without charge, to the Attorney General within five days of the request. The time for service may be extended by the Chief Justice of California or presiding justice or judge for good cause shown. No judgment or relief, temporary or permanent, shall be granted or opinion issued until proof of service of the brief or petition on the Attorney General is filed with the court.
(d)This section does not alter or abrogate the departments authority to enforce this division.
17085.(a)Any person that violates this division shall be subject to an injunction and liable for a civil penalty of not less than one thousand dollars ($1,000) or more than seven thousand five hundred dollars ($7,500) for each violation which shall be assessed and recovered in a civil action brought in the name of the people of the State of California by the Attorney General.
(b)(1)A violation of Section 17030, 17035, or 17045 17030 or 17035 is an act of unfair competition within the meaning of Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code. However, this article paragraph does not limit any other statutory or common law rights or remedies, including liability pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code).
(2)This subdivision does not alter or abrogate the departments authority to enforce this division.
(c)Notwithstanding any other law, the Attorney General shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this division and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
(d)The remedies or penalties provided by this chapter are cumulative to each other and to the remedies or penalties available under all other laws of this state.
17086.The provisions of this division are severable. If any provision of this division or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
17090.Beginning on or after January 1, 2026, the fines and administrative penalties collected pursuant to this chapter shall be deposited into the Pharmacy Benefit Manager Fines and Penalties Account, which is hereby established in the General Fund.
SEC. 8.The authority of the Attorney General to maintain or restore competitive, fair, and honest markets and prosecute violations of state and federal antitrust, consumer protection, unfair competition, unfair practices, or any other related law shall not be narrowed, abrogated, or otherwise altered by this act.
SEC. 9.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 10.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SEC. 11.The Legislature finds and declares that Section 7 of this act, which adds Sections 17025, 17050, and 17075 to the Insurance Code, imposes a limitation on the publics right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 5 of Article I of the California Constitution. Pursuant to that constitutional provision, the Legislature makes the following findings to demonstrate the interest protected by this limitation and the need for protecting that interest:
In order to protect the confidentiality of information received by state agencies from pharmacy benefit managers, it is necessary that those documents be presumptively confidential, except as otherwise provided by law.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an enrollees cost sharing at an amount that exceeds the actual rate paid for the prescription drug. drug, and shall include cost-sharing provisions consistent with Section 4079 of the Business and Professions Code.
(b)(1)Commencing January 1, 2025, if a preexisting contract between 2026, a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) of the Insurance Code and shall offer a health care service plan authorizes spread pricing, as that term is defined by Section 17000 of the Insurance Code, any subsequent amendment or renewal of that contract shall not authorize spread pricing. the option of a non-spread pricing contract.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) of the Insurance Code and a health care service plan shall not authorize spread pricing, as that term is defined by Section 17000 of the Insurance Code. SEC. 2.Section 1367.243 of the Health and Safety Code is amended to read:1367.243.(a)(1)A health care service plan that reports rate information pursuant to Section 1385.03 or 1385.045 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(vi)The aggregate income from pharmacy benefit management services fees that pharmacy benefit managers receive.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health care service plans.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2019, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 1385.045.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 3.Section 1367.2431 is added to the Health and Safety Code, immediately following Section 1367.243, to read:1367.2431.In preparing the report required as set forth in subdivision (b) of Section 1367.243, the department shall ensure that the information regarding rebates is aggregated and does not reveal information specific to individual health care service plans or manufacturers, or reveal any manufacturers individual or aggregated discounted prices for a drug.
SEC. 3.SEC. 4.Section 10123.2045 is added to the Insurance Code, immediately following Section 10123.204, to read:10123.2045.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an insureds cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
(b)(1)Commencing January 1, 2025, if a preexisting contract between 2026, a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) and shall offer a health insurer authorizes spread pricing, as that term is defined by Section 17000, any subsequent amendment or renewal of that contract shall not authorize spread pricing. the option of a non-spread pricing contract.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) and a health insurer shall not authorize spread pricing, as that term is defined by Section 17000.SEC. 4.SEC. 5.Section 10123.205 of the Insurance Code is amended to read:10123.205.(a)(1)A health insurer that reports rate information pursuant to Section 10181.3 or 10181.45 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(vi)The aggregate income from pharmacy benefit management services fees that pharmacy benefit managers receive.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health insurers.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2018, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 6.Section 10123.2051 is added to the Insurance Code, immediately following Section 10123.205, to read:10123.2051.In preparing the report required as set forth in subdivision (b) of Section 10123.205, the department shall ensure that the information regarding rebates is aggregated and does not reveal information specific to individual health insurers or manufacturers, or reveal any manufacturers individual or aggregated discounted prices for a drug.
SEC. 5.SEC. 7.Division 6 (commencing with Section 17000) is added to the Insurance Code, to read:6.Regulation of Pharmacy Benefit Managers1.General Provisions17000.For purposes of this division:
(a)Affiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a pharmacy benefit manager.
(b)Claim means a request for payment for administering, filling, or refilling a drug or for providing a pharmacy service or a medical supply or device to an enrollee or insured.
(c)Contract pharmacy means a retail pharmacy or other pharmacy that contracts directly or through a pharmacy services administration organization with a pharmacy benefit manager.
(d)Drug has the same meaning as defined in Section 4025 of the Business and Professions Code.
(e)Financially viable means that either of the following conditions is met:
(1)The pharmacy benefit manager has received an unqualified opinion from an independent public accountant, as described in Section 260.613(b) of Title 10 of the California Code of Regulations.
(2)If an independent public accountant opinion is not obtained, the pharmacy benefit manager remains solvent after adjusting for goodwill and intangible assets.
(f)Group purchasing organization means a third party or affiliated person employed by, contracted with, or otherwise utilized by a pharmacy benefits manager to negotiate, obtain, or otherwise procure rebates from drug manufacturers or wholesalers.
(f)(g)Health care service plan means an entity licensed pursuant to the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code).
(g)(h)Health insurer means a disability insurer that issues health insurance, as defined in Section 106.
(h)(i)Manufacturer has the same meaning as defined in Section 4033 of the Business and Professions Code.
(i)(j)Nonaffiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, does not control, is not controlled by, and is not under common control with, a pharmacy benefit manager.
(j)(k)Passthrough pricing model means a payment model used by a pharmacy benefit manager in which the payments made by the health care service plan or health insurer client to the pharmacy benefit manager for the covered outpatient drugs are both of the following:
(1)Equivalent to the payments the pharmacy benefit manager makes to a pharmacy or provider for those drugs, including any contracted professional dispensing fee between the pharmacy benefit manager and its network of pharmacies. That dispensing fee would be paid if the pharmacy benefits plan or program health care service plan or health insurer was making the payments directly.
(2)Passed through in their entirety by the health care service plan or health insurer client or by the pharmacy benefit manager to the pharmacy or provider that dispenses the drugs, and the payments are made in a manner that is not offset by any reconciliation.
(k)(l)Person has the same meaning as defined in Section 4035 of the Business and Professions Code.
(l)(m)Personal representative means an individual who has authority to make a health care decision on behalf of another individual pursuant to Division 4.7 (commencing with Section 4600) of the Probate Code.
(m)(n)Pharmacist has the same meaning as defined in Section 4036 of the Business and Professions Code.
(n)(o)Pharmacist services means products, goods, and services, or any combination of products, goods, and services, provided as a part of the practice of pharmacy.
(o)(p)Pharmacy has the same meaning as defined in Section 4037 of the Business and Professions Code.
(p)(q)Pharmacy benefit management fee means a flat, defined, dollar-amount fee that covers the cost of providing one or more pharmacy benefit management services and that does not exceed the value of the service or services actually performed by the pharmacy benefit manager. The value of the service or services shall be based on the value to the health insurer or health care service plan. A pharmacy benefit management fee may not be based on or contingent upon any of the following:
(1)The acquisition cost or any other price metric of a drug.
(2)The amount of savings, rebates, or other fees charged, realized, or collected by, or generated based on the activity of, the pharmacy benefit manager, that is retained by the pharmacy benefit manager.
(3)The amount of premiums, deductibles, or other cost sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.
(q)(r)Pharmacy benefit management service means all of the following:
(1)Negotiating the price of prescription drugs, including negotiating and contracting for direct or indirect rebates, discounts, or other price concessions.
(2)Managing any aspect of a prescription drug benefit, including, but not limited to, developing or managing a drug formulary, including utilization management or quality assurance programs, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with pharmacies, management of retail, mail order, or specialty pharmacies, controlling the cost of covered prescription drugs, managing or providing data relating to the prescription drug benefit, or the provision of services related thereto.
(3)Performing any administrative, managerial, clinical, pricing, financial, reimbursement, data administration or reporting, or billing service.
(4)Other services as the department may define in regulation.
(r)(s)Pharmacy benefit manager means a person, business, or other entity that, either directly or indirectly, manages the prescription drug coverage, including, but not limited to, the following: clinical or other formulary or preferred drug list development or management; the processing and payment of claims for prescription drugs; the negotiation or administration of rebates, discounts, payment differentials, or other incentives; the inclusion of particular prescription drugs in a particular category or to promote the purchase of particular prescription drugs; the performance of drug utilization review; the processing of drug prior authorization requests; the adjudication of appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. Pharmacy benefit manager does not include either any of the following:
(1)A health care service plan that is part of a fully integrated delivery system in which enrollees primarily use pharmacies that are entirely owned and operated by the health care service plan, and the health care service plans enrollees may use any pharmacy in the health care service plans network that has the ability to dispense the medication or provide the services.
(2)An entity providing services pursuant to a contract authorized by Section 4600.2 of the Labor Code.
(3)A health care service plan or its contracted provider, as defined in subdivision (i) of Section 1345 of the Health and Safety Code, performing the services described in this subdivision.
(4)A health insurer.
(5)A city or county that develops or manages drug coverage programs for uninsured patients for which no reimbursement is received.
(6)An entity exclusively providing services to patients covered by Part 418 (commencing with Section 418.1) of Subchapter B of Chapter IV of Title 42 of the Code of Federal Regulations.
(s)(t)Pharmacy services administration organization means an entity that provides contracting and other administrative services relating to prescription drug benefits to pharmacies.
(t)(u)Rebate means a formulary discount or remuneration attributable to the use of prescription drugs that is paid by a manufacturer or third party, directly or indirectly, to a pharmacy benefit manager after a claim has been adjudicated at a pharmacy. Rebate does not include a fee, including a bona fide service fee or administrative fee, that is not a formulary discount or remuneration.
(u)(v)Spread pricing means the model of prescription drug pricing in which a pharmacy benefit manager charges a health care service plan or health insurer a contracted price for prescription drugs, and the contracted price for the prescription drugs differs from the amount the pharmacy benefit manager directly or indirectly pays the pharmacist or pharmacy.
(v)(w)Third party means a person that is not an enrollee, insured, or pharmacy benefit manager.
17004.5.Any activity conducted by a pharmacy benefit manager, as defined in this division, shall be construed as the business of insurance.
17005.The department shall adopt regulations necessary to implement this division. division, including, but not limited to, regulations regarding group purchasing organizations and the use of those organizations.
(a)Until January 1, 2028, necessary regulations for the purpose of implementing this division may be adopted as emergency regulations in accordance with the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The adoption of emergency regulations pursuant to this section shall be deemed to be an emergency and necessary for the immediate preservation of the public peace, health and safety, or general welfare.
(b)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, including subdivisions (e) and (h) of Section 11346.1, an emergency regulation adopted pursuant to this section shall be repealed by operation of law unless the adoption, amendment, or repeal of the regulation is promulgated by the department pursuant to Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code within five years of the initial adoption of the emergency regulation.
(c)A regulation adopted pursuant to this section shall be discussed by the department during at least one public stakeholder meeting before the department adopts the rule or regulation.
17006.(a)The department shall establish procedures for receiving, investigating, tracking, and publicly reporting consumer complaints against pharmacy benefit managers.
(b)The department shall publish on its internet website a record of consumer complaints against a pharmacy benefit manager that have been determined by the department to be justified. Complaint data shall not be published unless it has been provided to the pharmacy benefit manager in accordance with subdivision (c) of Section 12921.1.
2.Licensing17010.(a)The department shall license and regulate pharmacy benefit managers. The department shall have the authority to enforce this division and Chapter 9.5 (commencing with Section 4430) of Division 2 of the Business and Professions Code and Article 3 (commencing with Section 127470) of Chapter 2.5 of Part 2 of Division 107 of the Health and Safety Code.
(b)No later than January 1, 2027, a pharmacy benefit manager that provides services in this state shall apply for a license to operate as a pharmacy benefit manager from the department. A pharmacy benefit manager shall maintain its license in good standing.
(c)An application for a pharmacy benefit manager license shall be submitted in a form and manner determined by the department, and shall be signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the application form and any attachments are correct. The application shall include all of the following:
(1)A nonrefundable application fee in an amount established by the department under Section 17015.
(2)A list of every health care service plan or health insurer on behalf of which the pharmacy benefit manager contracts with a pharmacy or a pharmacy services administration organization to provide health services to individuals covered by the health care service plan or health insurer.
(3)A statement indicating all jurisdictions where the applicant has an application pending or has been registered, licensed, or otherwise certified to transact business as a pharmacy benefit manager.
(4)A statement indicating whether either of the following has occurred:
(A)The pharmacy benefit manager or any individual responsible for the conduct of the affairs of the pharmacy benefit manager has had a pharmacy benefit manager certificate of authority or license denied or revoked for cause in another state.
(B)Any individual responsible for the conduct of the affairs of the pharmacy benefit manager has been convicted of, or has entered a plea of guilty or nolo contender contendere to a felony without regard to whether adjudication was withheld.
(5)A copy of a power of attorney duly executed by the pharmacy benefit manager if not domiciled in this state, appointing the department, the departments successors in office, and the departments authorized deputies as the attorney of the pharmacy benefit manager in and for this state, on whom process in any legal action or proceeding against the pharmacy benefit manager on a cause of action arising in this state may be served.
(6)The names, addresses, official positions, and professional qualifications of each individual who is responsible for the conduct of the affairs of the pharmacy benefit manager.
(7)A copy of a recent financial statements showing the pharmacy benefit managers assets, liabilities, and sources of financial support that the department determines are sufficient to show that the pharmacy benefit manager is financially viable. If the pharmacy benefit managers financial statements are prepared by an independent accountant public accountant, a copy of the most recent regular financial statement satisfies the requirement to show financial viability unless the department determines that additional or more recent financial information is required for the proper administration of this act.
(8)A document providing the names, addresses, dates of birth, social security numbers, official positions, and professional qualifications of each individual who owns, legally or the information as to each person beneficially, 10 percent or more in equity in the entity interested therein or any person with management or control over the pharmacy benefit manager.
(9)A copy of all basic organizational and governing documents of the pharmacy benefit manager, including, but not limited to, the articles of incorporation, bylaws, articles of association, trade name certificate, and other similar documents and all amendments to those documents.
(10)A description of the pharmacy benefit manager, its services, facilities, and personnel.
(11)A document in which the pharmacy benefit manager confirms that its business practices and each ongoing contract comply with this chapter.
(12)Any other relevant information required by the department.
(d)The individual responsible for the conduct or affairs of the pharmacy benefit manager and any of the organizations partners, members, controlling persons, officers, directors, and managers shall comply with the background check requirements as required by the commissioner.
(e)Within 30 days after a modification of the information or documents submitted pursuant to subdivision (b), a pharmacy benefit manager shall file a notice of the modification with the department.
(f)An applicant for a pharmacy benefit manager license or licensed pharmacy benefit manager shall be subject to Sections 1702 and 1703, Article 6.5 (commencing with Section 790) of Chapter 1 of, and Article 3 (commencing with Section 1631), Article 4 (commencing with Section 1652), Article 6 (commencing with Section 1666), Article 10 (commencing with Section 1708), Article 12 (commencing with Section 1724), and Article 13 (commencing with Section 1737) of Chapter 5 of Part 2 of Division 1, and Article 1 (commencing with Section 12919), Article 3.5 (commencing with Section 12962), and Article 4 (commencing with Section 12970) of Chapter 2 of Division 3, excluding Sections 1634, 1635, 1640, 1642, 1647.5, 1649.5, 1661, 1725, 1725.5, 1726, 1728, 1729.5, 1730.5, 1730.6, 1731, 1732, and 1735.5.
(g)A pharmacy benefit manager shall not operate in this state unless it is licensed pursuant to this division.
(h)This division does not abrogate compliance by a pharmacy benefit manager with any applicable requirements of Chapter 5A (commencing with Section 1759) of Part 2 of Division 1.
(i)A violation of this division constitutes an unfair practice under Article 6.5 (commencing with Section 790) of Chapter 1 of Part 2 of Division 1.
(j)Notwithstanding any other law, the commissioner shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
17015.(a)A pharmacy benefit manager license applicant shall pay the initial application fee as determined by the department. A license shall be renewed every two years, beginning on the last calendar day of the month in which the initial license was issued. The license is nontransferable.
(b)To renew a pharmacy benefit manager license, an applicant shall submit to the department both of the following:
(1)A renewal application in a form and manner determined by the department that is signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the renewal form are correct.
(2)A renewal schedule and fee as determined by the department.
(c)(1)A pharmacy benefit manager license shall expire if a complete renewal filing and fee is not received by the due date established by the department.
(2)The application for renewal of an expired license may be filed after the expiration date and until that same month and day of the next succeeding year. The fee for a renewal application under this subdivision shall be the fee specified in subdivision (d) and a delinquent fee in the amount specified for a one-year period in subdivision (d) for the filing. Each licensee shall be subject to payment of delinquent fees under this section.
(d)An application fee of ____ dollars ($____), eleven thousand one hundred sixty dollars ($11,160), and for each year of the two-year license term thereafter, a fee of five thousand sixty dollars ($5,060), for a total renewal fee of ____ dollars ($____). ten thousand one hundred twenty dollars ($10,120). The commissioner may increase or decrease fees, and schedule fees and charges as set forth in Section 12978.
17020.Beginning no earlier than January 1, 2026, the fees for a pharmacy benefit manager initial license and renewal application shall be sufficient to fund the departments duties in relation to responsibilities under this chapter, but in no case shall the fee exceed the reasonable regulatory cost to administer the act. Fees received under the act shall be deposited into the Pharmacy Benefit Manager Account, which is hereby created in the Insurance Fund, and shall be subject to an annual appropriation each fiscal year for the support of the Department of Insurance related to the licensing and regulation of pharmacy benefit managers.
3.Licensee Duties17025.(a)On or before July 1, 2028, and on or before each July 1 thereafter, a pharmacy benefit manager shall file with the department a report that contains all of the information required by subdivision (e) of Section 4441 of the Business and Professions Code from the preceding calendar year.
(b)On or before January 1, 2029, and on or before each January 1 thereafter, the department shall prepare a report based on the information received by the department pursuant to subdivision (a) and shall publish the report on its internet website. The report shall contain aggregate data and shall exclude any information that the department determines would cause financial, competitive, or proprietary harm to a pharmacy benefit manager.
(c)On or before July 1, 2027, and on or before each July 1 thereafter, a pharmacy benefit manager shall report to the department all of the following information:
(1)A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. For each drug that falls into the above categories, the pharmacy benefit manager shall report both of the following:
(A)The pharmacy type used to fill the drug prescription, such as integrated, chain, independent, specialty, and mail order pharmacies.
(B)Pricing and rebate information, including the net price paid, the amount of rebate the pharmacy benefit manager receives from the manufacturer, the amount of rebate the pharmacy benefit manager passes to the health care service plan or health insurer, the amount the health care service plan or health insurer pays the pharmacy benefit manager, and the amount the pharmacy benefit manager pays the pharmacy.
(C)For each list in subparagraphs (A) and (B), all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(vi)Deidentified claims level information in electronic format that allows the commissioner to sort and analyze the following information for each claim, whether the claim required prior authorization.
(vii)The amount paid to the pharmacy for each prescription, net of the aggregate amount of fees or other assessments imposed on the pharmacy, including point-of-sale and retroactive charges. These data are confidential pursuant to subdivision (e).
(2)All of the following information in the aggregate:
(A)The purchasers purchasers, as described in paragraphs (1) to (4), inclusive, of subdivision (a) of Section 127675 of the Health and Safety Code, with which the pharmacy benefit manager contracts, the scope of services provided to the purchasers, and the number of enrollees, insureds, and plan members served.
(B)Pharmacy benefit manager revenue, including revenue from manufacturers, purchasers, and other revenue.
(C)Pharmacy benefit manager expenses, including payments to pharmacies, claims processing, special programs, administration, and other expenses.
(3)The following regarding group purchasing organizations:
(A)The identity of any group purchasing organization that the pharmacy benefit manager employed, contracted with, utilized, or otherwise has any affiliation with.
(B)A copy of any contract with an identified group purchasing organization.
(C)The aggregate financial benefit derived from the use of the identified group purchasing organizations.
(d)The department shall compile the information reported pursuant to subdivision (c) into a report for the public and Legislature that demonstrates the overall impact of pharmacy benefit managers on drug costs. The data in the report shall be aggregated and shall not reveal information specific to individual purchasers. purchasers or individual manufacturers, or reveal a manufacturers individual or aggregated discounted prices for a drug.
(1)On or before January 1, 2029, and on or before each January 1 thereafter, the department shall publish the report on its internet website.
(2)The department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(3) The department may consolidate the reports required by this section.
(e)Except for the reports required pursuant to subdivisions (b) and (d), the information submitted to the department pursuant to subdivisions (a) and (c) shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). This section does not prevent disclosure to the Attorney General to investigate, prosecute, or defend any legitimate legal claim or cause or action, or to use the reports in any court or proceeding of law.
(f)For purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
17030.(a)A pharmacy benefit manager shall not impose any requirements, conditions, or exclusions that discriminate against a nonaffiliated pharmacy in connection with dispensing drugs.
(b)Discrimination prohibited pursuant to subdivision (a) includes all of the following:
(1)Terms or conditions applied to nonaffiliated pharmacies based on their status as a nonaffiliated pharmacy.
(2)Refusing to contract with or terminating a contract with a nonaffiliated pharmacy on the basis that the pharmacy is a nonaffiliated pharmacy or for reasons other than those that apply equally to affiliated pharmacies.
(3)Retaliation against a nonaffiliated pharmacy based on its exercise of any right or remedy under this chapter.
(4)Reimbursing a nonaffiliated pharmacy less for a pharmacy service than the pharmacy benefit manager would reimburse an affiliated pharmacy for the same pharmacy service.
(c)This division does not preclude a pharmacy benefit manager or a purchaser of pharmacy benefit manager services from establishing a network of contracting pharmacies.
17035.A pharmacy benefit manager shall not do any of the following:
(a)Require an enrollee or insured to use only an affiliated pharmacy if there are nonaffiliated pharmacies in the network.
(b)Financially induce an enrollee, insured, or prescriber to transfer a prescription only to an affiliated pharmacy if there are nonaffiliated pharmacies in the network.
(c)Require a retail nonaffiliated pharmacy to transfer a prescription to a retail an affiliated pharmacy if there are nonaffiliated pharmacies in the network. This paragraph does not prevent a purchaser or pharmacy benefit manager from offering and communicating to enrollees or insureds financial incentives to use a particular pharmacy, such as lower copays or costs copays, coinsurance, or any other cost sharing for a prescription when the prescription is dispensed.
(d)Unreasonably restrict an enrollee or insured from using a particular contracted retail pharmacy for the purpose of receiving pharmacist services covered by the enrollees or insureds contract or policy.
(e)Communicate to an enrollee or insured, in any manner, that the enrollee or insured is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other nonaffiliated pharmacies that have the ability to dispense the medication or provide the services and are also in network.
(f)Deny a nonaffiliated contract pharmacy the opportunity to participate in a pharmacy benefit manager network as preferred participation status if the pharmacy is willing to accept the same terms and conditions that the pharmacy benefit manager has established for affiliated pharmacies as a condition of preferred network participation status.
17040.(a)A contract issued, amended, or renewed on or after January 1, 2025, between a nonaffiliated retail pharmacy and a pharmacy benefit manager shall not prohibit the retail pharmacy from offering either of the following as an ancillary service of the retail pharmacy:
(1)The delivery of a prescription drug by mail or common carrier to a patient or personal representative on request of the patient or personal representative if the request is made before the drug is delivered.
(2)The delivery of a prescription to a patient or personal representative by an employee or contractor of the retail pharmacy.
(b)Except as otherwise provided in a contract described in subdivision (a), the retail pharmacy shall not charge a pharmacy benefit manager for the delivery service described in subdivision (a). This section does not prohibit the use of remote pharmacies, secure locker systems, or other types of pickup stations if those services are otherwise permitted by law.
(c)Contracts entered into pursuant to this section shall be open for inspection by the department.
17045.A pharmacy benefit manager shall not require more than two accreditations from an independent accrediting organization for pharmacists and pharmacies to dispense specialty drugs and shall make every effort to ensure that enhanced standards are not imposed to dispense specialty drugs beyond those related to the safety and competency necessary to comply with requirements for dispensing specified medications and providing optimal patient care.
17050.(a)A pharmacy benefit manager shall not derive income from pharmacy benefit management services provided to an insurer or health care service plan in this state except for income derived from a flat, defined, dollar-amount pharmacy benefit management fee for pharmacy benefit management services provided. The amount of any pharmacy benefit management fee shall be set forth in the agreement between the pharmacy benefit manager and the insurer or health care service plan. The pharmacy benefit manager shall disclose the amount and types of the pharmacy benefit management service fees to the health insurer or health care service plan.
(b)A pharmacy benefit manager shall use offer a passthrough pricing model. model, in addition to other pricing options offered to a health care service plan or health insurer.
(c)Pharmacy benefit managers shall pass 100 percent of all prescription drug manufacturer rebates received to the health care service plan, health insurer, or program, plan or health insurer if the contractual arrangement delegates the negotiation of rebates to the pharmacy benefit manager, for the sole purpose of offsetting defined cost sharing, deductibles, and coinsurance contributions and reducing premiums of enrollees or insureds.
(d)This section does not preclude a health insurer or health care service plan from paying performance bonuses to a pharmacy benefit manager based on savings to the health care service plan or health insurer that affects rated paid by the enrollee and insured or subscriber and policy holder, as long as the performance bonus is not based or contingent on any of the following:(1)The acquisition cost or any other price metric of a drug.(2)The amount of savings, rebates, or other fees charged, realized, or collected by, or generated based on the activity of, the pharmacy benefit manager, that is retained by the pharmacy benefit manager.(3)The amount of premiums, deductibles, or other cost sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.(4)Compensation arrangements governed by this section shall be open for inspection by the department.(d)(1)A pharmacy benefit manager shall disclose to the department all types of pharmacy benefit management service fees that it receives, including all of the following:
(A)Pharmacy benefit management service fees related to the acquisition cost or any other price metric of a drug.
(B)Pharmacy benefit management service fees related to the amount of additional savings, additional rebates, or other fees charged, realized or collected by, or generated based on the activity of the pharmacy benefit manager, that is retained by the pharmacy manager.
(C)The amount of premiums, deductibles, or other cost sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.
(2)Compensation arrangements governed by this section shall be open for inspection by the department.
(3)The department shall keep confidential all information it receives pursuant to this subdivision, and the information shall not be subject to disclosure, including disclosure under the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code).
(e)A pharmacy benefit manager shall not make or permit any reduction of payment for pharmacist services by a pharmacy benefit manager or a health insurer or health care service plan directly or indirectly to a pharmacy under a reconciliation process to an effective rate of reimbursement, including without limitation generic effective rates, brand effective rates, direct and indirect remuneration fees, or any other reduction or aggregate reduction of payment.
(f)A claim or aggregate of claims for pharmacist services shall not be directly or indirectly retroactively denied or reduced after adjudication of the claim or aggregate of claims unless any of the following have occurred:
(1)The original claim was submitted fraudulently.
(2)The original claim payment was incorrect because the pharmacy or pharmacist had already been paid for the pharmacist services.
(3)The pharmacist services were not properly rendered by the pharmacy or pharmacist.
(g)A pharmacy benefit manager shall not reverse and resubmit the claim of a contract pharmacy under any of the following circumstances:
(1)Without prior written notification to the contract pharmacy.
(2)Without just cause or attempt to first reconcile the claim with the pharmacy.
(3)More than 90 days after the claim was first affirmatively adjudicated.
(h)A pharmacy benefit manager shall not charge a pharmacy or pharmacist a fee to process a claim electronically.
(i)The termination of a contract with a nonaffiliated pharmacy by a pharmacy benefit manager shall not release the pharmacy benefit manager from the obligation to make a payment due to the pharmacy for an affirmatively adjudicated claim unless payments are withheld because of an investigation relating to insurance fraud.
(j)A pharmacy benefit manager shall not retaliate against a pharmacist or pharmacy based on the pharmacists or pharmacys exercise of a right or remedy under this chapter. Prohibited retaliation includes any of the following:
(1)Terminating or refusing to renew a contract with the pharmacist or pharmacy.
(2)Subjecting the pharmacist or pharmacy to increased audits.
(3)Failing to promptly pay the pharmacist or pharmacy money owed by the pharmacy benefit manager to the pharmacist or pharmacy.
17055.(a)Except as permitted under existing law, a pharmacy benefit manager shall not unreasonably obstruct or interfere with a patients right to timely access a prescription drug or device that has been legally prescribed for that patient at a contract pharmacy of their choice.
(b)A pharmacy benefit manager shall not make, disseminate, or cause or permit the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
(c)The department may investigate referrals provided by the California State Board of Pharmacy.
17060.Commencing January 1, 2025, a pharmacy benefit manager shall not conduct spread pricing in this state. If a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizes spread pricing, any subsequent amendment or renewal of that contract shall not contain that authorization. Any such spread pricing terms shall be void on and after January 1, 2028.17060.Commencing January 1, 2026, a pharmacy benefit manager shall offer a health care service plan or health insurer the option of a non-spread pricing contract.
17065.(a)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with manufacturers who do business in California that expressly or implicitly restrict, or implements implicit or express exclusivity for, those manufacturers drugs, medical devices, or other products.
(b)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with pharmacies or pharmacy administrative services organizations who do business in California that expressly or implicitly restrict, or impose implicit or express exclusivity on, nonaffiliated pharmacies ability to contract with employers, health insurers, and health care service plans.
4.Enforcement17070.(a)In addition to any of the grounds to deny a license listed in Section 17010, the department may deny, suspend, or revoke the license of a pharmacy benefit manager if the department finds that any of the following are true:
(1)The pharmacy benefit manager has violated a statute or regulation applicable to the pharmacy benefit manager.
(2)The pharmacy benefit manager has refused to be examined or to produce its accounts, records, and files for examination by the department, or an individual responsible for the conduct of affairs of the pharmacy benefit manager has refused to give information with respect to its affairs or has refused to perform any other legal obligation as to an examination required by the department.
(3)The pharmacy benefit manager has, without just cause, exhibited a pattern or practice of refusing to pay proper claims or perform services arising under its contracts or has, without just cause, caused enrollees or insureds to accept less than the amount due them.
(4)The pharmacy benefit manager is required under this chapter to have a license and fails to continue to meet the qualifications for licensure during its active licensure.
(5)The pharmacy benefit manager failed to file a timely report as required by Section 17025.
(6)The pharmacy benefit manager is not financially viable.
(b)If a hearing is held pursuant to this section, it shall be conducted in accordance with the Administrative Procedure Act (Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code).
17075.(a)The department may examine or audit any books and records of a pharmacy benefit manager pursuant to Article 4 (commencing with Section 729) of Chapter 1 of Part 2 of Division 1 to determine if the pharmacy benefit manager is in compliance with this division. A pharmacy benefit manager shall pay for reasonable expenses for any examinations or audits conducted pursuant to this section. Those payments shall be deposited into the Pharmacy Benefit Manager Account.
(b)The department may produce and disclose publicly an examination report describing any act or omission committed by a pharmacy benefit manager that violates this division.
(c)(1)The department shall establish a retention schedule for all records, books, papers, and other data on file with the department related to the enforcement of this chapter.
(2)The department shall not order the destruction or other disposal of a record, book, paper, or other data that is required to be filed or kept on file with the department during the retention period.
(d)Section 735.5 does not prevent disclosure of information and data acquired during an examination to the Attorney General to investigate, prosecute, or defend any legal claim or cause of action, or to use the information and data in any court or proceeding of law. In any matter arising under this chapter, the department may provide to the Attorney General information related to competition and obtain an opinion from a consultant or consultants with the expertise to assess the competitive impact of the matter.
17080.(a)(1)Notwithstanding Section 4441 of the Business and Professions Code and Chapter 2.2 (commencing with Section 1385.001) of Division 2 of the Health and Safety Code, a pharmacy benefit manager shall have a duty and obligation to the health care service plan of the enrollee or subscriber covered by the health care service plan contract, or the health insurer of the insured or policyholder of the policy of health insurance, and shall perform its services with care, skill, prudence, diligence, and professionalism, and for the best interests of the health care service plan or health insurer. When there is a conflict between the pharmacy benefit managers duty or obligation under this subdivision to the individual enrollee or insured and any other party, the duty or obligation to the individual enrollee or insured shall be primary.
(2)A pharmacy benefit manager shall disclose to a health insurer or health care service plan information of clinical efficacy and clinical evidence regarding the inclusion, exclusion, or limitation of prescription drugs in the formulary.
(b)Any pharmacy benefit manager that violates this division shall, in addition to any other penalty provided by law, be liable for restitution to any enrollee or insured harmed by the violation.
(c)If a violation of this section, or Section 17030, 17035, or 17045 is alleged and is at issue in any proceeding in the Supreme Court, a state court of appeal, or the appellate division of a superior court, a person filing a brief or petition with the court in that proceeding shall serve, within three days of filing with the court, a copy of the brief or petition on the Attorney General at a service address designated on the Attorney Generals internet website for service of papers under this section, or, if a service address is not designated, at the Attorney Generals office in San Francisco. Upon the Attorney Generals request, a person who has filed any other document, including all or a portion of the appellate record, with the court in addition to a brief or petition shall provide a copy of that document, without charge, to the Attorney General within five days of the request. The time for service may be extended by the Chief Justice of California or presiding justice or judge for good cause shown. No judgment or relief, temporary or permanent, shall be granted or opinion issued until proof of service of the brief or petition on the Attorney General is filed with the court.
(d)This section does not alter or abrogate the departments authority to enforce this division.
17085.(a)Any person that violates this division shall be subject to an injunction and liable for a civil penalty of not less than one thousand dollars ($1,000) or more than seven thousand five hundred dollars ($7,500) for each violation which shall be assessed and recovered in a civil action brought in the name of the people of the State of California by the Attorney General.
(b)(1)A violation of Section 17030, 17035, or 17045 is an act of unfair competition within the meaning of Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code. However, this article does not limit any other statutory or common law rights or remedies, including liability pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code).
(2)This subdivision does not alter or abrogate the departments authority to enforce this division.
(c)Notwithstanding any other law, the Attorney General shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this division and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
(d)The remedies or penalties provided by this chapter are cumulative to each other and to the remedies or penalties available under all other laws of this state.
17086.The provisions of this division are severable. If any provision of this division or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
17090.Beginning on or after January 1, 2026, the fines and administrative penalties collected pursuant to this chapter shall be deposited into the Pharmacy Benefit Manager Fines and Penalties Account, which is hereby established in the General Fund.
SEC. 6.SEC. 8.The authority of the Attorney General to maintain or restore competitive competitive, fair, and honest markets and prosecute violations of state and federal antitrust and unfair competition violations antitrust, consumer protection, unfair competition, unfair practices, or any other related law shall not be narrowed, abrogated, or otherwise altered by this act.
SEC. 7.SEC. 9.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 8.SEC. 10.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SEC. 9.SEC. 11.The Legislature finds and declares that Section 5 7 of this act, which adds Sections 17025 17025, 17050, and 17075 to the Insurance Code, imposes a limitation on the publics right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 5 of Article I of the California Constitution. Pursuant to that constitutional provision, the Legislature makes the following findings to demonstrate the interest protected by this limitation and the need for protecting that interest:
In order to protect the confidentiality of information received by state agencies from pharmacy benefit managers, it is necessary that those documents be presumptively confidential, except as otherwise provided by law.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an enrollees cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
(b)(1)Commencing January 1, 2025, if a preexisting contract between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) of the Insurance Code and a health care service plan authorizes spread pricing, as that term is defined by Section 17000 of the Insurance Code, any subsequent amendment or renewal of that contract shall not authorize spread pricing.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) of the Insurance Code and a health care service plan shall not authorize spread pricing, as that term is defined by Section 17000 of the Insurance Code.
SEC. 2.Section 1367.243 of the Health and Safety Code is amended to read:1367.243.(a)(1)A health care service plan that reports rate information pursuant to Section 1385.03 or 1385.045 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health care service plans.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2019, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 1385.045.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 3.Section 10123.2045 is added to the Insurance Code, immediately following Section 10123.204, to read:10123.2045.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an insureds cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
(b)(1)Commencing January 1, 2025, if a preexisting contract between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) and a health insurer authorizes spread pricing, as that term is defined by Section 17000, any subsequent amendment or renewal of that contract shall not authorize spread pricing.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) and a health insurer shall not authorize spread pricing, as that term is defined by Section 17000.
SEC. 4.Section 10123.205 of the Insurance Code is amended to read:10123.205.(a)(1)A health insurer that reports rate information pursuant to Section 10181.3 or 10181.45 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health insurers.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2018, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 5.Division 6 (commencing with Section 17000) is added to the Insurance Code, to read:6.Regulation of Pharmacy Benefit Managers1.General Provisions17000.For purposes of this division:
(a)Affiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a pharmacy benefit manager.
(b)Claim means a request for payment for administering, filling, or refilling a drug or for providing a pharmacy service or a medical supply or device to an enrollee or insured.
(c)Contract pharmacy means a retail pharmacy or other pharmacy that contracts directly or through a pharmacy services administration organization with a pharmacy benefit manager.
(d)Drug has the same meaning as defined in Section 4025 of the Business and Professions Code.
(e)Financially viable means that either of the following conditions is met:
(1)The pharmacy benefit manager has received an unqualified opinion from an independent public accountant, as described in Section 260.613(b) of Title 10 of the California Code of Regulations.
(2)If an independent public accountant opinion is not obtained, the pharmacy benefit manager remains solvent after adjusting for goodwill and intangible assets.
(f)Health care service plan means an entity licensed pursuant to the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code).
(g)Health insurer means a disability insurer that issues health insurance, as defined in Section 106.
(h)Manufacturer has the same meaning as defined in Section 4033 of the Business and Professions Code.
(i)Nonaffiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, does not control, is not controlled by, and is not under common control with, a pharmacy benefit manager.
(j)Passthrough pricing model means a payment model used by a pharmacy benefit manager in which the payments made by the health care service plan or health insurer client to the pharmacy benefit manager for the covered outpatient drugs are both of the following:
(1)Equivalent to the payments the pharmacy benefit manager makes to a pharmacy or provider for those drugs, including any contracted professional dispensing fee between the pharmacy benefit manager and its network of pharmacies. That dispensing fee would be paid if the pharmacy benefits plan or program was making the payments directly.
(2)Passed through in their entirety by the health care service plan or health insurer client or by the pharmacy benefit manager to the pharmacy or provider that dispenses the drugs, and the payments are made in a manner that is not offset by any reconciliation.
(k)Person has the same meaning as defined in Section 4035 of the Business and Professions Code.
(l)Personal representative means an individual who has authority to make a health care decision on behalf of another individual pursuant to Division 4.7 (commencing with Section 4600) of the Probate Code.
(m)Pharmacist has the same meaning as defined in Section 4036 of the Business and Professions Code.
(n)Pharmacist services means products, goods, and services, or any combination of products, goods, and services, provided as a part of the practice of pharmacy.
(o)Pharmacy has the same meaning as defined in Section 4037 of the Business and Professions Code.
(p)Pharmacy benefit management fee means a fee that covers the cost of providing one or more pharmacy benefit management services and that does not exceed the value of the service or services actually performed by the pharmacy benefit manager. The value of the service or services shall be based on the value to the health insurer or health care service plan.
(q)Pharmacy benefit management service means all of the following:
(1)Negotiating the price of prescription drugs, including negotiating and contracting for direct or indirect rebates, discounts, or other price concessions.
(2)Managing any aspect of a prescription drug benefit, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with pharmacies, controlling the cost of covered prescription drugs, managing or providing data relating to the prescription drug benefit, or the provision of services related thereto.
(3)Performing any administrative, managerial, clinical, pricing, financial, reimbursement, data administration, administration or reporting, or billing service.
(4)Other services as the department may define in regulation.
(r)Pharmacy benefit manager means a person, business, or other entity that, either directly or indirectly, manages the prescription drug coverage, including, but not limited to, the following: clinical or other formulary or preferred drug list development or management; the processing and payment of claims for prescription drugs, drugs; the negotiation or administration of rebates, discounts, payment differentials, or other incentives; for the inclusion of particular prescription drugs in a particular category or to promote the purchase of particular prescription drugs; the performance of drug utilization review; the processing of drug prior authorization requests; the adjudication of appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. Pharmacy benefit manager does not include either of the following:
(1)A health care service plan that is part of a fully integrated delivery system in which enrollees primarily use pharmacies that are entirely owned and operated by the health care service plan, and the health care service plans enrollees may use any pharmacy in the health care service plans network that has the ability to dispense the medication or provide the services.
(2)An entity providing services pursuant to a contract authorized by Section 4600.2 of the Labor Code.
(3)A health care service plan or its contracted provider, as defined in subdivision (i) of Section 1345 of the Health and Safety Code, performing the services described in this subdivision.
(4)A health insurer.
(s)Pharmacy services administration organization means an entity that provides contracting and other administrative services relating to prescription drug benefits to pharmacies.
(t)Rebate means a formulary discount or remuneration attributable to the use of prescription drugs that is paid by a manufacturer or third party, directly or indirectly, to a pharmacy benefit manager after a claim has been adjudicated at a pharmacy. Rebate does not include a fee, including a bona fide service fee or administrative fee, that is not a formulary discount or remuneration.
(u)Spread pricing means the model of prescription drug pricing in which a pharmacy benefit manager charges a health care service plan or health insurer a contracted price for prescription drugs, and the contracted price for the prescription drugs differs from the amount the pharmacy benefit manager directly or indirectly pays the pharmacist or pharmacy.
(v)Third party means a person that is not an enrollee, insured, or pharmacy benefit manager.
17004.5.Any activity conducted by a pharmacy benefit manager, as defined in this division, shall be construed as the business of insurance.
17005.The department shall adopt regulations necessary to implement this division.
(a)Until January 1, 2028, necessary regulations for the purpose of implementing this division may be adopted as emergency regulations in accordance with the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The adoption of emergency regulations pursuant to this section shall be deemed to be an emergency and necessary for the immediate preservation of the public peace, health and safety, or general welfare.
(b)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, including subdivisions (e) and (h) of Section 11346.1, an emergency regulation adopted pursuant to this section shall be repealed by operation of law unless the adoption, amendment, or repeal of the regulation is promulgated by the department pursuant to Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code within five years of the initial adoption of the emergency regulation.
(c)A regulation adopted pursuant to this section shall be discussed by the department during at least one public stakeholder meeting before the department adopts the rule or regulation.
17006.(a)The department shall establish procedures for receiving, investigating, tracking, and publicly reporting consumer complaints against pharmacy benefit managers.
(b)The department shall publish on its internet website a record of consumer complaints against a pharmacy benefit manager that have been determined by the department to be justified. Complaint data shall not be published unless it has been provided to the pharmacy benefit manager in accordance with subdivision (c) of Section 12921.1.
2.Licensing17010.(a)The department shall license and regulate pharmacy benefit managers. The department shall have the authority to enforce this division and Chapter 9.5 (commencing with Section 4430) of Division 2 of the Business and Professions Code and Article 3 (commencing with Section 127470) of Chapter 2.5 of Part 2 of Division 107 of the Health and Safety Code.
(b)No later than January 1, 2027, a pharmacy benefit manager that provides services in this state shall apply for a license to operate as a pharmacy benefit manager from the department. A pharmacy benefit manager shall maintain its license in good standing.
(c)An application for a pharmacy benefit manager license shall be submitted in a form and manner determined by the department, and shall be signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the application form and any attachments are correct. The application shall include all of the following:
(1)A nonrefundable application fee in an amount established by the department under Section 17015.
(2)A list of every health care service plan or health insurer on behalf of which the pharmacy benefit manager contracts with a pharmacy or a pharmacy services administration organization to provide health services to individuals covered by the health care service plan or health insurer.
(3)A statement indicating all jurisdictions where the applicant has an application pending or has been registered, licensed, or otherwise certified to transact business as a pharmacy benefit manager.
(4)A statement indicating whether either of the following has occurred:
(A)The pharmacy benefit manager or any individual responsible for the conduct of the affairs of the pharmacy benefit manager has had a pharmacy benefit manager certificate of authority or license denied or revoked for cause in another state.
(B)Any individual responsible for the conduct of the affairs of the pharmacy benefit manager has been convicted of, or has entered a plea of guilty or nolo contender to a felony without regard to whether adjudication was withheld.
(5)A copy of a power of attorney duly executed by the pharmacy benefit manager if not domiciled in this state, appointing the department, the departments successors in office, and the departments authorized deputies as the attorney of the pharmacy benefit manager in and for this state, on whom process in any legal action or proceeding against the pharmacy benefit manager on a cause of action arising in this state may be served.
(6)The names, addresses, official positions, and professional qualifications of each individual who is responsible for the conduct of the affairs of the pharmacy benefit manager.
(7)A copy of a recent financial statements showing the pharmacy benefit managers assets, liabilities, and sources of financial support that the department determines are sufficient to show that the pharmacy benefit manager is financially viable. If the pharmacy benefit managers financial statements are prepared by an independent accountant public accountant, a copy of the most recent regular financial statement satisfies the requirement to show financial viability unless the department determines that additional or more recent financial information is required for the proper administration of this act.
(8)A document providing the names, addresses, dates of birth, social security numbers, official positions, and professional qualifications of each individual who owns, legally or the information as to each person beneficially, 10 percent or more in equity in the entity interested therein or any person with management or control over the pharmacy benefit manager.
(9)A copy of all basic organizational and governing documents of the pharmacy benefit manager, including, but not limited to, the articles of incorporation, bylaws, articles of association, trade name certificate, and other similar documents and all amendments to those documents.
(10)A description of the pharmacy benefit manager, its services, facilities, and personnel.
(11)A document in which the pharmacy benefit manager confirms that its business practices and each ongoing contract comply with this chapter.
(12)Any other relevant information required by the department.
(d)The individual responsible for the conduct or affairs of the pharmacy benefit manager and any of the organizations partners, members, controlling persons, officers, directors, and managers shall comply with the background check requirements as required by the commissioner.
(e)Within 30 days after a modification of the information or documents submitted pursuant to subdivision (b), a pharmacy benefit manager shall file a notice of the modification with the department.
(f)An applicant for a pharmacy benefit manager license or licensed pharmacy benefit manager shall be subject to Sections 1702 and 1703, Article 6.5 (commencing with Section 790) of Chapter 1 of, and Article 3 (commencing with Section 1631), Article 4 (commencing with Section 1652), Article 6 (commencing with Section 1666), Article 10 (commencing with Section 1708), Article 12 (commencing with Section 1724), and Article 13 (commencing with Section 1737) of Chapter 5 of Part 2 of Division 1, and Article 1 (commencing with Section 12919), Article 3.5 (commencing with Section 12962), and Article 4 (commencing with Section 12970) of Chapter 2 of Division 3, excluding Sections 1634, 1635, 1640, 1642, 1647.5, 1649.5, 1661, 1725, 1725.5, 1726, 1728, 1729.5, 1730.5, 1730.6, 1731, 1732, and 1735.5.
(g)A pharmacy benefit manager shall not operate in this state unless it is licensed pursuant to this division.
(h)This division does not abrogate compliance by a pharmacy benefit manager with any applicable requirements of Chapter 5A (commencing with Section 1759) of Part 2 of Division 1.
(i)A violation of this division constitutes an unfair practice under Article 6.5 (commencing with Section 790) of Chapter 1 of Part 2 of Division 1.
(j)Notwithstanding any other law, the commissioner shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
17015.(a)A pharmacy benefit manager license applicant shall pay the initial application fee as determined by the department. A license shall be renewed every two years, beginning on the last calendar day of the month in which the initial license was issued. The license is nontransferable.
(b)To renew a pharmacy benefit manager license, an applicant shall submit to the department both of the following:
(1)A renewal application in a form and manner determined by the department that is signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the renewal form are correct.
(2)A renewal schedule and fee as determined by the department.
(c)(1)A pharmacy benefit manager license shall expire if a complete renewal filing and fee is not received by the due date established by the department.
(2)The application for renewal of an expired license may be filed after the expiration date and until that same month and day of the next succeeding year. The fee for a renewal application under this subdivision shall be the fee specified in subdivision (d) and a delinquent fee in the amount specified for a one-year period in subdivision (d) for the filing. Each licensee shall be subject to payment of delinquent fees under this section.
(d)An application fee of ____ dollars ($____), and for each year of the two-year license term thereafter, a renewal fee of ____ dollars ($____). The commissioner may increase or decrease fees, and schedule fees and charges as set forth in Section 12978.
17020.Beginning no earlier than January 1, 2026, the fees for a pharmacy benefit manager initial license and renewal application shall be sufficient to fund the departments duties in relation to responsibilities under this chapter, but in no case shall the fee exceed the reasonable regulatory cost to administer the act. Fees received under the act shall be deposited into the Pharmacy Benefit Manager Account, which is hereby created in the Insurance Fund, and shall be subject to an annual appropriation each fiscal year for the support of the Department of Insurance related to the licensing and regulation of pharmacy benefit managers.
3.Licensee Duties17025.(a)On or before July 1, 2028, and on or before each July 1 thereafter, a pharmacy benefit manager shall file with the department a report that contains all of the information required by subdivision (e) of Section 4441 of the Business and Professions Code from the preceding calendar year.
(b)On or before January 1, 2029, and on or before each January 1 thereafter, the department shall prepare a report based on the information received by the department pursuant to subdivision (a) and shall publish the report on its internet website. The report shall contain aggregate data and shall exclude any information that the department determines would cause financial, competitive, or proprietary harm to a pharmacy benefit manager.
(c)On or before July 1, 2027, and on or before each July 1 thereafter, a pharmacy benefit manager shall report to the department all of the following information:
(1)A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. For each drug that falls into the above categories, the pharmacy benefit manager shall report both of the following:
(A)The pharmacy type used to fill the drug prescription, such as integrated, chain, independent, specialty, and mail order pharmacies.
(B)Pricing and rebate information, including the net price paid, the amount of rebate the pharmacy benefit manager receives from the manufacturer, the amount of rebate the pharmacy benefit manager passes to the health care service plan or health insurer, the amount the health care service plan or health insurer pays the pharmacy benefit manager, and the amount the pharmacy benefit manager pays the pharmacy.
(C)For each list in subparagraphs (A) and (B), all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(vii)(vi)Deidentified claims level information in electronic format that allows the commissioner to sort and analyze the following information for each claim, whether the claim required prior authorization.
(viii)(vii)The amount paid to the pharmacy for each prescription, net of the aggregate amount of fees or other assessments imposed on the pharmacy, including point-of-sale and retroactive charges. These data are confidential pursuant to subdivision (e).
(2)All of the following information in the aggregate:
(A)The purchasers with which the pharmacy benefit manager contracts, the scope of services provided to the purchasers, and the number of enrollees, insureds, and plan members served.
(B)Pharmacy benefit manager revenue, including revenue from manufacturers, purchasers, and other revenue.
(C)Pharmacy benefit manager expenses, including payments to pharmacies, claims processing, special programs, administration, and other expenses.
(d)The department shall compile the information reported pursuant to subdivision (c) into a report for the public and Legislature that demonstrates the overall impact of pharmacy benefit managers on drug costs. The data in the report shall be aggregated and shall not reveal information specific to individual purchasers.
(1)On or before January 1, 2029, and on or before each January 1 thereafter, the department shall publish the report on its internet website.
(2)The department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(3) The department may consolidate the reports required by this section.
(e)Except for the reports required pursuant to subdivisions (b) and (d), the information submitted to the department pursuant to subdivisions (a) and (c) shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). This section does not prevent disclosure to the Attorney General to investigate, prosecute, or defend any legitimate legal claim or cause or action, or to use the reports in any court or proceeding of law.
(f)For purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
17030.(a)A pharmacy benefit manager shall not impose any requirements, conditions, or exclusions that discriminate against a nonaffiliated pharmacy in connection with dispensing drugs.
(b)Discrimination prohibited pursuant to subdivision (a) includes all of the following:
(1)Terms or conditions applied to nonaffiliated pharmacies based on their status as a nonaffiliated pharmacy.
(2)Refusing to contract with or terminating a contract with a nonaffiliated pharmacy on the basis that the pharmacy is a nonaffiliated pharmacy or for reasons other than those that apply equally to affiliated pharmacies.
(3)Retaliation against a nonaffiliated pharmacy based on its exercise of any right or remedy under this chapter.
(4)Reimbursing a nonaffiliated pharmacy less for a pharmacy service than the pharmacy benefit manager would reimburse an affiliated pharmacy for the same pharmacy service.
(c)This division does not preclude a pharmacy benefit manager or a purchaser of pharmacy benefit manager services from establishing a network of contracting pharmacies.
17035.A pharmacy benefit manager shall not do any of the following:
(a)Require an enrollee or insured to use only an affiliated pharmacy if there are nonaffiliated pharmacies in the network.
(b)Financially induce an enrollee, insured, or prescriber to transfer a prescription only to an affiliated pharmacy if there are nonaffiliated pharmacies in the network.
(c)Require a retail nonaffiliated pharmacy to transfer a prescription to a retail affiliated pharmacy if there are nonaffiliated pharmacies in the network. This paragraph does not prevent a purchaser or pharmacy benefit manager from offering and communicating to enrollees or insureds financial incentives to use a particular pharmacy, such as lower copays or costs for a prescription when the prescription is dispensed.
(d)Unreasonably restrict an enrollee or insured from using a particular contracted retail pharmacy for the purpose of receiving pharmacist services covered by the enrollees or insureds contract or policy.
(e)Communicate to an enrollee or insured verbally, electronically, or in writing insured, in any manner, that the enrollee or insured is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other nonaffiliated pharmacies that have the ability to dispense the medication or provide the services and are also in network.
(f)Deny a nonaffiliated contract pharmacy the opportunity to participate in a pharmacy benefit manager network as preferred participation status if the pharmacy is willing to accept the same terms and conditions that the pharmacy benefit manager has established for affiliated pharmacies as a condition of preferred network participation status.
17040.(a)A contract issued, amended, or renewed on or after January 1, 2025, between a nonaffiliated retail pharmacy and a pharmacy benefit manager shall not prohibit the retail pharmacy from offering either of the following as an ancillary service of the retail pharmacy:
(1)The delivery of a prescription drug by mail or common carrier to a patient or personal representative on request of the patient or personal representative if the request is made before the drug is delivered.
(2)The delivery of a prescription to a patient or personal representative by an employee or contractor of the retail pharmacy.
(b)Except as otherwise provided in a contract described in subdivision (a), the retail pharmacy shall not charge a pharmacy benefit manager for the delivery service described in subdivision (a). This section does not prohibit the use of remote pharmacies, secure locker systems, or other types of pickup stations if those services are otherwise permitted by law.
(c)Contracts entered into pursuant to this section shall be open for inspection by the department.
17045.A pharmacy benefit manager shall not require more than one accreditation two accreditations from an independent accrediting organization for pharmacists and pharmacies to dispense specialty drugs and shall make every effort to ensure that enhanced standards are not imposed to dispense specialty drugs beyond those related to the safety and competency necessary to comply with requirements for dispensing specified medications and providing optimal patient care.
17050.(a)A pharmacy benefit manager shall not derive income from pharmacy benefit management services provided to an insurer or health care service plan in this state except for income derived from a flat, defined, dollar-amount pharmacy benefit management fee for pharmacy benefit management services provided. The amount of any pharmacy benefit management fee shall be set forth in the agreement between the pharmacy benefit manager and the insurer or health care service plan. The pharmacy benefit manager shall disclose the amount and types of the pharmacy benefit management fees to the health insurer or health care service plan.
(b)A pharmacy benefit manager shall use a passthrough pricing model.
(c)Pharmacy benefit managers shall pass 100 percent of all prescription drug manufacturer rebates received to the health care service plan, health insurer, or program, if the contractual arrangement delegates the negotiation of rebates to the pharmacy benefit manager, for the sole purpose of offsetting defined cost sharing, deductibles, and coinsurance contributions and reducing premiums of enrollees or insureds.
(d)This section does not preclude a health insurer or health care service plan from paying performance bonuses to a pharmacy benefit manager based on savings to the health care service plan or health insurer that affects rated paid by the enrollee and insured or subscriber and policy holder, as long as the performance bonus is not based or contingent on any of the following:
(1)The acquisition cost or any other price metric of a drug.
(2)The amount of savings, rebates, or other fees charged, realized, or collected by, or generated based on the activity of, the pharmacy benefit manager, that is retained by the pharmacy benefit manager.
(3)The amount of premiums, deductibles, or other cost sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.
(4)Compensation arrangements governed by this section shall be open for inspection by the department.
(e)A pharmacy benefit manager shall not make or permit any reduction of payment for pharmacist services by a pharmacy benefit manager or a health insurer or health care service plan directly or indirectly to a pharmacy under a reconciliation process to an effective rate of reimbursement, including without limitation generic effective rates, brand effective rates, direct and indirect remuneration fees, or any other reduction or aggregate reduction of payment.
(f)A claim or aggregate of claims for pharmacist services shall not be directly or indirectly retroactively denied or reduced after adjudication of the claim or aggregate of claims unless any of the following have occurred:
(1)The original claim was submitted fraudulently.
(2)The original claim payment was incorrect because the pharmacy or pharmacist had already been paid for the pharmacist services.
(3)The pharmacist services were not properly rendered by the pharmacy or pharmacist.
(g)A pharmacy benefit manager shall not reverse and resubmit the claim of a contract pharmacy under any of the following circumstances:
(1)Without prior written notification to the contract pharmacy.
(2)Without just cause or attempt to first reconcile the claim with the pharmacy.
(3)More than 90 days after the claim was first affirmatively adjudicated.
(h)A pharmacy benefit manager shall not charge a pharmacy or pharmacist a fee to process a claim electronically.
(i)The termination of a contract with a nonaffiliated pharmacy by a pharmacy benefit manager shall not release the pharmacy benefit manager from the obligation to make a payment due to the pharmacy for an affirmatively adjudicated claim unless payments are withheld because of an investigation relating to insurance fraud.
(j)A pharmacy benefit manager shall not retaliate against a pharmacist or pharmacy based on the pharmacists or pharmacys exercise of a right or remedy under this chapter. Prohibited retaliation includes any of the following:
(1)Terminating or refusing to renew a contract with the pharmacist or pharmacy.
(2)Subjecting the pharmacist or pharmacy to increased audits.
(3)Failing to promptly pay the pharmacist or pharmacy money owed by the pharmacy benefit manager to the pharmacist or pharmacy.
17055.(a)Except as permitted under existing law, a pharmacy benefit manager shall not unreasonably obstruct or interfere with a patients right to timely access a prescription drug or device that has been legally prescribed for that patient at a contract pharmacy of their choice.
(b)A pharmacy benefit manager shall not make, disseminate, or cause or permit the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
(c)The department may investigate referrals provided by the California State Board of Pharmacy.
17060.Commencing January 1, 2025, a pharmacy benefit manager shall not conduct spread pricing in this state. If a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizes spread pricing, any subsequent amendment or renewal of that contract shall not contain that authorization. Any such spread pricing terms shall be void on and after January 1, 2028.
17065.(a)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with manufacturers who do business in California that expressly or implicitly restrict, or implements implicit or express exclusivity for, those manufacturers drugs, medical devices, or other products.
(b)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with pharmacies or pharmacy administrative services organizations who do business in California that expressly or implicitly restrict, or impose implicit or express exclusivity on, nonaffiliated pharmacies ability to contract with employers, health insurers, and health care service plans.
4.Enforcement17070.(a)In addition to any of the grounds to deny a license listed in Section 17010, the department may deny, suspend, or revoke the license of a pharmacy benefit manager if the department finds that any of the following are true:
(1)The pharmacy benefit manager has violated a statute or regulation applicable to the pharmacy benefit manager.
(2)The pharmacy benefit manager has refused to be examined or to produce its accounts, records, and files for examination by the department, or an individual responsible for the conduct of affairs of the pharmacy benefit manager has refused to give information with respect to its affairs or has refused to perform any other legal obligation as to an examination required by the department.
(3)The pharmacy benefit manager has, without just cause, exhibited a pattern or practice of refusing to pay proper claims or perform services arising under its contracts or has, without just cause, caused enrollees or insureds to accept less than the amount due them.
(4)The pharmacy benefit manager is required under this chapter to have a license and fails to continue to meet the qualifications for licensure during its active licensure.
(5)The pharmacy benefit manager failed to file a timely report as required by Section 17025.
(6)The pharmacy benefit manager is not financially viable.
(b)If a hearing is held pursuant to this section, it shall be conducted in accordance with the Administrative Procedure Act (Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code).
17075.(a)The department may examine or audit any books and records of a pharmacy benefit manager pursuant to Article 4 (commencing with Section 729) of Chapter 1 of Part 2 of Division 1 to determine if the pharmacy benefit manager is in compliance with this division. A pharmacy benefit manager shall pay for reasonable expenses for any examinations or audits conducted pursuant to this section. Those payments shall be deposited into the Pharmacy Benefit Manager Account.
(b)The department may produce and disclose publicly an examination report describing any act or omission committed by a pharmacy benefit manager that violates this division.
(c)(1)The department shall establish a retention schedule for all records, books, papers, and other data on file with the department related to the enforcement of this chapter.
(2)The department shall not order the destruction or other disposal of a record, book, paper, or other data that is required to be filed or kept on file with the department during the retention period.
(d)Section 735.5 does not prevent disclosure of information and data acquired during an examination to the Attorney General to investigate, prosecute, or defend any legitimate legal claim or cause of action, or to use the information and data in any court or proceeding of law. In any matter arising under this chapter, the department may provide to the Attorney General information related to competition and obtain an opinion from a consultant or consultants with the expertise to assess the competitive impact of the matter.
17080.(a)(1)Notwithstanding Section 4441 of the Business and Professions Code and Chapter 2.2 (commencing with Section 1385.001) of Division 2 of the Health and Safety Code, a pharmacy benefit manager shall have a duty and obligation to the health care service plan of the enrollee or subscriber covered by the health care service plan contract, or the insurer of the insured or policyholder of the policy of health insurance, and shall perform its services with care, skill, prudence, diligence, and professionalism, and for the best interests of the health care service plan or health insurer. When there is a conflict between the pharmacy benefit managers duty or obligation under this subdivision to the individual enrollee or insured and any other party, the duty or obligation to the individual enrollee or insured shall be primary.
(2)A pharmacy benefit manager shall disclose to a health insurer or health care service plan information of clinical efficacy and clinical evidence regarding the inclusion, exclusion, or limitation of prescription drugs in the formulary.
(b)Any pharmacy benefit manager that violates this division shall, in addition to any other penalty provided by law, be liable for restitution to any enrollee or insured harmed by the violation.
(c)Notwithstanding any other law, the Attorney General shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorneys fees and costs incurred in remedying each violation. This subdivision does not alter or abrogate the departments authority to enforce this division.(c)If a violation of this section, or Section 17030, 17035, or 17045 is alleged and is at issue in any proceeding in the Supreme Court, a state court of appeal, or the appellate division of a superior court, a person filing a brief or petition with the court in that proceeding shall serve, within three days of filing with the court, a copy of the brief or petition on the Attorney General at a service address designated on the Attorney Generals internet website for service of papers under this section, or, if a service address is not designated, at the Attorney Generals office in San Francisco. Upon the Attorney Generals request, a person who has filed any other document, including all or a portion of the appellate record, with the court in addition to a brief or petition shall provide a copy of that document, without charge, to the Attorney General within five days of the request. The time for service may be extended by the Chief Justice or presiding justice or judge for good cause shown. No judgment or relief, temporary or permanent, shall be granted or opinion issued until proof of service of the brief or petition on the Attorney General is filed with the court.
17085.(a)Any person that violates this division shall be subject to an injunction and liable for a civil penalty of not less than one thousand dollars ($1,000) or more than seven thousand five hundred dollars ($7,500) for each violation which shall be assessed and recovered in a civil action brought in the name of the people of the State of California by the Attorney General.
(b)(1)A violation of Section 17030, 17035, or 17045 is an act of unfair competition within the meaning of Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code. But nothing in this article shall However, this article does not limit any other statutory or common law rights or remedies, including liability pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code).
(2)An action shall not be brought in the name of the people of the State of California that seeks relief under this section pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code) without the written consent and permission of the Attorney General.(3)(2)This subdivision does not alter or abrogate the departments authority to enforce this division.
(c)Notwithstanding any other law, the Attorney General shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this division and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
(c)(d)The remedies or penalties provided by this chapter are cumulative to each other and to the remedies or penalties available under all other laws of this state.
17086.The provisions of this division are severable. If any provision of this division or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
17090.Beginning on or after January 1, 2026, the fines and administrative penalties collected pursuant to this chapter shall be deposited into the Pharmacy Benefit Manager Fines and Penalties Account, which is hereby established in the General Fund.
SEC. 6.The authority of the Attorney General to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations shall not be narrowed, abrogated, or otherwise altered by this act.
SEC. 7.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 8.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SEC. 9.The Legislature finds and declares that Section 5 of this act, which adds Sections 17025 and 17075 to the Insurance Code, imposes a limitation on the publics right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 5 of Article I of the California Constitution. Pursuant to that constitutional provision, the Legislature makes the following findings to demonstrate the interest protected by this limitation and the need for protecting that interest:
In order to protect the confidentiality of information received by state agencies from pharmacy benefit managers, it is necessary that those documents be presumptively confidential, except as otherwise provided by law.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an enrollees cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
(b)(1)Commencing January 1, 2025, if a preexisting contract between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) of the Insurance Code and a health care service plan authorizes spread pricing, as that term is defined by Section 17000 of the Insurance Code, any subsequent amendment or renewal of that contract shall not authorize spread pricing.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) of the Insurance Code and a health care service plan shall not authorize spread pricing, as that term is defined by Section 17000 of the Insurance Code.
SEC. 2.Section 1367.243 of the Health and Safety Code is amended to read:1367.243.(a)(1)A health care service plan that reports rate information pursuant to Section 1385.03 or 1385.045 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health care service plans.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2019, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 1385.045.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 3.Section 10123.2045 is added to the Insurance Code, immediately following Section 10123.204, to read:10123.2045.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an insureds cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
(b)(1)Commencing January 1, 2025, if a preexisting contract between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) and a health insurer authorizes spread pricing, as that term is defined by Section 17000, any subsequent amendment or renewal of that contract shall not authorize spread pricing.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) and a health insurer shall not authorize spread pricing, as that term is defined by Section 17000.
SEC. 4.Section 10123.205 of the Insurance Code is amended to read:10123.205.(a)(1)A health insurer that reports rate information pursuant to Section 10181.3 or 10181.45 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health insurers.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2018, the department shall publish on its internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 5.Division 6 (commencing with Section 17000) is added to the Insurance Code, to read:6.Regulation of Pharmacy Benefit Managers1.General Provisions17000.For purposes of this division:
(a)Affiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a pharmacy benefit manager.
(b)Claim means a request for payment for administering, filling, or refilling a drug or for providing a pharmacy service or a medical supply or device to an enrollee or insured.
(c)Contract pharmacy means a retail pharmacy or other pharmacy that contracts directly or through a pharmacy services administration organization with a pharmacy benefit manager.
(d)Drug has the same meaning as defined in Section 4025 of the Business and Professions Code.
(e)Financially viable means that either of the following conditions is met:
(1)The pharmacy benefit manager has received an unqualified opinion from an independent public accountant, as described in Section 260.613(b) of Title 10 of the California Code of Regulations.
(2)If an independent public accountant opinion is not obtained, the pharmacy benefit manager remains solvent after adjusting for goodwill and intangible assets.
(e)(f)Health care service plan means an entity licensed pursuant to the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code).
(f)(g)Health insurer means a disability insurer that issues health insurance, as defined in Section 106.
(g)(h)Manufacturer has the same meaning as defined in Section 4033 of the Business and Professions Code.
(h)(i)Nonaffiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, does not control, is not controlled by, and is not under common control with, a pharmacy benefit manager.
(i)Nonresident pharmacy has the same meaning as described in Section 4112 of the Business and Professions Code.(j)Passthrough pricing model means a payment model used by a pharmacy benefit manager in which the payments made by the health care service plan or health insurer client to the pharmacy benefit manager for the covered outpatient drugs are both of the following:
(1)Equivalent to the payments the pharmacy benefit manager makes to a pharmacy or provider for those drugs, including any contracted professional dispensing fee between the pharmacy benefit manager and its network of pharmacies. That dispensing fee would be paid if the pharmacy benefits plan or program was making the payments directly.
(2)Passed through in their entirety by the health care service plan or health insurer client or by the pharmacy benefit manager to the pharmacy or provider that dispenses the drugs, and the payments are made in a manner that is not offset by any reconciliation.
(j)(k)Person has the same meaning as defined in Section 4035 of the Business and Professions Code.
(k)(l)Personal representative means an individual who has authority to make a health care decision on behalf of another individual pursuant to Division 4.7 (commencing with Section 4600) of the Probate Code.
(l)(m)Pharmacist has the same meaning as defined in Section 4036 of the Business and Professions Code.
(m)(n)Pharmacist services means products, goods, and services, or any combination of products, goods, and services, provided as a part of the practice of pharmacy.
(n)(o)Pharmacy has the same meaning as defined in Section 4037 of the Business and Professions Code.
(o)(p)Pharmacy benefit management fee means a fee that covers the cost of providing one or more pharmacy benefit management services and that does not exceed the value of the service or services actually performed by the pharmacy benefit manager. The value of the service or services shall be based on the value to the health insurer or health care service plan.
(p)(q)Pharmacy benefit management service means all of the following:
(1)Negotiating the price of prescription drugs, including negotiating and contracting for direct or indirect rebates, discounts, or other price concessions.
(2)Managing any aspect of a prescription drug benefit, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with pharmacies, controlling the cost of covered prescription drugs, managing or providing data relating to the prescription drug benefit, or the provision of services related thereto.
(3)Performing any administrative, managerial, clinical, pricing, financial, reimbursement, data administration, or reporting, or billing service.
(4)Other services as the department may define in regulation.
(q)(r)Pharmacy benefit manager means a person, business, or other entity that, either directly or indirectly, manages the prescription drug coverage, including, but not limited to, the following: clinical or other formulary or preferred drug list development or management; the processing and payment of claims for prescription drugs, the negotiation or administration of rebates, discounts, payment differentials, or other incentives; for the inclusion of particular prescription drugs in a particular category or to promote the purchase of particular prescription drugs; the performance of drug utilization review; the processing of drug prior authorization requests; the adjudication of appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. Pharmacy benefit manager does not include either of the following:
(1)A health care service plan that is part of a fully integrated delivery system in which enrollees primarily use pharmacies that are entirely owned and operated by the health care service plan, and the health care service plans enrollees may use any pharmacy in the health care service plans network that has the ability to dispense the medication or provide the services.
(2)A An entity providing services pursuant to a contract authorized by Section 4600.2 of the Labor Code.
(3)A health care service plan or its contracted provider, as defined in subdivision (i) of Section 1345 of the Health and Safety Code, performing the services described in this subdivision.
(4)A health insurer.
(r)(s)Pharmacy services administration organization means an entity that provides contracting and other administrative services relating to prescription drug benefits to pharmacies.
(s)(t)Rebate means a formulary discount or remuneration attributable to the use of prescription drugs that is paid by a manufacturer or third party, directly or indirectly, to a pharmacy benefit manager after a claim has been adjudicated at a pharmacy. Rebate does not include a fee, including a bona fide service fee or administrative fee, that is not a formulary discount or remuneration.
(t)Retail pharmacy means a pharmacy that dispenses prescription drugs to the public at retail typically by face-to-face interaction with the individual or the individuals caregiver.(u)Spread pricing means the model of prescription drug pricing in which a pharmacy benefit manager charges a health care service plan or health insurer a contracted price for prescription drugs, and the contracted price for the prescription drugs differs from the amount the pharmacy benefit manager directly or indirectly pays the pharmacist or pharmacy.
(v)Third party means a person that is not an enrollee, insured, or pharmacy benefit manager.
(w)Wholesaler has the same meaning as defined in Section 4043 of the Business and Professions Code.17004.5.Any activity conducted by a pharmacy benefit manager, as defined in this division, shall be construed as the business of insurance.
17005.The department shall adopt regulations necessary to implement this division.
(a)Until January 1, 2028, necessary regulations for the purpose of implementing this division may be adopted as emergency regulations in accordance with the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The adoption of emergency regulations pursuant to this section shall be deemed to be an emergency and necessary for the immediate preservation of the public peace, health and safety, or general welfare.
(b)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, including subdivisions (e) and (h) of Section 11346.1, an emergency regulation adopted pursuant to this section shall be repealed by operation of law unless the adoption, amendment, or repeal of the regulation is promulgated by the department pursuant to Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code within five years of the initial adoption of the emergency regulation.
(c)A regulation adopted pursuant to this section shall be discussed by the department during at least one public stakeholder meeting before the department adopts the rule or regulation.
17006.(a)The department shall establish procedures for receiving, investigating, tracking, and publicly reporting consumer complaints against pharmacy benefit managers.
(b)The department shall publish on its internet website a record of consumer complaints against a pharmacy benefit manager that have been determined by the department to be justified. Complaint data shall not be published unless it has been provided to the pharmacy benefit manager in accordance with subdivision (c) of Section 12921.1.
2.Licensing17010.(a)The department shall license and regulate pharmacy benefit managers. The department shall have the authority to enforce this division and Chapter 9.5 (commencing with Section 4430) of Division 2 of the Business and Professions Code and Article 3 (commencing with Section 127470) of Chapter 2.5 of Part 2 of Division 107 of the Health and Safety Code.
(b)On and after January 1, 2026, No later than January 1, 2027, a pharmacy benefit manager that provides services in this state shall apply for, obtain, and maintain for a license to operate as a pharmacy benefit manager from the department. A pharmacy benefit manager shall maintain its license in good standing.
(c)An application for a pharmacy benefit manager license shall be submitted in a form and manner determined by the department. department, and shall be signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the application form and any attachments are correct. The application shall include all of the following:
(1)The information as to each person beneficially interested therein or any person with management or control over the pharmacy benefit manager.(1)A nonrefundable application fee in an amount established by the department under Section 17015.
(2)A list of every health care service plan or health insurer on behalf of which the pharmacy benefit manager contracts with a pharmacy or a pharmacy services administration organization to provide health services to individuals covered by the health care service plan or health insurer.
(3)A statement indicating all jurisdictions where the applicant has an application pending or has been registered, licensed, or otherwise certified to transact business as a pharmacy benefit manager.
(4)A statement indicating whether either of the following has occurred:
(A)The pharmacy benefit manager or any individual responsible for the conduct of the affairs of the pharmacy benefit manager has had a pharmacy benefit manager certificate of authority or license denied or revoked for cause in another state.
(B)Any individual responsible for the conduct of the affairs of the pharmacy benefit manager has been convicted of, or has entered a plea of guilty or nolo contender to a felony without regard to whether adjudication was withheld.
(5)A copy of a power of attorney duly executed by the pharmacy benefit manager if not domiciled in this state, appointing the department, the departments successors in office, and the departments authorized deputies as the attorney of the pharmacy benefit manager in and for this state, on whom process in any legal action or proceeding against the pharmacy benefit manager on a cause of action arising in this state may be served.
(6)The names, addresses, official positions, and professional qualifications of each individual who is responsible for the conduct of the affairs of the pharmacy benefit manager.
(7)A copy of a recent financial statements showing the pharmacy benefit managers assets, liabilities, and sources of financial support that the department determines are sufficient to show that the pharmacy benefit manager is financially viable. If the pharmacy benefit managers financial statements are prepared by an independent accountant public accountant, a copy of the most recent regular financial statement satisfies the requirement to show financial viability unless the department determines that additional or more recent financial information is required for the proper administration of this act.
(8)A document providing the names, addresses, dates of birth, social security numbers, official positions, and professional qualifications of each individual who owns, legally or the information as to each person beneficially, 10 percent or more in equity in the entity interested therein or any person with management or control over the pharmacy benefit manager.
(2)(9)A copy of all basic organizational and governing documents of the pharmacy benefit manager. manager, including, but not limited to, the articles of incorporation, bylaws, articles of association, trade name certificate, and other similar documents and all amendments to those documents.
(3)(10)A description of the pharmacy benefit manager, its services, facilities, and personnel.
(4)(11)A document in which the pharmacy benefit manager confirms that its business practices and each ongoing contract comply with this chapter.
(12)Any other relevant information required by the department.
(d)The individual responsible for the conduct or affairs of the pharmacy benefit manager and any of the organizations partners, members, controlling persons, officers, directors, and managers shall comply with the background check requirements as required by the commissioner.
(d)(e)Within 30 days after a significant modification of the information or documents submitted pursuant to subdivision (b), a pharmacy benefit manager shall file a notice of the modification with the department.
(f)An applicant for a pharmacy benefit manager license or licensed pharmacy benefit manager shall be subject to Sections 1702 and 1703, Article 6.5 (commencing with Section 790) of Chapter 1 of, and Article 3 (commencing with Section 1631), Article 4 (commencing with Section 1652), Article 6 (commencing with Section 1666), Article 10 (commencing with Section 1708), Article 12 (commencing with Section 1724), and Article 13 (commencing with Section 1737) of Chapter 5 of Part 2 of Division 1, and Article 1 (commencing with Section 12919), Article 3.5 (commencing with Section 12962), and Article 4 (commencing with Section 12970) of Chapter 2 of Division 3, excluding Sections 1634, 1635, 1640, 1642, 1647.5, 1649.5, 1661, 1725, 1725.5, 1726, 1728, 1729.5, 1730.5, 1730.6, 1731, 1732, and 1735.5.
(g)A pharmacy benefit manager shall not operate in this state unless it is licensed pursuant to this division.
(h)This division does not abrogate compliance by a pharmacy benefit manager with any applicable requirements of Chapter 5A (commencing with Section 1759) of Part 2 of Division 1.
(i)A violation of this division constitutes an unfair practice under Article 6.5 (commencing with Section 790) of Chapter 1 of Part 2 of Division 1.
(j)Notwithstanding any other law, the commissioner shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
17015.(a)A pharmacy benefit manager license applicant shall pay the initial application fee as determined by the department. A license shall be renewed every two years and years, beginning on the last calendar day of the month in which the initial license was issued. The license is nontransferable.
(b)To renew a pharmacy benefit manager license, an applicant shall submit to the department both of the following:
(1)A renewal application in a form and manner determined by the department that is signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the renewal form are correct.
(2)A renewal schedule and fee as determined by the department.
(c)(1)A pharmacy benefit manager license shall expire if a complete renewal filing and fee is not received by the due date established by the department.
(2)The application for renewal of an expired license may be filed after the expiration date and until that same month and day of the next succeeding year. The fee for a renewal application under this subdivision shall be the fee specified in subdivision (d) and a delinquent fee in the amount specified for a one-year period in subdivision (d) for the filing. Each licensee shall be subject to payment of delinquent fees under this section.
(d)An application fee of ____ dollars ($____), and for each year of the two-year license term thereafter, a renewal fee of ____ dollars ($____). The commissioner may increase or decrease fees, and schedule fees and charges as set forth in Section 12978.
17020.(a)There is hereby established in the State Treasury the Pharmacy Benefit Manager Fund. The fund shall be available to the department for use, upon appropriation by the Legislature, for costs related to the licensing and regulation of pharmacy benefit managers.(b)The17020.Beginning no earlier than January 1, 2026, the fees for a pharmacy benefit manager initial license and renewal application shall be sufficient to fund the departments duties in relation to responsibilities under this chapter, but in no case shall the fee exceed the reasonable regulatory cost to administer this division. Fees shall be collected into the Pharmacy Benefit Manager Fund. the act. Fees received under the act shall be deposited into the Pharmacy Benefit Manager Account, which is hereby created in the Insurance Fund, and shall be subject to an annual appropriation each fiscal year for the support of the Department of Insurance related to the licensing and regulation of pharmacy benefit managers.
3.Licensee Duties17025.(a)On or before April 1, 2027, July 1, 2028, and on or before each April July 1 thereafter, a pharmacy benefit manager shall file with the department a report that contains all of the information required by subdivision (e) of Section 4441 of the Business and Professions Code from the preceding calendar year.
(b)On or before August 1, 2027, January 1, 2029, and on or before each August January 1 thereafter, the department shall prepare a report based on the information received by the department pursuant to subdivision (a) and shall submit the report to the Legislature in compliance with Section 9795 of the Government Code. publish the report on its internet website. The report shall contain aggregate data and shall exclude any information that the department determines would cause financial, competitive, or proprietary harm to a pharmacy benefit manager. The department shall post the report on the departments internet website.
(c)On or before October 1, 2025, July 1, 2027, and on or before each October July 1 thereafter, a pharmacy benefit manager shall report to the department all of the following information:
(1)A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. For each drug that falls into the above categories, the pharmacy benefit manager shall report both of the following:
(A)The pharmacy type used to fill the drug prescription, such as integrated, chain, independent, specialty, and mail order pharmacies.
(B)Pricing and rebate information, including the net price paid, the amount of rebate the pharmacy benefit manager receives from the manufacturer, the amount of rebate the pharmacy benefit manager passes to the health care service plan or health insurer, the amount the health care service plan or health insurer pays the pharmacy benefit manager, and the amount the pharmacy benefit manager pays the pharmacy.
(C)For each list in subparagraphs (A) and (B), all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(vii)Deidentified claims level information in electronic format that allows the commissioner to sort and analyze the following information for each claim, whether the claim required prior authorization.
(viii)The amount paid to the pharmacy for each prescription, net of the aggregate amount of fees or other assessments imposed on the pharmacy, including point-of-sale and retroactive charges. These data are confidential pursuant to subdivision (e).
(2)All of the following information in the aggregate:
(A)The purchasers with which the pharmacy benefit manager contracts, the scope of services provided to the purchasers, and the number of enrollees, insureds, and plan members served.
(B)Pharmacy benefit manager revenue, including revenue from manufacturers, purchasers, and other revenue.
(C)Pharmacy benefit manager expenses, including payments to pharmacies, claims processing, special programs, administration, and other expenses.
(d)The department shall compile the information reported pursuant to subdivision (c) into a report for the public and Legislature that demonstrates the overall impact of pharmacy benefit managers on drug costs. The data in the report shall be aggregated and shall not reveal information specific to individual purchasers.
(1)On or before January 1, 2026, 2029, and on or before each January 1 thereafter, the department shall publish the report on its internet website.
(2)The report shall be submitted to the Legislature in compliance with Section 9795 of the Government Code.(3)(2)The department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(3) The department may consolidate the reports required by this section.
(e)Except for the reports required pursuant to subdivisions (b) and (d), the information submitted to the department pursuant to subdivisions (a) and (c) shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). This section does not prevent disclosure to the Attorney General to investigate, prosecute, or defend any legitimate legal claim or cause or action, or to use the reports in any court or proceeding of law.
(f)For purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
17030.(a)A pharmacy benefit manager shall not impose any requirements, conditions, or exclusions that discriminate against a nonaffiliated pharmacy in connection with dispensing drugs.
(b)Discrimination prohibited pursuant to subdivision (a) includes all of the following:
(1)Terms or conditions applied to nonaffiliated pharmacies based on their status as a nonaffiliated pharmacy.
(2)Refusing to contract with or terminating a contract with a nonaffiliated pharmacy on the basis that the pharmacy is a nonaffiliated pharmacy or for reasons other than those that apply equally to affiliated pharmacies.
(3)Retaliation against a nonaffiliated pharmacy based on its exercise of any right or remedy under this chapter.
(4)Reimbursing a nonaffiliated pharmacy less for a pharmacy service than the pharmacy benefit manager would reimburse an affiliated pharmacy for the same pharmacy service.
(c)This division does not preclude a pharmacy benefit manager or a purchaser of pharmacy benefit manager services from establishing a network of contracting or participating pharmacies.
17035.A pharmacy benefit manager shall not do any of the following:
(a)Require an enrollee or insured to use only an affiliated pharmacy that is a retail pharmacy if there are nonaffiliated pharmacies in the network.
(b)Financially induce an enrollee, insured, or prescriber to transfer a prescription only to a retail an affiliated pharmacy if there are nonaffiliated pharmacies in the network.
(c)Require a retail nonaffiliated pharmacy to transfer a prescription to a retail affiliated pharmacy if there are nonaffiliated pharmacies in the network. This paragraph does not prevent a purchaser or pharmacy benefit manager from offering and communicating to enrollees enrollees or insureds financial incentives to use a particular pharmacy, such as lower copays or costs for a prescription when the prescription is dispensed.
(d)Unreasonably restrict an enrollee or insured from using a particular contracted retail pharmacy for the purpose of receiving pharmacist services covered by the enrollees or insureds contract or policy.
(e)Communicate to an enrollee or insured verbally, electronically, or in writing that the enrollee or insured is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other nonaffiliated pharmacies that have the ability to dispense the medication or provide the services and are also in network.
(f)Deny a nonaffiliated contract pharmacy the opportunity to participate in a pharmacy benefits benefit manager network as preferred participation status if the pharmacy is willing to accept the same terms and conditions that the pharmacy benefit manager has established for other affiliated pharmacies as a condition of preferred network participation status.
17040.(a)A contract issued, amended, or renewed on or after January 1, 2025, between a nonaffiliated retail pharmacy and a pharmacy benefit manager shall not prohibit the retail pharmacy from offering either of the following as an ancillary service of the retail pharmacy:
(1)The delivery of a prescription drug by mail or common carrier to a patient or personal representative on request of the patient or personal representative if the request is made before the drug is delivered.
(2)The delivery of a prescription to a patient or personal representative by an employee or contractor of the retail pharmacy.
(b)Except as otherwise provided in a contract described in subdivision (a), the retail pharmacy shall not charge a pharmacy benefit manager for the delivery service described in subdivision (a). This section does not prohibit the use of remote pharmacies, secure locker systems, or other types of pickup stations if those services are otherwise permitted by law.
(c)Contracts entered into pursuant to this section shall be open for inspection by the department.
17045.A pharmacy benefit manager shall not require more than two accreditations one accreditation from an independent accrediting organization for pharmacists and pharmacies that apply to be in a specialty network to dispense specialty drugs and shall make every effort to ensure that enhanced standards are not imposed for participation in a specialty network to dispense specialty drugs beyond those related to the safety and competency necessary to comply with requirements for dispensing specified medications and providing optimal patient care.
17050.(a)A pharmacy benefit manager shall not derive income from pharmacy benefit management services provided to an insurer or health plan in this state except for income derived from pharmacy benefit management fees for services provided. The amount of any pharmacy benefit management fees shall be set forth in the agreement between the pharmacy benefit manager and the insurer or health plan.(b)(1)The pharmacy benefit management fee charged by or paid to a pharmacy benefit manager from an insurer or health plan shall not be directly or indirectly based or contingent upon:(A)The acquisition cost or any other price metric of a drug.(B)The amount of savings, rebates, or other fees charged, realized, or collected by or generated based on the activity of the pharmacy benefit manager.(C)The amount of premiums, deductibles, or other cost sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.(2)This subdivision does not preclude a health care service plan or insurer from paying performance bonuses to a pharmacy benefit manager.(3)Compensation arrangements governed by this section shall be open for inspection by the department.(c)A pharmacy benefit manager shall not reverse and resubmit the claim of a contract pharmacy:(1)Without prior and proper notification to the contract pharmacy.(2)Without just cause or attempt to first reconcile the claim with the pharmacy.(3)More than 90 days after the claim was first affirmatively adjudicated.(d)A pharmacy benefit manager shall not directly or indirectly, including indirectly through a pharmacy services administrative organization, charge or hold a pharmacist or pharmacy responsible for a fee related to a claim or reduce the amount of the claim at the time of the claims adjudication or after the claim is adjudicated.(e)Subdivision (a) does not apply to an audit of a pharmacys records pursuant to Chapter 9.5 (commencing with Section 4430) of Division 2 of the Business and Professions Code if either of the following apply:(1)The review of claims data or statements indicates criminal wrongdoing, willful misrepresentation, fraud, or abuse.(2)An investigative method, other than a review described in paragraph (1), indicates that the pharmacy is or has committed criminal wrongdoing, willful misrepresentation, fraud, or abuse.(f)A pharmacy benefit manager shall not charge a pharmacy or pharmacist a fee to process a claim electronically.(g)The termination of a contract with a pharmacy by a pharmacy benefit manager shall not release the pharmacy benefit manager from the obligation to make a payment due to the pharmacy for an affirmatively adjudicated claim unless payments are withheld because of an investigation relating to insurance fraud.(h)A pharmacy benefit manager shall not retaliate against a pharmacist or pharmacy based on the pharmacists or pharmacys exercise of a right or remedy under this chapter. Prohibited retaliation includes any of the following:(1)Terminating or refusing to renew a contract with the pharmacist or pharmacy.(2)Subjecting the pharmacist or pharmacy to increased audits.(3)Failing to promptly pay the pharmacist or pharmacy money owed by the pharmacy benefit manager to the pharmacist or pharmacy.17050.(a)The pharmacy benefit manager shall disclose the amount and types of the pharmacy benefit management fees to the health insurer or health care service plan.
(b)A pharmacy benefit manager shall use a passthrough pricing model.
(c)Pharmacy benefit managers shall pass 100 percent of all prescription drug manufacturer rebates received to the health care service plan, health insurer, or program, if the contractual arrangement delegates the negotiation of rebates to the pharmacy benefit manager, for the sole purpose of offsetting defined cost sharing, deductibles, and coinsurance contributions and reducing premiums of enrollees or insureds.
(d)This section does not preclude a health insurer or health care service plan from paying performance bonuses to a pharmacy benefit manager based on savings to the health care service plan or health insurer that affects rated paid by the enrollee and insured or subscriber and policy holder, as long as the performance bonus is not based or contingent on any of the following:
(1)The acquisition cost or any other price metric of a drug.
(2)The amount of savings, rebates, or other fees charged, realized, or collected by, or generated based on the activity of, the pharmacy benefit manager, that is retained by the pharmacy manager.
(3)The amount of premiums, deductibles, or other cost sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.
(4)Compensation arrangements governed by this section shall be open for inspection by the department.
(e)A pharmacy benefit manager shall not make or permit any reduction of payment for pharmacist services by a pharmacy benefit manager or a health insurer or health care service plan directly or indirectly to a pharmacy under a reconciliation process to an effective rate of reimbursement, including without limitation generic effective rates, brand effective rates, direct and indirect remuneration fees, or any other reduction or aggregate reduction of payment.
(f)A claim or aggregate of claims for pharmacist services shall not be directly or indirectly retroactively denied or reduced after adjudication of the claim or aggregate of claims unless any of the following have occurred:
(1)The original claim was submitted fraudulently.
(2)The original claim payment was incorrect because the pharmacy or pharmacist had already been paid for the pharmacist services.
(3)The pharmacist services were not properly rendered by the pharmacy or pharmacist.
(g)A pharmacy benefit manager shall not reverse and resubmit the claim of a contract pharmacy under any of the following circumstances:
(1)Without prior written notification to the contract pharmacy.
(2)Without just cause or attempt to first reconcile the claim with the pharmacy.
(3)More than 90 days after the claim was first affirmatively adjudicated.
(h)A pharmacy benefit manager shall not charge a pharmacy or pharmacist a fee to process a claim electronically.
(i)The termination of a contract with a nonaffiliated pharmacy by a pharmacy benefit manager shall not release the pharmacy benefit manager from the obligation to make a payment due to the pharmacy for an affirmatively adjudicated claim unless payments are withheld because of an investigation relating to insurance fraud.
(j)A pharmacy benefit manager shall not retaliate against a pharmacist or pharmacy based on the pharmacists or pharmacys exercise of a right or remedy under this chapter. Prohibited retaliation includes any of the following:
(1)Terminating or refusing to renew a contract with the pharmacist or pharmacy.
(2)Subjecting the pharmacist or pharmacy to increased audits.
(3)Failing to promptly pay the pharmacist or pharmacy money owed by the pharmacy benefit manager to the pharmacist or pharmacy.
17055.(a)Except as permitted under existing law, a pharmacy benefit manager shall not unreasonably obstruct or interfere with a patients right to timely access a prescription drug or device that has been legally prescribed for that patient at a contract pharmacy of their choice.
(b)A pharmacy benefit manager shall not make, disseminate, or cause or permit the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
(c)The department may investigate referrals provided by the California State Board of Pharmacy.
17060.Commencing January 1, 2025, a pharmacy benefit manager shall not conduct spread pricing in this state. If a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizes spread pricing, any subsequent amendment or renewal of that contract shall not contain that authorization. Any such spread pricing terms shall be void on and after January 1, 2028.
17065.(a)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with manufacturers who do business in California that expressly or implicitly restrict, or implements implicit or express exclusivity for, those manufacturers drugs, medical devices, or other products.
(b)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with pharmacies or pharmacy administrative services organizations who do business in California that expressly or implicitly restrict, or impose implicit or express exclusivity on, nonaffiliated pharmacies ability to contract with employers, health insurers, and health care service plans.
4.Enforcement17070.(a)The department may refuse to issue a pharmacy benefit manager license if the department determines that the pharmacy benefit manager or an individual responsible for the conduct of affairs of the pharmacy benefit manager has had a pharmacy benefit manager certificate of authority or license denied or revoked for cause in another state.(b)The department may deny, suspend, or revoke the license of a pharmacy benefit manager, or may issue a cease and desist order if the pharmacy benefit manager is not licensed, if the department finds, after notice and opportunity for hearing, that any of the following are true:(1)The pharmacy benefit manager has violated a statute or regulation applicable to the pharmacy benefit manager.(2)The pharmacy benefit manager has refused to be examined or to produce its accounts, records, and files for examination by the department, or an individual responsible for the conduct of affairs of the pharmacy benefit manager has refused to give information with respect to its affairs or has refused to perform any other legal obligation as to an examination required by the department.(3)The pharmacy benefit manager has, without just cause, exhibited a pattern or practice of refusing to pay proper claims or perform services arising under its contracts or has, without just cause, caused enrollees or insureds to accept less than the amount due them.(4)The pharmacy benefit manager is required under this chapter to have a license and fails to continue to meet the qualifications for licensure during its active licensure, unless the department issued a license with knowledge of the failure to qualify and waived the relevant requirement.(5)An individual responsible for the conduct of affairs of the pharmacy benefit manager has been convicted of, or has entered a plea of guilty or nolo contendere to, a felony without regard to whether adjudication was withheld.(6)The pharmacy benefit managers license or registration has been suspended or revoked in another state.(7)The pharmacy benefit manager failed to file a timely report as required by Section 17025.(c)If a pharmacy benefit managers license is suspended or restricted, the department may permit the operation of the pharmacy benefit manager for a limited time not to exceed 60 days. However, the department may permit a pharmacy benefit manager whose license has been suspended or restricted to operate for a period that exceeds 60 days if the department determines that the continued operation of the pharmacy benefit manager is in the beneficial interests of enrollees and insureds by ensuring minimal disruptions to the continuity of care.(d)A pharmacy benefit manager whose license has been suspended or restricted is subject to a fine each month, as determined by the department, not to exceed twenty thousand dollars ($20,000) per month, until the pharmacy benefit manager has remedied the violation leading to the suspension or restriction.(e)The department may revoke the license of a pharmacy benefit manager if the pharmacy benefit manager has been operating under a suspended license for a period of more than 60 days.(f)For purposes of this section, a pharmacy benefit manager has the right to appropriate notice and opportunity for hearing in accordance with the Administrative Procedure Act (Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code).17070.(a)In addition to any of the grounds to deny a license listed in Section 17010, the department may deny, suspend, or revoke the license of a pharmacy benefit manager if the department finds that any of the following are true:
(1)The pharmacy benefit manager has violated a statute or regulation applicable to the pharmacy benefit manager.
(2)The pharmacy benefit manager has refused to be examined or to produce its accounts, records, and files for examination by the department, or an individual responsible for the conduct of affairs of the pharmacy benefit manager has refused to give information with respect to its affairs or has refused to perform any other legal obligation as to an examination required by the department.
(3)The pharmacy benefit manager has, without just cause, exhibited a pattern or practice of refusing to pay proper claims or perform services arising under its contracts or has, without just cause, caused enrollees or insureds to accept less than the amount due them.
(4)The pharmacy benefit manager is required under this chapter to have a license and fails to continue to meet the qualifications for licensure during its active licensure.
(5)The pharmacy benefit manager failed to file a timely report as required by Section 17025.
(6)The pharmacy benefit manager is not financially viable.
(b)If a hearing is held pursuant to this section, it shall be conducted in accordance with the Administrative Procedure Act (Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code).
17075.(a)The department may examine or audit any books and records of a pharmacy benefit manager pursuant to Article 4 (commencing with Section 729) of Chapter 1 of Part 2 of Division 1 to determine if the pharmacy benefit manager is in compliance with this division. A pharmacy benefit manager shall pay for reasonable expenses for any examinations or audits conducted pursuant to this section. Those payments shall be deposited into the Pharmacy Benefit Manager Fund. Examinations conducted by the department shall be pursuant to the same examination authority of the department relative to insurers. Pharmacy benefit managers shall have the same rights as insurers. Account.
(b)Information or data acquired during an examination pursuant to subdivision (a), or otherwise acquired under this division shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). This section does not prevent disclosure to the Attorney General to investigate, prosecute, defend any legitimate legal claim or cause or action, or to use the information and data in any court or proceeding of law.(b)The department may produce and disclose publicly an examination report describing any act or omission committed by a pharmacy benefit manager that violates this division.
(c)(1)The department shall establish a retention schedule for all records, books, papers, and other data on file with the department related to the enforcement of this chapter.
(2)The department shall not order the destruction or other disposal of a record, book, paper, or other data that is either of the following: required to be filed or kept on file with the department during the retention period.
(A)Required by law to be filed or kept on file with the department.(B)Filed during the departments administration or administrations.(d)In Section 735.5 does not prevent disclosure of information and data acquired during an examination to the Attorney General to investigate, prosecute, or defend any legitimate legal claim or cause of action, or to use the information and data in any court or proceeding of law. In any matter arising under this chapter, the department may provide to the Attorney General information related to competition and obtain an opinion from a consultant or consultants with the expertise to assess the competitive impact of the matter.
17080.(a)(1)Notwithstanding the Section 4441 of the Business and Professions Code and Chapter 2.2 (commencing with Section 1385.001) of Division 2 of the Health and Safety Code, a pharmacy benefit manager shall have a duty and obligation to the health care service plan or insurer, of the enrollee or subscriber covered by the health care service plan contract, or the insurer of the insured or policyholder of the policy of health insurance, and shall perform its services with care, skill, prudence, diligence, and professionalism, and for the best interests of the health care service plan or health insurer.
(2)A pharmacy benefit manager shall disclose to a health insurer or health care service plan information of clinical efficacy and clinical evidence regarding the inclusion, exclusion, or limitation of prescription drugs in the formulary.
(b)Any pharmacy benefit manager that violates Chapter 3 (commencing with Section 17025) this division shall, in addition to any other penalty provided by law, be liable for restitution to any enrollee or insured harmed by the violation and shall also be subject to a penalty not exceeding the greater of (1) one thousand dollars ($1,000) for the first violation and two thousand five hundred dollars ($2,500) for each subsequent violation or (2) the aggregate economic gross receipts attributable to all violations. violation.
(c)Notwithstanding any other law, the Attorney General shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorneys fees and costs incurred in remedying each violation. This subdivision does not alter or abrogate the departments authority to enforce this division.
17085.(a)Any person that violates this division shall be subject to an injunction and liable for a civil penalty of not less than one thousand dollars ($1,000) or more than seven thousand five hundred dollars ($7,500) for each violation which shall be assessed and recovered in a civil action brought in the name of the people of the State of California by the Attorney General.
(b)(1)A violation of Section 17030, 17035, or 17045 is an act of unfair competition within the meaning of Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code. But nothing in this article shall limit any other statutory or common law rights or remedies, including liability pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code).
(2)An action shall not be brought in the name of the people of the State of California that seeks relief under this section pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code) without the written consent and permission of the Attorney General.
(3)This subdivision does not alter or abrogate the departments authority to enforce this division.
(c)The remedies or penalties provided by this chapter are cumulative to each other and to the remedies or penalties available under all other laws of this state.
17090.There is hereby established in the State Treasury the Pharmacy Benefit Manager Fines and Penalties Fund. The Beginning on or after January 1, 2026, the fines and administrative penalties collected pursuant to this chapter shall be deposited into the Pharmacy Benefit Manager Fines and Penalties Fund for use upon appropriation by the Legislature. Account, which is hereby established in the General Fund.
SEC. 6.The authority of the Attorney General to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations shall not be narrowed, abrogated, or otherwise altered by this act.
SEC. 7.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 8.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SEC. 9.The Legislature finds and declares that Section 5 of this act, which adds Sections 17025 and 17075 to the Insurance Code, imposes a limitation on the publics right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 3 Section 5 of Article I of the California Constitution. Pursuant to that constitutional provision, the Legislature makes the following findings to demonstrate the interest protected by this limitation and the need for protecting that interest:
In order to protect the confidentiality of information received by state agencies from pharmacy benefit managers, it is necessary that those documents be presumptively confidential, except as otherwise provided by law.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an enrollees cost-sharing amount, including deductible and coinsurance, as applicable, based exclusively on its negotiated rate for the prescription drug. This subdivision does not prevent a health care service plan from deducting rebates, as that term is defined by Section 17000 of the Insurance Code, or any other discounts it receives, from the negotiated rate for a prescription drug from which cost-sharing amounts are calculated. cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
(b)(1)Commencing January 1, 2025, if a preexisting contract between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) of the Insurance Code and a health care service plan authorizes spread pricing, as that term is defined by Section 17000 of the Insurance Code, any subsequent amendment or renewal of that contract shall not authorize spread pricing.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) of the Insurance Code and a health care service plan shall not authorize spread pricing, as that term is defined by Section 17000 of the Insurance Code.
SEC. 2.Section 1367.243 of the Health and Safety Code is amended to read:1367.243.(a)(1)A health care service plan that reports rate information pursuant to Section 1385.03 or 1385.045 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health care service plans.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2019, the department shall publish on its Internet Web site internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 1385.045.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 2.SEC. 3.Section 10123.2045 is added to the Insurance Code, immediately following Section 10123.204, to read:10123.2045.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall not calculate an insureds cost-sharing amount, including deductible and coinsurance, as applicable, based exclusively on its negotiated rate for the prescription drug. This subdivision does not prevent a health insurer from deducting rebates, as that term is defined by Section 17000, or any other discounts it receives, from the negotiated rate for a prescription drug from which cost-sharing amounts are calculated. cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
(b)(1)Commencing January 1, 2025, if a preexisting contract between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) and a health insurer authorizes spread pricing, as that term is defined by Section 17000, any subsequent amendment or renewal of that contract shall not authorize spread pricing.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Division 6 (commencing with Section 17000) and a health insurer shall not authorize spread pricing, as that term is defined by Section 17000.
SEC. 4.Section 10123.205 of the Insurance Code is amended to read:10123.205.(a)(1)A health insurer that reports rate information pursuant to Section 10181.3 or 10181.45 shall report the information described in paragraph (2) to the department no later than October 1 of each year, beginning October 1, 2018.
(2)For all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, all of the following shall be reported:
(A)The 25 most frequently prescribed drugs.
(B)The 25 most costly drugs by total annual plan spending.
(C)The 25 drugs with the highest year-over-year increase in total annual plan spending.
(D)For each list in subparagraphs (A) to (C), inclusive, all of the following:
(i)The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
(ii)The aggregate amount of rebates received by the pharmacy benefit manager for each drug.
(iii)Any administrative fees received from the pharmaceutical manufacturer or labeler.
(iv)The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the pharmacy benefit manager for each drug.
(v)The aggregate of payments made by the pharmacy benefit manager to pharmacies not owned or collected by the pharmacy benefit manager for each drug.
(b)The department shall compile the information reported pursuant to subdivision (a) into a report for the public and legislators that demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health insurers.
(c)For the purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
(d)By January 1 of each year, beginning January 1, 2018, the department shall publish on its Internet Web site internet website the report required pursuant to subdivision (b).
(e)After the report required in subdivision (b) is released, the department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(f)Except for the report required pursuant to subdivision (b), the department shall keep confidential all of the information provided to the department pursuant to this section, and the information shall be protected from public disclosure.
SEC. 3.SEC. 5.Division 6 (commencing with Section 17000) is added to the Insurance Code, to read:6.Regulation of Pharmacy Benefit Managers1.General Provisions17000.For purposes of this division:
(a)Affiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a pharmacy benefit manager.
(b)Claim means a request for payment for administering, filling, or refilling a drug or for providing a pharmacy service or a medical supply or device to an enrollee or insured.
(c)Contract pharmacy means a retail pharmacy or other pharmacy that contracts directly or through a pharmacy services administration organization with a pharmacy benefit manager.
(d)Drug has the same meaning as defined in Section 4025 of the Business and Professions Code.
(e)Health care service plan means an entity licensed pursuant to the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code), including an entity that enters into a contract with the State Department of Health Care Services for the delivery of health care services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), Chapter 8.75 (commencing with Section 14591), or Chapter 8.9 (commencing with Section 14700) of Part 3 of Division 9 of the Welfare and Institutions Code. An entity that is licensed as a health care service plan and that operates a prescription drug plan that is subject to the provisions of the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code) is subject to this chapter unless preempted by federal law. Code).
(f)Health insurer means a disability insurer that issues health insurance, as defined in Section 106.
(g)Manufacturer has the same meaning as defined in Section 4033 of the Business and Professions Code.
(h)Nonaffiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, does not control, is not controlled by, and is not under common control with, a pharmacy benefit manager.
(i)Nonresident pharmacy has the same meaning as described in Section 4112 of the Business and Professions Code.
(j)Person has the same meaning as defined in Section 4035 of the Business and Professions Code.
(k)Personal representative means an individual who has authority to make a health care decision on behalf of another individual pursuant to Division 4.7 (commencing with Section 4600) of the Probate Code.
(l)Pharmacist has the same meaning as defined in Section 4036 of the Business and Professions Code.
(m)Pharmacist services means products, goods, and services, or any combination of products, goods, and services, provided as a part of the practice of pharmacy.
(n)Pharmacy has the same meaning as defined in Section 4037 of the Business and Professions Code.
(o)Pharmacy benefit management fee means a fee that covers the cost of providing one or more pharmacy benefit management services and that does not exceed the value of the service or services actually performed by the pharmacy benefit manager.
(p)Pharmacy benefit management service means all of the following:
(1)Negotiating the price of prescription drugs, including negotiating and contracting for direct or indirect rebates, discounts, or other price concessions.
(2)Managing any aspect of a prescription drug benefit, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with pharmacies, controlling the cost of covered prescription drugs, managing or providing data relating to the prescription drug benefit, or the provision of services related thereto.
(3)Performing any administrative, managerial, clinical, pricing, financial, reimbursement, data administration, or reporting, or billing service.
(4)Other services as the department may define in regulation.
(q)Pharmacy benefit manager means a person, business, or other entity that, either directly or indirectly, manages the prescription drug coverage, including, but not limited to, the following: clinical or other formulary or preferred drug list development or management; the processing and payment of claims for prescription drugs, the negotiation or administration of rebates, discounts, payment differentials, or other incentives; for the inclusion of particular prescription drugs in a particular category or to promote the purchase of particular prescription drugs; the performance of drug utilization review; the processing of drug prior authorization requests; the adjudication of appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. Pharmacy benefit manager does not include either of the following:
(1)A health care service plan that is part of a fully integrated delivery system in which enrollees primarily use pharmacies that are entirely owned and operated by the health care service plan, and the plans enrollees may use any pharmacy in the health care service plans network that has the ability to dispense the medication or provide the services.
(2)A contract authorized by Section 4600.2 of the Labor Code.
(r)Pharmacy services administration organization means an entity that provides contracting and other administrative services relating to prescription drug benefits to pharmacies.
(s)Rebate means a formulary discount or remuneration attributable to the use of prescription drugs that is paid by a manufacturer or third party, directly or indirectly, to a pharmacy benefit manager after a claim has been adjudicated at a pharmacy. Rebate does not include a fee, including a bona fide service fee or administrative fee, that is not a formulary discount or remuneration.
(t)Retail pharmacy means a pharmacy that dispenses prescription drugs to the public at retail typically by face-to-face interaction with the individual or the individuals caregiver.
(u)Spread pricing means the model of prescription drug pricing in which a pharmacy benefit manager charges a health care service plan or health insurer a contracted price for prescription drugs, and the contracted price for the prescription drugs differs from the amount the pharmacy benefit manager directly or indirectly pays the pharmacist or pharmacy.
(v)Third party means a person that is not an enrollee, insured, or pharmacy benefit manager.
(w)Wholesaler has the same meaning as defined in Section 4043 of the Business and Professions Code.
17005.The department shall adopt regulations necessary to implement this division.
(a)Until January 1, 2028, necessary regulations for the purpose of implementing this division may be adopted as emergency regulations in accordance with the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code). The adoption of emergency regulations pursuant to this section shall be deemed to be an emergency and necessary for the immediate preservation of the public peace, health and safety, or general welfare.
(b)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, including subdivisions (e) and (h) of Section 11346.1, an emergency regulation adopted pursuant to this section shall be repealed by operation of law unless the adoption, amendment, or repeal of the regulation is promulgated by the department pursuant to Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code within five years of the initial adoption of the emergency regulation.
(c)A regulation adopted pursuant to this section shall be discussed by the department during at least one public stakeholder meeting before the department adopts the rule or regulation.
17006.The department shall establish procedures for receiving, investigating, tracking, and publicly reporting consumer complaints against pharmacy benefit managers.
2.Licensing17010.(a)The department shall license and regulate pharmacy benefit managers.
(b)A On and after January 1, 2026, a pharmacy benefit manager that provides services in this state shall apply for, obtain, and maintain a license to operate as a pharmacy benefit manager from the department.
(c)An application for a pharmacy benefit manager license shall be submitted in a form and manner determined by the department. The application shall include all of the following:
(1)The information as to each person beneficially interested therein or any person with management or control over the pharmacy benefit manager.
(2)A copy of all organizational and governing documents of the pharmacy benefit manager.
(3)A description of the pharmacy benefit manager, its services, facilities, and personnel.
(4)A document in which the pharmacy benefit manager confirms that its business practices and each ongoing contract comply with this chapter.
(d)Within 30 days after a significant modification of the information or documents submitted pursuant to subdivision (b), a pharmacy benefit manager shall file a notice of the modification with the department.
17015.(a)A pharmacy benefit manager license shall be renewed every two years and is nontransferable.
(b)To renew a pharmacy benefit manager license, an applicant shall submit to the department both of the following:
(1)A renewal application in a form and manner determined by the department that is signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the renewal form are correct.
(2)A renewal schedule and fee as determined by the department.
(c)A pharmacy benefit manager license shall expire if a complete renewal filing and fee is not received by the due date established by the department.
17020.(a)The fee for a pharmacy benefit manager license shall be ____ dollars ($____) and may be increased to ____ dollars ($____). The fee for the issuance of a temporary pharmacy permit shall be ____ dollars ($____) and may be increased to ____ dollars ($____).(b)The fee for a pharmacy benefit manager license annual renewal shall be ____ dollars ($____) and may be increased to ____ dollars ($____).17020.(a)There is hereby established in the State Treasury the Pharmacy Benefit Manager Fund. The fund shall be available to the department for use, upon appropriation by the Legislature, for costs related to the licensing and regulation of pharmacy benefit managers.
(b)The fees for a pharmacy benefit manager initial license and renewal application shall be sufficient to fund the departments duties in relation to responsibilities under this chapter, but in no case shall the fee exceed the reasonable regulatory cost to administer this division. Fees shall be collected into the Pharmacy Benefit Manager Fund.
3.Licensee Duties17025.(a)On or before April 1, 2027, and on or before each April 1 thereafter, a pharmacy benefit manager shall file with the department a report that contains all of the information required by subdivision (e) of Section 4441 of the Business and Professions Code from the preceding calendar year.
(b)The report submitted pursuant to subdivision (a) shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). Nothing in this section shall prevent disclosure to the Attorney General to investigate, prosecute, defend any legitimate legal claim or cause or action, or to use the reports in any court or proceeding of law.(c)(b)On or before August 1, 2027, and on or before each August 1 thereafter, the department shall prepare a report based on the information received by the department pursuant to subdivision (a) and shall submit the report to the Legislature in compliance with Section 9795 of the Government Code. The report shall contain aggregate data and shall exclude any information that the department determines would cause financial, competitive, or proprietary harm to a pharmacy benefit manager. The department shall post the report on the departments internet website.
(c)On or before October 1, 2025, and on or before each October 1 thereafter, a pharmacy benefit manager shall report to the department all of the following information:
(1)A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. For each drug that falls into the above categories, the pharmacy benefit manager shall report both of the following:
(A)The pharmacy type used to fill the drug prescription, such as integrated, chain, independent, specialty, and mail order pharmacies.
(B)Pricing and rebate information, including the net price paid, the amount of rebate the pharmacy benefit manager receives from the manufacturer, the amount of rebate the pharmacy benefit manager passes to the health care service plan or health insurer, the amount the plan or insurer pays the pharmacy benefit manager, and the amount the pharmacy benefit manager pays the pharmacy.
(2)All of the following information in the aggregate:
(A)The purchasers with which the pharmacy benefit manager contracts, the scope of services provided to the purchasers, and the number of enrollees, insureds, and plan members served.
(B)Pharmacy benefit manager revenue, including revenue from manufacturers, purchasers, and other revenue.
(C)Pharmacy benefit manager expenses, including payments to pharmacies, claims processing, special programs, administration, and other expenses.
(d)The department shall compile the information reported pursuant to subdivision (c) into a report for the public and Legislature that demonstrates the overall impact of pharmacy benefit managers on drug costs. The data in the report shall be aggregated and shall not reveal information specific to individual purchasers.
(1)On or before January 1, 2026, and on or before each January 1 thereafter, the department shall publish the report on its internet website.
(2)The report shall be submitted to the Legislature in compliance with Section 9795 of the Government Code.
(3)The department shall include the report as part of the public meeting required pursuant to subdivision (b) of Section 10181.45.
(e)Except for the reports required pursuant to subdivisions (b) and (d), the information submitted to the department pursuant to subdivisions (a) and (c) shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). This section does not prevent disclosure to the Attorney General to investigate, prosecute, or defend any legitimate legal claim or cause or action, or to use the reports in any court or proceeding of law.
(f)For purposes of this section, a specialty drug is one that exceeds the threshold for a specialty drug under the Medicare Part D program (Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173)).
17030.(a)A pharmacy benefit manager shall not impose any requirements, conditions, or exclusions that discriminate against a nonaffiliated pharmacy in connection with dispensing drugs.
(b)Discrimination prohibited pursuant to subdivision (a) includes all of the following:
(1)Terms or conditions applied to nonaffiliated pharmacies based on their status as a nonaffiliated pharmacy.
(2)Refusing to contract with or terminating a contract with a nonaffiliated pharmacy on the basis that the pharmacy is a nonaffiliated pharmacy or for reasons other than those that apply equally to affiliated pharmacies.
(3)Retaliation against a nonaffiliated pharmacy based on its exercise of any right or remedy under this chapter.
(c)Before a prescription is dispensed, an affiliated pharmacy shall disclose to an enrollee or insured that the affiliated pharmacy is an affiliated pharmacy and that the enrollee or insured is not obligated to use the affiliated pharmacy.(c)This division does not preclude a pharmacy benefit manager or a purchaser of pharmacy benefit manager services from establishing a network of contracting or participating pharmacies.
17035.A pharmacy benefit manager shall not do any of the following:
(a)Require an enrollee or insured to use only an affiliated pharmacy that is a retail pharmacy. pharmacy if there are nonaffiliated pharmacies in the network.
(b)Financially induce an enrollee, insured, or prescriber to transfer a prescription only to a retail affiliated pharmacy. pharmacy if there are nonaffiliated pharmacies in the network.
(c)Require a retail nonaffiliated pharmacy to transfer a prescription to a retail affiliated pharmacy. pharmacy if there are nonaffiliated pharmacies in the network. This paragraph does not prevent a health care service plan or the agent of a health care service plan purchaser or pharmacy benefit manager from offering and communicating to enrollees financial incentives to use a particular pharmacy, including, but not limited to, reductions in copays or other financial incentives given to the enrollee such as lower copays or costs for a prescription when the prescription is dispensed.
(d)Unreasonably restrict an enrollee or insured from using a particular contracted retail pharmacy for the purpose of receiving pharmacist services covered by the enrollees or insureds contract or policy.
(e)Communicate to an enrollee verbally, electronically, or in writing that the enrollee is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other pharmacies that have the ability to dispense the medication or provide the services. services and are also in network.
(f)Deny a contract pharmacy the opportunity to participate in a pharmacy benefits manager network as preferred participation status if the pharmacy is willing to accept the same terms and conditions that the pharmacy benefit manager has established for other pharmacies as a condition of preferred network participation status.
17040.(a)A contract issued, amended, or renewed on or after January 1, 2025, between a retail pharmacy and a pharmacy benefit manager shall not prohibit the retail pharmacy from offering either of the following as an ancillary service of the retail pharmacy:
(1)The delivery of a prescription drug by mail or common carrier to a patient or personal representative on request of the patient or personal representative if the request is made before the drug is delivered.
(2)The delivery of a prescription to a patient or personal representative by an employee or contractor of the retail pharmacy.
(b)Except as otherwise provided in a contract described in subdivision (a), the retail pharmacy shall not charge a pharmacy benefit manager for the delivery service described in subdivision (a). This section does not prohibit the use of remote pharmacies, secure locker systems, or other types of pickup stations if those services are otherwise permitted by law.
(c)Contracts entered into pursuant to this section shall be open for inspection by the department.
17045.A pharmacy benefit manager shall not require more than two accreditations from an independent accrediting organization for pharmacists and pharmacies that apply to be in a specialty network and shall make every effort to ensure that enhanced standards are not imposed for participation in a specialty network beyond those related to the safety and competency necessary to comply with requirements for dispensing specified medications. medications and providing optimal patient care.
17050.(a)A pharmacy benefit manager shall not derive income from pharmacy benefit management services provided to an insurer or health plan in this state except for income derived from a pharmacy benefit management fee. fees for services provided. The amount of any pharmacy benefit management fees shall be set forth in the agreement between the pharmacy benefit manager and the insurer or health plan.
(b)(1)The pharmacy benefit management fee charged by or paid to a pharmacy benefit manager from an insurer or health plan shall not be directly or indirectly based or contingent upon:
(1)(A)The acquisition cost or any other price metric of a drug.
(2)(B)The amount of savings, rebates, or other fees charged, realized, or collected by or generated based on the activity of the pharmacy benefit manager.
(3)(C)The amount of premiums, deductibles, or other cost-sharing cost sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.
(2)This subdivision does not preclude a health care service plan or insurer from paying performance bonuses to a pharmacy benefit manager.
(3)Compensation arrangements governed by this section shall be open for inspection by the department.
(c)A pharmacy benefit manager shall not reverse and resubmit the claim of a contract pharmacy:
(1)Without prior and proper notification to the contract pharmacy.
(2)Without just cause or attempt to first reconcile the claim with the pharmacy.
(3)More than 90 days after the claim was first affirmatively adjudicated.
(d)A pharmacy benefit manager shall not directly or indirectly, including indirectly through a pharmacy services administrative organization, charge or hold a pharmacist or pharmacy responsible for a fee related to a claim or reduce the amount of the claim at the time of the claims adjudication or after the claim is adjudicated.
(e)Subdivision (a) does not apply to an audit of a pharmacys records pursuant to Chapter 9.5 (commencing with Section 4430) of Division 2 of the Business and Professions Code if either of the following apply:
(1)The review of claims data or statements indicates criminal wrongdoing, willful misrepresentation, fraud, or abuse.
(2)An investigative method, other than a review described in paragraph (1), indicates that the pharmacy is or has committed criminal wrongdoing, willful misrepresentation, fraud, or abuse.
(f)A pharmacy benefit manager shall not charge a pharmacy or pharmacist a fee to process a claim electronically.
(g)The termination of a contract with a pharmacy by a pharmacy benefit manager shall not release the pharmacy benefit manager from the obligation to make a payment due to the pharmacy for an affirmatively adjudicated claim unless payments are withheld because of an investigation relating to insurance fraud.
(h)A pharmacy benefit manager shall not retaliate against a pharmacist or pharmacy based on the pharmacists or pharmacys exercise of a right or remedy under this chapter. Prohibited retaliation includes any of the following:
(1)Terminating or refusing to renew a contract with the pharmacist or pharmacy.
(2)Subjecting the pharmacist or pharmacy to increased audits.
(3)Failing to promptly pay the pharmacist or pharmacy money owed by the pharmacy benefit manager to the pharmacist or pharmacy.
17055.(a)Except as permitted under existing law, a pharmacy benefit manager shall not unreasonably obstruct or interfere with a patients right to timely access a prescription drug or device that has been legally prescribed for that patient at a contract pharmacy of their choice.
(b)A pharmacy benefit manager shall not make, disseminate, or cause or permit the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
(c)The department may investigate referrals provided by the California State Board of Pharmacy.
17060.Commencing January 1, 2025, a pharmacy benefit manager shall not conduct spread pricing in this state. If a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizes spread pricing, any subsequent amendment or renewal of that contract shall not contain that authorization. Any such spread pricing terms shall be void after January 1, 2028.
17065.(a)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with manufacturers who do business in California that expressly or implicitly restrict, or implements implicit or express exclusivity for, those manufacturers drugs, medical devices, or other products.
(b)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with pharmacies or pharmacy administrative services organizations who do business in California that expressly or implicitly restrict, or impose implicit or express exclusivity on, nonaffiliated pharmacies ability to contract with employers, insurers, and health care service plans.
4.Enforcement17070.(a)The department may refuse to issue a pharmacy benefit manager license if the department determines that the pharmacy benefit manager or an individual responsible for the conduct of affairs of the pharmacy benefit manager has had a pharmacy benefit manager certificate of authority or license denied or revoked for cause in another state.
(b)The department may deny, suspend, or revoke the license of a pharmacy benefit manager, or may issue a cease and desist order if the pharmacy benefit manager is not licensed, if the department finds, after notice and opportunity for hearing, that any of the following are true:
(1)The pharmacy benefit manager has violated a statute or regulation applicable to the pharmacy benefit manager.
(2)The pharmacy benefit manager has refused to be examined or to produce its accounts, records, and files for examination by the department, or an individual responsible for the conduct of affairs of the pharmacy benefit manager has refused to give information with respect to its affairs or has refused to perform any other legal obligation as to an examination required by the department.
(3)The pharmacy benefit manager has, without just cause, exhibited a pattern or practice of refusing to pay proper claims or perform services arising under its contracts or has, without just cause, caused enrollees or insureds to accept less than the amount due them.
(4)The pharmacy benefit manager is required under this chapter to have a license and fails to continue to meet the qualifications for licensure during its active licensure, unless the department issued a license with knowledge of the failure to qualify and waived the relevant requirement.
(5)An individual responsible for the conduct of affairs of the pharmacy benefit manager has been convicted of, or has entered a plea of guilty or nolo contendere to, a felony without regard to whether adjudication was withheld.
(6)The pharmacy benefit managers license or registration has been suspended or revoked in another state.
(7)The pharmacy benefit manager failed to file a timely report as required by Section 17025.
(c)If a pharmacy benefit managers license is suspended or restricted, the department may permit the operation of the pharmacy benefit manager for a limited time not to exceed 60 days. However, the department may permit a pharmacy benefit manager whose license has been suspended or restricted to operate for a period that exceeds 60 days if the department determines that the continued operation of the pharmacy benefit manager is in the beneficial interests of enrollees and insureds by ensuring minimal disruptions to the continuity of care.
(d)A pharmacy benefit manager whose license has been suspended or restricted is subject to a fine each month, as determined by the department, not to exceed twenty thousand dollars ($20,000) per month, until the pharmacy benefit manager has remedied the violation leading to the suspension or restriction.
(e)The department may revoke the license of a pharmacy benefit manager if the pharmacy benefit manager has been operating under a suspended license for a period of more than 60 days.
(f)For purposes of this section, a pharmacy benefit manager has the right to appropriate notice and opportunity for hearing in accordance with the Administrative Procedure Act (Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code).
17075.(a)The department may examine or audit the relevant any books and records of a pharmacy benefit manager to determine if the pharmacy benefit manager is in compliance with this chapter. division. A pharmacy benefit manager shall pay for reasonable expenses for any examinations or audits conducted pursuant to this section. Those payments shall be deposited into the Pharmacy Benefit Manager Fund. Examinations conducted by the department shall be pursuant to the same examination authority of the department relative to insurers. Pharmacy benefit managers shall have the same rights as insurers.
(b)Information or data acquired during an examination pursuant to subdivision (a), or otherwise acquired under this division shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). This section does not prevent disclosure to the Attorney General to investigate, prosecute, defend any legitimate legal claim or cause or action, or to use the information and data in any court or proceeding of law.
(c)(1)The department shall establish a retention schedule for all records, books, papers, and other data on file with the department related to the enforcement of this chapter.
(2)The department shall not order the destruction or other disposal of a record, book, paper, or other data that is either of the following:
(A)Required by law to be filed or kept on file with the department.
(B)Filed during the departments administration or administrations.
(d)In any matter arising under this chapter, the department may provide to the Attorney General information related to competition and obtain an opinion from a consultant or consultants with the expertise to assess the competitive impact of the matter.
17080.(a)Notwithstanding the Section 4441 of the Business and Professions Code and Chapter 2.2 (commencing with Section 1385.001) of Division 2 of the Health and Safety Code, a pharmacy benefit manager shall have a duty and obligation to the enrollee or insured and the health care service plan, plan or insurer, or provider, and shall perform its services with care, skill, prudence, diligence, and professionalism, and for the best interests of the enrollee or insured, and the health care service plan, insurer, or provider. Where there is a conflict in the pharmacy benefit managers duty or obligation under this subdivision to the individual enrollee or insured and any other party, the duty or obligation to the individual enrollee or insured shall be primary. plan or insurer.
(b)An enrollee or insured shall be deemed to be third-party beneficiaries of the duties, obligations, and requirements applicable to the pharmacy benefit manager under this chapter and shall be entitled to legal or equitable relief for any injury or loss to the enrollee or insured caused by any violation of those duties, obligations, or requirements.(c)(b)Any pharmacy benefit manager that violates Chapter 3 (commencing with Section 17025) shall, in addition to any other penalty provided by law, be liable for restitution to any enrollee or insured harmed by the violation and shall also be subject to a penalty not exceeding the greater of (1) one thousand dollars ($1,000) for the first violation and two thousand five hundred dollars ($2,500) for each subsequent violation or (2) the aggregate economic gross receipts attributable to all violations.
(d)(c)Notwithstanding any other law, the Attorney General shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
17085.(a)Any person that violates this chapter division shall be subject to an injunction and liable for a civil penalty of not less than one thousand dollars ($1,000) or more than seven thousand five hundred dollars ($7,500) for each violation which shall be assessed and recovered in a civil action brought in the name of the people of the State of California by the Attorney General.
(b)(1)A violation of Section 17030, 17035, or 17045 is an act of unfair competition within the meaning of Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code. But nothing in this article shall limit any other statutory or common law rights or remedies, including liability pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code).
(2)An action shall not be brought in the name of the people of the State of California that seeks relief under this section pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code) without the written consent and permission of the Attorney General.
(c)The remedies or penalties provided by this chapter are cumulative to each other and to the remedies or penalties available under all other laws of this state.
17090.There is hereby established in the State Treasury the Pharmacy Benefit Manager Fines and Penalties Fund. The fines and administrative penalties collected pursuant to this chapter shall be deposited into the Pharmacy Benefit Manager Fines and Penalties Fund for use upon appropriation by the Legislature.
SEC. 4.SEC. 6.The authority of the Attorney General to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations shall not be narrowed, abrogated, or otherwise altered by this act.
SEC. 5.SEC. 7.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 6.SEC. 8.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SEC. 7.SEC. 9.The Legislature finds and declares that Section 3 5 of this act, which adds Sections 17025 and 17075 to the Insurance Code, imposes a limitation on the publics right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 3 of Article I of the California Constitution. Pursuant to that constitutional provision, the Legislature makes the following findings to demonstrate the interest protected by this limitation and the need for protecting that interest:
In order to protect the confidentiality of information received by state agencies from pharmacy benefit managers, it is necessary that those documents be presumptively confidential, except as otherwise provided by law.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall calculate an enrollees cost-sharing amount, including deductible and coinsurance, as applicable, based exclusively on its negotiated rate for the prescription drug. This subdivision does not prevent a health care service plan from deducting rebates, as that term is defined by Section 4445 of the Business and Professions 17000 of the Insurance Code, or any other discounts it receives, from the negotiated rate for a prescription drug from which cost-sharing amounts are calculated.
(b)(1)Commencing January 1, 2025, if a preexisting contract between a pharmacy benefit manager licensed pursuant to Chapter 9.6 (commencing with Section 4445) of Division 2 of the Business and Professions Division 6 (commencing with Section 17000) of the Insurance Code and a health care service plan authorizes spread pricing, as that term is defined by Section 4445 of the Business and Professions 17000 of the Insurance Code, any subsequent amendment or renewal of that contract shall not authorize spread pricing.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Chapter 9.6 (commencing with Section 4445) of Division 2 of the Business and Professions Division 6 (commencing with Section 17000) of the Insurance Code and a health care service plan shall not authorize spread pricing, as that term is defined by Section 4445 of the Business and Professions 17000 of the Insurance Code.
SEC. 4.SEC. 2.Section 10123.2045 is added to the Insurance Code, immediately following Section 10123.204, to read:10123.2045.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall calculate an insureds cost-sharing amount, including deductible and coinsurance, as applicable, based exclusively on its negotiated rate for the prescription drug. This subdivision does not prevent a health insurer from deducting rebates, as that term is defined by Section 4445 of the Business and Professions Code, 17000, or any other discounts it receives, from the negotiated rate for a prescription drug from which cost-sharing amounts are calculated.
(b)(1)Commencing January 1, 2025, if a preexisting contract between a pharmacy benefit manager licensed pursuant to Chapter 9.6 (commencing with Section 4445) of Division 2 of the Business and Professions Code Division 6 (commencing with Section 17000) and a health insurer authorizes spread pricing, as that term is defined by Section 4445 of the Business and Professions Code, 17000, any subsequent amendment or renewal of that contract shall not authorize spread pricing.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Chapter 9.6 of Division 2 of the Business and Professions Code (commencing with Section 4445) Division 6 (commencing with Section 17000) and a health insurer shall not authorize spread pricing, as that term is defined by Section 4445 of the Business and Professions Code. 17000.
SEC. 3.Division 6 (commencing with Section 17000) is added to the Insurance Code, to read:6.Regulation of Pharmacy Benefit Managers1.General Provisions17000.For purposes of this division:
(a)Affiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a pharmacy benefit manager.
(b)Claim means a request for payment for administering, filling, or refilling a drug or for providing a pharmacy service or a medical supply or device to an enrollee or insured.
(c)Contract pharmacy means a retail pharmacy or other pharmacy that contracts directly or through a pharmacy services administration organization with a pharmacy benefit manager.
(d)Drug has the same meaning as defined in Section 4025 of the Business and Professions Code.
(e)Health care service plan means an entity licensed pursuant to the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code), including an entity that enters into a contract with the State Department of Health Care Services for the delivery of health care services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), Chapter 8.75 (commencing with Section 14591), or Chapter 8.9 (commencing with Section 14700) of Part 3 of Division 9 of the Welfare and Institutions Code. An entity that is licensed as a health care service plan and that operates a prescription drug plan that is subject to the provisions of the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code) is subject to this chapter unless preempted by federal law.
(f)Health insurer means a disability insurer that issues health insurance, as defined in Section 106.
(g)Manufacturer has the same meaning as defined in Section 4033 of the Business and Professions Code.
(h)Nonaffiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, does not control, is not controlled by, and is not under common control with, a pharmacy benefit manager.
(i)Nonresident pharmacy has the same meaning as described in Section 4112 of the Business and Professions Code.
(j)Person has the same meaning as defined in Section 4035 of the Business and Professions Code.
(k)Personal representative means an individual who has authority to make a health care decision on behalf of another individual pursuant to Division 4.7 (commencing with Section 4600) of the Probate Code.
(l)Pharmacist has the same meaning as defined in Section 4036 of the Business and Professions Code.
(m)Pharmacist services means products, goods, and services, or any combination of products, goods, and services, provided as a part of the practice of pharmacy.
(n)Pharmacy has the same meaning as defined in Section 4037 of the Business and Professions Code.
(o)Pharmacy benefit management fee means a fee that covers the cost of providing one or more pharmacy benefit management services and that does not exceed the value of the service or services actually performed by the pharmacy benefit manager.
(p)Pharmacy benefit management service means all of the following:
(1)Negotiating the price of prescription drugs, including negotiating and contracting for direct or indirect rebates, discounts, or other price concessions.
(2)Managing any aspect of a prescription drug benefit, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with pharmacies, controlling the cost of covered prescription drugs, managing or providing data relating to the prescription drug benefit, or the provision of services related thereto.
(3)Performing any administrative, managerial, clinical, pricing, financial, reimbursement, data administration, or reporting, or billing service.
(4)Other services as the department may define in regulation.
(q)Pharmacy benefit manager means a person, business, or other entity that, either directly or indirectly, manages the prescription drug coverage, including, but not limited to, the following: clinical or other formulary or preferred drug list development or management; the processing and payment of claims for prescription drugs, the negotiation or administration of rebates, discounts, payment differentials, or other incentives; for the inclusion of particular prescription drugs in a particular category or to promote the purchase of particular prescription drugs; the performance of drug utilization review; the processing of drug prior authorization requests; the adjudication of appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. Pharmacy benefit manager does not include either of the following:
(1)A health care service plan that is part of a fully integrated delivery system in which enrollees primarily use pharmacies that are entirely owned and operated by the health care service plan, and the plans enrollees may use any pharmacy in the health care service plans network that has the ability to dispense the medication or provide the services.
(2)A contract authorized by Section 4600.2 of the Labor Code.
(r)Pharmacy services administration organization means an entity that provides contracting and other administrative services relating to prescription drug benefits to pharmacies.
(s)Rebate means a formulary discount or remuneration attributable to the use of prescription drugs that is paid by a manufacturer or third party, directly or indirectly, to a pharmacy benefit manager after a claim has been adjudicated at a pharmacy. Rebate does not include a fee, including a bona fide service fee or administrative fee, that is not a formulary discount or remuneration.
(t)Retail pharmacy means a pharmacy that dispenses prescription drugs to the public at retail typically by face-to-face interaction with the individual or the individuals caregiver.
(u)Spread pricing means the model of prescription drug pricing in which a pharmacy benefit manager charges a health care service plan or health insurer a contracted price for prescription drugs, and the contracted price for the prescription drugs differs from the amount the pharmacy benefit manager directly or indirectly pays the pharmacist or pharmacy.
(v)Third party means a person that is not an enrollee, insured, or pharmacy benefit manager.
(w)Wholesaler has the same meaning as defined in Section 4043 of the Business and Professions Code.
17005.The department shall adopt regulations necessary to implement this division.
2.Licensing17010.(a)The department shall license and regulate pharmacy benefit managers.
(b)A pharmacy benefit manager that provides services in this state shall apply for, obtain, and maintain a license to operate as a pharmacy benefit manager from the department.
(c)An application for a pharmacy benefit manager license shall be submitted in a form and manner determined by the department. The application shall include all of the following:
(1)The information as to each person beneficially interested therein or any person with management or control over the pharmacy benefit manager.
(2)A copy of all organizational and governing documents of the pharmacy benefit manager.
(3)A description of the pharmacy benefit manager, its services, facilities, and personnel.
(4)A document in which the pharmacy benefit manager confirms that its business practices and each ongoing contract comply with this chapter.
(d)Within 30 days after a significant modification of the information or documents submitted pursuant to subdivision (b), a pharmacy benefit manager shall file a notice of the modification with the department.
17015.(a)A pharmacy benefit manager license shall be renewed every two years and is nontransferable.
(b)To renew a pharmacy benefit manager license, an applicant shall submit to the department both of the following:
(1)A renewal application in a form and manner determined by the department that is signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the renewal form are correct.
(2)A renewal schedule and fee as determined by the department.
(c)A pharmacy benefit manager license shall expire if a complete renewal filing and fee is not received by the due date established by the department.
17020.(a)The fee for a pharmacy benefit manager license shall be ____ dollars ($____) and may be increased to ____ dollars ($____). The fee for the issuance of a temporary pharmacy permit shall be ____ dollars ($____) and may be increased to ____ dollars ($____).
(b)The fee for a pharmacy benefit manager license annual renewal shall be ____ dollars ($____) and may be increased to ____ dollars ($____).
3.Licensee Duties17025.(a)On or before April 1, 2027, and on or before each April 1 thereafter, a pharmacy benefit manager shall file with the department a report that contains all of the information required by subdivision (e) of Section 4441 of the Business and Professions Code from the preceding calendar year.
(b)The report submitted pursuant to subdivision (a) shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). Nothing in this section shall prevent disclosure to the Attorney General to investigate, prosecute, defend any legitimate legal claim or cause or action, or to use the reports in any court or proceeding of law.
(c)On or before August 1, 2027, and on or before each August 1 thereafter, the department shall prepare a report based on the information received by the department pursuant to subdivision (a) and shall submit the report to the Legislature in compliance with Section 9795 of the Government Code. The report shall contain aggregate data and shall exclude any information that the department determines would cause financial, competitive, or proprietary harm to a pharmacy benefit manager. The department shall post the report on the departments internet website.
17030.(a)A pharmacy benefit manager shall not impose any requirements, conditions, or exclusions that discriminate against a nonaffiliated pharmacy in connection with dispensing drugs.
(b)Discrimination prohibited pursuant to subdivision (a) includes all of the following:
(1)Terms or conditions applied to nonaffiliated pharmacies based on their status as a nonaffiliated pharmacy.
(2)Refusing to contract with or terminating a contract with a nonaffiliated pharmacy on the basis that the pharmacy is a nonaffiliated pharmacy or for reasons other than those that apply equally to affiliated pharmacies.
(3)Retaliation against a nonaffiliated pharmacy based on its exercise of any right or remedy under this chapter.
(c)Before a prescription is dispensed, an affiliated pharmacy shall disclose to an enrollee or insured that the affiliated pharmacy is an affiliated pharmacy and that the enrollee or insured is not obligated to use the affiliated pharmacy.
17035.A pharmacy benefit manager shall not do any of the following:
(a)Require an enrollee or insured to use only an affiliated pharmacy that is a retail pharmacy.
(b)Financially induce an enrollee, insured, or prescriber to transfer a prescription only to a retail affiliated pharmacy.
(c)Require a retail nonaffiliated pharmacy to transfer a prescription to a retail affiliated pharmacy. This paragraph does not prevent a health care service plan or the agent of a health care service plan from offering and communicating to enrollees financial incentives to use a particular pharmacy, including, but not limited to, reductions in copays or other financial incentives given to the enrollee when the prescription is dispensed.
(d)Unreasonably restrict an enrollee or insured from using a particular retail pharmacy for the purpose of receiving pharmacist services covered by the enrollees or insureds contract or policy.
(e)Communicate to an enrollee verbally, electronically, or in writing that the enrollee is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other pharmacies that have the ability to dispense the medication or provide the services.
17040.(a)A contract issued, amended, or renewed on or after January 1, 2025, between a retail pharmacy and a pharmacy benefit manager shall not prohibit the retail pharmacy from offering either of the following as an ancillary service of the retail pharmacy:
(1)The delivery of a prescription drug by mail or common carrier to a patient or personal representative on request of the patient or personal representative if the request is made before the drug is delivered.
(2)The delivery of a prescription to a patient or personal representative by an employee or contractor of the retail pharmacy.
(b)Except as otherwise provided in a contract described in subdivision (a), the retail pharmacy shall not charge a pharmacy benefit manager for the delivery service described in subdivision (a). This section does not prohibit the use of remote pharmacies, secure locker systems, or other types of pickup stations if those services are otherwise permitted by law.
17045.A pharmacy benefit manager shall not require more than two accreditations from an independent accrediting organization for pharmacists and pharmacies that apply to be in a specialty network and shall make every effort to ensure that enhanced standards are not imposed for participation in a specialty network beyond those related to the safety and competency necessary to comply with requirements for dispensing specified medications.
17050.(a)A pharmacy benefit manager shall not derive income from pharmacy benefit management services provided to an insurer or health plan in this state except for income derived from a pharmacy benefit management fee. The amount of any pharmacy benefit management fees shall be set forth in the agreement between the pharmacy benefit manager and the insurer or health plan.
(b)The pharmacy benefit management fee charged by or paid to a pharmacy benefit manager from an insurer or health plan shall not be directly or indirectly based or contingent upon:
(1)The acquisition cost or any other price metric of a drug.
(2)The amount of savings, rebates, or other fees charged, realized, or collected by or generated based on the activity of the pharmacy benefit manager.
(3)The amount of premiums, deductibles, or other cost-sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.
(c)A pharmacy benefit manager shall not reverse and resubmit the claim of a contract pharmacy:
(1)Without prior and proper notification to the contract pharmacy.
(2)Without just cause or attempt to first reconcile the claim with the pharmacy.
(3)More than 90 days after the claim was first affirmatively adjudicated.
(d)A pharmacy benefit manager shall not directly or indirectly, including indirectly through a pharmacy services administrative organization, charge or hold a pharmacist or pharmacy responsible for a fee related to a claim or reduce the amount of the claim at the time of the claims adjudication or after the claim is adjudicated.
(e)Subdivision (a) does not apply to an audit of a pharmacys records pursuant to Chapter 9.5 (commencing with Section 4430) of Division 2 of the Business and Professions Code if either of the following apply:
(1)The review of claims data or statements indicates criminal wrongdoing, willful misrepresentation, fraud, or abuse.
(2)An investigative method, other than a review described in paragraph (1), indicates that the pharmacy is or has committed criminal wrongdoing, willful misrepresentation, fraud, or abuse.
(f)A pharmacy benefit manager shall not charge a pharmacy or pharmacist a fee to process a claim electronically.
(g)The termination of a contract with a pharmacy by a pharmacy benefit manager shall not release the pharmacy benefit manager from the obligation to make a payment due to the pharmacy for an affirmatively adjudicated claim unless payments are withheld because of an investigation relating to insurance fraud.
(h)A pharmacy benefit manager shall not retaliate against a pharmacist or pharmacy based on the pharmacists or pharmacys exercise of a right or remedy under this chapter. Prohibited retaliation includes any of the following:
(1)Terminating or refusing to renew a contract with the pharmacist or pharmacy.
(2)Subjecting the pharmacist or pharmacy to increased audits.
(3)Failing to promptly pay the pharmacist or pharmacy money owed by the pharmacy benefit manager to the pharmacist or pharmacy.
17055.(a)Except as permitted under existing law, a pharmacy benefit manager shall not unreasonably obstruct or interfere with a patients right to timely access a prescription drug or device that has been legally prescribed for that patient at a pharmacy of their choice.
(b)A pharmacy benefit manager shall not make, disseminate, or cause or permit the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
17060.Commencing January 1, 2025, a pharmacy benefit manager shall not conduct spread pricing in this state. If a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizes spread pricing, any subsequent amendment or renewal of that contract shall not contain that authorization. Any such spread pricing terms shall be void after January 1, 2028.
17065.(a)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with manufacturers who do business in California that expressly or implicitly restrict, or implements implicit or express exclusivity for, those manufacturers drugs, medical devices, or other products.
(b)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with pharmacies or pharmacy administrative services organizations who do business in California that expressly or implicitly restrict, or impose implicit or express exclusivity on, nonaffiliated pharmacies ability to contract with employers, insurers, and health care service plans.
4.Enforcement17070.(a)The department may refuse to issue a pharmacy benefit manager license if the department determines that the pharmacy benefit manager or an individual responsible for the conduct of affairs of the pharmacy benefit manager has had a pharmacy benefit manager certificate of authority or license denied or revoked for cause in another state.
(b)The department may deny, suspend, or revoke the license of a pharmacy benefit manager, or may issue a cease and desist order if the pharmacy benefit manager is not licensed, if the department finds, after notice and opportunity for hearing, that any of the following are true:
(1)The pharmacy benefit manager has violated a statute or regulation applicable to the pharmacy benefit manager.
(2)The pharmacy benefit manager has refused to be examined or to produce its accounts, records, and files for examination by the department, or an individual responsible for the conduct of affairs of the pharmacy benefit manager has refused to give information with respect to its affairs or has refused to perform any other legal obligation as to an examination required by the department.
(3)The pharmacy benefit manager has, without just cause, exhibited a pattern or practice of refusing to pay proper claims or perform services arising under its contracts or has, without just cause, caused enrollees or insureds to accept less than the amount due them.
(4)The pharmacy benefit manager is required under this chapter to have a license and fails to continue to meet the qualifications for licensure during its active licensure, unless the department issued a license with knowledge of the failure to qualify and waived the relevant requirement.
(5)An individual responsible for the conduct of affairs of the pharmacy benefit manager has been convicted of, or has entered a plea of guilty or nolo contendere to, a felony without regard to whether adjudication was withheld.
(6)The pharmacy benefit managers license or registration has been suspended or revoked in another state.
(7)The pharmacy benefit manager failed to file a timely report as required by Section 17025.
(c)If a pharmacy benefit managers license is suspended or restricted, the department may permit the operation of the pharmacy benefit manager for a limited time not to exceed 60 days. However, the department may permit a pharmacy benefit manager whose license has been suspended or restricted to operate for a period that exceeds 60 days if the department determines that the continued operation of the pharmacy benefit manager is in the beneficial interests of enrollees and insureds by ensuring minimal disruptions to the continuity of care.
(d)A pharmacy benefit manager whose license has been suspended or restricted is subject to a fine each month, as determined by the department, not to exceed twenty thousand dollars ($20,000) per month, until the pharmacy benefit manager has remedied the violation leading to the suspension or restriction.
(e)The department may revoke the license of a pharmacy benefit manager if the pharmacy benefit manager has been operating under a suspended license for a period of more than 60 days.
(f)For purposes of this section, a pharmacy benefit manager has the right to appropriate notice and opportunity for hearing in accordance with the Administrative Procedure Act (Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code).
17075.(a)The department may examine or audit the relevant books and records of a pharmacy benefit manager to determine if the pharmacy benefit manager is in compliance with this chapter.
(b)Information or data acquired during an examination pursuant to subdivision (a), or otherwise acquired under this division shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). This section does not prevent disclosure to the Attorney General to investigate, prosecute, defend any legitimate legal claim or cause or action, or to use the information and data in any court or proceeding of law.
(c)(1)The department shall establish a retention schedule for all records, books, papers, and other data on file with the department related to the enforcement of this chapter.
(2)The department shall not order the destruction or other disposal of a record, book, paper, or other data that is either of the following:
(A)Required by law to be filed or kept on file with the department.
(B)Filed during the departments administration or administrations.
(d)In any matter arising under this chapter, the department may provide to the Attorney General information related to competition and obtain an opinion from a consultant or consultants with the expertise to assess the competitive impact of the matter.
17080.(a)Notwithstanding the Section 4441 of the Business and Professions Code and Chapter 2.2 (commencing with Section 1385.001) of Division 2 of the Health and Safety Code, a pharmacy benefit manager shall have a duty and obligation to the enrollee or insured and the health care service plan, insurer, or provider, and shall perform its services with care, skill, prudence, diligence, and professionalism, and for the best interests of the enrollee or insured, and the health care service plan, insurer, or provider. Where there is a conflict in the pharmacy benefit managers duty or obligation under this subdivision to the individual enrollee or insured and any other party, the duty or obligation to the individual enrollee or insured shall be primary.
(b)An enrollee or insured shall be deemed to be third-party beneficiaries of the duties, obligations, and requirements applicable to the pharmacy benefit manager under this chapter and shall be entitled to legal or equitable relief for any injury or loss to the enrollee or insured caused by any violation of those duties, obligations, or requirements.
(c)Any pharmacy benefit manager that violates Chapter 3 (commencing with Section 17025) shall, in addition to any other penalty provided by law, be liable for restitution to any enrollee or insured harmed by the violation and shall also be subject to a penalty not exceeding the greater of (1) one thousand dollars ($1,000) for the first violation and two thousand five hundred dollars ($2,500) for each subsequent violation or (2) the aggregate economic gross receipts attributable to all violations.
(d)Notwithstanding any other law, the Attorney General shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
17085.(a)Any person that violates this chapter shall be subject to an injunction and liable for a civil penalty of not less than one thousand dollars ($1,000) or more than seven thousand five hundred dollars ($7,500) for each violation which shall be assessed and recovered in a civil action brought in the name of the people of the State of California by the Attorney General.
(b)(1)A violation of Section 17030, 17035, or 17045 is an act of unfair competition within the meaning of Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code. But nothing in this article shall limit any other statutory or common law rights or remedies, including liability pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code).
(2)An action shall not be brought in the name of the people of the State of California that seeks relief under this section pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code) without the written consent and permission of the Attorney General.
(c)The remedies or penalties provided by this chapter are cumulative to each other and to the remedies or penalties available under all other laws of this state.
SEC. 5.SEC. 4.The authority of the Attorney General to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations shall not be narrowed, abrogated, or otherwise altered by this act.
SEC. 6.SEC. 5.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 7.SEC. 6.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SEC. 8.SEC. 7.The Legislature finds and declares that Section 2 3 of this act, which adds Sections 4445.21 and 4445.41 of the Business and Professions 17025 and 17075 to the Insurance Code, imposes a limitation on the publics right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 3 of Article I of the California Constitution. Pursuant to that constitutional provision, the Legislature makes the following findings to demonstrate the interest protected by this limitation and the need for protecting that interest:
In order to protect the confidentiality of information received by state agencies from pharmacy benefit managers, it is necessary that those documents be presumptively confidential, except as otherwise provided by law.
For purposes of this chapter:
(a)Affiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a pharmacy benefit manager.
(b)Board means the California State Board of Pharmacy.
(c)Claim means a request for payment for administering, filling, or refilling a drug or for providing a pharmacy service or a medical supply or device to an enrollee or insured.
(d)Drug has the same meaning as defined in Section 4025 of the Business and Professions Code.
(e)Health care service plan means an entity licensed pursuant to the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code), including an entity that enters into a contract with the State Department of Health Care Services for the delivery of health care services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), Chapter 8.75 (commencing with Section 14591), or Chapter 8.9 (commencing with Section 14700) of Part 3 of Division 9 of the Welfare and Institutions Code. An entity that is licensed as a health care service plan and that operates a prescription drug plan that is subject to the provisions of the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code) is subject to this chapter unless preempted by federal law.
(f)Health insurer means a disability insurer that issues health insurance, as defined in Section 106 of the Insurance Code.
(g)Manufacturer has the same meaning as defined in Section 4033.
(h)Contract pharmacy means a retail pharmacy or other pharmacy that contracts directly or through a pharmacy services administration organization with a pharmacy benefit manager.
(i)Nonaffiliated pharmacy means a contract pharmacy that directly, or indirectly through one or more intermediaries, does not control, is not controlled by, and is not under common control with, a pharmacy benefit manager.
(j)Nonresident pharmacy has the same meaning as described in Section 4112.
(k)Person has the same meaning as defined in Section 4035.
(l)Personal representative means an individual who has authority to make a health care decision on behalf of another individual pursuant to Division 4.7 (commencing with Section 4600) of the Probate Code.
(m)Pharmacist has the same meaning as defined in Section 4036.
(n)Pharmacist services means products, goods, and services, or any combination of products, goods, and services, provided as a part of the practice of pharmacy.
(o)Pharmacy has the same meaning as defined in Section 4037 of the Business and Professions Code.
(p)Pharmacy benefit manager means a person, business, or other entity that, either directly or indirectly, manages the prescription drug coverage, including, but not limited to, the following: clinical or other formulary or preferred drug list development or management; the processing and payment of claims for prescription drugs, the negotiation or administration of rebates, discounts, payment differentials, or other incentives; for the inclusion of particular prescription drugs in a particular category or to promote the purchase of particular prescription drugs; the performance of drug utilization review; the processing of drug prior authorization requests; the adjudication of appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. Pharmacy benefit manager does not include either of the following:
(1)A health care service plan that is part of a fully integrated delivery system in which enrollees primarily use pharmacies that are entirely owned and operated by the health care service plan, and the plans enrollees may use any pharmacy in the health care service plans network that has the ability to dispense the medication or provide the services.
(2)A contract authorized by Section 4600.2 of the Labor Code.
(q)Pharmacy benefit management fee means a fee that covers the cost of providing one or more pharmacy benefit management services and that does not exceed the value of the service or services actually performed by the pharmacy benefit manager.
(r)Pharmacy benefit management service means all of the following:
(1)Negotiating the price of prescription drugs, including negotiating and contracting for direct or indirect rebates, discounts, or other price concessions.
(2)Managing any aspect of a prescription drug benefit, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with pharmacies, controlling the cost of covered prescription drugs, managing or providing data relating to the prescription drug benefit, or the provision of services related thereto.
(3)Performing any administrative, managerial, clinical, pricing, financial, reimbursement, data administration, or reporting, or billing service.
(4)Other services as the board may define in regulation.
(s)Pharmacy services administration organization means an entity that provides contracting and other administrative services relating to prescription drug benefits to pharmacies.
(t)Rebate means a formulary discount or remuneration attributable to the use of prescription drugs that is paid by a manufacturer or third party, directly or indirectly, to a pharmacy benefit manager after a claim has been adjudicated at a pharmacy. Rebate does not include a fee, including a bona fide service fee or administrative fee, that is not a formulary discount or remuneration.
(u)Retail pharmacy means a pharmacy that dispenses prescription drugs to the public at retail typically by face-to-face interaction with the individual or the individuals caregiver.
(v)Spread pricing means the model of prescription drug pricing in which a pharmacy benefit manager charges a health care service plan or health insurer a contracted price for prescription drugs, and the contracted price for the prescription drugs differs from the amount the pharmacy benefit manager directly or indirectly pays the pharmacist or pharmacy.
(w)Third party means a person that is not an enrollee, insured, or pharmacy benefit manager.
(x)Wholesaler has the same meaning as defined in Section 4043 of the Business and Professions Code.
4445.1.The board shall adopt regulations necessary to implement this chapter.
2.Licensing4445.10.(a)The board shall license and regulate pharmacy benefit managers.
(b)A pharmacy benefit manager that provides services in this state shall apply for, obtain, and maintain a license to operate as a pharmacy benefit manager from the board.
(c)An application for a pharmacy benefit manager license shall be submitted in a form and manner determined by the board. The application shall include all of the following:
(1)The information as to each person beneficially interested therein or any person with management or control over the pharmacy benefit manager.
(2)A copy of all organizational and governing documents of the pharmacy benefit manager.
(3)A description of the pharmacy benefit manager, its services, facilities, and personnel.
(4)A document in which the pharmacy benefit manager confirms that its business practices and each ongoing contract comply with this chapter.
(d)Within 30 days after a significant modification of the information or documents submitted pursuant to subdivision (b), a pharmacy benefit manager shall file a notice of the modification with the board.
4445.11.(a)A pharmacy benefit manager license shall be renewed every two years and is nontransferable.
(b)To renew a pharmacy benefit manager license, an applicant shall submit to the board all of the following:
(1)A renewal application in a form and manner determined by the board that is signed by an officer or individual responsible for the conduct or affairs of the pharmacy benefit manager verifying that the contents of the renewal form are correct.
(2)A renewal schedule and fee as determined by the board.
(c)A pharmacy benefit manager license shall expire if a complete renewal filing and fee is not received by the due date established by the board.
4445.12.(a)The fee for a pharmacy benefit manager license shall be ______ dollars ($____) and may be increased to ______ dollars ($____). The fee for the issuance of a temporary pharmacy permit shall be ______ ($_____) and may be increased to ______ dollars ($_____).
(b)The fee for a pharmacy benefit manager license annual renewal shall be ______ dollars ($____) and may be increased to ______ dollars ($_____).
3.Licensee Duties4445.20.(a)On or before April 1, 2027, and on or before each April 1 thereafter, a pharmacy benefit manager shall file with the board a report that contains all of the information required by subdivision (e) of Section 4441 from the preceding calendar year.
(b)The report submitted pursuant to subdivision (a) shall be deemed confidential and shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). Nothing in this section shall prevent disclosure to the Attorney General to investigate, prosecute, defend any legitimate legal claim or cause or action, or to use the reports in any court or proceeding of law.
(c)On or before August 1, 2027, and on or before each August 1 thereafter, the board shall prepare a report based on the information received by the board pursuant to subdivision (a) and shall submit the report to the Legislature in compliance with Section 9795 of the Government Code. The report shall contain aggregate data and shall exclude any information that the board determines would cause financial, competitive, or proprietary harm to a pharmacy benefit manager. The board shall post the report on the boards internet website.
4445.21.(a)A pharmacy benefit manager shall not impose any requirements, conditions, or exclusions that discriminate against a nonaffiliated pharmacy in connection with dispensing drugs.
(b)Discrimination prohibited pursuant to subdivision (a) includes all of the following:
(1)Terms or conditions applied to nonaffiliated pharmacies based on their status as a nonaffiliated pharmacy.
(2)Refusing to contract with or terminating a contract with a nonaffiliated pharmacy on the basis that the pharmacy is a nonaffiliated pharmacy or for reasons other than those that apply equally to affiliated pharmacies.
(3)Retaliation against a nonaffiliated pharmacy based on its exercise of any right or remedy under this chapter.
(c)Before a prescription is dispensed, an affiliated pharmacy shall disclose to an enrollee or insured that the affiliated pharmacy is an affiliated pharmacy and that the enrollee or insured is not obligated to use the affiliated pharmacy.
4445.22.(a)A pharmacy benefit manager shall not do any of the following:
(1)Require an enrollee or insured to use only an affiliated pharmacy that is a retail pharmacy.
(2)Financially induce an enrollee, insured, or prescriber to transfer a prescription only to a retail affiliated pharmacy.
(3)Require a retail nonaffiliated pharmacy to transfer a prescription to a retail affiliated pharmacy. This paragraph does not prevent a health care service plan or the agent of a health care service plan from offering and communicating to enrollees financial incentives to use a particular pharmacy, including, but not limited to, reductions in copays or other financial incentives given to the enrollee when the prescription is dispensed.
(4)Unreasonably restrict an enrollee or insured from using a particular retail pharmacy for the purposes of receiving pharmacist services covered by the enrollees or insureds contract or policy.
(5)Communicate to an enrollee verbally, electronically, or in writing that the enrollee is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other pharmacies that have the ability to dispense the medication or provide the services.
4445.23.(a)A contract issued, amended, or renewed on or after January 1, 2025, between a retail pharmacy and a pharmacy benefit manager shall not prohibit the retail pharmacy from offering either of the following as an ancillary service of the retail pharmacy:
(1)The delivery of a prescription drug by mail or common carrier to a patient or personal representative on request of the patient or personal representative if the request is made before the drug is delivered.
(2)The delivery of a prescription to a patient or personal representative by an employee or contractor of the retail pharmacy.
(b)Except as otherwise provided in a contract described in subdivision (a), the retail pharmacy shall not charge a pharmacy benefit manager for the delivery service described in subdivision (a). This section does not prohibit the use of remote pharmacies, secure locker systems, or other types of pickup stations if those services are otherwise permitted by law.
4445.24.A pharmacy benefit manager shall not require pharmacist or pharmacy accreditation standards or recertification requirements inconsistent with, more stringent than, or in addition to federal and state requirements to obtain reimbursement for a covered drug.
4445.25.(a)No pharmacy benefit manager may derive income from pharmacy benefit management services provided to an insurer or health plan in this state except for income derived from a pharmacy benefit management fee. The amount of any pharmacy benefit management fees shall be set forth in the agreement between the pharmacy benefit manager and the insurer or health plan.
(b)The pharmacy benefit management fee charged by or paid to a pharmacy benefit manager from an insurer or health plan shall not be directly or indirectly based or contingent upon:
(1)The acquisition cost or any other price metric of a drug.
(2)The amount of savings, rebates, or other fees charged, realized, or collected by or generated based on the activity of the pharmacy benefit manager.
(3)The amount of premiums, deductibles, or other cost-sharing or fees charged, realized, or collected by the pharmacy benefit manager from patients or other persons on behalf of a patient.
(c)A pharmacy benefit manager shall not reverse and resubmit the claim of a contract pharmacy:
(1)Without prior and proper notification to the contract pharmacy.
(2)Without just cause or attempt to first reconcile the claim with the pharmacy.
(3)More than 90 days after the claim was first affirmatively adjudicated.
(d)A pharmacy benefit manager shall not directly or indirectly, including indirectly through a pharmacy services administrative organization, charge or hold a pharmacist or pharmacy responsible for a fee related to a claim or reduce the amount of the claim at the time of the claims adjudication or after the claim is adjudicated.
(e)Subdivision (a) does not apply to an audit of a pharmacys records pursuant to Chapter 9.5 (commencing with Section 4430) if either of the following applies:
(1)The review of claims data or statements indicates criminal wrongdoing, willful misrepresentation, fraud, or abuse.
(2)An investigative method, other than a review described in paragraph (1), indicates that the pharmacy is or has committed criminal wrongdoing, willful misrepresentation, fraud, or abuse.
(f)A pharmacy benefit manager shall not charge a pharmacy or pharmacist a fee to process a claim electronically.
(g)The termination of a contract with a pharmacy by a pharmacy benefit manager shall not release the pharmacy benefit manager from the obligation to make a payment due to the pharmacy for an affirmatively adjudicated claim unless payments are withheld because of an investigation relating to insurance fraud.
(h)A pharmacy benefit manager shall not retaliate against a pharmacist or pharmacy based on the pharmacists or pharmacys exercise of a right or remedy under this chapter. Prohibited retaliation includes any of the following:
(1)Terminating or refusing to renew a contract with the pharmacist or pharmacy.
(2)Subjecting the pharmacist or pharmacy to increased audits.
(3)Failing to promptly pay the pharmacist or pharmacy money owed by the pharmacy benefit manager to the pharmacist or pharmacy.
4445.26.(a)Except as permitted under existing law, a pharmacy benefit manager shall not unreasonably obstruct or interfere with a patients right to timely access a prescription drug or device that has been legally prescribed for that patient at a pharmacy of their choice.
(b)A pharmacy benefit manager shall not make, disseminate, or cause or permit the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
4445.27.Commencing January 1, 2025, a pharmacy benefit manager shall not conduct spread pricing in this state. If a preexisting contract between a pharmacy benefit manager and a health care service plan or health insurer authorizes spread pricing, any subsequent amendment or renewal of that contract shall not contain that authorization. Any such spread pricing terms shall be void after January 1, 2028.
4445.28.(a)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with manufacturers who do business in California that expressly or implicitly restrict, or implements implicit or express exclusivity for, those manufacturers drugs, medical devices, or other products.
(b)Notwithstanding any other law, a pharmacy benefit manager shall not enter into, amend, enforce, or renew a contract on or after January 1, 2025, with pharmacies or pharmacy administrative services organizations who do business in California that expressly or implicitly restrict, or impose implicit or express exclusivity on, nonaffiliated pharmacies ability to contract with employers, insurers, and health care service plans.
4.Enforcement4445.40.(a)The board may refuse to issue a pharmacy benefit manager license if the board determines that the pharmacy benefit manager or an individual responsible for the conduct of affairs of the pharmacy benefit manager has had a pharmacy benefit manager certificate of authority or license denied or revoked for cause in another state.
(b)The board may deny, suspend, or revoke the license of a pharmacy benefit manager, or may issue a cease and desist order if the pharmacy benefit manager is not licensed, if the board finds, after notice and opportunity for hearing, that any of the following is true:
(1)The pharmacy benefit manager has violated a statute or regulation applicable to the pharmacy benefit manager.
(2)The pharmacy benefit manager has refused to be examined or to produce its accounts, records, and files for examination by the board, or an individual responsible for the conduct of affairs of the pharmacy benefit manager has refused to give information with respect to its affairs or has refused to perform any other legal obligation as to an examination required by the board.
(3)The pharmacy benefit manager has, without just cause, exhibited a pattern or practice of refusing to pay proper claims or perform services arising under its contracts or has, without just cause, caused enrollees or insureds to accept less than the amount due them.
(4)The pharmacy benefit manager is required under this chapter to have a license and fails to continue to meet the qualifications for licensure during its active licensure, unless the board issued a license with knowledge of the failure to qualify and waived the relevant requirement.
(5)An individual responsible for the conduct of affairs of the pharmacy benefit manager has been convicted of, or has entered a plea of guilty or nolo contendere to, a felony without regard to whether adjudication was withheld.
(6)The pharmacy benefit managers license or registration has been suspended or revoked in another state.
(7)The pharmacy benefit manager failed to file a timely report as required by Section 4445.20.
(c)If a pharmacy benefit managers license is suspended or restricted, the board may permit the operation of the pharmacy benefit manager for a limited time not to exceed 60 days. However, the board may permit a pharmacy benefit manager whose license has been suspended or restricted to operate for a period that exceeds 60 days if the board determines that the continued operation of the pharmacy benefit manager is in the beneficial interests of enrollees and insureds by ensuring minimal disruptions to the continuity of care.
(d)A pharmacy benefit manager whose license has been suspended or restricted is subject to a fine each month, as determined by the board, not to exceed twenty thousand dollars ($20,000) per month, until the pharmacy benefit manager has remedied the violation leading to the suspension or restriction.
(e)The board may revoke the license of a pharmacy benefit manager if the pharmacy benefit manager has been operating under a suspended license for a period of more than 60 days.
(f)For purposes of this section, a pharmacy benefit manager has the right to appropriate notice and opportunity for hearing in accordance with the Administrative Procedure Act (Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code).
4445.41.(a)The board may examine or audit the relevant books and records of a pharmacy benefit manager to determine if the pharmacy benefit manager is in compliance with this chapter.
(b)Information or data acquired during an examination pursuant to subdivision (a), or otherwise acquired under this chapter shall be deemed confidential, shall not be disclosed to the public pursuant to the California Public Records Act (Division 10 (commencing with Section 7920.000) of Title 1 of the Government Code). Nothing in this section shall prevent disclosure to the Attorney General to investigate, prosecute, defend any legitimate legal claim or cause or action, or to use the information and data in any court or proceeding of law.
(c)(1)The board shall establish a retention schedule for all records, books, papers, and other data on file with the department related to the enforcement of this chapter.
(2)The board shall not order the destruction or other disposal of a record, book, paper, or other data that is either of the following:
(A)Required by law to be filed or kept on file with the board.
(B)Filed during the boards administration or administrations.
(d)In any matter arising under this chapter, the board may provide to the Attorney General information related to competition and obtain an opinion from a consultant or consultants with the expertise to assess the competitive impact of the matter.
4445.42.(a)Notwithstanding the requirements of Chapter 2.2 (commencing with Section 1385.001) of Division 2 of the Health and Safety Code and Section 4441, a pharmacy benefit manager shall have a duty and obligation to the enrollee or insured and the health care service plan, insurer, or provider, and shall perform its services with care, skill, prudence, diligence, and professionalism, and for the best interests of the enrollee or insured, and the health care service plan, insurer, or provider. Where there is a conflict in the pharmacy benefit managers duty or obligation under this subdivision to the individual enrollee or insured and any other party, the duty or obligation to the individual enrollee or insured shall be primary.
(b)An enrollee or insured shall be deemed to be third-party beneficiaries of the duties, obligations, and requirements applicable to the pharmacy benefit manager under this chapter and shall be entitled to legal or equitable relief for any injury or loss to the enrollee or insured caused by any violation of those duties, obligations, or requirements.
(c)Any pharmacy benefit manager that violates Article 3 (commencing with Section 4445.20) shall, in addition to any other penalty provided by law, be liable for restitution to any enrollee or insured harmed by the violation and shall also be subject to a penalty not exceeding the greater of (1) one thousand dollars ($1,000) for the first violation and two thousand five hundred dollars ($2,500) for each subsequent violation or (2) the aggregate economic gross receipts attributable to all violations.
(d)Notwithstanding any other law, the Attorney General shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorneys fees and costs incurred in remedying each violation.
4445.43.(a)Any person that violates this chapter shall be subject to an injunction and liable for a civil penalty of not less than one thousand dollars ($1,000) or more than seven thousand five hundred dollars ($7,500) for each violation which shall be assessed and recovered in a civil action brought in the name of the people of the State of California by the Attorney General.
(b)(1)A violation of Sections 4445.21, 4445.22, and 4445.24 is an act of unfair competition within the meaning of Chapter 5 (commencing with Section 17200) of Part 2 of Division 7. But nothing in this article shall limit any other statutory or common law rights or remedies, including liability pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7).
(2)No action shall be brought in the name of the people of the State of California that seeks relief under this section pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7) without the written consent and permission of the Attorney General.
(c)(1)Any person or trade association may institute a civil action for violations of this chapter for any of the following:
(A)To recover civil penalties not less than one hundred dollars ($100) or more than two thousand five hundred dollars ($2,500) for each violation.
(B)Injunctive or declaratory relief.
(C)Any other relief the court deems proper.
(2)In assessing the amount of civil penalties under this subdivision, the court shall consider any one or more of the relevant circumstances presented by any of the parties to the case, including, but not limited to, the nature and seriousness of the misconduct, the number of violations, the persistence of the misconduct, the length of time over which the misconduct occurred, the willfulness of the defendants misconduct, and the defendants assets, liabilities, and net worth.
(d)The remedies or penalties provided by this chapter are cumulative to each other and to the remedies or penalties available under all other laws of this state.
SEC. 3.Section 1367.2075 is added to the Health and Safety Code, immediately following Section 1367.207, to read:1367.2075.(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall calculate an enrollees cost-sharing amount, including deductible and coinsurance, as applicable, based exclusively on its negotiated rate for the prescription drug. This subdivision does not prevent a health care service plan from deducting rebates, as that term is defined by Section 4445 of the Business and Professions Code, or any other discounts it receives, from the negotiated rate for a prescription drug from which cost-sharing amounts are calculated.
(b)(1)Commencing January 1, 2025, if a preexisting contract between a pharmacy benefit manager licensed pursuant to Chapter 9.6 (commencing with Section 4445) of Division 2 of the Business and Professions Code and a health care service plan authorizes spread pricing, as that term is defined by Section 4445 of the Business and Professions Code, any subsequent amendment or renewal of that contract shall not authorize spread pricing.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Chapter 9.6 (commencing with Section 4445) of Division 2 of the Business and Professions Code and a health care service plan shall not authorize spread pricing, as that term is defined by Section 4445 of the Business and Professions Code.
SEC. 4.Section 10123.2045 is added to the Insurance Code, immediately following Section 10123.204, to read:10123.2045.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage shall calculate an insureds cost-sharing amount, including deductible and coinsurance, as applicable, based exclusively on its negotiated rate for the prescription drug. This subdivision does not prevent a health insurer from deducting rebates, as that term is defined by Section 4445 of the Business and Professions Code, or any other discounts it receives, from the negotiated rate for a prescription drug from which cost-sharing amounts are calculated.
(b)(1)Commencing January 1, 2025, if a preexisting contract between a pharmacy benefit manager licensed pursuant to Chapter 9.6 (commencing with Section 4445) of Division 2 of the Business and Professions Code and a health insurer authorizes spread pricing, as that term is defined by Section 4445 of the Business and Professions Code, any subsequent amendment or renewal of that contract shall not authorize spread pricing.
(2)A contract that is executed on or after January 1, 2025, between a pharmacy benefit manager licensed pursuant to Chapter 9.6 of Division 2 of the Business and Professions Code (commencing with Section 4445) and a health insurer shall not authorize spread pricing, as that term is defined by Section 4445 of the Business and Professions Code.
SEC. 5.The authority of the Attorney General to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations shall not be narrowed, abrogated, or otherwise altered by this act.
SEC. 6.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 7.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SEC. 8.The Legislature finds and declares that Section 2 of this act, which adds Sections 4445.21 and 4445.41 of the Business and Professions Code, imposes a limitation on the publics right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 3 of Article I of the California Constitution. Pursuant to that constitutional provision, the Legislature makes the following findings to demonstrate the interest protected by this limitation and the need for protecting that interest:
In order to protect the confidentiality of information received by state agencies from pharmacy benefit managers, it is necessary that those documents be presumptively confidential, except as otherwise provided by law.
|
Date
|
Status
|
|---|---|
| Sep 28, 2024 | In Senate. Consideration of Governor's veto pending. |
| Sep 28, 2024 | Vetoed by the Governor. |
| Sep 9, 2024 | Enrolled and presented to the Governor at 3 p.m. |
| Aug 29, 2024 | Assembly amendments concurred in. (Ayes 38. Noes 1. Page 5637.) Ordered to engrossing and enrolling. |
| Aug 28, 2024 | In Senate. Concurrence in Assembly amendments pending. |
| Aug 28, 2024 | Read third time. Passed. (Ayes 70. Noes 0. Page 6716.) Ordered to the Senate. |
| Aug 22, 2024 | Ordered to third reading. |
| Aug 22, 2024 | Read third time and amended. |
| Aug 20, 2024 | Read second time. Ordered to third reading. |
| Aug 19, 2024 | Read second time and amended. Ordered to second reading. |
| Aug 15, 2024 | From committee: Do pass as amended. (Ayes 11. Noes 0.) (August 15). |
| Aug 7, 2024 | August 7 set for first hearing. Placed on suspense file. |
| Jul 3, 2024 | Read second time and amended. Re-referred to Com. on APPR. |
| Jul 3, 2024 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 10. Noes 0.) (July 2). |
| Jun 26, 2024 | From committee: Do pass and re-refer to Com. on JUD. (Ayes 15. Noes 0.) (June 25). Re-referred to Com. on JUD. |
| Jun 18, 2024 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Jun 12, 2024 | June 18 set for first hearing canceled at the request of author. |
| Jun 3, 2024 | Referred to Coms. on HEALTH and JUD. |
| May 21, 2024 | In Assembly. Read first time. Held at Desk. |
| May 20, 2024 | Read third time. Passed. (Ayes 39. Noes 0. Page 4023.) Ordered to the Assembly. |
| May 16, 2024 | Read second time. Ordered to third reading. |
| May 16, 2024 | From committee: Do pass. (Ayes 7. Noes 0. Page 3965.) (May 16). |
| May 14, 2024 | Set for hearing May 16. |
| May 13, 2024 | May 13 hearing: Placed on APPR suspense file. |
| May 3, 2024 | Set for hearing May 13. |
| Apr 29, 2024 | Read second time and amended. Re-referred to Com. on APPR. |
| Apr 25, 2024 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 11. Noes 0. Page 3755.) (April 24). |
| Apr 18, 2024 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Apr 17, 2024 | Set for hearing April 24. |
| Apr 16, 2024 | From committee: Do pass and re-refer to Com. on HEALTH. (Ayes 12. Noes 0. Page 3605.) (April 15). Re-referred to Com. on HEALTH. |
| Apr 5, 2024 | Set for hearing April 15. |
| Feb 14, 2024 | Referred to Coms. on B., P. & E. D. and HEALTH. |
| Jan 25, 2024 | From printer. May be acted upon on or after February 24. |
| Jan 24, 2024 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 29, 2024 | Unfinished Business SB966 Wiener et al. Concurrence | Senate Floor |
Passed |
|
| Aug 28, 2024 | SB 966 Wiener Senate Third Reading By Wood | Assembly Floor |
Passed |
|
| Aug 15, 2024 | Do pass as amended. | Assembly Standing Committee on Appropriations |
Passed |
|
| Jul 2, 2024 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Judiciary |
Passed |
|
| Jun 25, 2024 | Do pass and be re-referred to the Committee on [Judiciary] | Assembly Standing Committee on Health |
Passed |
|
| May 20, 2024 | Senate 3rd Reading SB966 Wiener | Senate Floor |
Passed |
|
| May 16, 2024 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| May 13, 2024 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 24, 2024 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| Apr 15, 2024 | Do pass, but first be re-referred to the Committee on [Health] | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Abate-A-Weed | ** Against | |
| Aids Healthcare Foundation | ** Support | |
| Alliance for Patient Access | ** Support | |
| Alliance for Transparent and Affordable Prescriptions | ** Support | |
| ALS Association | ** Support | |
| American Benefits Council | ** Against | |
| American Diabetes Association | ** Support | |
| American GI Forum Education Foundation | ** Support | |
| American GI Forum Foundation | ** Against | |
| American Muslims for Coalition for Change | ** Against | |
| AmericaS Health Insurance Plans | ** Against | |
| Angel's Foundation | ** Against | |
| Angel’s Foundation | ** Against | |
| APLA Health | ** Support | |
| Association Of California Life And Health Insurance Companies | ** Against | |
| Association Of Northern California Oncologists | ** Support | |
| Association of Women in Rheumatology | ** Support | |
| Autoimmune & Autoinflammatory Arthritis | ** Support | |
| Axis Advocacy | ** Support | |
| Bell Chamber of Commerce | ** Against | |
| Bell Gardens Chamber Of Commerce | ** Against | |
| Biocom California | ** Support | |
| Black Business Association | ** Against | |
| Brea Chamber of Commerce | ** Against | |
| California Access Coalition | ** Support | |
| California Alliance for Prescription Affordability | ** Against | |
| California Association Of Health Plans | ** Against | |
| California Association Of Joint Powers Authorities | ** Support | |
| California Chamber Of Commerce | ** Against | |
| California Chronic Care Coalition | ** Support | |
| California Clothing Recyclers | ** Against | |
| California Delivery Association | ** Against | |
| California Ecuadorian Chamber of Commerce | ** Against | |
| California El Salvadoran Chambers of Commerce | ** Against | |
| California Farmworker Foundation | ** Support | |
| California Filipino Chamber of Commerce | ** Against | |
| California Guatemalan Chamber of Commerce | ** Against | |
| California Health Collaborative | ** Support | |
| California Hepatitis C Task Force | ** Support | |
| California Hispanic Chambers Of Commerce | ** Against | |
| California Legislative LGBTQ Caucus | ** Support | |
| California Life Sciences | ** Support | |
| California Manufacturers & Technology Association | ** Support | |
| California Medical Association | ** Support | |
| California Muslim Action Network | ** Against | |
| California Nicaraguan Chamber of Commerce | ** Against | |
| Californians for Lower Drug Costs | ** Against | |
| California Pharmacists Association | ** Support | |
| California Poultry Federation | ** Against | |
| California Rheumatology Alliance | ** Support | |
| California Society of Health System Pharmacists | ** Support | |
| California State Association Of Electrical Workers | ** Against | |
| California State Association of Psychiatrists | ** Support | |
| California State Board of Pharmacy | ** Support | |
| California State Pipe Trades Council | ** Against | |
| California Teamsters Public Affairs Council | ** Against | |
| Carrie’s Touch | ** Support | |
| Cerna Home Care | ** Against | |
| CJ Basso & Associates | ** Against | |
| Coalition for Small and Disabled Veteran Businesses | ** Against | |
| Coalition of California Chambers – Orange County | ** Against | |
| Coalition of Small and Disabled Veteran Businesses | ** Against | |
| Coalition of State Rheumatology Organizations | ** Support | |
| Community Church Oakland | ** Against | |
| Corinthian Baptist Church | ** Against | |
| Council of Community Behavioral Health Agencies | ** Support | |
| Crisp Catering | ** Against | |
| Cystic Fibrosis Research, Inc. | ** Support | |
| Defisal Foundation | ** Against | |
| Dublin Chamber of Commerce | ** Against | |
| Energías del Corazón Foundation | ** Against | |
| Ephesian Missionary Baptist Church | ** Against | |
| Ethnos Church | ** Against | |
| Evergreen Missionary Baptist Church | ** Against | |
| Faith Action for All | ** Against | |
| First Union Baptist Church | ** Against | |
| Flasher Barricade Association | ** Against | |
| Gary McKinsey Strategies | ** Against | |
| Granite Bay Benefits | ** Against | |
| Health Access California | ** Against | |
| Hemophilia Council Of California | ** Support | |
| INDIAN PHARMACISTS ASSOCIATION | ** Support | |
| Infusion Access Foundation | ** Support | |
| International Bipolar Foundation | ** Support | |
| International Foundation For Autoimmune & Autoinflammatory Arthritis | ** Support | |
| Keck Medicine USC | ** Support | |
| King Courier | ** Against | |
| Latin Business Association | ** Against | |
| Law Offices of James E. Mahoney, Jr. | ** Against | |
| Looms for Lupus | ** Support | |
| Los Angeles Civil Rights Association | ** Against | |
| Los Angeles LGBT Center | ** Support | |
| Marina Chamber of Commerce | ** Against | |
| MARTINEZ COMMUNICATIONS | ** Against | |
| Medical Oncology Association Of Southern California | ** Support | |
| Menifee Bicycles | ** Against | |
| Mervyn Dymally African American Political & Economic Institute | ** Support | |
| M&l Brothers Foundation | ** Against | |
| Mount Gilead Baptist Church | ** Against | |
| National Association Of Chain Drug Stores | ** Support | |
| National Community Pharmacists Association | ** Support | |
| National Infusion Center Association | ** Support | |
| National Multiple Sclerosis Society | ** Support | |
| National Psoriasis Foundation | ** Support | |
| Neuropathy Action Foundation | ** Support | |
| North East Medical Services | ** Support | |
| Numerous Individuals and Business Owners | ** Against | |
| Orange County Hispanic Chamber of Commerce | ** Against | |
| Osteopathic Physicians And Surgeons Of California | ** Support | |
| Pharmaceutical Care Management Association | ** Against | |
| Pharmaceutical Research And Manufacturers Of America | ** Support | |
| Professional Small Business Services, INC. | ** Against | |
| Pro Small Biz CA | ** Against | |
| Proyecto 555 Foundation | ** Against | |
| Psychiatric Physicians Alliance of California | ** Support | |
| Ricardo Lara, Commissioner California Department of Insurance | ** Support | |
| Salinas City Council | ** Against | |
| Sal's Mexican Restaurant | ** Against | |
| Sal’s Mexican Restaurant | ** Against | |
| San Diego Regional Chamber Of Commerce | ** Against | |
| San Francisco Aids Foundation | ** Support | |
| san francisco marin medical society | ** Support | |
| San Juan Capistrano Chamber of Commerce | ** Against | |
| Seabreeze Books & Charts | ** Against | |
| Shalom International | ** Against | |
| Shalom International Outreach | ** Against | |
| slavic-american chamber of commerce | ** Against | |
| SPACES RENEWED | ** Against | |
| Sperantia Foundation | ** Against | |
| Spondylitis Association of America | ** Support | |
| St. Jude’s Hospital Foundation | ** Against | |
| Strategies for Your Success | ** Against | |
| The Community Church | ** Against | |
| The Council for Citizens Against Government Waste | ** Against | |
| The Erisa Industry Committee | ** Against | |
| The Partnership for Safe Medicines | ** Support | |
| The Row LA | ** Against | |
| Tournament Advisors LLC | ** Against | |
| United Nurses Association Of California/Union Of Health Care Professionals | ** Support | |
| URAC | ** Against | |
| US-Mexican Chamber of Commerce | ** Against | |
| Vournas Coffee Trading Company | ** Against | |
| Western Pacific Roofing Company | ** Against | |
| Western States Council Sheet Metal, Air, Rail And Transportation | ** Against |
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 966 |
VETO
Bill No: SB 966
Author: Wiener (D) and Wahab (D), et al.
Enrolled: 9/3/24
Vote: 27
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 12-0, 4/15/24
AYES: Ashby, Nguyen, Alvarado-Gil, Archuleta, Becker, Dodd, Eggman, Glazer, Menjivar, Roth, Smallwood-Cuevas, Wilk
NO VOTE RECORDED: Niello
SENATE HEALTH COMMITTEE: 11-0, 4/24/24
AYES: Roth, Nguyen, Glazer, Gonzalez, Grove, Hurtado, Limón, Menjivar, Rubio, Smallwood-Cuevas, Wiener
SENATE APPROPRIATIONS COMMITTEE: 7-0, 5/16/24
AYES: Caballero, Jones, Ashby, Becker, Bradford, Seyarto, Wahab
SENATE FLOOR: 39-0, 5/20/24
AYES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Caballero, Cortese, Dahle, Dodd, Durazo, Eggman, Glazer, Gonzalez, Grove, Hurtado, Jones, Laird, Limón, McGuire, Menjivar, Newman, Nguyen, Niello, Ochoa Bogh, Padilla, Portantino, Roth, Rubio, Seyarto, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
NO VOTE RECORDED: Min
SENATE FLOOR: 38-2, 8/29/24
AYES: Allen, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Caballero, Cortese, Dahle, Dodd, Durazo, Eggman, Glazer, Gonzalez, Grove, Hurtado, Laird, Limón, McGuire, Menjivar, Min, Newman, Nguyen, Niello, Ochoa Bogh, Padilla, Portantino, Roth, Rubio, Seyarto, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
NOES: Alvarado-Gil, Jones
ASSEMBLY FLOOR: 70-0, 8/28/24 - See last page for vote
SUBJECT: Pharmacy benefits
SOURCE: California Pharmacist Association
California Chronic Care Coalition
Los Angeles LGBT Center
San Francisco AIDS Foundation
DIGEST: This bill establishes a licensing requirement for pharmacy benefit managers (PBMs) at the California Department of Insurance (CDI), and several contracting and compensation requirements and prohibitions affecting PBMs, health plans and insurers, pharmacists and pharmacies. Creates duties and obligations on PBMs, legal remedies for health plans, insurers, as well as penalties and unfair competition declarations for violations of this bill.
ANALYSIS:
This bill:
- Requires CDI to license and regulate PBMs, requires PBM applications beginning on and after January 1, 2027, requires, on or before July 1, 2028 and annually thereafter, a PBM to file with CDI a report that contains information required in existing law. Requires CDI to publish a report, by January 1, 2029 and annually thereafter, containing aggregate data and to exclude information that would cause financial, competitive, or proprietary harm to a PBM.
- Requires on or before July 1, 2027, and annually, a PBM to report, among other items, a list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. Specifies fees, costs, claims and rebate disclosures. Requires CDI to compile the information into a report for the public and the Legislature due on or before January 1, 2029, and annually, that details the PBM impacts on drug costs.
- Prohibits a contract issued, amended, or renewed on or after January 1, 2025, between a nonaffiliated pharmacy and PBM from prohibiting the pharmacy from delivering a prescription drug by mail or common carrier to a patient or personal representative on request by the patient if the request is made prior to delivery, or, delivering a prescription to a patient or personal representative by an employee or contact or the retail pharmacy. Prohibits the pharmacy from charging the PBM for the delivery except as otherwise provided in the contract.
- Requires the PBM to disclose the amount and types of fees it charges for PBM services to the health plan and insurer. Requires the PBM to transmit 100% of rebates received if the contractual arrangement delegate the negotiation of rebates to the PBM for the sole purpose of offsetting cost-sharing, deductibles, and coinsurance and reducing premiums. Requires specified disclosures to CDI.
- Prohibits a PBM from reversing and resubmitting the claim of a contract pharmacy without prior and proper notification to the contract pharmacy, without just cause or attempting to first reconcile the claim, more than 90 days after the claim was affirmatively adjudicated. Prohibits a pharmacy or pharmacist from being charged a fee to process a claim electronically, and prohibits retaliation against a pharmacist or pharmacy for exercising rights or remedies under this bill, including terminating or refusing to renew a contract, increased audits, and failing to promptly pay money owed.
Comments
According to the author, “this bill reins in the worst abuses by PBMs. This legislation will protect consumers, provide transparency on prescription drug prices, and improve our healthcare system by ensuring that PBMs are being appropriately regulated. Vertical integration and a lack of oversight have allowed some PBMs’ to engage in unfair business practices that undermine healthcare access and drive up the cost of prescription drugs. By raising fees and lowering reimbursement rates, PBMs are making it hard for many independent pharmacies to stock vital medications, and forcing many of them to close. The complete lack of oversight has also allowed some PBMs to steer patients toward pharmacies they own, pocket large portions of the rebates they negotiate with drug manufacturers, and make misleading statements to customers. This bill fills that regulatory gap by requiring that all PBMs be licensed and disclose basic information regarding their business practices to the licensing entity.”
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
SUPPORT: (Verified 10/8/24)
California Pharmacists Association (co-source)
California Chronic Care Coalition (co-source)
Los Angeles LGBT Center (co-source)
San Francisco AIDS Foundation (co-source)
AIDS Healthcare Foundation
Alliance for Patient Access
Alliance for Transparent and Affordable Prescriptions
ALS Association
American Diabetes Association
American GI Forum Education Foundation
APLA Health
Association of Women in Rheumatology
Autoimmune & Autoinflammatory Arthritis
Axis Advocacy
Biocom California
CA Council of Community Behavioral Health Agencies
California Access Coalition
California Association of Joint Powers Authorities
California Farmworker Foundation
California Health Collaborative
California Hepatitis C Task Force
California Life Sciences
California Manufacturers & Technology Association
California Medical Association
California Rheumatology Alliance
California Society of Health System Pharmacists
California State Association of Psychiatrists
California State Board of Pharmacy
Carrie’s Touch
Coalition of State Rheumatology Organizations
Cystic Fibrosis Research, INC.
Hemophilia Council of California
Indian Pharmacists Association
Infusion Access Foundation
International Bipolar Foundation
International Foundation for Autoimmune & Autoinflammatory Arthritis
Keck Medicine USC
Looms for Lupus
National Association of Chain Drug Stores
National Community Pharmacists Association
National Infusion Center Association
National Multiple Sclerosis Society
National Psoriasis Foundation
Neuropathy Action Foundation
North East Medical Services
Los Angeles LGBT Center
Osteopathic Physicians and Surgeons of California
Pharmaceutical Research and Manufacturers of America
Psychiatric Physicians Alliance of California
Ricardo Lara, Commissioner California Department of Insurance
San Francisco Marin Medical Society
Spondylitis Association of America
The Partnership for Safe Medicines
United Nurses Association of California/Union of Health Care Professionals
2 individuals
OPPOSITION: (Verified 10/8/24)
America’s Health Insurance Plans
American Benefits Council
American GI Forum Foundation
Angel’s Foundation
Association of California Life and Health Insurance Companies
California Alliance for Prescription Affordability
California Association of Health Plans
California Chamber of Commerce
California Ecuadorian Chamber of Commerce
California El Salvadoran Chambers of Commerce
California Filipino Chamber of Commerce
California Guatemalan Chamber of Commerce
California Hispanic Chambers of Commerce
California Muslim Action Network
California Nicaraguan Chamber of Commerce
California Poultry Federation
California State Association of Electrical Workers
California State Pipe Trades Council
California Teamsters Public Affairs Council
Californians for Lower Drug Costs
Defisal Foundation
Energías del Corazón Foundation
Ethnos Church
Evergreen Missionary Baptist Church
Faith Action for All
Los Angeles Civil Rights Association
Pharmaceutical Care Management Association
Proyecto 555 Foundation
San Diego Regional Chamber of Commerce
Shalom International Outreach
Sperantia Foundation
St. Jude’s Hospital Foundation
The Community Church
The Council for Citizens Against Government Waste
The Erisa Industry Committee
The Row LA
Tournament Advisors LLC
URAC
US-Mexican Chamber of Commerce
Western States Council Sheet metal, Air, Rail and Transportation
3 individuals
ARGUMENTS IN SUPPORT: The California Pharmacist Association, a cosponsor, writes PBMs are squarely in the middle of negotiating prices, demanding rebates, and driving formulary decisions. Their unfair business practices have become more pervasive as vertical integration has increased. Some PBMs own their own pharmacy chains and mail order pharmacies, creating potential conflicts of interest. Studies have shown that patients are more likely to adhere to their medication regimens when they have a close relationship with their pharmacist. Most of the states have cracked down on PBM abuses, recognizing that community pharmacy is key to the healthcare system. In addition to owning pharmacies, in many cases, health plans and PBMs are now one in the same. In recent years, the largest PBMs merged with large health insurers. CVS acquired Aetna Inc., Express Scripts was acquired by Cigna, and OptumRx was already affiliated with United Healthcare. While there may be some efficiencies, vertical integration can create conflicts of interest that prioritize the financial interests of the integrated company over patient care. The California Board of Pharmacy writes that it has received public comments and complaints from consumers and health care providers stemming from actions by PBMs. Such complaints range in the types of medications involved from maintenance medications (such as the treatment of high blood pressure) to specialty medications (generally high-cost medications used to treat complex, chronic conditions). Investigations have revealed that the root cause of some delays in access, for example, stems from mandates established by PBM. Regrettably at this time the Board lacks jurisdiction and cannot take any meaningful action for the patient nor can the Board evaluate the system and regulate for systemic changes to address the root causes of such delays, thereby preventing future harm.
ARGUMENTS IN OPPOSITION: Pharmaceutical Care Management Association writes while ostensibly seeking to bring PBMs under state agency oversight, several provisions in the bill blatantly promote independent retail pharmacies under the guise of regulating PBMs. This legislation does nothing to lower costs for patients; it simply seeks to financially promote one industry over another with no consumer benefit. America’s Health Insurance Plans, the Association of California Life and Health Insurance Companies, and the California Association of Health plans have many questions regarding the implementation, cost, and oversight of adding CDI as a regulator of PBMs. They also write that the current performance-based model incentivizes PBMs based on rebates and discounts, leading to lower prices for consumers. By removing the existing incentive structure, this bill would likely lead to health plans paying significantly more to manufacturers and pharmacies due to the loss of rebates and discounts, causing a significant increase in health insurance premiums that are passed onto patients.
The San Diego Regional Chamber of Commerce writes that they have concerns with this bill’s restrictions on accreditation standards for specialty pharmacies they believe this bill would limit a health plan’s ability to require specialty pharmacies to meet more than two specialty accreditations. They indicate it would also negatively impact a plan sponsor’s ability to assess performance metrics (including customer service, drug therapy management, and patient adherence standards) for specialty pharmacies when creating a specialty network. These restrictions on specialty network design can lead to diminished patient safety as plans could use unaccredited pharmacies that do not meet high standards for specialty drug storage and dispensing.
GOVERNOR'S VETO MESSAGE:
This bill would require CDI to establish a licensing and oversight structure for PBMs and require PBMs and health plans to report additional data on prescription drugs. The costs of many prescription drugs - brand name and generic - are too high, and these prices continue to trend upwards. Together with the Legislature, we have taken action to address this problem. We created CalRx to bring in-demand pharmaceutical products to the market with low, transparent pricing, starting with biosimilar insulin and naloxone. We also worked together in 2022 to establish the Office of Health Care Affordability (OHCA) to collect, analyze, and publicly report data on total health care expenditures with the goal to achieve California health care that is accessible, affordable, equitable, high-quality, and universal. Without a doubt, the public and the Legislature need a clearer understanding of how much PBM practices are driving up prescription drug costs. I commend the author for working to further tackle this issue through regulating PBM participation in the pharmacy delivery system. Currently, PBMs manage all aspects of prescription drug services for California's commercial health care market. I believe that PBMs must be held accountable to ensure that prescription drugs remain accessible throughout pharmacies across California and available at the lowest price possible. However, I am not convinced that SB 966's expansive licensing scheme will achieve such results. My Administration is committed to increasing access and lowering the costs of prescription drugs. As such, I am directing the California Health and Human Services Agency to propose a legislative approach to gather much needed data on PBMs next year, which can be considered in conjunction with data from our entire health care delivery system. There is some existing transparency regarding prescription drug prices provided through the reporting required by SB 17 (Hernandez, Chapter 603, Statutes of 2017) and the establishment of the Healthcare Payments Database. However, we need more granular information to fully understand the cost drivers in the prescription drug market and the role that PMBs play in pricing. Specifically, California should collect comprehensive information from the pharmacy delivery system about the total cost of care for providing individual prescription drug products, including but not limited to wholesale acquisition costs, fees, payments, discounts, and rebates paid to and received by PBMs. These next steps, together with the CalRx program and OHCA’s work, will offer a multi-pronged approach to improving affordability of prescription drugs in California.
ASSEMBLY FLOOR: 70-0, 8/28/24
AYES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Connolly, Megan Dahle, Dixon, Essayli, Flora, Mike Fong, Friedman, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, Mathis, McCarty, Muratsuchi, Stephanie Nguyen, Pacheco, Papan, Jim Patterson, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Rendon, Reyes, Luz Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NO VOTE RECORDED: Cervantes, Chen, Davies, Gallagher, Lackey, McKinnor, Ortega, Ramos, Villapudua
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
10/16/24 14:11:56
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 966 |
UNFINISHED BUSINESS
Bill No: SB 966
Author: Wiener (D) and Wahab (D), et al.
Amended: 8/22/24
Vote: 21
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 12-0, 4/15/24
AYES: Ashby, Nguyen, Alvarado-Gil, Archuleta, Becker, Dodd, Eggman, Glazer, Menjivar, Roth, Smallwood-Cuevas, Wilk
NO VOTE RECORDED: Niello
SENATE HEALTH COMMITTEE: 11-0, 4/24/24
AYES: Roth, Nguyen, Glazer, Gonzalez, Grove, Hurtado, Limón, Menjivar, Rubio, Smallwood-Cuevas, Wiener
SENATE APPROPRIATIONS COMMITTEE: 7-0, 5/16/24
AYES: Caballero, Jones, Ashby, Becker, Bradford, Seyarto, Wahab
SENATE FLOOR: 39-0, 5/20/24
AYES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Caballero, Cortese, Dahle, Dodd, Durazo, Eggman, Glazer, Gonzalez, Grove, Hurtado, Jones, Laird, Limón, McGuire, Menjivar, Newman, Nguyen, Niello, Ochoa Bogh, Padilla, Portantino, Roth, Rubio, Seyarto, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
NO VOTE RECORDED: Min
ASSEMBLY FLOOR: 70-0, 8/28/24 - See last page for vote
SUBJECT: Pharmacy benefits
SOURCE: California Pharmacist Association
California Chronic Care Coalition
Los Angeles LGBT Center
San Francisco AIDS Foundation
DIGEST:
This bill establishes a licensing requirement for pharmacy benefit managers (PBMs) at the California Department of Insurance (CDI), and several contracting and compensation requirements and prohibitions affecting PBMs, health plans and insurers, pharmacists and pharmacies. Creates duties and obligations on PBMs, legal remedies for health plans, insurers, as well as penalties and unfair competition declarations for violations of this bill.
Assembly Amendments
add a provision that cost-sharing is consistent with existing law. Eliminate the prohibition on spread pricing in contracts between PBMs and insurers and health plans. Require health plan and insurer reporting of the aggregate fees that PBMs receive, and require the information to be publicly reported in aggregate not revealing health plans, insurers, or manufacturer’s individual or aggregated discounted prices for a drug. Add financially viable definition. Eliminate the definition of PBM fee, revise the definition of PBM to exclude a city or county that develops or manages drug coverage programs for uninsured and an entity exclusively providing service under hospice, as specified, add group purchasing definition, and, eliminate the definition of wholesaler, and spread pricing. Eliminate Taft-Hartley self-insured prescription drug plan, as specified, from the provisions of this bill. Delay to January 1, 2027 the requirement that PBM apply for licensure. Add PBM reporting requirements as part of licensure. Indicate the application fee is $11,160, and license fee of $10,120 for a two year term. Authorize beginning no earlier than January 1, 2026 the fees to be sufficient to fund duties. Delay initial PBM report to CDI to July 1, 2028, delay CDI’s report to January 1, 2029, and, revise reporting requirements and delay PBM reports on costly drugs to on or before July 1, 2027. Eliminate a prohibition on PBMs from requiring more than two accreditations from an independent accrediting organization in order for a pharmacy to dispense specialty drugs. Eliminate fee for service PBM structure. Require PBMs to transmit 100% of all rebates, as specified. Includes as discrimination reimbursing a nonaffiliated pharmacy less that an affiliated pharmacy, and engaging in unlawful action against a 340B covered entity. Delete reference to retail pharmacies in PBM prohibitions. Expand specific PBM fee disclosures to CDI. Eliminate a requirement that CDI keep information confidential. Add a requirement that disclosure to the Attorney General is not prevented. Require CDI to compile information for a public report to the Legislature. Add back a duty of obligation from the PBM to the subscriber and enrollee, insurer and policy holder. Require a PBM to disclose to a health insurer or health plan information of clinical efficacy and clinical evidence with regard to the formulary. Eliminate specific restitution amounts a PBM may owe to an enrollee or insured. Make other changes to ensure the Attorney General’s authority.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Requires a PBM to disclose specified information to purchasers, upon request, including, but not limited to, the aggregate wholesale acquisition costs for each therapeutic category of drugs containing three or more drugs, as specified; and, the aggregate amount of rebates received by therapeutic category of drugs containing three or more drugs, including any utilization discounts received from the manufacturer or labeler.[BPC §4441]
This bill:
- Requires CDI to license and regulate PBMs, requires PBM applications beginning on and after January 1, 2027, requires, on or before July 1, 2028 and annually thereafter, a PBM to file with CDI a report that contains information required in existing law. Requires CDI to publish a report, by January 1, 2029 and annually thereafter, containing aggregate data and to exclude information that would cause financial, competitive, or proprietary harm to a PBM.
- Requires on or before July 1, 2027, and annually, a PBM to report, among other items, a list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. Specifies fees, costs, claims and rebate disclosures. Requires CDI to compile the information into a report for the public and the Legislature due on or before January 1, 2029, and annually, that details the PBM impacts on drug costs.
- Deems some date confidential and not disclosable under the California Public Records Act. Specifies that nothing prevents the Attorney General from investigating, prosecuting, defining any legitimate claim or cause of action, or to use the reports in any court proceeding of law.
- Prohibits a PBM from denying a contract pharmacy the opportunity to participate in a PBM network as preferred participation status if the pharmacy is willing to accept the same terms and conditions that the PBM has established for other pharmacies as a condition of preferred network participation status.
- Prohibits a contract issued, amended, or renewed on or after January 1, 2025, between a nonaffiliated pharmacy and PBM from prohibiting the pharmacy from delivering a prescription drug by mail or common carrier to a patient or personal representative on request by the patient if the request is made prior to delivery, or, delivering a prescription to a patient or personal representative by an employee or contact or the retail pharmacy. Prohibits the pharmacy from charging the PBM for the delivery except as otherwise provided in the contract.
- Requires the PBM to disclose the amount and types of fees it charges for PBM services to the health plan and insurer. Requires the PBM to transmit 100% of rebates received if the contractual arrangement delegate the negotiation of rebates to the PBM for the sole purpose of offsetting cost-sharing, deductibles, and coinsurance and reducing premiums. Requires specified disclosures to CDI.
- Prohibits a PBM from reversing and resubmitting the claim of a contract pharmacy without prior and proper notification to the contract pharmacy, without just cause or attempting to first reconcile the claim, more than 90 days after the claim was affirmatively adjudicated. Prohibits a pharmacy or pharmacist from being charged a fee to process a claim electronically, and prohibits retaliation against a pharmacist or pharmacy for exercising rights or remedies under this bill, including terminating or refusing to renew a contract, increased audits, and failing to promptly pay money owed.
- Prohibits a PBM from unreasonably obstructing or interfering with a patient’s right to timely access to a prescription drug or device, except as permitted under existing law. Establishes enforcement authority, a duty and obligation to enrollees, insureds, subscribers and policyholders, and legal remedies associated with violations of this bill.
Comments
According to the author, “this bill reins in the worst abuses by PBMs. This legislation will protect consumers, provide transparency on prescription drug prices, and improve our healthcare system by ensuring that PBMs are being appropriately regulated. Vertical integration and a lack of oversight have allowed some PBMs’ to engage in unfair business practices that undermine healthcare access and drive up the cost of prescription drugs. By raising fees and lowering reimbursement rates, PBMs are making it hard for many independent pharmacies to stock vital medications, and forcing many of them to close. The complete lack of oversight has also allowed some PBMs to steer patients toward pharmacies they own, pocket large portions of the rebates they negotiate with drug manufacturers, and make misleading statements to customers. This bill fills that regulatory gap by requiring that all PBMs be licensed and disclose basic information regarding their business practices to the licensing entity.”
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Assembly Appropriations Committee, CDI estimates costs as follows: $514,000 in fiscal year (FY) 2024-25; $699,000 in FY 2025-26; and, $180,000 in FY 2026-27 and ongoing (Insurance Fund, Pharmacy Benefit Manager Fund). Actual costs could be higher.
DMHC estimates annual costs of about $51,000 beginning in FY 2025-26 (Managed Care Fund).
The Department of Justice estimates costs of $250,000 to $5 million in FY 2024-25 (Legal Services Revolving Fund) and $1 million to $10 million in FY 2025-26 and ongoing for enforcement and defense. Background checks for PBM personnel is estimated to cost $100,000 to $500,000 in FY 2024-25 and $300,000 to $1 million in FY 2025-26 (Fingerprint Fees Account). The Public Rights Division also notes costs of an unknown but potentially significant amount for the Healthcare Rights and Access section to investigate potential violations; such costs could potentially be billed to CDI.
Cost pressures of an unknown but potentially significant amount to the courts to adjudicate enforcement actions (Trial Court Trust Fund, General Fund).
SUPPORT: (Verified 8/28/24)
California Pharmacists Association (co-source)
California Chronic Care Coalition (co-source)
Los Angeles LGBT Center (co-source)
San Francisco AIDS Foundation (co-source)
AIDS Healthcare Foundation
Alliance for Patient Access
Alliance for Transparent and Affordable Prescriptions
ALS Association
American Diabetes Association
American GI Forum Education Foundation
APLA Health
Association of Women in Rheumatology
Autoimmune & Autoinflammatory Arthritis
Axis Advocacy
Biocom California
CA Council of Community Behavioral Health Agencies
California Access Coalition
California Association of Joint Powers Authorities
California Department of Insurance, Commissioner Ricardo Lara
California Farmworker Foundation
California Health Collaborative
California Hepatitis C Task Force
California Life Sciences
California Manufacturers & Technology Association
California Medical Association
California Rheumatology Alliance
California Society of Health System Pharmacists
California State Association of Psychiatrists
California State Board of Pharmacy
Carrie’s Touch
Coalition of State Rheumatology Organizations
Cystic Fibrosis Research, INC.
Hemophilia Council of California
Indian Pharmacists Association
Infusion Access Foundation
International Bipolar Foundation
International Foundation for Autoimmune & Autoinflammatory Arthritis
Keck Medicine USC
Looms for Lupus
National Association of Chain Drug Stores
National Community Pharmacists Association
National Infusion Center Association
National Multiple Sclerosis Society
National Psoriasis Foundation
Neuropathy Action Foundation
North East Medical Services
Los Angeles LGBT Center
Osteopathic Physicians and Surgeons of California
Pharmaceutical Research and Manufacturers of America
Psychiatric Physicians Alliance of California
Ricardo Lara, Insurance Commissioner
San Francisco Marin Medical Society
Spondylitis Association of America
The Partnership for Safe Medicines
United Nurses Association of California/Union of Health Care Professionals
Two individuals
OPPOSITION: (Verified )
America’s Health Insurance Plans
American Benefits Council (unless amended)
American GI Forum Foundation
Angel’s Foundation (unless amended)
Association of California Life and Health Insurance Companies
California Alliance for Prescription Affordability
California Association of Health Plans
California Chamber of Commerce (unless amended)
California Ecuadorian Chamber of Commerce
California El Salvadoran Chambers of Commerce
California Filipino Chamber of Commerce
California Guatemalan Chamber of Commerce
California Hispanic Chambers of Commerce
California Muslim Action Network
California Nicaraguan Chamber of Commerce
California Poultry Federation
California State Association of Electrical Workers (unless amended)
California State Pipe Trades Council (unless amended)
California Teamsters Public Affairs Council
Californians for Lower Drug Costs
Defisal Foundation
Energías del Corazón Foundation (unless amended)
Ethnos Church
Evergreen Missionary Baptist Church (unless amended)
Faith Action for All
Los Angeles Civil Rights Association (unless amended)
Pharmaceutical Care Management Association
Proyecto 555 Foundation
San Diego Regional Chamber of Commerce (unless amended)
Shalom International Outreach
Sperantia Foundation
St. Jude’s Hospital Foundation
The Community Church
The Council for Citizens Against Government Waste
The Erisa Industry Committee (unless amended)
The Row LA
Tournament Advisors LLC
URAC (unless amended)
US-Mexican Chamber of Commerce
Western States Council Sheet metal, Air, Rail and Transportation (unless amended)
Three individuals
ARGUMENTS IN SUPPORT: The California Pharmacist Association, a cosponsor, writes PBMs are squarely in the middle of negotiating prices, demanding rebates, and driving formulary decisions. Their unfair business practices have become more pervasive as vertical integration has increased. Some PBMs own their own pharmacy chains and mail order pharmacies, creating potential conflicts of interest. Studies have shown that patients are more likely to adhere to their medication regimens when they have a close relationship with their pharmacist. Most of the states have cracked down on PBM abuses, recognizing that community pharmacy is key to the healthcare system. In addition to owning pharmacies, in many cases, health plans and PBMs are now one in the same. In recent years, the largest PBMs merged with large health insurers. CVS acquired Aetna Inc., Express Scripts was acquired by Cigna, and OptumRx was already affiliated with United Healthcare. While there may be some efficiencies, vertical integration can create conflicts of interest that prioritize the financial interests of the integrated company over patient care. The California Board of Pharmacy writes that it has received public comments and complaints from consumers and health care providers stemming from actions by PBMs. Such complaints range in the types of medications involved from maintenance medications (such as the treatment of high blood pressure) to specialty medications (generally high-cost medications used to treat complex, chronic conditions). Investigations have revealed that the root cause of some delays in access, for example, stems from mandates established by PBM. Regrettably at this time the Board lacks jurisdiction and cannot take any meaningful action for the patient nor can the Board evaluate the system and regulate for systemic changes to address the root causes of such delays, thereby preventing future harm.
ARGUMENTS IN OPPOSITION: Pharmaceutical Care Management Accociation writes while ostensibly seeking to bring PBMs under state agency oversight, several provisions in the bill blatantly promote independent retail pharmacies under the guise of regulating PBMs. This legislation does nothing to lower costs for patients; it simply seeks to financially promote one industry over another with no consumer benefit. America’s Health Insurance Plans, the Association of California Life and Health Insurance Companies, and the California Association of Health plans have many questions regarding the implementation, cost, and oversight of adding CDI as a regulator of PBMs. They also write that the current performance-based model incentivizes PBMs based on rebates and discounts, leading to lower prices for consumers. By removing the existing incentive structure, this bill would likely lead to health plans paying significantly more to manufacturers and pharmacies due to the loss of rebates and discounts, causing a significant increase in health insurance premiums that are passed onto patients.
The San Diego Regional Chamber of Commerce writes that they have concerns with this bill’s restrictions on accreditation standards for specialty pharmacies they believe this bill would limit a health plan’s ability to require specialty pharmacies to meet more than two specialty accreditations. They indicate it would also negatively impact a plan sponsor’s ability to assess performance metrics (including customer service, drug therapy management, and patient adherence standards) for specialty pharmacies when creating a specialty network. These restrictions on specialty network design can lead to diminished patient safety as plans could use unaccredited pharmacies that do not meet high standards for specialty drug storage and dispensing.
ASSEMBLY FLOOR: 70-0, 8/28/24
AYES: Addis, Aguiar-Curry, Alanis, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Connolly, Megan Dahle, Dixon, Essayli, Flora, Mike Fong, Friedman, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Holden, Hoover, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, Mathis, McCarty, Muratsuchi, Stephanie Nguyen, Pacheco, Papan, Jim Patterson, Joe Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Rendon, Reyes, Luz Rivas, Rodriguez, Blanca Rubio, Sanchez, Santiago, Schiavo, Soria, Ta, Ting, Valencia, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NO VOTE RECORDED: Cervantes, Chen, Davies, Gallagher, Lackey, McKinnor, Ortega, Ramos, Villapudua
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
8/28/24 22:34:44
**** END ****
SENATE THIRD READING
STR Bill Id:SB 966
Author:(Wiener and Wahab)
As Amended Ver:August 22, 2024
Majority vote
SUMMARY
Establishes licensure and regulation requirements for pharmacy benefit managers (PBMs) under the California Department of Insurance (CDI). Requires initial license and renewal fees to be collected into the PBM Account in the Insurance Fund. Adds reporting requirements to existing prescription drug data reporting, including the aggregate amount of rebates received by the PBM for each drug.
Major Provisions
- Prohibit a health plan contract or insurance policy from calculating an enrollee or insured's cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
- Add to existing prescription drug reporting requirements, including the aggregate wholesale acquisition costs from a pharmaceutical manufacturer; the aggregate amount of rebates; any administrative fees received; aggregate of payments made by the PBM to pharmacies; and, the aggregate fees that PBMs receives.
- Require CDI to license and regulate PBMs. Grants CDI the authority to enforce this bill, as specified.
- Require a PBM to disclose the amount and types of fees it charges for the PBM services to the health insurer or health plan. Require PBMs to transmit 100% of all prescription drug manufacturer rebates received to the health plan or insurer. Require the PBM to disclose to CDI all types of fees it receives, and how the fees are calculated, including all of the following:
- Fees for PBM services related to the acquisition cost or any other price metric of a drug;
- Fees for PBM services related to the amount of additional savings, additional rebates, or other fees charged, realized or collected by, or generated based on the activing of the PBM, that is retained by the PBM; and,
- The amount of premiums, deductibles, or other cost sharing or fees charged, realized or collected by the PBM from patients or other persons on behalf of a patient.
- Require CDI to compile the information collected pursuant to 4) above into a report for the public and legislators that demonstrates the impact of fees on drug costs and quantifies the impact of the retention of fees by PBMs. Require the data in the report to be aggregated.
- Exempt from the PBM licensure requirements, collectively bargained Taft-Hartley self-insured prescription drug plan offered pursuant to the federal Employee Retirement Income Security Act of 1974 or to a PBM's provision of PBM services pursuant to that plan. Specify that to the extent a PBM is providing services for other health plans or insurers in addition to the self-insured plan, the provisions of this bill will continue to apply to the PBM.
COMMENTS
- Prescription Drug Spending and SB 17 Department of Managed Health Care (DMHC) Report. According to the DMHC, health plans paid almost $1.3 billion more on prescription drugs in 2022 than in 2021, the highest year-over-year increase since SB 17 (Hernandez), Chapter 603, Statutes of 2017, reporting began. The cost of prescription drugs continues to impact the affordability of health care overall, with health plans paying about $12.1 billion for prescription drugs in 2022. SB 17 requires health plans in the commercial market to annually report their prescription drug costs to the DMHC. This report looks at the impact of the cost of prescription drugs on health plan premiums and compares this data across the reporting years.
- Existing California PBM law. PBMs play a major role in negotiating the prices of prescription drugs, creating and managing formularies, and several other functions key to the management of pharmacy benefits for millions of Californians. However, despite a PBM's interaction with most major players, including drug manufacturers, health plans and insurers, and pharmacies, very little is known about those relationships. AB 315 (Wood), Chapter 905, Statutes of 2018, establishes a regulatory structure for PBMs, and provides for the registration of PBMs to the DMHC. AB 315 requires DMHC, by July 1, 2019, and in collaboration with other agencies, departments, advocates, experts, health plan representatives, and other entities and stakeholders that it deems appropriate, to convene a Task Force on PBM Reporting to determine what information related to pharmaceutical costs, if any, it should require to be reported by health plans or their contracted PBMs, in addition to reporting required in existing law.
- 2020 AB 315 Task Force Report. In 2019, the DMHC facilitated a series of public Task Force meetings to develop the recommendations contained in this report. The report noted that the PBM marketplace appears to be highly concentrated, with the top three PBMs representing approximately 75% of covered lives in California. Some suggest that this concentration is evidence of a stable and functioning market, whereas others believe it is evidence that the largest PBMs have a stranglehold on the market and therefore wield too much negotiating power. Stakeholders attending the Task Force meetings asserted that dominant PBMs may negotiate higher rebates only to keep the bulk of the rebate. By not passing the rebate on to health plans, consumers may be adversely affected by higher costs. Market concentration is seen not only across the marketplace, but also vertically within the supply chain. Some PBMs own their own pharmacies, referred to as an "integrated pharmacy." This may result in misaligned incentives, as a PBM may favor an integrated pharmacy even if competing pharmacies have lower costs. Additionally, the Task Force heard from pharmacy representatives who stated PBMs may improperly utilize prescription information to steer patients who are prescribed high-cost drugs to the PBM's integrated pharmacies. Some PBMs and health plans have common ownership which could lead to PBMs increasing drug costs to rival health plans. The Task Force recommended gathering data to increase transparency and understand how PBMs impact the cost of prescription drugs, including gathering information on PBMs, including revenue and expense information, to determine PBM market impact and the value PBMs provide to consumers.
- Federal Report on PBM regulation to Address Prescription Drug Spending. The United States Government Accountability Office (GAO) published a March 2024 report indicating that prescription drug spending by private health plans climbed to nearly $152 billion in 2021, an 18% increase from 2016. Health plans generally rely on PBMs to process claims, develop pharmacy networks, and negotiate rebates from drug manufacturers. However, some researchers and stakeholders have questioned certain PBM practices, such as PBMs retaining a share of the rebates and use of spread pricing. According to the GAO, PBMs receive compensation from health plans for their services in a variety of ways. Health plans may opt for an administrative fee contract, where they pay the PBM directly for all the services provided. Alternatively, health plans may elect to use a spread pricing option. Under spread pricing, the health plan pays the PBM a set price for each prescription filled, and the PBM retains the difference between the price paid by the health plan and the price paid to the pharmacy as a form of compensation. Additionally, PBMs may retain a portion of manufacturer rebates to offset the fees health plans would otherwise pay.
In response, all 50 states having enacted at least one PBM-related law between 2017 and 2023. The GAO reviewed states' regulation of PBMs, many of which are similar to the provisions of this bill. These laws include pharmacy reimbursement, transparency, through licensing and reporting, and pharmacy network and access requirements. One of the lessons learned includes providing regulators with broad regulatory authority was more effective than enacting specific statutory provisions as doing so allowed regulators to address emerging issues without new legislation, according to regulators from one state. Some regulators also stressed the need for robust enforcement of PBM laws and effective penalties to enforce them.
According to the Author
This bill reins in the worst abuses by PBMs. This bill will protect consumer choice, provide transparency on prescription drug prices, and improve our healthcare system by ensuring that PBMs are appropriately regulated. Vertical integration and a lack of oversight have allowed some PBMs to engage in unfair business practices that undermine healthcare access and drive up the cost of prescription drugs. By raising fees and lowering reimbursement rates, PBMs are making it hard for many independent pharmacies to stock vital medications, and forcing many of them to close. The complete lack of oversight has also allowed some PBMs to steer patients toward pharmacies they own, pocket large portions of the rebates they negotiate with drug manufacturers, and make misleading statements to customers. The author concludes that this bill fills that regulatory gap by requiring that all PBMs be licensed by CDI and disclose basic information regarding their business practices to the state.
Arguments in Support
The California Pharmacists Association, California Chronic Care Coalition, San Francisco AIDS Foundation, and Los Angeles LGBT Center, cosponsors, write that while the initial purpose of PBMs was to negotiate contracts on behalf of their clients (health plans), there is now an inherent conflict of interest and lack of transparency in how they operate. PBMs are squarely in the middle of negotiating prices, demanding rebates, and driving formulary decisions—controlling virtually every aspect of prescription drug program. The self-dealing nature of PBMs is on full display when they steer patients to their company-owned mail-order, community and special pharmacies, all of which calls into question the ability of PBMs to fairly represent the employers, providers, and patients they purport to serve. The cosponsors write that the only healthcare entities that have seemingly avoided transparency and oversight are PBMs.
The Association of Northern California Oncologists, the Medical Oncology Association of Southern California and the Association for Clinical Oncology, in support if amended, request amendments to extend this bill's protections for pharmacists from patient steering to physicians, in order to better enable California's oncologists to provide the best care possible to California's cancer patient population.
Arguments in Opposition
Various organizations representing the California Alliance for Prescription Affordability write that PBMs have proven to be the only entity helping to negotiate and drive prescription drug costs and this bill puts pharmacy profits ahead of California's small businesses, their employees and families, and will make the postpandemic recovery that much more difficult, if not impossible, in the years ahead. According to the Department of Finance, this bill results in significant impacts to various special funds and the General Fund not included in the 2024 Budget Act. This bill allows the CDI to adopt necessary and emergency regulations related to the immediate preservation of the public peace, health and safety, or general welfare until January 1, 2028. Existing law requires a health plan to report rate information to the CDI no later than October 1 of each year and include drugs that are the 25 most frequently used, costly, and highest year-over-year increase in total annual plan spending. This bill requires a pharmacy benefit manager, on or before July 1, 2027, and on or before July 1 thereafter, to report to CDI a list of the 50 costliest drugs, 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, as specified. Additionally, this bill requires CDI to prepare a report based on the information received from pharmacy benefit managers by January 1, 2029, and on or before each January 1 thereafter and publish it on its internet website.
San Diego Regional Chamber of Commerce (SD Chamber), in oppose unless amended, contends that this bill seeks to limit pharmacy network design by prohibiting health plans from using preferred pharmacies. Limiting pharmacy network design for health plans can drive up premiums and will simply increase revenue for a small number of pharmacies. Additionally, SD Chamber writes that restrictions on specialty network design can lead to diminished patient safety as plans could use unaccredited pharmacies that do not meet high standards for specialty drug storage and dispensing.
FISCAL COMMENTS
According to the Assembly Appropriations Committee, CDI estimates costs as follows: $514,000 in fiscal year (FY) 2024-25; $699,000 in FY 2025-26; and, $180,000 in FY 2026-27 and ongoing (Insurance Fund, Pharmacy Benefit Manager Fund). Actual costs could be higher.
DMHC estimates annual costs of about $51,000 beginning in FY 2025-26 (Managed Care Fund).
The Department of Justice estimates costs of $250,000 to $5 million in FY 2024-25 (Legal Services Revolving Fund) and $1 million to $10 million in FY 2025-26 and ongoing for enforcement and defense. Background checks for PBM personnel is estimated to cost $100,000 to $500,000 in FY 2024-25 and $300,000 to $1 million in FY 2025-26 (Fingerprint Fees Account). The Public Rights Division also notes costs of an unknown but potentially significant amount for the Healthcare Rights and Access section to investigate potential violations; such costs could potentially be billed to CDI.
Cost pressures of an unknown but potentially significant amount to the courts to adjudicate enforcement actions (Trial Court Trust Fund, General Fund).
VOTES
SENATE FLOOR: 39-0-1
YES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Caballero, Cortese, Dahle, Dodd, Durazo, Eggman, Glazer, Gonzalez, Grove, Hurtado, Jones, Laird, Limón, McGuire, Menjivar, Newman, Nguyen, Niello, Ochoa Bogh, Padilla, Portantino, Roth, Rubio, Seyarto, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
ABS, ABST OR NV: Min
ASM HEALTH: 15-0-1
YES: Bonta, Waldron, Aguiar-Curry, Arambula, Wendy Carrillo, Flora, Haney, Wood, Jackson, McCarty, Joe Patterson, Rodriguez, Santiago, Schiavo, Weber
ABS, ABST OR NV: Sanchez
ASM JUDICIARY: 10-0-2
YES: Kalra, Dixon, Bauer-Kahan, Bryan, Connolly, Haney, Maienschein, Pacheco, Joe Patterson, Reyes
ABS, ABST OR NV: McKinnor, Sanchez
ASM APPROPRIATIONS: 11-0-4
YES: Wicks, Arambula, Bryan, Calderon, Wendy Carrillo, Mike Fong, Grayson, Haney, Hart, Pellerin, Villapudua
ABS, ABST OR NV: Sanchez, Dixon, Jim Patterson, Ta
UPDATED
VERSION: August 22, 2024
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0004543
SENATE THIRD READING
STR Bill Id:SB 966
Author:(Wiener and Wahab)
As Amended Ver:August 19, 2024
Majority vote
SUMMARY
Establishes licensure and regulation requirements for pharmacy benefit managers (PBMs) under the California Department of Insurance (CDI). Requires initial license and renewal fees to be collected into the PBM Account in the Insurance Fund. Adds reporting requirements to existing prescription drug data reporting, including the aggregate amount of rebates received by the PBM for each drug. Requires a PBM to disclose to CDI all types of PBM management fees that it receives, and requires CDI to keep it confidential. Allows PBMs to offer the option of a non-spread pricing contract.
Major Provisions
- Prohibits a health plan contract or insurance policy from calculating an enrollee or insured's cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
- Adds to existing prescription drug reporting requirements, including the aggregate wholesale acquisition costs from a pharmaceutical manufacturer; the aggregate amount of rebates; any administrative fees received; aggregate of payments made by the PBM to pharmacies; and, the aggregate income from PBM service fees that the PBMs receives.
- Requires CDI to license and regulate PBMs. Grants CDI the authority to enforce this bill, as specified.
- Requires a PBM to offer a passthrough pricing model, in addition to other pricing options offered to a health plan or insurer. Requires a PBM to pass 100% of all prescription drug rebates received to the health plan or insurer if the contractual arrangement delegates the negotiation of rebates to the PBM, for the sole purpose of offsetting defined cost sharing, deductibles, and coinsurance contributions and reducing premiums of enrollees or insureds.
- Requires a PBM to disclose to CDI all types of PBM service fees that it receives, including all of the following:
- PBM service fees related to the acquisition cost or any other price metric of a drug;
- PBM service fees related to the amount of additional savings, additional rebates, or other fees charged, realized or collected by, or generated based on the activing of the PBM, that is retained by the PBM; and,
- The amount of premiums, deductibles, or other cost sharing or fees charged, realized or collected by the PBM from patients or other persons on behalf of a patient.
- Defines various terms, including passthrough pricing model; PBM fee; PBM service; rebate; and, spread pricing.
COMMENTS
- Prescription Drug Spending and SB 17 Department of Managed Health Care (DMHC) Report. According to the DMHC, health plans paid almost $1.3 billion more on prescription drugs in 2022 than in 2021, the highest year-over-year increase since SB 17 (Hernandez), Chapter 603, Statutes of 2017, reporting began. The cost of prescription drugs continues to impact the affordability of health care overall, with health plans paying about $12.1 billion for prescription drugs in 2022. SB 17 requires health plans in the commercial market to annually report their prescription drug costs to the DMHC. This report looks at the impact of the cost of prescription drugs on health plan premiums and compares this data across the reporting years.
- Existing California PBM law. PBMs play a major role in negotiating the prices of prescription drugs, creating and managing formularies, and several other functions key to the management of pharmacy benefits for millions of Californians. However, despite a PBM's interaction with most major players, including drug manufacturers, health plans and insurers, and pharmacies, very little is known about those relationships. AB 315 (Wood), Chapter 905, Statutes of 2018, establishes a regulatory structure for PBMs, and provides for the registration of PBMs to the DMHC. AB 315 requires DMHC, by July 1, 2019, and in collaboration with other agencies, departments, advocates, experts, health plan representatives, and other entities and stakeholders that it deems appropriate, to convene a Task Force on PBM Reporting to determine what information related to pharmaceutical costs, if any, it should require to be reported by health plans or their contracted PBMs, in addition to reporting required in existing law.
- 2020 AB 315 Task Force Report. In 2019, the DMHC facilitated a series of public Task Force meetings to develop the recommendations contained in this report. The report noted that the PBM marketplace appears to be highly concentrated, with the top three PBMs representing approximately 75% of covered lives in California. Some suggest that this concentration is evidence of a stable and functioning market, whereas others believe it is evidence that the largest PBMs have a stranglehold on the market and therefore wield too much negotiating power. Stakeholders attending the Task Force meetings asserted that dominant PBMs may negotiate higher rebates only to keep the bulk of the rebate. By not passing the rebate on to health plans, consumers may be adversely affected by higher costs. Market concentration is seen not only across the marketplace, but also vertically within the supply chain. Some PBMs own their own pharmacies, referred to as an "integrated pharmacy." This may result in misaligned incentives, as a PBM may favor an integrated pharmacy even if competing pharmacies have lower costs. Additionally, the Task Force heard from pharmacy representatives who stated PBMs may improperly utilize prescription information to steer patients who are prescribed high-cost drugs to the PBM's integrated pharmacies. Some PBMs and health plans have common ownership which could lead to PBMs increasing drug costs to rival health plans. The Task Force recommended gathering data to increase transparency and understand how PBMs impact the cost of prescription drugs, including gathering information on PBMs, including revenue and expense information, to determine PBM market impact and the value PBMs provide to consumers.
- Federal Report on PBM regulation to Address Prescription Drug Spending. The United States Government Accountability Office (GAO) published a March 2024 report indicating that prescription drug spending by private health plans climbed to nearly $152 billion in 2021, an 18% increase from 2016. Health plans generally rely on PBMs to process claims, develop pharmacy networks, and negotiate rebates from drug manufacturers. However, some researchers and stakeholders have questioned certain PBM practices, such as PBMs retaining a share of the rebates and use of spread pricing. According to the GAO, PBMs receive compensation from health plans for their services in a variety of ways. Health plans may opt for an administrative fee contract, where they pay the PBM directly for all the services provided. Alternatively, health plans may elect to use a spread pricing option. Under spread pricing, the health plan pays the PBM a set price for each prescription filled, and the PBM retains the difference between the price paid by the health plan and the price paid to the pharmacy as a form of compensation. Additionally, PBMs may retain a portion of manufacturer rebates to offset the fees health plans would otherwise pay.
In response, all 50 states having enacted at least one PBM-related law between 2017 and 2023. The GAO reviewed states' regulation of PBMs, many of which are similar to the provisions of this bill. These laws include pharmacy reimbursement, transparency, through licensing and reporting, and pharmacy network and access requirements. One of the lessons learned includes providing regulators with broad regulatory authority was more effective than enacting specific statutory provisions as doing so allowed regulators to address emerging issues without new legislation, according to regulators from one state. Some regulators also stressed the need for robust enforcement of PBM laws and effective penalties to enforce them.
According to the Author
This bill reins in the worst abuses by PBMs. This bill will protect consumer choice, provide transparency on prescription drug prices, and improve our healthcare system by ensuring that PBMs are appropriately regulated. Vertical integration and a lack of oversight have allowed some PBMs to engage in unfair business practices that undermine healthcare access and drive up the cost of prescription drugs. By raising fees and lowering reimbursement rates, PBMs are making it hard for many independent pharmacies to stock vital medications, and forcing many of them to close. The complete lack of oversight has also allowed some PBMs to steer patients toward pharmacies they own, pocket large portions of the rebates they negotiate with drug manufacturers, and make misleading statements to customers. The author concludes that this bill fills that regulatory gap by requiring that all PBMs be licensed by CDI and disclose basic information regarding their business practices to the state.
Arguments in Support
The California Pharmacists Association, California Chronic Care Coalition, San Francisco AIDS Foundation, and Los Angeles LGBT Center, cosponsors, write that while the initial purpose of PBMs was to negotiate contracts on behalf of their clients (health plans), there is now an inherent conflict of interest and lack of transparency in how they operate. PBMs are squarely in the middle of negotiating prices, demanding rebates, and driving formulary decisions—controlling virtually every aspect of prescription drug program. The self-dealing nature of PBMs is on full display when they steer patients to their company-owned mail-order, community and special pharmacies, all of which calls into question the ability of PBMs to fairly represent the employers, providers, and patients they purport to serve. The cosponsors write that the only healthcare entities that have seemingly avoided transparency and oversight are PBMs.
Arguments in Opposition
Various organizations representing the California Alliance for Prescription Affordability write that PBMs have proven to be the only entity helping to negotiate and drive prescription drug costs and this bill puts pharmacy profits ahead of California's small businesses, their employees and families, and will make the postpandemic recovery that much more difficult, if not impossible, in the years ahead. According to the Department of Finance, this bill results in significant impacts to various special funds and the General Fund not included in the 2024 Budget Act. This bill allows the CDI to adopt necessary and emergency regulations related to the immediate preservation of the public peace, health and safety, or general welfare until January 1, 2028. Existing law requires a health plan to report rate information to the CDI no later than October 1 of each year and include drugs that are the 25 most frequently used, costly, and highest year-over-year increase in total annual plan spending. This bill requires a pharmacy benefit manager, on or before July 1, 2027, and on or before July 1 thereafter, to report to CDI a list of the 50 costliest drugs, 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, as specified. Additionally, this bill requires CDI to prepare a report based on the information received from pharmacy benefit managers by January 1, 2029, and on or before each January 1 thereafter and publish it on its internet website.
FISCAL COMMENTS
According to the Assembly Appropriations Committee, CDI estimates costs as follows: $514,000 in fiscal year (FY) 2024-25; $699,000 in FY 2025-26; and, $180,000 in FY 2026-27 and ongoing (Insurance Fund, Pharmacy Benefit Manager Fund). Actual costs could be higher.
DMHC estimates annual costs of about $51,000 beginning in FY 2025-26 (Managed Care Fund).
The Department of Justice estimates costs of $250,000 to $5 million in FY 2024-25 (Legal Services Revolving Fund) and $1 million to $10 million in FY 2025-26 and ongoing for enforcement and defense. Background checks for PBM personnel is estimated to cost $100,000 to $500,000 in FY 2g024-25 and $300,000 to $1 million in FY 2025-26 (Fingerprint Fees Account). The Public Rights Division also notes costs of an unknown but potentially significant amount for the Healthcare Rights and Access section to investigate potential violations; such costs could potentially be billed to CDI.
Cost pressures of an unknown but potentially significant amount to the courts to adjudicate enforcement actions (Trial Court Trust Fund, General Fund).
VOTES
SENATE FLOOR: 39-0-1
YES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Caballero, Cortese, Dahle, Dodd, Durazo, Eggman, Glazer, Gonzalez, Grove, Hurtado, Jones, Laird, Limón, McGuire, Menjivar, Newman, Nguyen, Niello, Ochoa Bogh, Padilla, Portantino, Roth, Rubio, Seyarto, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener, Wilk
ABS, ABST OR NV: Min
ASM HEALTH: 15-0-1
YES: Bonta, Waldron, Aguiar-Curry, Arambula, Wendy Carrillo, Flora, Haney, Wood, Jackson, McCarty, Joe Patterson, Rodriguez, Santiago, Schiavo, Weber
ABS, ABST OR NV: Sanchez
ASM JUDICIARY: 10-0-2
YES: Kalra, Dixon, Bauer-Kahan, Bryan, Connolly, Haney, Maienschein, Pacheco, Joe Patterson, Reyes
ABS, ABST OR NV: McKinnor, Sanchez
ASM APPROPRIATIONS: 11-0-4
YES: Wicks, Arambula, Bryan, Calderon, Wendy Carrillo, Mike Fong, Grayson, Haney, Hart, Pellerin, Villapudua
ABS, ABST OR NV: Sanchez, Dixon, Jim Patterson, Ta
UPDATED
VERSION: August 19, 2024
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0004124
Date of Hearing: August 7, 2024
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
SBPCA Bill Id:SB 966
Author:(Wiener) – As Amended Ver:July 3, 2024
Policy Committee: | Health | Vote: | 15 - 0 |
Judiciary | 10 - 0 | ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill establishes a licensing framework for pharmacy benefit managers (PBMs) under the California Department of Insurance (CDI) and requires initial license and renewal fees to be collected in the PBM Account in the Insurance Fund. The bill prohibits a PBM from specified activities, including “spread pricing,” and requires a PBM to report specified data to CDI, including the aggregate amount of rebates the PBM receives for each drug.
Specifically, this bill:
- Defines a PBM as a person, business, or other entity that directly or indirectly manages prescription drug coverage, including: developing or managing formularies or preferred drug lists; processing and paying claims for prescription drugs; negotiating or administering rebates, discounts, payment differentials, or other incentives; categorizing drugs to promote the purchase of particular prescription drugs; reviewing drug utilization; processing prior authorization requests for drugs; adjudicating appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. A PBM is not a health plan or its contracted provider; a vertically integrated health plan, as specified; a health insurer; or an entity providing services pursuant to a contract authorized under Workers’ Compensation and Insurance.
- Defines “spread pricing” as the model of prescription drug pricing in which a PBM charges a health plan or insurer a contracted price for prescription drugs, and the contracted price for the prescription drugs differs from the amount the PBM directly or indirectly pays the pharmacist or pharmacy.
- Defines “passthrough pricing model” as a payment model in which the payments made by the health plan or health insurer client to a PBM for covered outpatient drugs are equivalent to the payments the PBM makes to a pharmacy or provider for those drugs, passed through in their entirety by the health plan or health insurer client or by the PBM to the pharmacy or provider that dispenses the drugs, as specified.
- Requires CDI to license and regulate PBMs, charge a license application fee and subsequent renewal fee of unspecified amounts, authorizes the Insurance Commissioner to change fees, as specified, and grants CDI the authority to enforce this bill, as specified. Specifies components of the PBM license application.
- Requires, on or after January 1, 2026, the fees for a PBM initial license and renewal application to be sufficient to fund CDI’s duties under this bill. Requires fees received under this bill to be deposited into the PBM Account, created in the Insurance Fund, and to be subject to an annual appropriation each fiscal year to support CDI activities related to licensing and regulating PBMs.
- Requires CDI to adopt regulations to implement this bill, and allows, until January 1, 2028, regulations to be adopted as emergency regulations, as specified.
- Requires, no later than January 1, 2027, a PBM that provides services in this state to apply to CDI for a license to operate as a PBM, as specified, and to maintain its license in good standing. Requires the PBM to provide to CDI specified information and documents for licensure. Prohibits a PBM from operating in this state unless it is licensed.
- Requires a PBM license applicant to pay the initial application fee in a form and manner determined by CDI and to renew the license every two years. Requires a renewing applicant to submit to CDI a renewal application, specified information, and fee as determined by CDI.
- Entitles the Insurance Commissioner to specific performance, injunctive relief, and other remedies, and to recover attorney’s fees and costs incurred in remedying each violation of this bill’s provisions.
- Requires, beginning on or after January 1, 2026, the fines and administrative penalties collected to be deposited into the PBM Fines and Penalties Account, which is established in the General Fund.
- Requires a PBM, by July 1, 2027, and by July 1 annually thereafter, report to CDI the following information:
- A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. Requires the PBM to report specified data for each drug that falls into the above categories.
- Aggregated data on purchasers contracting with the PBM, revenues from various entities, expenses, as specified, and other specified information.
- A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. Requires the PBM to report specified data for each drug that falls into the above categories.
- Requires CDI, by January 1, 2029, and annually thereafter, to compile the information received pursuant to item 11, above, prepare a report demonstrating the impact of PBMs on drug costs, and publish the report on CDI’s website. Requires the report to contain aggregate data and exclude any information that CDI determines would cause financial, competitive, or proprietary harm to a PBM.
- Requires a PBM, by July 1, 2028, and annually thereafter, file with CDI a report that contains all the information the PBM is required, under existing law, to report to the Board of Pharmacy. Requires CDI, by January 1, 2029, and annually thereafter, prepare a report based on this information, and to publish the report on CDI’s website, as specified.
- Requires a health plan or insurer, in addition to prescription drug reporting required by existing law for specified drugs, also report the following information in aggregate, for each drug, as specified: wholesale acquisition costs from a manufacturer or labeler; amount of rebates received by the PBM; administrative fees received from the manufacturer or labeler; payments made by a PBM to pharmacies owned or controlled by the PBM; and payments made by a PBM to pharmacies not owned by the PBM.
- Requires CDI to compile the information reported pursuant to item 14, above, into a report that demonstrates the overall impact of PBMs on drug costs. Requires the data in the report to be aggregated and to not reveal information specific to individual purchasers. Requires CDI, on or before January 1, 2029, and on or before each January 1 thereafter, to publish the report on its website. Allows CDI to consolidate reports.
- Prohibits a PBM from discriminating, as defined, against a noncontracting pharmacy in connection with dispensing drugs, and from trying to induce a patient to use an affiliated pharmacy, as specified.
- Prohibits a PBM from imposing specified restrictions in a contract with an unaffiliated retail pharmacy.
- Prohibits a PBM from deriving income from pharmacy benefit management services provided to a health plan or insurer except for income derived from a flat, defined, dollar-amount pharmacy benefit management fee, the amount of which must be established in the agreement between the PBM and the health plan or insurer.
- Requires a PBM to use a passthrough pricing model: requires a PBM to pass 100% of all prescription drug manufacturer rebates received to the health plan, insurer, or program, as specified.
- Prohibits a PBM contract with a health plan, commencing January 1, 2025, from authorizing spread pricing and voids any spread pricing terms on and after January 1, 2028.
- Prohibits a health plan that provides prescription drug coverage from calculating an enrollee’s cost sharing to exceed the rate paid for the drug.
- Requires a PBM to have a duty and obligation to the health plan of the enrollee or subscriber or insurer of the insured or policyholder, to perform its services in the best interests of the health plan or insurer. Clarifies that, when there is a conflict between the PBM’s duty or obligation to an individual enrollee or insured and any other party, the duty or obligation to the individual enrollee or insured is primary.
- Imposes numerous other rules on a PBM.
- Authorizes CDI to examine or audit any books and records of a PBM to determine whether the PBM is in compliance with this bill, and to deny, suspend, or revoke the license of a PBM that violates any of the licensing provisions and for other specified violations.
- Requires a PBM to pay for reasonable expenses for any examinations or audits conducted pursuant to this bill. Requires CDI conduct examinations pursuant to the same authority of CDI relative to insurers. Provides that PBMs have the same rights as insurers.
- Authorizes CDI to provide to the Attorney General (AG) information related to competition and obtain an opinion from a consultant or consultants with the expertise to assess the competitive impact of the matter.
- Entitles the AG to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this bill and to recover attorney’s fees and costs incurred in remedying each violation. Clarifies that this bill does not alter or abrogate the CDI’s authority to enforce this provision.
- Provides that any person who violates this bill is subject to an injunction and liable for a civil penalty of $1,000 to $7,500 for each violation, to be assessed and recovered in a civil action brought by the AG.
- Requires CDI to establish procedures for receiving, investigating, tracking, and publicly reporting consumer complaints against PBMs.
- Requires CDI to publish on its website a record of consumer complaints against a PBM that CDI has determined to be justified. Prohibits complaint data from being published unless it has been provided to the PBM in accordance with existing law requiring the Insurance Commissioner to provide to the insurer a description of any complaint against the insurer.
- Prohibits the authority of the AG to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations from being narrowed, abrogated, or otherwise altered by this bill.
- Includes a severability clause.
FISCAL EFFECT:
- CDI estimates costs as follows:
- $514,000 in fiscal year (FY) 2024-25.
- $699,000 in FY 2025-26.
- $180,000 in FY 2026-27 and ongoing (Insurance Fund, Pharmacy Benefit Manager Fund).
Actual costs could be higher to establish a licensing and regulatory program, develop regulations, provide additional consumer service support to address complaints received from the public and the Board of Pharmacy, analyze large amounts of information reported by PBMs, and prepare and publish required reports. Other costs could include information technology resources to build infrastructure to support licensing and complaint intake systems. CDI would likely require Insurance Fund or other fund support until it establishes and collects fee revenue sufficient to support administration and enforcement operations of the PBM licensure program. The fee level necessary to offset CDI’s administrative and enforcement costs is unknown. To illustrate the potential for higher costs: for FY 2019-20, the Department of Managed Health Care (DMHC) requested, and the Department of Finance approved, a budget change proposal for more than $2 million in the initial year of implementation, and funding in the hundreds of thousands of dollars annually thereafter to implement AB 315 (Wood), Chapter 905, Statutes of 2018, which establishes regulation of PBMs and requires PBMs to register with DMHC.
- DMHC estimates ongoing annual costs of approximately $51,000 beginning in FY 2025-26 to its Office of Financial Review for additional workload related to revising reporting templates, reviewing health plan filings, and compiling data for annual reporting and compliance requirements (Managed Care Fund).
- The Department of Justice (DOJ) anticipates costs of an unquantifiable but potentially significant amount. The Public Rights Division – Healthcare Rights and Access section would investigate potential violations and could be called on to defend the bill against attacks by PBMs or their trade association. DOJ estimates costs between $250,000 and $5 million in FY 2024-25 (Legal Services Revolving Fund) and between $1 million and $10 million in FY 2025-26 and ongoing related to enforcement and defense. In addition, DOJ’s Criminal Justice Information Services anticipates an increase in background checks for PBM and partners’ members, controlling persons, officers, directors, and managers, at costs of $100,000 to $500,000 in FY 2024-25 and $300,000 to $1 million in FY 2025-26 to process background checks (Fingerprint Fees Account). The Public Rights Division also notes costs of an unknown but potentially significant amount for the Healthcare Rights and Access section to investigate potential violations; such costs could potentially be billed to CDI.
- Cost pressures of an unknown but potentially significant amount to the courts to adjudicate enforcement actions (Trial Court Trust Fund, General Fund). Actual costs will depend on the number of actions filed and the amount of court time needed to resolve each case. It generally costs approximately $1,000 to operate a courtroom for one hour. Although courts are not funded on the basis of workload, increased pressure on the Trial Court Trust Fund may create a need for increased funding for courts from the General Fund. The FY 2024-25 state budget provides $37.3 million ongoing General Fund to backfill declining revenue to the Trial Court Trust Fund.
According to the Legislative Analyst’s Office, the General Fund faces a structural deficit in the tens of billions of dollars over the next several fiscal years.
COMMENTS:
- Purpose. This bill is sponsored by the California Pharmacist Association, Chronic Care Coalition, San Francisco AIDS Foundation, and the Los Angeles LGBT Center. According to the author:
Senate Bill 966 reins in the worst abuses by PBMs. This legislation will protect consumer choice, provide transparency on prescription drug prices, and improve our healthcare system by ensuring that PBMs are appropriately regulated. Vertical integration and a lack of oversight have allowed some PBMs to engage in unfair business practices that undermine healthcare access and drive up the cost of prescription drugs. By raising fees and lowering reimbursement rates, PBMs are making it hard for many independent pharmacies to stock vital medications, and forcing many of them to close. The complete lack of oversight has also allowed some PBMs to steer patients toward pharmacies they own, pocket large portions of the rebates they negotiate with drug manufacturers, and make misleading statements to customers. SB 966 fills that regulatory gap by requiring that all PBMs be licensed by the Department of Insurance and disclose basic information regarding their business practices to the state.
- Background.
PBMs. According to the California Health Benefits Review Program (CHBRP), PBMs have evolved significantly over recent decades. PBMs went from primarily processing prescription claims (which was largely an administrative function) in the late 1960s to serving as gatekeeper to outpatient prescriptions through active management of formularies and pharmacy networks. Early PBMs focused on developing innovations that allowed them to keep costs down for employers, health plans, and patients. CHBRP states PBMs also play a role in pricing as they negotiate directly with drug manufacturer. However, PBMs reveal little about how those savings are passed onto consumers. During the 1990s, the focus of PBMs shifted from pharmaceutical claims management to more complex business models with a diversified portfolio of services, including the use of incentives to modify consumer behavior, and disease management programs. Today, PBMs use their buying power, combined with utilization management strategies, to lower the total cost of pharmaceuticals. PBMs have consolidated significantly in recent years and now three large PBMs – CVS, Express Scripts, and Optum – account for 80% of the market.
AB 315 Task Force and Pilot Project. AB 315 establishes a regulatory structure for PBMs, and requires PBMs register with DMHC. AB 315 required DMHC, by July 1, 2019, and in collaboration with other agencies, departments, advocates, experts, health plan representatives, and other stakeholders, to convene a Task Force on PBM Reporting to determine what information related to pharmaceutical costs, if any, it should require to be reported by health plans or their contracted PBMs, in addition to reporting required in existing law. In 2019, DMHC facilitated a series of public Task Force meetings to develop the recommendations contained in this report. Stakeholders attending the Task Force meetings asserted:- Dominant PBMs may negotiate higher rebates only to keep the bulk of the rebate.
- Market concentration is seen not only across the marketplace, but also vertically within the supply chain. Some PBMs own their own pharmacies, referred to as “integrated pharmacies,” which may result in misaligned incentives, as a PBM favoring an integrated pharmacy even if competing pharmacies have lower costs.
- Pharmacy representatives stated PBMs might improperly use prescription information to steer patients who are prescribed high-cost drugs to the PBM’s integrated pharmacies.
- Some PBMs and health plans have common ownership, which could lead to PBMs increasing drug costs to rival health plans.
The Task Force recommended gathering data to increase transparency and understand how PBMs affect the cost of prescription drugs, including gathering information on PBMs, such as revenue and expense information, to determine PBM market impact and the value PBMs provide to consumers.
AB 315 also established a pilot project, effective January 1, 2020, in Riverside and Sonoma counties to assess the impact of health plan and PBM prohibitions on the dispensing of certain amounts of prescriptions drugs by network retail pharmacies. In its summary of the pilot project, DMHC stated the average costs paid to non-owned or non-controlled pharmacies appeared to be lower than those paid to pharmacies owned or controlled by a health plan or PBM.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: July 2, 2024
ASSEMBLY COMMITTEE ON JUDICIARY
Ash Kalra, Chair
SBPCA Bill Id:SB 966
Author:(Wiener) – As Amended Ver:June 18, 2024
As Proposed to be Amended
SENATE VOTE: 39-0
SUBJECT: PHARMACY BENEFITS
KEY ISSUES:
- IN ORDER TO REIN IN THE WORST ABUSES BY PHARMACY BENEFIT MANAGERS (PBMs) SHOULD THE LEGISLATURE ESTABLISH A LICENSING FRAMEWORK FOR PBMs, INCLUDING DUTIES, OBLIGATIONS, AND POTENTIAL LIABILITY FOR NONCOMPLIANCE?
- SHOULD INFORMATION THAT PBMs ARE REQUIRED TO SUBMIT TO THE DEPARTMENT OF INSURANCE BE EXEMPT FROM DISCLOSURE PURSUANT TO THE CALIFORNIA PUBLIC RECORDS ACT?
SYNOPSIS
In response to mounting concerns over rising healthcare costs and opaque pricing practices within the pharmaceutical sectors, this measure aims to establish a comprehensive regulatory framework to rein in abuses by pharmacy benefit managers (PBMs), including licensing obligations and enforcement procedures. Despite PBMs’ important role in the healthcare market, they remain largely unregulated under state or federal law. Existing California law requires PBMs to comply with specified requirements, including registration with the Department of Managed Health Care, and a requirement to exercise good faith and fair dealing in the performance of its duties. (Health and Safety Code Sections 1385.004 and 1385.005.) The failure to comply with the requirements could subject a violator to disciplinary action. (Id. at 1385.006.) In the absence of specific regulation and enforcement provisions relating to unfair practices by PBMs, California Attorney General Bonta has attempted to prosecute PBMs under California’s Unfair Competition Law. In January 2023, the AG filed suit against the nation's largest insulin makers and PBMs for driving up the cost of the lifesaving drug under that broad statute.
This measure seeks to address longstanding criticisms of PBMs’ influence on drug pricing, with direct oversight and enforcement, to ensure that PBMs’ activities are driven by patient concerns and not profit motives. The Committee on Health, which recently approved the bill by a vote of 15-0, thoroughly analyzed issues relating to the regulation of PBMs. This analysis therefore focuses on the portion of the bill that limits access to records submitted to the Department of Insurance and the Attorney General’s enforcement authority, topics that are in this Committee’s jurisdiction. Importantly, the bill establishes numerous avenues for enforcement by the Attorney General (in addition to those provided to the Department of Insurance). The AG is entitled to specific performance, injunctive relief, and other equitable remedies, as well as attorney’s fees and costs incurred in remedying each violation of a PBMs’ duties, as provided by the bill. The AG has enforcement power for violations of a PBM’s statutory duty of care, with injunctive relief and civil penalties ranging $1,000-$7,500 for each violation. A violation of this legislation is deemed an act of unfair competition pursuant to the Unfair Competition Law (UCL). The UCL expressly permits claims to be brought by any “person,” which it defines to include “natural persons, corporations, firms, partnerships, joint stock companies, associations and other organizations of persons.” Standing is limited to the Attorney General and other public prosecutors “in the name of the people of the State of California”, as well as any person “who has suffered injury in fact and has lost money or property as a result of the unfair competition.”
The bill imposes significant reporting requirements on PBMs. The information they report is confidential and shielded from inspection and disclosure in response to a Public Record Act request. The information is subject to the Attorney General’s investigatory and legal authority, however, and is required to be compiled by the Department into a report for the public and legislators. These provisions are consistent with provisions in existing law that protect sensitive business and financial information such as trade secrets, or personal financial data.
The author proposes a number of amendments to clarify that the PBM’s principal duty is to the consumer and that CDI and the Insurance Commissioner are allowed to bring forth a claim to the AG on behalf of the People of the State of California. The amendments are incorporated into the SUMMARY, below, and explained in the analysis. The bill is supported by a large number of consumer and health care access groups. It is opposed by business and labor organizations, among others.
SUMMARY: Establishes a licensing requirement for pharmacy benefit managers (PBMs) at the California Department of Insurance; imposes several contracting and compensation requirements and prohibitions affecting PBMs, health plans and insurers, pharmacists and pharmacies; creates duties and obligations on PBMs, legal remedies for health plans and insurers; makes reports confidential and exempt from the California Public Records Act; and imposes civil penalties for violations. Specifically, this bill:
- Requires the California Department of Insurance (CDI) to license and regulate PBMs. Grants CDI the authority to enforce this bill, as specified.
- Requires PBMs that provide services in this state to, no later than January 1, 2027, apply for a license to operate as a PBM from CDI. Requires a PBM to maintain its license in good standing.
- Requires an application for a PBM license to be submitted in a form and manner determined by CDI and to be signed by an officer or individual responsible for the conduct or affairs of the PBM verifying that the contents of the application form and any attachments are correct. Requires the application to include all of the following:
- A nonrefundable application fee in an amount established by CDI under 11) below;
- A list of every health plan or health insurer on behalf of which the PBM contracts with a pharmacy or a pharmacy services administration organization to provide health services to individuals covered by the health plan or health insurer;
- A statement indicating all jurisdictions where the applicant has an application pending or has been registered, licensed, or otherwise certified to transact business as a PBM;
- A statement indicating whether either of the following has occurred:
- The PBM or any individual responsible for the conduct of the affairs of the PBM has had a PBM certificate of authority or license denied or revoked for cause in another state; or,
- Any individual responsible for the conduct of the affairs of the PBM has been convicted of, or has entered a plea of guilty or nolo contender to a felony without regard to whether adjudication was withheld;
- A copy of a power of attorney duly executed by the PBM if not domiciled in this state, appointing CDI, CDI’s successors in office, and CDI’s authorized deputies as the attorney of the PBM in and for this state, on whom process in any legal action or proceeding against the PBM on a cause of action arising in this state may be served;
- The names, addresses, official positions, and professional qualifications of each individual who is responsible for the conduct of the affairs of the PBM;
- A copy of a recent financial statement showing the PBM’s assets, liabilities, and sources of financial support that CDI determines are sufficient to show that the PBM is financially viable. If the PBM’s financial statements are prepared by an independent accountant public accountant, a copy of the most recent regular financial statement satisfies the requirement to show financial viability unless CDI determines that additional or more recent financial information is required for the proper administration of this bill;
- A document providing the names, addresses, dates of birth, social security numbers, official positions, and professional qualifications of each individual who owns, legally or the information as to each person beneficially, 10% or more in equity in the entity interested therein or any person with management or control over the PBM;
- A copy of all basic organizational and governing documents of the PBM, including, but not limited to, the articles of incorporation, bylaws, articles of association, trade name certificate, and other similar documents and all amendments to those documents;
- A description of the PBM, its services, facilities, and personnel;
- A document in which the PBM confirms that its business practices and each ongoing contract comply with this bill; and,
- Any other relevant information required by CDI.
- Requires the individual responsible for the conduct or affairs of the PBM and any of the organization’s partners, members, controlling persons, officers, directors, and managers to comply with the background check requirements as required by the CDI Commissioner.
- Requires a PBM to file a notice of the modification with CDI within 30 days after a significant modification of the information or documents submitted pursuant to 3) above.
- Subjects an applicant for a PBM license or licensed PBM to existing law relating to the business of insurance.
- Prohibits a PBM from operating in this state unless it is licensed pursuant to this bill.
- Does not abrogate compliance by a PBM with any applicable requirements of existing law.
- Specifies that a violation of this bill constitutes an unfair practice, as specified.
- Entitles the CDI Commissioner to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this bill and to recover attorney’s fees and costs incurred in remedying each violation.
- Requires a PBM license applicant to pay the initial application fee as determined by CDI and to be renewed every two years and is nontransferable.
- Requires a renewing applicant to submit to CDI both of the following:
- A renewal application in a form and manner determined by CDI that is signed by an officer or individual responsible for the conduct or affairs of the PBM verifying that the contents of the renewal form are correct; and,
- A renewal schedule and fee as determined by CDI.
- Requires a PBM license to expire if a complete renewal filing and fee is not received by the due date established by CDI.
- Allows the application for renewal of an expired license to be filed after the expiration date and until that same month and day of the next succeeding year. Requires the fee for a renewal application under this bill to be the fee specified in 15) below and a delinquent fee in the amount specified for a one-year period in 15) below for the filing. Subjects each licensee to payment of delinquent fees under this bill.
- Provides an application fee of dollars ($ ), and for each year of the two-year license term thereafter, a renewal fee of dollars ($ ). Authorizes the CDI Commissioner to increase or decrease fees, and schedule fees and charges, as specified.
- Requires PBMs to, on or before July 1, 2028, and on or before each July 1 thereafter, file with CDI a report that contains all of the information required by 14) of existing law below from the preceding calendar year.
- Requires CDI to, on or before January 1, 2029, and on or before each January 1 thereafter, prepare a report based on the information received by CDI pursuant to 16) above and to publish the report on its internet website. Requires the report to contain aggregate data and to exclude any information that CDI determines would cause financial, competitive, or proprietary harm to a PBM.
- Requires a PBM to, on or before July 1, 2027, and on or before each July 1 thereafter, report to CDI all of the following information:
- A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. Requires the PBM to report both of the following, for each drug that falls into the above categories:
- The pharmacy type used to fill the drug prescription, such as integrated, chain, independent, specialty, and mail order pharmacies; and,
- Pricing and rebate information, including the net price paid, the amount of rebate the PBM receives from the manufacturer, the amount of rebate the PBM passes to the health plan or health insurer, the amount the health plan or insurer pays the PBM, and the amount the PBM pays the pharmacy.
- For each list in 18) a) above, all of the following:
- The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug;
- The aggregate amount of rebates received by the PBM for each drug;
- Any administrative fees received from the pharmaceutical manufacturer or labeler;
- The aggregate of payments, or the equivalent economic benefit, made by the PBM to pharmacies owned or controlled by the PBM for each drug;
- The aggregate of payments made by the PBM to pharmacies not owned or collected by the PBM for each drug;
- Deidentified claims level information in electronic format that allows the CDI Commissioner to sort and analyze the following information for each claim, whether the claim required prior authorization; and,
- The amount paid to the pharmacy for each prescription, net of the aggregate amount of fees or other assessments imposed on the pharmacy, including point of sale and retroactive charges. Deems data as confidential pursuant to 21) below.
- All of the following information in the aggregate:
- The purchasers with which the PBM contracts, the scope of services provided to the purchasers, and the number of enrollees, insureds, and plan members served;
- PBM revenue, including revenue from manufacturers, purchasers, and other revenue; and,
- PBM expenses, including payments to pharmacies, claims processing, special programs, administration, and other expenses.
- A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. Requires the PBM to report both of the following, for each drug that falls into the above categories:
- Requires CDI to compile the information reported pursuant to 18) above into a report for the public and Legislature that demonstrates the overall impact of PBMs on drug costs. Requires the data in the report to be aggregated and to not reveal information specific to individual purchasers.
- Requires CDI to, on or before January 1, 2029, and on or before each January 1 thereafter, publish the report on its internet website and include as part of the public meeting, as required. Allows CDI to consolidate reports.
- Deems information submitted to CDI, except for the reports required pursuant to 17) and 19) above, confidential and not disclosed to the public pursuant to the California Public Records Act. Provides that this bill does not prevent disclosure to the Attorney General (AG) to investigate, prosecute, or defend any legitimate legal claim or cause of action, or to use the reports in any court or proceeding of law.
- Defines a specialty drug as one that exceeds the threshold for a specialty drug under the Medicare Part D program for purposes of the reporting requirements under this bill.
- Prohibits a PBM from imposing any requirements, conditions, or exclusions that discriminate against a nonaffiliated pharmacy in connection with dispensing drugs.
- Prohibits discrimination pursuant to 23) above that includes all of the following:
- Terms or conditions applied to nonaffiliated pharmacies based on their status as a nonaffiliated pharmacy;
- Refusing to contract with or terminating a contract with a nonaffiliated pharmacy on the basis that the pharmacy is a nonaffiliated pharmacy or for reasons other than those that apply equally to affiliated pharmacies;
- Retaliation against a nonaffiliated pharmacy based on its exercise of any right or remedy under this bill; and,
- Reimbursing a nonaffiliated pharmacy less for a pharmacy service than the PBM would reimburse an affiliated pharmacy for the same pharmacy service.
- Specifies that this bill does not preclude a PBM or a purchaser of PBM services from establishing a network of contracting or participating pharmacies.
- Prohibits a PBM from doing any of the following:
- Require an enrollee or insured to use only an affiliated pharmacy if there are nonaffiliated pharmacies in the network;
- Financially induce an enrollee, insured, or prescriber to transfer a prescription only to an affiliated pharmacy if there are nonaffiliated pharmacies in the network;
- Require a retail nonaffiliated pharmacy to transfer a prescription to a retail affiliated pharmacy if there are nonaffiliated pharmacies in the network. Does not prevent a purchaser or PBM from offering and communicating to enrollees or insured’ financial incentives to use a particular pharmacy, such as lower copays or costs for a prescription when the prescription is dispensed;
- Unreasonably restrict an enrollee or insured from using a particular contracted retail pharmacy for the purpose of receiving pharmacist services covered by the enrollee’s or insured’s contract or policy;
- Communicate to an enrollee or insured verbally, electronically, or in writing that the enrollee or insured is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other nonaffiliated pharmacies that have the ability to dispense the medication or provide the services and are also in network; and,
- Deny a nonaffiliated contract pharmacy the opportunity to participate in a PBM network as preferred participation status if the pharmacy is willing to accept the same terms and conditions that the PBM has established for affiliated pharmacies as a condition of preferred network participation status.
- Disallows a contract issued, amended, or renewed on or after January 1, 2025, between a nonaffiliated pharmacy and a PBM from prohibiting the retail pharmacy from offering either of the following as an ancillary service of the retail pharmacy:
- The delivery of a prescription drug by mail or common carrier to a patient or personal representative on request of the patient or personal representative if the request is made before the drug is delivered; or,
- The delivery of a prescription to a patient or personal representative by an employee or contractor of the retail pharmacy.
- Prohibits the retail pharmacy, except as otherwise provided in a contract described in 27) above, from charging a PBM for the delivery service described in 27) above. Does not prohibit the use of remote pharmacies, secure locker systems, or other types of pickup stations if those services are otherwise permitted by law.
- Requires contracts entered into pursuant to this bill to be open for inspection by CDI.
- Prohibits a PBM from requiring more than one accreditation from an independent accrediting organization for pharmacists and pharmacies to dispense specialty drugs and requires a PBM to make every effort to ensure that enhanced standards are not imposed to dispense specialty drugs beyond those related to the safety and competency necessary to comply with requirements for dispensing specified medications and providing optimal patient care.
- Requires the PBM to disclose the amount and types of the PBM fees to the health insurer or health plan.
- Requires a PBM to use a passthrough pricing model.
- Requires a PBM to pass 100% of all prescription drug manufacturer rebates received to the health plan, health insurer, or program, if the contractual arrangement delegates the negotiation of rebates to the PBM, for the sole purpose of offsetting defined cost sharing, deductibles, and coinsurance contributions and reducing premiums of enrollees or insureds.
- Specifies that this bill does not preclude a health insurer or health plan from paying performance bonuses to a PBM based on savings to the health plan or health insurer that affects rates paid by the enrollee and insured or subscriber and policy holder, as long as the performance bonus is not based or contingent on any of the following:
- The acquisition cost or any other price metric of a drug;
- The amount of savings, rebates, or other fees charged, realized, or collected by, or generated based on the activity of, the PBM, that is retained by the pharmacy manager;
- The amount of premiums, deductibles, or other cost sharing or fees charged, realized, or collected by the PBM from patients or other persons on behalf of a patient; and,
- Compensation arrangements governed by this bill to be open for inspection by CDI.
- Prohibits a PBM from making or permitting any reduction of payment for pharmacist services by a PBM or a health insurer or health plan directly or indirectly to a pharmacy under a reconciliation process to an effective rate of reimbursement, including without limitation generic effective rates, brand effective rates, direct and indirect remuneration fees, or any other reduction or aggregate reduction of payment.
- Prohibits a claim or aggregate of claims for pharmacist services from being directly or indirectly retroactively denied or reduced after adjudication of the claim or aggregate of claims unless any of the following have occurred:
- The original claim was submitted fraudulently;
- The original claim payment was incorrect because the pharmacy or pharmacist had already been paid for the pharmacist services; and,
- The pharmacist services were not properly rendered by the pharmacy or pharmacist.
- Prohibits a PBM from reversing and resubmitting the claim of a contract pharmacy under any of the following circumstances:
- Without prior written notification to the contract pharmacy;
- Without just cause or attempt to first reconcile the claim with the pharmacy; or,
- More than 90 days after the claim was first affirmatively adjudicated.
- Prohibits a PBM from charging a pharmacy or pharmacist a fee to process a claim electronically.
- Prohibits the termination of a contract with a nonaffiliated pharmacy from releasing the PBM from the obligation to make a payment due to the pharmacy for an affirmatively adjudicated claim unless payments are withheld because of an investigation relating to insurance fraud.
- Prohibits a PBM from retaliating against a pharmacist or pharmacy based on the pharmacist’s or pharmacy’s exercise of a right or remedy under this bill. Includes, as prohibited retaliation, any of the following:
- Terminating or refusing to renew a contract with the pharmacist or pharmacy;
- Subjecting the pharmacist or pharmacy to increased audits; and,
- Failing to promptly pay the pharmacist or pharmacy money owed by the PBM to the pharmacist or pharmacy.
- Prohibits a PBM from, except as permitted under existing law, unreasonably obstructing or interfering with a patient’s right to timely access a prescription drug or device that has been legally prescribed for that patient at a contract pharmacy of their choice.
- Prohibits a PBM from making, disseminating, or causing or permitting the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
- Authorizes CDI to investigate referrals provided by the Board of Pharmacy (BoP).
- Prohibits a PBM, commencing January 1, 2025, from conducting spread pricing. Prohibits any subsequent amendment or renewal of that contract from containing spread pricing if a preexisting contract between a PBM and a health plan or health insurer authorizes spread pricing. Voids any spread pricing terms on and after January 1, 2028.
- Prohibits a PBM from entering into, amending, enforcing, or renewing a contract on or after January 1, 2025, with manufacturers who do business in California that expressly or implicitly restrict, or implements implicit or express exclusivity for, those manufacturers’ drugs, medical devices, or other products.
- Prohibits a PBM from entering into, amending, enforcing, or renewing a contract on or after January 1, 2025, with pharmacies or pharmacy administrative services organizations who do business in California that expressly or implicitly restrict, or impose implicit or express exclusivity on, nonaffiliated pharmacies’ ability to contract with employers, insurers, and health plans.
- Authorizes CDI to, in addition to any of the grounds listed in 1) above, deny, suspend, or revoke the license of a PBM if the CDI finds that any of the following are true:
- The PBM has violated a statute or regulation applicable to the PBM;
- The PBM has refused to be examined or to produce its accounts, records, and files for examination by CDI, or an individual responsible for the conduct of affairs of the PBM has refused to give information with respect to its affairs or has refused to perform any other legal obligation as to an examination required by the CDI;
- The PBM has, without just cause, exhibited a pattern or practice of refusing to pay proper claims or perform services arising under its contracts or has, without just cause, caused enrollees or insureds to accept less than the amount due them;
- The PBM is required under this chapter to have a license and fails to continue to meet the qualifications for licensure during its active licensure;
- The PBM failed to file a timely report as required by 16) above; and,
- The PBM is not financially viable.
- Requires a hearing pursuant to this bill to be conducted in accordance with the Administrative Procedure Act (APA), as specified.
- Authorizes CDI to examine or audit any books and records of a PBM to determine if the PBM is in compliance with this bill. Requires a PBM to pay for reasonable expenses for any examinations or audits conducted pursuant to this bill. Requires payments to be deposited into the PBM Account. Requires examinations conducted by CDI to be pursuant to the same examination authority of CDI relative to insurers. Provides that PBMs have the same rights as insurers.
- Allows CDI to produce and disclose publicly an examination report describing any act or omission committed by a PBM that violates this division.
- Requires CDI to establish a retention schedule for all records, books, papers, and other data on file with the CDI related to the enforcement of this bill.
- Prohibits CDI from ordering the destruction or other disposal of a record, book, paper, or other data that is required to be filed or kept on file with CDI during the retention period.
- Specifies that existing law relating to examinations by the CDI Commissioner does not prevent disclosure of information and data acquired during an examination to the AG to investigate, prosecute, or defend any legitimate legal claim or cause of action, or to use the information and data in any court or proceeding of law. Authorizes CDI to provide to the AG information related to competition and obtain an opinion from a consultant or consultants with the expertise to assess the competitive impact of the matter.
- Requires a PBM to have a duty and obligation to the health plan of the enrollee or subscriber or insurer of the insured or policyholder, and to perform its services with care, skill, prudence, diligence, and professionalism, and for the best interests of the health plan or insurer. Where there is a conflict in the pharmacy benefit manager’s duty or obligation under this subdivision to the individual enrollee or insured and any other party, the duty or obligation to the individual enrollee or insured shall be primary.
- Requires a PBM to disclose to a health insurer or health plan information of clinical efficacy and clinical evidence regarding the inclusion, exclusion, or limitation of prescription drugs in the formulary.
- Requires any PBM that this bill applies to be liable for restitution to any enrollee or insured harmed by the violation, in addition to any other penalty provided by law.
- Provides that if a violation of Sections 17030, 17032, 17045, or 17080 is alleged and is in issue in any proceeding in the Supreme Court of California, a state court of appeal, or the appellate division of a superior court, each person filing any brief or petition with the court in that proceeding shall serve, within three days of filing with the court, a copy of that brief or petition on the Attorney General at a service address designated on the Attorney General’s official Web site for service of papers under this section or, if no service address is designated, at the AG’s office in San Francisco, California. Upon the Attorney General’s request, each person who has filed any other document, including all or a portion of the appellate record, with the court in addition to a brief or petition shall provide a copy of that document without charge to the AG within five days of the request. The time for service may be extended by the Chief Justice or presiding justice or judge for good cause shown. No judgment or relief, temporary or permanent, shall be granted or opinion issued until proof of service of the brief or petition on the AG is filed with the court.
- Subjects any person that violates this bill to an injunction and liable for a civil penalty of not less than one thousand dollars ($1,000) or more than seven thousand five hundred dollars ($7,500) for each violation to be assessed and recovered in a civil action brought by the AG.
- Specifies that a violation of specified provisions is an act of unfair competition within the meaning of the Business and Professions Code (BPC) and nothing in this bill limits any other statutory or common law rights or remedies, including liability pursuant to the Unfair Competition Law.
- Prohibits an action by a county or city from being brought, unless by CDI, in the name of the People of the State of California that seeks relief under this bill pursuant to the Unfair Competition Law of the BPC without the written consent and permission of the AG. Specifies that this bill does not alter or abrogate the CDI’s authority to enforce this provision.
- Provides that notwithstanding any other law, the AG shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorney’s fees and costs incurred in remedying each violation.
- Provides for the remedies or penalties provided by this bill to be cumulative to each other and to the remedies or penalties available under all other laws of this state.
- Provides that the provisions of this division are severable. If any provision of this division or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
- Requires, beginning on or after January 1, 2026, the fines and administrative penalties collected to be deposited into the PBM Fines and Penalties Account, which is established in the General Fund.
- Requires, no earlier than January 1, 2026, the fees for a PBM initial license and renewal application to be sufficient to fund CDI’s duties in relation to responsibilities under this bill, but in no case exceed the reasonable regulatory cost to administer this bill. Requires fees received under this bill to be deposited into the PBM Account, created in the Insurance Fund, and to be subject to an annual appropriation each fiscal year for the support of CDI related to the licensing and regulation of PBMs.
- Construes any activity conducted by a PBM, as defined in this bill, as the business of insurance.
- Requires CDI to adopt regulations necessary to implement this bill, and subject to the following:
- Allows, until January 1, 2028, necessary regulations for the purpose of implementing this bill to be adopted as emergency regulations in accordance with the APA. Deems the adoption of emergency regulations pursuant to this bill to be an emergency and necessary for the immediate preservation of the public peace, health and safety, or general welfare;
- Requires an emergency regulation adopted pursuant to this bill to be repealed by operation of law unless the adoption, amendment, or repeal of the regulation is promulgated by CDI within five years of the initial adoption of the emergency regulation; and,
- Requires a regulation adopted pursuant to this bill to be discussed by CDI during at least one public stakeholder meeting before CDI adopts the rule or regulation.
- Requires CDI to establish procedures for receiving, investigating, tracking, and publicly reporting consumer complaints against PBMs.
- Requires CDI to publish on its internet website a record of consumer complaints against a PBM that have been determined by CDI to be justified. Prohibits complaint data from being published unless it has been provided to the PBM in accordance with existing law requiring the CDI Commissioner to provide to the insurer a description of any complaint against the insurer.
- Prohibits the authority of the AG to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations from being narrowed, abrogated, or otherwise altered by this bill.
- Adds a severability clause that if any provision of this bill or its application is held invalid, that invalidity not affect other provisions or applications that can be given effect without the invalid provision or application.
- Finds and declares that this bill, which adds 16) and 49) above to the Insurance Code, imposes a limitation on the public’s right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 3 of Article I of the California Constitution. Makes findings to demonstrate the interest protected by this limitation and the need for protecting the confidentiality of information received by state agencies from PBMs, as necessary to be presumptively confidential, except as otherwise provided by law.
- Defines the following for purposes of this bill:
- Affiliated pharmacy as a contract pharmacy that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a PBM;
- Claim as a request for payment for administering, filling, or refilling a drug or for providing a pharmacy service or a medical supply or device to an enrollee or insured;
- Contract pharmacy as a retail pharmacy or other pharmacy that contracts directly or through a pharmacy services administration organization with a PBM;
- Financially viable means that either of the following conditions is met:
- The PBM has received an unqualified opinion from an independent public accountant; or,
- If an independent public accountant opinion is not obtained, the PBM remains solvent after adjusting for goodwill and intangible assets.
- Nonaffiliated pharmacy as a contract pharmacy that directly, or indirectly through one or more intermediaries, does not control, is not controlled by, and is not under common control with, a PBM;
- Passthrough pricing model means a payment model used by a PBM in which the payments made by the health care service plan or health insurer client to the PBM for the covered outpatient drugs are both of the following:
- Equivalent to the payments the PBM makes to a pharmacy or provider for those drugs, including any contracted professional dispensing fee between the PBM and its network of pharmacies. That dispensing fee would be paid if the pharmacy benefits plan or program was making the payments directly; and,
- Passed through in their entirety by the health plan or health insurer client or by the PBM to the pharmacy or provider that dispenses the drugs, and the payments are made in a manner that is not offset by any reconciliation.
- Pharmacist services as products, goods, and services, or any combination of products, goods, and services, provided as a part of the practice of pharmacy;
- PBM fee as a fee that covers the cost of providing one or more PBM services and that does not exceed the value of the service or services actually performed by the PBM. Requires the value of the service or services to be based on the value to the health insurer or health plan;
- PBM service as all of the following:
- Negotiating the price of prescription drugs, including negotiating and contracting for direct or indirect rebates, discounts, or other price concessions;
- Managing any aspect of a prescription drug benefit, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with pharmacies, controlling the cost of covered prescription drugs, managing or providing data relating to the prescription drug benefit, or the provision of services related thereto;
- Performing any administrative, managerial, clinical, pricing, financial, reimbursement, data administration, or reporting, or billing service; and,
- Other services as CDI defines in regulation;
- PBM as a person, business, or other entity that, either directly or indirectly, manages the prescription drug coverage, including, but not limited to, the following: clinical or other formulary or preferred drug list development or management; the processing and payment of claims for prescription drugs, the negotiation or administration of rebates, discounts, payment differentials, or other incentives; for the inclusion of particular prescription drugs in a particular category or to promote the purchase of particular prescription drugs; the performance of drug utilization review; the processing of drug prior authorization requests; the adjudication of appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. Does not include the following:
- A health plan that is part of a fully integrated delivery system in which enrollees primarily use pharmacies that are entirely owned and operated by the health plan, and the health plan’s enrollees may use any pharmacy in the health plan’s network that has the ability to dispense the medication or provide the services;
- An entity providing services pursuant to a contract authorized by the Labor Code under Workers’ Compensation and Insurance;
- A health plan, or its contracted provider, as defined; or,
- A health insurer.
- Pharmacy services administration organization as an entity that provides contracting and other administrative services relating to prescription drug benefits to pharmacies;
- Rebate as a formulary discount or remuneration attributable to the use of prescription drugs that is paid by a manufacturer or third party, directly or indirectly, to a PBM after a claim has been adjudicated at a pharmacy. Does not include a fee, including a bona fide service fee or administrative fee, that is not a formulary discount or remuneration;
- Spread pricing as the model of prescription drug pricing in which a PBM charges a health plan or health insurer a contracted price for prescription drugs, and the contracted price for the prescription drugs differs from the amount the PBM directly or indirectly pays the pharmacist or pharmacy; and,
- Third party as a person that is not an enrollee, insured, or PBM.
- Prohibits a health plan contract or insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage from calculating an enrollee or insured’s cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
- Prohibits any contract or policy or any subsequent amendment or renewal of an existing contract or policy, commencing January 1, 2025 from authorizing spread pricing.
- Requires health plans or insurers, in addition to prescription drug reporting set forth in 6) of existing law below of the 25 most frequently prescribed drugs, most costly drugs by total annual plan spending, and 25 drugs with the highest year over year increase to also report all of the following:
- The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug;
- The aggregate amount of rebates received by the PBM for each drug;
- Any administrative fees received from the pharmaceutical manufacturer or labeler;
- The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the PBM for each drug; and,
- The aggregate of payments made by the PBM to pharmacies not owned or collected by the PBM for each drug.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans in the Health and Safety Code; CDI to regulate health insurers under the Insurance Code. (Health and Safety Code Section 1340 et seq. and Insurance Code Section 106 et seq.)
- Establishes as California's Essential Health Benefits (EHBs) benchmark, the Kaiser Small Group Health Maintenance Organization, existing California mandates, and federal Patient and Protection Affordable Care Act mandated benefits, including prescription drugs. (Health and Safety Code Section 1367.005 and Insurance Code Section 10112.27.)
- Requires health plans to maintain the following:
- Complete drug formulary or formularies, including a list of prescription drugs on the formulary of the plan by major therapeutic category with an indication of whether any drugs are preferred over other drugs;
- Records developed by the pharmacy and therapeutic committee of the health plan that fully describe the reasoning behind formulary decisions; and,
- Health plan arrangements with entities that are associated with activities of the health plan to encourage formulary compliance or otherwise manage prescription drug benefits. (Health and Safety Code Section 1367.005.)
- Requires a plan or insurer that provides EHBs to allow an enrollee or insured to access prescription drug benefits at an in-network retail pharmacy unless the prescription drug is subject to restricted distribution by the United States Food and Drug Administration (FDA) or requires special handling, provider coordination, or patient education that cannot be provided by a retail pharmacy. Permits a non-grandfathered individual or small group health plan contract or insurance policy to charge an enrollee or insured a different cost sharing for obtaining a covered drug at a retail pharmacy, but requires all cost sharing to count toward the annual limitation on cost sharing. (Health and Safety Code Section 1367.42 and Insurance Code Section 10123.201.)
- Requires a health plan or health insurer that reports rate information, as specified, to report information no later than October 1 of each year that demonstrates the overall impact of drug costs on health care premiums. (Health and Safety Code Section 1356.243 and Insurance Code Section 10123.205.)
- Requires health plans and insurers, for all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, to report:
- The 25 most frequently prescribed drugs;
- The 25 most costly drugs by total annual plan spending; and,
- The 25 drugs with the highest year-over-year increase in total annual plan spending. (Ibid.)
- Requires DMHC and CDI to compile the information from 5) and 6) above into a report for the public and Legislators where the data is aggregated and does not reveal information specific to individual plans. Requires the report to be published on DMHC’s and CDI’s website. (Ibid.)
- Defines a PBM as a person, business, or other entity that, pursuant to a contract with a health plan, manages the prescription drug coverage provided by the health plan, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to prescription drug coverage, contracting with network pharmacies, and controlling the cost of covered prescription drugs. (Health and Safety Code Section 1385.001.)
- Requires a health plan that contracts with a PBM to require the PBM to comply with specified requirements, including registration with DMHC and to exercise good faith and fair dealing in the performance of its duties. (Health and Safety Code Sections 1385.004 and 1385.005.)
- Requires the failure by a health plan to comply with PBM contractual requirements to constitute grounds for disciplinary action. Requires the DMHC Director, as appropriate, to investigate and take enforcement action against a health plan that fails to comply with these requirements and to periodically evaluate contracts between health plans and PBMs to determine if any audit, evaluation, or enforcement actions should be undertaken by DMHC. (Health and Safety Code Section 1385.006.)
- Establishes a pilot project in Riverside and Sonoma Counties, effective January 1, 2020, to assess the impact of health plan and PBM prohibitions on the dispensing of certain amounts of prescription drugs by network retail pharmacies. Specifies the following:
- Prohibit a health plan, pursuant to the pilot project, from prohibiting, or permitting any delegated PBM to prohibit, a pharmacy provider from dispensing a particular amount of a prescribed medication if the plan or PBM allows that amount to be dispensed through a pharmacy owned or controlled by the plan or PBM, unless the prescription drug is subject to restricted distribution by the FDA or requires special handling, provider coordination, or patient education that cannot be provided by a retail pharmacy; and,
- Require health plans subject to the pilot project, on or before July 1, 2020, to report annually to DMHC information and data relating to changes, if any, to costs and utilization of prescription drugs attributable to the prohibition of contract terms, as provided. (Health and Safety Code Section 1368.6.)
- Provides for the licensure and regulation of pharmacists and pharmacies by the Board of Pharmacy. (Business and Professions Code Section 4200 et seq.)
- Requires a PBM that reimburses a contracting pharmacy for a drug on a maximum allowable cost basis to do the following, among other provisions related to maximum allowable cost:
- Include in a contract, initially entered into, or renewed on its scheduled renewal date, on or after January 1, 2016, with the contracting pharmacy information identifying any national drug pricing compendia or other data sources used to determine the maximum allowable cost for the drugs on a maximum allowable cost list; and,
- Make available to a contracting pharmacy, upon request, the most up-to-date maximum allowable cost list or lists used by the PBM for patients served by that pharmacy in a readily accessible, secure, and usable web-based format or other comparable format. (Business and Professions Code Section 4440.)
- Establishes audits of pharmacy benefits by the Board of Pharmacy and requires PBMs to disclose, upon the request of the purchaser, the following information with respect to prescription product benefits specific to the purchaser, on a quarterly basis:
- The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each therapeutic category of drugs containing three or more drugs, as outlined in the EHBs;
- The aggregate amount of rebates received by the PBM by therapeutic category of drugs containing three or more drugs, as outlined in the EHBs. Requires the aggregate amount of rebates to include any utilization discounts the PBM receives from a pharmaceutical manufacturer or labeler;
- Any administrative fees received from the pharmaceutical manufacturer or labeler;
- Whether the PBM has a contract, agreement, or other arrangement with a pharmaceutical manufacturer to exclusively dispense or provide a drug to a purchaser’s employees, insureds, or enrollees, and the application of all consideration or economic benefits collected or received pursuant to that arrangement;
- Prescription drug utilization information for the purchaser’s enrollees or insureds that is not specific to any individual enrollee or insured;
- The aggregate of payments, or the equivalent economic benefit, made by the PBM to pharmacies owned or controlled by the PBM;
- The aggregate of payments made by the PBM to pharmacies not owned or collected by the PBM; and,
- The aggregate amount of the fees imposed on, or collected from, network pharmacies or other assessments against network pharmacies, and the application of those amounts collected pursuant to the contract with the purchaser. (Business and Professions Code Section 4441.)
- Prohibits a PBM from including in a contract with a pharmacy network provider or its contracting agent a provision that prohibits the provider from informing a patient of a less costly alternative to a prescribed medication. (Ibid.)
- Regulates trade practices in the business of insurance and establishes practices which constitute unfair methods of competition or unfair or deceptive acts under the Insurance Code. (Insurance Code Section 790.)
- Establishes the Unfair Competition Law (UCL), which provides a statutory cause of action for any unlawful, unfair, or fraudulent business act or practice and unfair, deceptive, untrue, or misleading advertising, including over the internet. (Business and Professions Code Section 17200 et seq.)
- Establishes an Unfair Competition Law Fund, created as a special account within the General Fund, which is funded by penalties assessed by public prosecutors for violations of the UCL. (Business and Professions Code Section 17206.)
FISCAL EFFECT: As currently in print this bill is keyed fiscal.
COMMENTS: In response to mounting concerns over rising healthcare costs and opaque pricing practices within the pharmaceutical sectors, the author of SB 966 introduces a landmark legislative measure aimed at establishing a comprehensive regulatory framework to rein in abuses by pharmacy benefit managers (PBMs), including licensing obligations and enforcement procedures. This measure seeks to address longstanding criticisms of PBMs’ influence on drug pricing, with direct oversight and enforcement, to ensure that PBMs’ activities are driven by patient concerns and not profit motives. The author explains the impetus for this measure:
Senate Bill 966 reins in the worst abuses by pharmacy benefit managers (PBMs). This legislation will protect consumer choice, provide transparency on prescription drug prices, and improve our healthcare system by ensuring that PBMs are appropriately regulated. Vertical integration and a lack of oversight have allowed some PBMs to engage in unfair business practices that undermine healthcare access and drive up the cost of prescription drugs. By raising fees and lowering reimbursement rates, PBMs are making it hard for many independent pharmacies to stock vital medications, and forcing many of them to close. The complete lack of oversight has also allowed some PBMs to steer patients toward pharmacies they own, pocket large portions of the rebates they negotiate with drug manufacturers, and make misleading statements to customers. SB 966 fills that regulatory gap by requiring that all PBMs be licensed by the Department of Insurance and disclose basic information regarding their business practices to the state.
The Committee on Health, which recently approved the bill by a vote of 15-0, thoroughly analyzed issues relating to the regulation of PBMs. This analysis therefore focuses on the portion of the bill that limits access to records submitted to the Department of Insurance and the Attorney General’s enforcement authority, topics that are in this Committee’s jurisdiction.
What are PBMs and why are they important drivers of health costs? PBMs work as third parties that go between health insurance providers and drug manufacturers. PBMs help negotiate costs and payments between drug manufacturers, pharmacies, and healthcare insurance providers. PBMs also create prescription drug lists, called formularies. PBMs play a major role in negotiating the prices of prescription drugs, creating and managing formularies, and several other functions key to the management of pharmacy benefits for millions of Californians. However, despite a PBM's interaction with most major players, including drug manufacturers, health plans and insurers, and pharmacies, very little is known about those relationships. Their opacity comes in stark contrast to their importance: PBMs have consolidated significantly in recent years and there are now three large PBMs — CVS, Express Scripts, and Optum — that account for 80% of the market. Indeed, their business practices touch virtually every American family—even those who are not on prescription medication. PBMs are important drivers of health costs for several reasons. PBMs negotiate discounts and rebates from drug manufacturers.
While these discounts can lower costs, the complex rebate system has been criticized for lacking transparency and potentially inflating list prices. PBMs often set higher co-payments or co-insurance for non-preferred drugs, encouraging patients to choose cheaper alternatives. This cost-shifting can impact patients who need specific medications not on the formulary. PBMs charge administrative fees to health plans for their services. These fees contribute to overall healthcare costs, although they are intended to offset costs through negotiated savings. A recent New York Times investigation revealed that the largest PBMs often engage in business practices that advance their own financial interest at the expense of their clients and patients, including overcharging customers, driving independent drugstores out of business, and delaying or even preventing patients from getting their prescriptions. (N.Y. Times, The Opaque Industry Secretly Inflating Prices for Prescription Drugs, June 21, 2024, https://www.nytimes.com/2024/06/21/business/prescription-drug-costs-pbm.html.)
Existing law establishes some regulation of PBMs. Despite PBMs’ important role in the healthcare market, they remain largely unregulated under state or federal law. Existing California law requires PBMs to comply with certain specified requirements, including registration with the Department of Managed Health Care, and a requirement to exercise good faith and fair dealing in the performance of its duties. (Health and Safety Code Sections 1385.004 and 1385.005.) The failure to comply with the requirements could subject a violator to disciplinary action. (Id. at 1385.006.) But in the absence of specific regulation and enforcement provisions relating to unfair practices by PBMs, California Attorney General Bonta has attempted to prosecute PBMs under California’s Unfair Competition Law. In January 2023, the AG filed suit against the nation's largest insulin makers and PBMs for driving up the cost of the lifesaving drug under that broad statute. That case remains pending in Los Angeles Superior Court.
As discussed below, this measure would establish a clear and comprehensive framework for compliance, as well as specific enforcement mechanisms by the Attorney General.
This bill creates a comprehensive regulatory and licensing frameworks for PBMs. As discussed throughout the Assembly Health Committee’s analysis of this measure, which has primary jurisdiction over this bill, this measure creates a comprehensive regulatory and licensing framework for PBMs. First, it adopts a set of definitions, specifically tailored at PBMs and establishes that any activity conducted by a PBM is to be construed as the business of insurance. Second, the bill requires the Department of Insurance to adopt regulations and establish procedures for receiving and investigating customer complaints. Third, it establishes a licensing framework to be administered by the Department of Insurance, specifying licensee duties, which include significant reporting requirements (that are confidential, shielded from disclosure in response to a Public Record Act request, but subject to the Attorney General’s investigatory and legal authority). The licensing provisions entrust the Insurance Commissioner with broad authority far beyond disciplinary action, including specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of the licensing provisions, as well as attorney’s fees and costs. A license applicant is also subject to existing laws and penalties for unfair conduct relating to insurance practices. Fourth, the bill attempts to level the playing field between affiliated and nonaffiliated pharmacies, by requiring PBMs, among other things, to not impose any requirements or conditions that discriminate against a nonaffiliated pharmacy in connection with dispensing drugs. Finally, the bill mandates transparency between PBMs and health insurers—PBMs are mandated to use a “passthrough” model, without charging a markup for prescriptions, are prohibited from “spread pricing,” and are required to disclose the amount and types of PBM fees to the insurer.
This bill prohibits public disclosure of and access to PBM reporting records, implicating the California Public Records Act. Under the California Public Records Act (CPRA), public records are open to inspection at all times during the office hours of a public agency for inspection by the public, unless exempted. (Section 7922.525.) A public record is defined as any writing containing information relating to the conduct of the public’s business prepared, owned, used, or retained by any public agency regardless of physical form or characteristics. (Section 7920.530.) The CPRA allows a public agency 10 days or, in specified “unusual circumstances,” within 14 days of the 10-day period to respond to a request for the requested public record, and authorizes the agency to charge a fee for its “direct costs of duplication” of the record. (Government Code Sections 7922.530 (a), 7922.535.)
Despite the CPRA’s general rule that makes public records open to inspection and subject to disclosure, the CPRA provides exceptions when a document, or a portion thereof, is exempt from public disclosure. An exemption can be explicit in the CPRA itself, pursuant to another law that is incorporated by reference into the CPRA, or justified by the agency’s determination--based on the facts of the particular case—that the public interest served by not disclosing the record clearly outweighs the public interest served by disclosure of the record. (See Government Code Sections 7922.000, 7922.525, 7922.530.)
As stated above, the bill imposes significant reporting requirements on PBMs. The information they report is confidential and shielded from inspection and disclosure in response to a Public Record Act request. The information is subject to the Attorney General’s investigatory and legal authority, however, and is required to be compiled by the Department into a report for the public and legislators. The report is required to demonstrates the overall impact of drug costs on health care premiums. The data in the report shall be aggregated and shall not reveal information specific to individual health care service plans.
These provisions are consistent with provisions in existing law that protect sensitive business and financial information such as trade secrets (Government Code Section 7924.510), or personal financial data (Government Code Section 7925.005). It therefore seems to appropriately provide access to important information about PBMs by means of the aggregated information produced in the reports by the Department, but does not unduly expose sensitive information to the public.
This bill includes robust enforcement provisions. The bill seeks to enforce its mandates in numerous different ways. As discussed above, there are significant licensing obligations and repercussions for failure to comply. In addition to the authority provided to the Insurance Commissioner related to licensure, the Insurance Department may deny, suspend or revoke the license of a PBM for a variety of reasons, including the PBMs violation of any applicable regulation or state, and failure to meet licensing qualifications, and failure to submit timely reports to the Department. In addition to the reporting requirements discussed above, PBMs are obligated to maintain books and record, and are subject to regular audits.
Importantly, the bill establishes numerous avenues for enforcement by the Attorney General (in addition to those provided to the Department of Insurance). The AG is entitled to specific performance, injunctive relief, and other equitable remedies, as well as attorney’s fees and costs incurred in remedying each violation of a PBMs’ duties, as provided by the bill. The AG has enforcement power for violations of a PBM’s statutory duty of care, with injunctive relief and civil penalties ranging $1,000-$7,500 for each violation. In addition to this enforcement mechanism for a breach of its duty, PBMs are subject to restitution to any enrollee or insured that is harmed – in other words, if a PBM overcharges, it will have to return the overcharged amount to the harmed insured person.
A violation of this legislation is deemed an act of unfair competition pursuant to the Unfair Competition Law (UCL). The UCL expressly permits claims to be brought by any “person,” which it defines to include “natural persons, corporations, firms, partnerships, joint stock companies, associations and other organizations of persons.” (Business and Professions Code Section 17201, 17204.) Standing is limited to the Attorney General and other public prosecutors “in the name of the people of the State of California”, as well as any person “who has suffered injury in fact and has lost money or property as a result of the unfair competition.” (Id. at 17204). SB 966 slightly cabins UCL enforcement, by requiring an action brought “in the name of the people of the State of California” (i.e., public prosecutors) to first obtain written consent and permission of the AG before bringing a claim.
In sum, a UCL cause of action, and the remedies it provides (no damages; just injunctive relief, restitution, and civil penalties) are reserved to the AG, a public prosecutor who has received written approval by the AG, and people who have suffered an injury in fact and lost money as a result of the PBMs’ conduct. The bill provides that any administrative penalties and fines collected are to be deposited into the Pharmacy Benefit Manager Fines and Penalties Account, which is to be established in the General Fund.
Author’s amendments. The author proposes amendments to clarify that the PBM’s principal duty is to the consumer, not a health plan that owns the PBM. The amendments clarify that while a PBM may have a duty and obligation to act “for the best interests of the health care service plan or health insurer,” in the case of a “conflict in the pharmacy benefit manager’s duty or obligation under this subdivision to the individual enrollee or insured and any other party, the duty or obligation to the individual enrollee or insured shall be primary.”
The amendments also clarify that CDI and the Insurance Commissioner are allowed to bring forth a claim to the AG on behalf of the People of the State of California.
17080. (a) (1) Notwithstanding Section 4441 of the Business and Professions Code and Chapter 2.2 (commencing with Section 1385.001) of Division 2 of the Health and Safety Code, a pharmacy benefit manager shall have a duty and obligation to the health care service plan of the enrollee or subscriber covered by the health care service plan contract, or the insurer of the insured or policyholder of the policy of health insurance, and shall perform its services with care, skill, prudence, diligence, and professionalism, and for the best interests of the health care service plan or health insurer. Where there is a conflict in the pharmacy benefit manager’s duty or obligation under this subdivision to the individual enrollee or insured and any other party, the duty or obligation to the individual enrollee or insured shall be primary.
(2) A pharmacy benefit manager shall disclose to a health insurer or health care service plan information of clinical efficacy and clinical evidence regarding the inclusion, exclusion, or limitation of prescription drugs in the formulary.
(b) Any pharmacy benefit manager that violates this division shall, in addition to any other penalty provided by law, be liable for restitution to any enrollee or insured harmed by the violation.
(c) Notwithstanding any other law, the Attorney General shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorney’s fees and costs incurred in remedying each violation. This subdivision does not alter or abrogate the department’s authority to enforce this division. If a violation of Sections 17030, 17032, 17045, or 17080 is alleged and is in issue in any proceeding in the Supreme Court of California, a state court of appeal, or the appellate division of a superior court, each person filing any brief or petition with the court in that proceeding shall serve, within three days of filing with the court, a copy of that brief or petition on the Attorney General at a service address designated on the Attorney General’s official Web site for service of papers under this section or, if no service address is designated, at the Attorney General’s office in San Francisco, California. Upon the Attorney General’s request, each person who has filed any other document, including all or a portion of the appellate record, with the court in addition to a brief or petition shall provide a copy of that document without charge to the Attorney General within five days of the request. The time for service may be extended by the Chief Justice or presiding justice or judge for good cause shown. No judgment or relief, temporary or permanent, shall be granted or opinion issued until proof of service of the brief or petition on the Attorney General is filed with the court.
17085. (a) Any person that violates this division shall be subject to an injunction and liable for a civil penalty of not less than one thousand dollars ($1,000) or more than seven thousand five hundred dollars ($7,500) for each violation which shall be assessed and recovered in a civil action brought in the name of the people of the State of California by the Attorney General.
(b) (1) A violation of Section 17030, 17035, or 17045 is an act of unfair competition within the meaning of Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code. But nothing in this article shall limit any other statutory or common law rights or remedies, including liability pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code).
(2) An action by a county or a city shall not be brought, unless by the Insurance Commissioner or Department of Insurance, in the name of the people People of the State of California that seeks relief under this section pursuant to the Unfair Competition Law (Chapter 5 (commencing with Section 17200) of Part 2 of Division 7 of the Business and Professions Code) without the written consent and permission of the Attorney General.
(c) Notwithstanding any other law, the Attorney General shall be entitled to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this chapter and shall be entitled to recover attorney’s fees and costs incurred in remedying each violation.
(3) This subdivision does not alter or abrogate the department’s authority to enforce this division.
(d) (c) The remedies or penalties provided by this chapter are cumulative to each other and to the remedies or penalties available under all other laws of this state.
17086. The provisions of this division are severable. If any provision of this division or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
ARGUMENTS IN SUPPORT: Health advocacy organizations and medical associations, join the co-sponsors of this measure, the California Pharmacists Association, the San Francisco AIDS Foundation, Los Angeles LGBT Center, California Chronic Care Coalition, in support. They argue:
With soaring healthcare costs, there is increasing scrutiny on providers, hospitals, manufacturers and insurance companies. The only healthcare entities that have seemingly avoided transparency and oversight are PBMs.
By providing transparency and oversight of PBMs, the following harmful practices can be subject to scrutiny and, in some cases, prohibited:
- Rebate Pumping: PBMs favoring higher-cost drugs on a formulary because the PBM can negotiate a higher rebate, which they retain as profit.
- Spread Pricing: PBMs charge the health plan a higher cost than what it pays to the pharmacy. This can lead to higher costs for the plan sponsor, which in turn can increase premiums and co-pays for patients.
- Claw-backs: After a prescription is filled, PBMs retroactively recoup the difference between a patient’s copay and the actual price of a drug when the copay amount is higher. It is important to note that the PBMs require a pharmacy to collect a copay from a patient that is set by the PBM. If the patient copay imposed by the PBM is higher than the ultimate reimbursement to the pharmacy, the PBM claws back the excess copay from the pharmacy, keeping it as a profit.
- Rebate retention: PBMs retain a portion of the drug manufacturer rebate as profit instead of returning full amount to the consumer or health plan.
- Patient Steering: PBMs require patients to transfer prescriptions to the PBM-owned mail-order or community pharmacies or the consumer faces higher copay amounts for their medications.
It is time that California joins the vast majority of states in ensuring that pharmacy benefits managers are held to the same standard as every other person and entity in health care. We have no doubt that this important measure will improve health outcomes, reduce overall healthcare spending, and create a more equitable healthcare system.
ARGUMENTS IN OPPOSITION: A broad coalition of organizations, representing more than 18,500 small and ethnic-owned businesses and community organizations throughout California, oppose this measure, arguing that it will have devastating consequences for millions of Californians. They explain:
In our experience, Pharmacy Benefit Managers, or PBMs, have proven to be the only entity helping to negotiate and drive down prescription drug costs. We rely on them to administer prescription drug benefits and provide access to affiliated mail-order and specialty pharmacies, enabling us to offer prescription drug benefits for our employees.
Soaring health care costs remain the number one concern among small employers along with small-to-midsize businesses and organizations. We know firsthand the importance and value of providing our employees and their families with affordable health care, and our ability to do so is an ongoing economic struggle. PBMs help ensure our employees have access to safe and affordable prescription drugs, allowing us to keep our doors open and provide healthcare benefits to our employees and their families.
There is nothing in SB 966 that will lower prices for California consumers. Instead, SB 966 will require PBMs to be licensed/regulated by the Board of Pharmacy even though PBMs do not purchase, sell or dispense prescription drugs. PBM-affiliated mail-order entities are already licensed and regulated by the Board of Pharmacy. SB 966 seeks to increase profits for pharmacists on the backs of our organizations and employees. Encouraging lawsuits will not lead to lower costs for California employers and employees.
SB 966, if enacted, will add more uncertainty and turmoil for job creators, patients, families and communities by diminishing the savings PBMs provide to employers like us. It will result in higher prescription drug costs and fewer health care choices for all Californians by prohibiting the cost-saving tools we rely on, like allowing any pharmacy to be in our network without having to adhere to any quality standards or payments rates.
Families, businesses and communities in our state deserve a healthy dose of hope and certainty – not a new wall of frustration and fear, as they attempt to emerge from the pandemic and this stressful economy. This flawed legislation puts pharmacy profits ahead of California’s small businesses, their employees and families, and will make the post-pandemic recovery that much more difficult, if not impossible, in the years ahead.
REGISTERED SUPPORT / OPPOSITION:
Support
California Chronic Care Coalition (co-sponsor)
California Pharmacists Association (co-sponsor)
Los Angeles LGBT Center (co-sponsor)
San Francisco Aids Foundation (co-sponsor)
AIDS Healthcare Foundation
Alliance for Patient Access
American Diabetes Association
Biocom California
California Farmworker Foundation
California Health Collaborative
California Insurance Commissioner, Ricardo Lara
California Life Sciences
California Medical Association
California Rheumatology Alliance
California Society of Health System Pharmacists
California State Association of Psychiatrists (CSAP)
Cystic Fibrosis Research, INC. (CFRI)
Hemophilia Council of California
International Bipolar Foundation
International Foundation for Autoimmune & Autoinflammatory Arthritis
Mervyn Dymally African American Political & Economic Institute
National Association of Chain Drug Stores
National Community Pharmacists Association (UNREG)
National Multiple Sclerosis Society, MS-CAN
National Psoriasis Foundation
North East Medical Services
Pharmaceutical Research and Manufacturers of America
San Francisco Marin Medical Society
Spondylitis Association of America
The ALS Association
United Nurses Associations of California/union of Health Care Professionals
Association of Northern California Oncologists (if amended)
Medical Oncology Association of Southern California (if amended)
Opposition
Abate-a-weed
American Gi Forum Foundation
American Muslims for Coalition for Change
Angel's Foundation
Bell Chamber of Commerce
Bell Gardens Chamber of Commerce
Black Business Association
Brea Chamber of Commerce
California Alliance for Prescription Affordability (CAPA)
California Association of Health Plans
California Clothing Recyclers
California Delivery Association
California El Salvadoran Chamber of Commerce
California Hispanic Chamber of Commerce
California Hispanic Chambers of Commerce
California Muslim Action Network
California State Association of Electrical Workers
California State Pipe Trades Council
Cerna Home Care
CJ Basso & Associates
Coalition for Small and Disabled Veteran Businesses
Coalition of California Chambers – Orange County
Coalition of Small and Disabled Veteran Businesses
Community Church Oakland
Corinthian Baptist Church
Crisp Catering
Cypress Chamber of Commerce
Defisal Foundation
Dublin Chamber of Commerce
Energías Del Corazón Foundation
Ephesian Missionary Baptist Church
Ethnos Church
Evergreen Missionary Baptist Church
Faith Action for All
First Union Baptist Church
Flasher Barricade Association
Gary McKinsey Strategies
Granite Bay Benefits
King Courier
Latin Business Association
Law Offices of James E. Mahoney, Jr.
Los Angeles Civil Rights Association
M&l Brothers Foundation
Marina Chamber of Commerce
Martinez Communications
Menifee Bicycles
Mount Gilead Baptist Church
Orange County Hispanic Chamber of Commerce
Pharmaceutical Care Management Association
Pro Small Biz CA
Professional Small Business Services, INC.
Proyecto 555 Foundation
Sal's Mexican Restaurant
Salinas City Council (FORMER)
San Juan Capistrano Chamber of Commerce
Seabreeze Books & Charts
Shalom International
Slavic-American Chamber of Commerce
Spaces Renewed
Sperantia
Strategies for Your Success
The Row LA - the Church Without Walls - Skid Row
Tournament Advisors LLC
Vournas Coffee Trading Company
Western Pacific Roofing Company
Western States Council Sheet Metal, Air, Rail and Transportation
California Chamber of Commerce (unless amended)
San Diego Regional Chamber of Commerce (unless amended)
Analysis Prepared by: Alison Merrilees and Shiran Zohar / JUD. / (916) 319-2334
Date of Hearing: June 25, 2024
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
SBPCA Bill Id:SB 966
Author:(Wiener) – As Amended Ver:June 18, 2024
SENATE VOTE: 39-0
SUBJECT: Pharmacy benefits.
SUMMARY: Establishes licensure and regulation requirements for pharmacy benefit managers (PBMs) under the California Department of Insurance (CDI). Requires initial license and renewal fees to be collected into the PBM Account in the Insurance Fund. Adds reporting requirements to existing prescription drug data reporting, including the aggregate amount of rebates received by the PBM for each drug. Prohibits spread pricing from being offered in PBM contracts and policies. Specifically, this bill:
CDI Licensure and Regulation of PBMs
- Requires CDI to license and regulate PBMs. Grants CDI the authority to enforce this bill, as specified.
- Requires PBMs that provide services in this state to, no later than January 1, 2027, apply for a license to operate as a PBM from CDI. Requires a PBM to maintain its license in good standing.
- Requires an application for a PBM license to be submitted in a form and manner determined by CDI and to be signed by an officer or individual responsible for the conduct or affairs of the PBM verifying that the contents of the application form and any attachments are correct. Requires the application to include all of the following:
- A nonrefundable application fee in an amount established by CDI under 11) below;
- A list of every health plan or health insurer on behalf of which the PBM contracts with a pharmacy or a pharmacy services administration organization to provide health services to individuals covered by the health plan or health insurer;
- A statement indicating all jurisdictions where the applicant has an application pending or has been registered, licensed, or otherwise certified to transact business as a PBM;
- A statement indicating whether either of the following has occurred:
- The PBM or any individual responsible for the conduct of the affairs of the PBM has had a PBM certificate of authority or license denied or revoked for cause in another state; or,
- Any individual responsible for the conduct of the affairs of the PBM has been convicted of, or has entered a plea of guilty or nolo contender to a felony without regard to whether adjudication was withheld;
- A copy of a power of attorney duly executed by the PBM if not domiciled in this state, appointing CDI, CDI’s successors in office, and CDI’s authorized deputies as the attorney of the PBM in and for this state, on whom process in any legal action or proceeding against the PBM on a cause of action arising in this state may be served;
- The names, addresses, official positions, and professional qualifications of each individual who is responsible for the conduct of the affairs of the PBM;
- A copy of a recent financial statements showing the PBM’s assets, liabilities, and sources of financial support that CDI determines are sufficient to show that the PBM is financially viable. If the PBM’s financial statements are prepared by an independent accountant public accountant, a copy of the most recent regular financial statement satisfies the requirement to show financial viability unless CDI determines that additional or more recent financial information is required for the proper administration of this bill;
- A document providing the names, addresses, dates of birth, social security numbers, official positions, and professional qualifications of each individual who owns, legally or the information as to each person beneficially, 10% or more in equity in the entity interested therein or any person with management or control over the PBM;
- A copy of all basic organizational and governing documents of the PBM, including, but not limited to, the articles of incorporation, bylaws, articles of association, trade name certificate, and other similar documents and all amendments to those documents;
- A description of the PBM, its services, facilities, and personnel;
- A document in which the PBM confirms that its business practices and each ongoing contract comply with this bill; and,
- Any other relevant information required by CDI.
- Requires the individual responsible for the conduct or affairs of the PBM and any of the organization’s partners, members, controlling persons, officers, directors, and managers to comply with the background check requirements as required by the CDI Commissioner.
- Requires a PBM to file a notice of the modification with CDI within 30 days after a significant modification of the information or documents submitted pursuant to 2) above.
- Subjects an applicant for a PBM license or licensed PBM to existing law relating to the business of insurance.
- Prohibits a PBM from operating in this state unless it is licensed pursuant to this bill.
- Does not abrogate compliance by a PBM with any applicable requirements of existing law.
- Specifies that a violation of this bill constitutes an unfair practice, as specified.
- Entitles the CDI Commissioner to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this bill and to recover attorney’s fees and costs incurred in remedying each violation.
- Requires a PBM license applicant to pay the initial application fee as determined by CDI and to be renewed every two years and is nontransferable.
- Requires a renewing applicant to submit to CDI both of the following:
- A renewal application in a form and manner determined by CDI that is signed by an officer or individual responsible for the conduct or affairs of the PBM verifying that the contents of the renewal form are correct; and,
- A renewal schedule and fee as determined by CDI.
- Requires a PBM license to expire if a complete renewal filing and fee is not received by the due date established by CDI.
- Allows the application for renewal of an expired license to be filed after the expiration date and until that same month and day of the next succeeding year. Requires the fee for a renewal application under this bill to be the fee specified in 15) below and a delinquent fee in the amount specified for a one-year period in 15) below for the filing. Subjects each licensee to payment of delinquent fees under this bill.
- Provides an application fee of dollars ($ ), and for each year of the two-year license term thereafter, a renewal fee of dollars ($ ). Authorizes the CDI Commissioner to increase or decrease fees, and schedule fees and charges, as specified.
PBM Reporting Requirements
- Requires PBMs to, on or before July 1, 2028, and on or before each July 1 thereafter, file with CDI a report that contains all of the information required by 14) of existing law below from the preceding calendar year.
- Requires CDI to, on or before January 1, 2029, and on or before each January 1 thereafter, prepare a report based on the information received by CDI pursuant to 16) above and to publish the report on its internet website. Requires the report to contain aggregate data and to exclude any information that CDI determines would cause financial, competitive, or proprietary harm to a PBM.
- Requires a PBM to, on or before July 1, 2027, and on or before each July 1 thereafter, report to CDI all of the following information:
- A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. Requires the PBM to report both of the following, for each drug that falls into the above categories:
- The pharmacy type used to fill the drug prescription, such as integrated, chain, independent, specialty, and mail order pharmacies; and,
- Pricing and rebate information, including the net price paid, the amount of rebate the PBM receives from the manufacturer, the amount of rebate the PBM passes to the health plan or health insurer, the amount the health plan or insurer pays the PBM, and the amount the PBM pays the pharmacy.
- For each list in 18) a) above, all of the following:
- The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug;
- The aggregate amount of rebates received by the PBM for each drug;
- Any administrative fees received from the pharmaceutical manufacturer or labeler;
- The aggregate of payments, or the equivalent economic benefit, made by the PBM to pharmacies owned or controlled by the PBM for each drug;
- The aggregate of payments made by the PBM to pharmacies not owned or collected by the PBM for each drug;
- Deidentified claims level information in electronic format that allows the CDI Commissioner to sort and analyze the following information for each claim, whether the claim required prior authorization; and,
- The amount paid to the pharmacy for each prescription, net of the aggregate amount of fees or other assessments imposed on the pharmacy, including point of sale and retroactive charges. Deems data as confidential pursuant to 21) below.
- All of the following information in the aggregate:
- The purchasers with which the PBM contracts, the scope of services provided to the purchasers, and the number of enrollees, insureds, and plan members served;
- PBM revenue, including revenue from manufacturers, purchasers, and other revenue; and,
- PBM expenses, including payments to pharmacies, claims processing, special programs, administration, and other expenses.
- A list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. Requires the PBM to report both of the following, for each drug that falls into the above categories:
- Requires CDI to compile the information reported pursuant to 18) above into a report for the public and Legislature that demonstrates the overall impact of PBMs on drug costs. Requires the data in the report to be aggregated and to not reveal information specific to individual purchasers.
- Requires CDI to, on or before January 1, 2029, and on or before each January 1 thereafter, publish the report on its internet website and include as part of the public meeting, as required. Allows CDI to consolidate reports.
- Deems information submitted to CDI, except for the reports required pursuant to 17) and 19) above, confidential and not disclosed to the public pursuant to the California Public Records Act. Provides that this bill does not prevent disclosure to the Attorney General (AG) to investigate, prosecute, or defend any legitimate legal claim or cause or action, or to use the reports in any court or proceeding of law.
- Defines a specialty drug as one that exceeds the threshold for a specialty drug under the Medicare Part D program for purposes of the reporting requirements under this bill.
PBM Prohibitions
- Prohibits a PBM from imposing any requirements, conditions, or exclusions that discriminate against a nonaffiliated pharmacy in connection with dispensing drugs.
- Prohibits discrimination pursuant to 23) above that includes all of the following:
- Terms or conditions applied to nonaffiliated pharmacies based on their status as a nonaffiliated pharmacy;
- Refusing to contract with or terminating a contract with a nonaffiliated pharmacy on the basis that the pharmacy is a nonaffiliated pharmacy or for reasons other than those that apply equally to affiliated pharmacies;
- Retaliation against a nonaffiliated pharmacy based on its exercise of any right or remedy under this bill; and,
- Reimbursing a nonaffiliated pharmacy less for a pharmacy service than the PBM would reimburse an affiliated pharmacy for the same pharmacy service.
- Specifies that this bill does not preclude a PBM or a purchaser of PBM services from establishing a network of contracting or participating pharmacies.
- Prohibits a PBM from doing any of the following:
- Require an enrollee or insured to use only an affiliated pharmacy if there are nonaffiliated pharmacies in the network;
- Financially induce an enrollee, insured, or prescriber to transfer a prescription only to an affiliated pharmacy if there are nonaffiliated pharmacies in the network;
- Require a retail nonaffiliated pharmacy to transfer a prescription to a retail affiliated pharmacy if there are nonaffiliated pharmacies in the network. Does not prevent a purchaser or PBM from offering and communicating to enrollees or insured’ financial incentives to use a particular pharmacy, such as lower copays or costs for a prescription when the prescription is dispensed;
- Unreasonably restrict an enrollee or insured from using a particular contracted retail pharmacy for the purpose of receiving pharmacist services covered by the enrollee’s or insured’s contract or policy;
- Communicate to an enrollee or insured verbally, electronically, or in writing that the enrollee or insured is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other nonaffiliated pharmacies that have the ability to dispense the medication or provide the services and are also in network; and,
- Deny a nonaffiliated contract pharmacy the opportunity to participate in a PBM network as preferred participation status if the pharmacy is willing to accept the same terms and conditions that the PBM has established for affiliated pharmacies as a condition of preferred network participation status.
- Disallows a contract issued, amended, or renewed on or after January 1, 2025, between a nonaffiliated pharmacy and a PBM from prohibiting the retail pharmacy from offering either of the following as an ancillary service of the retail pharmacy:
- The delivery of a prescription drug by mail or common carrier to a patient or personal representative on request of the patient or personal representative if the request is made before the drug is delivered; or,
- The delivery of a prescription to a patient or personal representative by an employee or contractor of the retail pharmacy.
- Prohibits the retail pharmacy, except as otherwise provided in a contract described in 27) above, from charging a PBM for the delivery service described in 27) above. Does not prohibit the use of remote pharmacies, secure locker systems, or other types of pickup stations if those services are otherwise permitted by law.
- Requires contracts entered into pursuant to this bill to be open for inspection by CDI.
- Prohibits a PBM from requiring more than one accreditation from an independent accrediting organization for pharmacists and pharmacies to dispense specialty drugs and requires a PBM to make every effort to ensure that enhanced standards are not imposed to dispense specialty drugs beyond those related to the safety and competency necessary to comply with requirements for dispensing specified medications and providing optimal patient care.
- Requires the PBM to disclose the amount and types of the PBM fees to the health insurer or health plan.
- Requires a PBM to use a passthrough pricing model.
- Requires a PBM to pass 100% of all prescription drug manufacturer rebates received to the health plan, health insurer, or program, if the contractual arrangement delegates the negotiation of rebates to the PBM, for the sole purpose of offsetting defined cost sharing, deductibles, and coinsurance contributions and reducing premiums of enrollees or insureds.
- Specifies that this bill does not preclude a health insurer or health plan from paying performance bonuses to a PBM based on savings to the health plan or health insurer that affects rated paid by the enrollee and insured or subscriber and policy holder, as long as the performance bonus is not based or contingent on any of the following:
- The acquisition cost or any other price metric of a drug;
- The amount of savings, rebates, or other fees charged, realized, or collected by, or generated based on the activity of, the PBM, that is retained by the pharmacy manager;
- The amount of premiums, deductibles, or other cost sharing or fees charged, realized, or collected by the PBM from patients or other persons on behalf of a patient; and,
- Compensation arrangements governed by this bill to be open for inspection by CDI.
- Prohibits a PBM from making or permitting any reduction of payment for pharmacist services by a PBM or a health insurer or health plan directly or indirectly to a pharmacy under a reconciliation process to an effective rate of reimbursement, including without limitation generic effective rates, brand effective rates, direct and indirect remuneration fees, or any other reduction or aggregate reduction of payment.
- Prohibits a claim or aggregate of claims for pharmacist services from being directly or indirectly retroactively denied or reduced after adjudication of the claim or aggregate of claims unless any of the following have occurred:
- The original claim was submitted fraudulently;
- The original claim payment was incorrect because the pharmacy or pharmacist had already been paid for the pharmacist services; and,
- The pharmacist services were not properly rendered by the pharmacy or pharmacist.
- Prohibits a PBM from reversing and resubmitting the claim of a contract pharmacy under any of the following circumstances:
- Without prior written notification to the contract pharmacy;
- Without just cause or attempt to first reconcile the claim with the pharmacy; or,
- More than 90 days after the claim was first affirmatively adjudicated.
- Prohibits a PBM from charging a pharmacy or pharmacist a fee to process a claim electronically.
- Prohibits the termination of a contract with a nonaffiliated pharmacy from releasing the PBM from the obligation to make a payment due to the pharmacy for an affirmatively adjudicated claim unless payments are withheld because of an investigation relating to insurance fraud.
- Prohibits a PBM from retaliating against a pharmacist or pharmacy based on the pharmacist’s or pharmacy’s exercise of a right or remedy under this bill. Includes, as prohibited retaliation, any of the following:
- Terminating or refusing to renew a contract with the pharmacist or pharmacy;
- Subjecting the pharmacist or pharmacy to increased audits; and,
- Failing to promptly pay the pharmacist or pharmacy money owed by the PBM to the pharmacist or pharmacy.
- Prohibits a PBM from, except as permitted under existing law, unreasonably obstructing or interfering with a patient’s right to timely access a prescription drug or device that has been legally prescribed for that patient at a contract pharmacy of their choice.
- Prohibits a PBM from making, disseminating, or causing or permitting the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
- Authorizes CDI to investigate referrals provided by the Board of Pharmacy (BoP).
- Prohibits a PBM, commencing January 1, 2025, from conducting spread pricing. Prohibits any subsequent amendment or renewal of that contract from containing spread pricing if a preexisting contract between a PBM and a health plan or health insurer authorizes spread pricing. Voids any spread pricing terms on and after January 1, 2028.
- Prohibits a PBM from entering into, amending, enforcing, or renewing a contract on or after January 1, 2025, with manufacturers who do business in California that expressly or implicitly restrict, or implements implicit or express exclusivity for, those manufacturers’ drugs, medical devices, or other products.
- Prohibits a PBM from entering into, amending, enforcing, or renewing a contract on or after January 1, 2025, with pharmacies or pharmacy administrative services organizations who do business in California that expressly or implicitly restrict, or impose implicit or express exclusivity on, nonaffiliated pharmacies’ ability to contract with employers, insurers, and health plans.
Enforcement
- Authorizes CDI to, in addition to any of the grounds listed in 1) above, deny, suspend, or revoke the license of a PBM if the CDI finds that any of the following are true:
- The PBM has violated a statute or regulation applicable to the PBM;
- The PBM has refused to be examined or to produce its accounts, records, and files for examination by CDI, or an individual responsible for the conduct of affairs of the PBM has refused to give information with respect to its affairs or has refused to perform any other legal obligation as to an examination required by the CDI;
- The PBM has, without just cause, exhibited a pattern or practice of refusing to pay proper claims or perform services arising under its contracts or has, without just cause, caused enrollees or insureds to accept less than the amount due them;
- The PBM is required under this chapter to have a license and fails to continue to meet the qualifications for licensure during its active licensure;
- The PBM failed to file a timely report as required by 16) above; and,
- The PBM is not financially viable.
- Requires a hearing pursuant to this bill to be conducted in accordance with the Administrative Procedure Act (APA), as specified.
- Authorizes CDI to examine or audit any books and records of a PBM to determine if the PBM is in compliance with this bill. Requires a PBM to pay for reasonable expenses for any examinations or audits conducted pursuant to this bill. Requires payments to be deposited into the PBM Account. Requires examinations conducted by CDI to be pursuant to the same examination authority of CDI relative to insurers. Provides that PBMs have the same rights as insurers.
- Allows CDI to produce and disclose publicly an examination report describing any act or omission committed by a PBM that violates this division.
- Requires CDI to establish a retention schedule for all records, books, papers, and other data on file with the CDI related to the enforcement of this bill.
- Prohibits CDI from ordering the destruction or other disposal of a record, book, paper, or other data that is required to be filed or kept on file with CDI during the retention period.
- Specifies that existing law relating to examinations by the CDI Commissioner does not prevent disclosure of information and data acquired during an examination to the AG to investigate, prosecute, or defend any legitimate legal claim or cause of action, or to use the information and data in any court or proceeding of law. Authorizes CDI to provide to the AG information related to competition and obtain an opinion from a consultant or consultants with the expertise to assess the competitive impact of the matter.
- Requires a PBM to have a duty and obligation to the health plan of the enrollee or subscriber or insurer of the insured or policyholder, and to perform its services with care, skill, prudence, diligence, and professionalism, and for the best interests of the health plan or insurer.
- Requires a PBM to disclose to a health insurer or health plan information of clinical efficacy and clinical evidence regarding the inclusion, exclusion, or limitation of prescription drugs in the formulary.
- Requires any PBM that this bill applies to be liable for restitution to any enrollee or insured harmed by the violation, in addition to any other penalty provided by law.
- Entitles the AG to specific performance, injunctive relief, and other equitable remedies a court deems appropriate for enforcement of this bill and to recover attorney’s fees and costs incurred in remedying each violation. Specifies that this bill does not alter or abrogate the CDI’s authority to enforce this provision.
- Subjects any person that violates this bill to an injunction and liable for a civil penalty of not less than one thousand dollars ($1,000) or more than seven thousand five hundred dollars ($7,500) for each violation to be assessed and recovered in a civil action brought by the AG.
- Specifies that a violation of specified provisions is an act of unfair competition within the meaning of the Business and Professions Code (BPC) and nothing in this bill limits any other statutory or common law rights or remedies, including liability pursuant to the Unfair Competition Law.
- Prohibits an action from being brought in the name of the people of the State of California that seeks relief under this bill pursuant to the Unfair Competition Law of the BPC without the written consent and permission of the AG. Specifies that this bill does not alter or abrogate the CDI’s authority to enforce this provision.
- Provides for the remedies or penalties provided by this bill to be cumulative to each other and to the remedies or penalties available under all other laws of this state.
PBM Fines and Penalties Account
- Requires, beginning on or after January 1, 2026, the fines and administrative penalties collected to be deposited into the PBM Fines and Penalties Account, which is established in the General Fund.
PBM Account
- Requires, no earlier than January 1, 2026, the fees for a PBM initial license and renewal application to be sufficient to fund CDI’s duties in relation to responsibilities under this bill, but in no case exceed the reasonable regulatory cost to administer this bill. Requires fees received under this bill to be deposited into the PBM Account, created in the Insurance Fund, and to be subject to an annual appropriation each fiscal year for the support of CDI related to the licensing and regulation of PBMs.
Other CDI Provisions
- Construes any activity conducted by a PBM, as defined in this bill, as the business of insurance.
- Requires CDI to adopt regulations necessary to implement this bill, and subject to the following:
- Allows, until January 1, 2028, necessary regulations for the purpose of implementing this bill to be adopted as emergency regulations in accordance with the APA. Deems the adoption of emergency regulations pursuant to this bill to be an emergency and necessary for the immediate preservation of the public peace, health and safety, or general welfare;
- Requires an emergency regulation adopted pursuant to this bill to be repealed by operation of law unless the adoption, amendment, or repeal of the regulation is promulgated by CDI within five years of the initial adoption of the emergency regulation; and,
- Requires a regulation adopted pursuant to this bill to be discussed by CDI during at least one public stakeholder meeting before CDI adopts the rule or regulation.
- Requires CDI to establish procedures for receiving, investigating, tracking, and publicly reporting consumer complaints against PBMs.
- Requires CDI to publish on its internet website a record of consumer complaints against a PBM that have been determined by CDI to be justified. Prohibits complaint data from being published unless it has been provided to the PBM in accordance with existing law requiring the CDI Commissioner to provide to the insurer a description of any complaint against the insurer.
- Prohibits the authority of the AG to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations from being narrowed, abrogated, or otherwise altered by this bill.
- Adds a severability clause that if any provision of this bill or its application is held invalid, that invalidity not affect other provisions or applications that can be given effect without the invalid provision or application.
- Finds and declares that this bill, which adds 16) and 49) above to the Insurance Code, imposes a limitation on the public’s right of access to the meetings of public bodies or the writings of public officials and agencies within the meaning of Section 3 of Article I of the California Constitution. Makes findings to demonstrate the interest protected by this limitation and the need for protecting the confidentiality of information received by state agencies from PBMs, as necessary to be presumptively confidential, except as otherwise provided by law.
Definitions
- Defines the following for purposes of this bill:
- Affiliated pharmacy as a contract pharmacy that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a PBM;
- Claim as a request for payment for administering, filling, or refilling a drug or for providing a pharmacy service or a medical supply or device to an enrollee or insured;
- Contract pharmacy as a retail pharmacy or other pharmacy that contracts directly or through a pharmacy services administration organization with a PBM;
- Financially viable means that either of the following conditions is met:
- The PBM has received an unqualified opinion from an independent public accountant; or,
- If an independent public accountant opinion is not obtained, the PBM remains solvent after adjusting for goodwill and intangible assets.
- Nonaffiliated pharmacy as a contract pharmacy that directly, or indirectly through one or more intermediaries, does not control, is not controlled by, and is not under common control with, a PBM;
- Passthrough pricing model means a payment model used by a PBM in which the payments made by the health care service plan or health insurer client to the PBM for the covered outpatient drugs are both of the following:
- Equivalent to the payments the PBM makes to a pharmacy or provider for those drugs, including any contracted professional dispensing fee between the PBM and its network of pharmacies. That dispensing fee would be paid if the pharmacy benefits plan or program was making the payments directly; and,
- Passed through in their entirety by the health plan or health insurer client or by the PBM to the pharmacy or provider that dispenses the drugs, and the payments are made in a manner that is not offset by any reconciliation.
- Pharmacist services as products, goods, and services, or any combination of products, goods, and services, provided as a part of the practice of pharmacy;
- PBM fee as a fee that covers the cost of providing one or more PBM services and that does not exceed the value of the service or services actually performed by the PBM. Requires the value of the service or services to be based on the value to the health insurer or health plan;
- PBM service as all of the following:
- Negotiating the price of prescription drugs, including negotiating and contracting for direct or indirect rebates, discounts, or other price concessions;
- Managing any aspect of a prescription drug benefit, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with pharmacies, controlling the cost of covered prescription drugs, managing or providing data relating to the prescription drug benefit, or the provision of services related thereto;
- Performing any administrative, managerial, clinical, pricing, financial, reimbursement, data administration, or reporting, or billing service; and,
- Other services as CDI defines in regulation;
- PBM as a person, business, or other entity that, either directly or indirectly, manages the prescription drug coverage, including, but not limited to, the following: clinical or other formulary or preferred drug list development or management; the processing and payment of claims for prescription drugs, the negotiation or administration of rebates, discounts, payment differentials, or other incentives; for the inclusion of particular prescription drugs in a particular category or to promote the purchase of particular prescription drugs; the performance of drug utilization review; the processing of drug prior authorization requests; the adjudication of appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. Does not include the following:
- A health plan that is part of a fully integrated delivery system in which enrollees primarily use pharmacies that are entirely owned and operated by the health plan, and the health plan’s enrollees may use any pharmacy in the health plan’s network that has the ability to dispense the medication or provide the services;
- An entity providing services pursuant to a contract authorized by the Labor Code under Workers’ Compensation and Insurance;
- A health plan, or its contracted provider, as defined; or,
- A health insurer.
- Pharmacy services administration organization as an entity that provides contracting and other administrative services relating to prescription drug benefits to pharmacies;
- Rebate as a formulary discount or remuneration attributable to the use of prescription drugs that is paid by a manufacturer or third party, directly or indirectly, to a PBM after a claim has been adjudicated at a pharmacy. Does not include a fee, including a bona fide service fee or administrative fee, that is not a formulary discount or remuneration;
- Spread pricing as the model of prescription drug pricing in which a PBM charges a health plan or health insurer a contracted price for prescription drugs, and the contracted price for the prescription drugs differs from the amount the PBM directly or indirectly pays the pharmacist or pharmacy; and,
- Third party as a person that is not an enrollee, insured, or PBM.
Health Plan and Insurance PBM Provisions
- Prohibits a health plan contract or insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage from calculating an enrollee or insured’s cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
- Prohibits any contract or policy or any subsequent amendment or renewal of an existing contract or policy, commencing January 1, 2025 from authorizing spread pricing.
Prescription Drug Reporting
Requires health plans or insurers, in addition to prescription drug reporting set forth in 6) of existing law below of the 25 most frequently prescribed drugs, most costly drugs by total annual plan spending, and 25 drugs with the highest year over year increase to also report all of the following:
The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug;
The aggregate amount of rebates received by the PBM for each drug;
Any administrative fees received from the pharmaceutical manufacturer or labeler;
The aggregate of payments, or the equivalent economic benefit, made by the pharmacy benefit manager to pharmacies owned or controlled by the PBM for each drug; and,
The aggregate of payments made by the PBM to pharmacies not owned or collected by the PBM for each drug.
EXISTING LAW:
Health Plan and Health Insurance
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans in the Health and Safety Code; CDI to regulate health insurers under the Insurance Code. [Health and Safety Code (HSC) § 1340, et seq. and Insurance Code (INS) § 106, et seq.]
- Establishes as California's Essential Health Benefits (EHBs) benchmark, the Kaiser Small Group Health Maintenance Organization, existing California mandates, and federal Patient and Protection Affordable Care Act mandated benefits, including prescription drugs. [HSC §1367.005 and INS §10112.27]
- Requires health plans to maintain the following:
- Complete drug formulary or formularies, including a list of prescription drugs on the formulary of the plan by major therapeutic category with an indication of whether any drugs are preferred over other drugs;
- Records developed by the pharmacy and therapeutic committee of the health plan that fully describe the reasoning behind formulary decisions; and,
- Health plan arrangements with entities that are associated with activities of the health plan to encourage formulary compliance or otherwise manage prescription drug benefits. [HSC §1367.005]
- Requires a plan or insurer that provides EHBs to allow an enrollee or insured to access prescription drug benefits at an in-network retail pharmacy unless the prescription drug is subject to restricted distribution by the United States Food and Drug Administration (FDA) or requires special handling, provider coordination, or patient education that cannot be provided by a retail pharmacy. Permits a nongrandfathered individual or small group health plan contract or insurance policy to charge an enrollee or insured a different cost sharing for obtaining a covered drug at a retail pharmacy, but requires all cost sharing to count toward the annual limitation on cost sharing. [HSC §1367.42 and INS §10123.201]
- Requires a health plan or health insurer that reports rate information, as specified, to report information no later than October 1 of each year that demonstrates the overall impact of drug costs on health care premiums. [HSC §1356.243 and INS §10123.205]
- Requires health plans and insurers, for all covered prescription drugs, including generic drugs, brand name drugs, and specialty drugs dispensed at a plan pharmacy, network pharmacy, or mail order pharmacy for outpatient use, to report:
- The 25 most frequently prescribed drugs;
- The 25 most costly drugs by total annual plan spending; and,
- The 25 drugs with the highest year-over-year increase in total annual plan spending. [Ibid.]
- Requires DMHC and CDI to compile the information from 5) and 6) above into a report for the public and Legislators where the data is aggregated and does not reveal information specific to individual plans. Requires the report to be published on DMHC’s and CDI’s website. [Ibid.]
PBM Registration Under the DMHC
- Defines a PBM as a person, business, or other entity that, pursuant to a contract with a health plan, manages the prescription drug coverage provided by the health plan, including, but not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to prescription drug coverage, contracting with network pharmacies, and controlling the cost of covered prescription drugs. [HSC §1385.001]
- Requires a health plan that contracts with a PBM to require the PBM to comply with specified requirements, including registration with DMHC and to exercise good faith and fair dealing in the performance of its duties. [HSC §1385.004 and §1385.005]
- Requires the failure by a health plan to comply with PBM contractual requirements to constitute grounds for disciplinary action. Requires the DMHC Director, as appropriate, to investigate and take enforcement action against a health plan that fails to comply with these requirements and to periodically evaluate contracts between health plans and PBMs to determine if any audit, evaluation, or enforcement actions should be undertaken by DMHC. [HSC §1385.006]
- Establishes a pilot project in Riverside and Sonoma Counties, effective January 1, 2020, to assess the impact of health plan and PBM prohibitions on the dispensing of certain amounts of prescription drugs by network retail pharmacies. Specifies the following:
- Prohibit a health plan, pursuant to the pilot project, from prohibiting, or permitting any delegated PBM to prohibit, a pharmacy provider from dispensing a particular amount of a prescribed medication if the plan or PBM allows that amount to be dispensed through a pharmacy owned or controlled by the plan or PBM, unless the prescription drug is subject to restricted distribution by the FDA or requires special handling, provider coordination, or patient education that cannot be provided by a retail pharmacy; and,
- Require health plans subject to the pilot project, on or before July 1, 2020, to report annually to DMHC information and data relating to changes, if any, to costs and utilization of prescription drugs attributable to the prohibition of contract terms in 12) a) above. [HSC §1368.6]
Board of Pharmacy
- Provides for the licensure and regulation of pharmacists and pharmacies by the BoP. [BPC §4200, et seq.]
- Requires a PBM that reimburses a contracting pharmacy for a drug on a maximum allowable cost basis to do the following, among other provisions related to maximum allowable cost:
- Include in a contract, initially entered into, or renewed on its scheduled renewal date, on or after January 1, 2016, with the contracting pharmacy information identifying any national drug pricing compendia or other data sources used to determine the maximum allowable cost for the drugs on a maximum allowable cost list; and,
- Make available to a contracting pharmacy, upon request, the most up-to-date maximum allowable cost list or lists used by the PBM for patients served by that pharmacy in a readily accessible, secure, and usable web-based format or other comparable format. [BPC §4440]
- Establishes audits of pharmacy benefits by BoP and requires PBMs to disclose, upon the request of the purchaser, the following information with respect to prescription product benefits specific to the purchaser, on a quarterly basis:
- The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each therapeutic category of drugs containing three or more drugs, as outlined in the EHBs;
- The aggregate amount of rebates received by the PBM by therapeutic category of drugs containing three or more drugs, as outlined in the EHBs. Requires the aggregate amount of rebates to include any utilization discounts the PBM receives from a pharmaceutical manufacturer or labeler;
- Any administrative fees received from the pharmaceutical manufacturer or labeler;
- Whether the PBM has a contract, agreement, or other arrangement with a pharmaceutical manufacturer to exclusively dispense or provide a drug to a purchaser’s employees, insureds, or enrollees, and the application of all consideration or economic benefits collected or received pursuant to that arrangement;
- Prescription drug utilization information for the purchaser’s enrollees or insureds that is not specific to any individual enrollee or insured;
- The aggregate of payments, or the equivalent economic benefit, made by the PBM to pharmacies owned or controlled by the PBM;
- The aggregate of payments made by the PBM to pharmacies not owned or collected by the PBM; and,
- The aggregate amount of the fees imposed on, or collected from, network pharmacies or other assessments against network pharmacies, and the application of those amounts collected pursuant to the contract with the purchaser. [BPC §4441]
- Prohibits a PBM from including in a contract with a pharmacy network provider or its contracting agent a provision that prohibits the provider from informing a patient of a less costly alternative to a prescribed medication. [Ibid.]
FISCAL EFFECT: According to the Senate Appropriations Committee:
- Unknown likely significant fiscal impact ranging in the high hundreds of thousands to low millions of dollars for CDI to license PBMs (Insurance Fund and PBM Fund). CDI would likely require Insurance Fund or other fund support until it establishes and collects fee revenue sufficient to support the ongoing administration and enforcement operations of the PBM licensure program. Costs to CDI will likely include additional staff resources to develop regulations, establish the licensing framework, provide additional consumer service support to address complaints received from the public and the BoP, and to intake information from PBMs and publish required reports. There will also likely be additional enforcement and legal costs to ensure compliance with licensure requirements and prohibitions. Other costs may include informational technology resources to build infrastructure to support licensing or complaint intake systems. PBM license fee revenue may offset CDI’s costs. It is unknown at what level fees would need to be set for CDI to recoup its administrative and enforcement costs.
- DMHC reports ongoing annual costs of approximately $51,000 beginning in Fiscal Year 2025-26 to its Office of Financial Review for additional workload related to revising reporting templates, reviewing health plan filings, and compiling data for annual reporting and compliance requirements (Managed Care Fund).
- Unknown, potentially significant workload cost pressures to the courts to adjudicate cases brought by the AG against PBMs engaged in specified prohibited activities and practices (Trial Court Trust Fund, General Fund).
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, this bill reins in the worst abuses by PBMs. This bill will protect consumer choice, provide transparency on prescription drug prices, and improve our healthcare system by ensuring that PBMs are appropriately regulated. Vertical integration and a lack of oversight have allowed some PBMs to engage in unfair business practices that undermine healthcare access and drive up the cost of prescription drugs. By raising fees and lowering reimbursement rates, PBMs are making it hard for many independent pharmacies to stock vital medications, and forcing many of them to close. The complete lack of oversight has also allowed some PBMs to steer patients toward pharmacies they own, pocket large portions of the rebates they negotiate with drug manufacturers, and make misleading statements to customers. The author concludes that this bill fills that regulatory gap by requiring that all PBMs be licensed by CDI and disclose basic information regarding their business practices to the state.
- BACKGROUND.
- Prescription Drug Spending and SB 17 DMHC Report. According to the DMHC, health plans paid almost $1.3 billion more on prescription drugs in 2022 than in 2021, the highest year-over-year increase since SB 17 (Hernandez), Chapter 603, Statutes of 2017, reporting began. The cost of prescription drugs continues to impact the affordability of health care overall, with health plans paying about $12.1 billion for prescription drugs in 2022. SB 17 requires health plans in the commercial market to annually report their prescription drug costs to the DMHC. This report looks at the impact of the cost of prescription drugs on health plan premiums and compares this data across the reporting years. The most recent report of 2022 data notes the following key findings:
- Health plans paid about $12.1 billion for prescription drugs in 2022, an increase of almost $1.3 billion, or 12.3%, from 2021. Since 2017, prescription drug costs paid by health plans increased by $3.4 billion or 39%;
- Prescription drugs accounted for 14.2% of total health plan premiums in 2022, an increase from 13.3% in 2021;
- Total prescription drug costs increased by 12.3% in 2022, whereas total medical expenses increased by 7.9%. Overall, total health plan premiums increased by 4.4% from 2021 to 2022;
- Manufacturer drug rebates totaled approximately $2.068 billion, up from $1.674 billion in 2021 and $1.437 billion in 2020. This represents about 17.1% of the $12.1 billion spent on prescription drugs in 2022;
- While specialty drugs accounted for only 1.6% of all prescription drugs dispensed, they accounted for 64% of total annual spending on prescription drugs;
- Generic drugs accounted for 88.9% of all prescribed drugs but only 14.4% of the total annual spending on prescription drugs;
- Brand name drugs accounted for 9.5% of prescriptions and constituted 21.6% of the total annual spending on prescription drugs;
- The Pfizer and Moderna COVID-19 vaccines were amongst the most frequently prescribed brand name drugs and the most costly brand name drugs. Also, this is the first year which shows COVID-19 tests amongst the brand name drugs with the highest year-over-year increase in total spending; and,
- The primary drugs that are driving the increase in the total prescription drug cost spending for 2022 are in the specialty and brand name drug categories. In particular, several drugs used in the management of diabetes or weight loss and biological immunological drugs have risen in the rankings or appeared on the top 25 lists for the first time and are among the most expensive and rapidly expanding drugs.
- PBM History. According to the National Academy for State Health Policy, regulating PBMs is a legislative priority for states to lower prescription drug costs. Between 2017 and 2023, laws regulating PBMs accounted for more than half of all enacted prescription drug legislation.
- Prescription Drug Spending and SB 17 DMHC Report. According to the DMHC, health plans paid almost $1.3 billion more on prescription drugs in 2022 than in 2021, the highest year-over-year increase since SB 17 (Hernandez), Chapter 603, Statutes of 2017, reporting began. The cost of prescription drugs continues to impact the affordability of health care overall, with health plans paying about $12.1 billion for prescription drugs in 2022. SB 17 requires health plans in the commercial market to annually report their prescription drug costs to the DMHC. This report looks at the impact of the cost of prescription drugs on health plan premiums and compares this data across the reporting years. The most recent report of 2022 data notes the following key findings:
According to the California Health Benefits Review Program (CHBRP), PBMs have evolved significantly over recent decades. PBMs went from primarily processing prescription claims (which was largely an administrative function) in the late 1960s to serving as gatekeeper to outpatient prescriptions through active management of formularies and pharmacy networks. The first generation PBMs were heavily focused on developing innovations that allowed them to keep costs down for employers/health plans and for patients. CHBRP states that PBMs also play a role in pricing as they negotiate directly with drug manufacturer but reveal little about how those savings are passed onto consumers. The current formulary-for-rebate arrangement between PBMs and manufacturers is a form of selective contracting that has been employed in the provision of health care since the 1980s. During the 1990s, the focus of PBMs shifted from pharmaceutical claims management to more complex business models with a diversified portfolio of services, including the use of incentives to modify consumer behavior, and disease management programs. Today, PBMs use their buying power, combined with utilization management strategies, to lower the total cost of pharmaceuticals. PBMs have consolidated significantly in recent years and there are now three large PBMs — CVS, Express Scripts, and Optum — that account for 80% of the market.
- Existing California PBM law. PBMs play a major role in negotiating the prices of prescription drugs, creating and managing formularies, and several other functions key to the management of pharmacy benefits for millions of Californians. However, despite a PBM's interaction with most major players, including drug manufacturers, health plans and insurers, and pharmacies, very little is known about those relationships. AB 315 (Wood), Chapter 905, Statutes of 2018, establishes a regulatory structure for PBMs, and provides for the registration of PBMs to the DMHC. AB 315 requires DMHC, by July 1, 2019, and in collaboration with other agencies, departments, advocates, experts, health plan representatives, and other entities and stakeholders that it deems appropriate, to convene a Task Force on PBM Reporting to determine what information related to pharmaceutical costs, if any, it should require to be reported by health plans or their contracted PBMs, in addition to reporting required in existing law.
- 2020 AB 315 Task Force Report. In 2019, the DMHC facilitated a series of public Task Force meetings to develop the recommendations contained in this report. The report noted that the PBM marketplace appears to be highly concentrated, with the top three PBMs representing approximately 75% of covered lives in California. Some suggest that this concentration is evidence of a stable and functioning market, whereas others believe it is evidence that the largest PBMs have a stranglehold on the market and therefore wield too much negotiating power. Stakeholders attending the Task Force meetings asserted that dominant PBMs may negotiate higher rebates only to keep the bulk of the rebate. By not passing the rebate on to health plans, consumers may be adversely affected by higher costs. Market concentration is seen not only across the marketplace, but also vertically within the supply chain. Some PBMs own their own pharmacies, referred to as an “integrated pharmacy.” This may result in misaligned incentives, as a PBM may favor an integrated pharmacy even if competing pharmacies have lower costs. Additionally, the Task Force heard from pharmacy representatives who stated PBMs may improperly utilize prescription information to steer patients who are prescribed high-cost drugs to the PBM’s integrated pharmacies. Some PBMs and health plans have common ownership which could lead to PBMs increasing drug costs to rival health plans. The Task Force recommended gathering data to increase transparency and understand how PBMs impact the cost of prescription drugs, including gathering information on PBMs, including revenue and expense information, to determine PBM market impact and the value PBMs provide to consumers.
- Pilot Project. AB 315 also established a pilot project, effective January 1, 2020, in Riverside and Sonoma counties to assess the impact of health plan and PBM prohibitions on the dispensing of certain amounts of prescriptions drugs by network retail pharmacies. During the pilot project, health plans and PBMs were required to permit prescription drugs to be dispensed at all network pharmacies in the same quantities that are dispensed at pharmacies owned or controlled by the health plans or PBMs. The most commonly dispensed prescription drugs were generic drugs for maintenance of chronic conditions, such as high cholesterol and hypothyroidism and frequently dispensed in 90-day supplies. The total prescription cost for the six health plans was approximately $170.7 million, of which 9.1%, or approximately $15.6 million, was attributed to the impacted drugs. Given that costs were reduced during the pilot project, it appears that the average costs paid to non-owned or non-controlled pharmacies were lower than those paid to health plan or PBM owned or controlled pharmacies. It should be noted that the public health emergency related to the COVID-19 pandemic occurred not long after the start of the pilot project and likely impacted the number prescriptions filled at network pharmacies, particularly in the first year.
- Federal Report on PBM regulation to Address Prescription Drug Spending. The United States Government Accountability Office (GAO) published a March 2024 report indicating that prescription drug spending by private health plans climbed to nearly $152 billion in 2021, an 18% increase from 2016. Health plans generally rely on PBMs to process claims, develop pharmacy networks, and negotiate rebates from drug manufacturers. However, some researchers and stakeholders have questioned certain PBM practices, such as PBMs retaining a share of the rebates and use of spread pricing. According to the GAO, PBMs receive compensation from health plans for their services in a variety of ways. Health plans may opt for an administrative fee contract, where they pay the PBM directly for all the services provided. Alternatively, health plans may elect to use a spread pricing option. Under spread pricing, the health plan pays the PBM a set price for each prescription filled, and the PBM retains the difference between the price paid by the health plan and the price paid to the pharmacy as a form of compensation. Additionally, PBMs may retain a portion of manufacturer rebates to offset the fees health plans would otherwise pay.
- Existing California PBM law. PBMs play a major role in negotiating the prices of prescription drugs, creating and managing formularies, and several other functions key to the management of pharmacy benefits for millions of Californians. However, despite a PBM's interaction with most major players, including drug manufacturers, health plans and insurers, and pharmacies, very little is known about those relationships. AB 315 (Wood), Chapter 905, Statutes of 2018, establishes a regulatory structure for PBMs, and provides for the registration of PBMs to the DMHC. AB 315 requires DMHC, by July 1, 2019, and in collaboration with other agencies, departments, advocates, experts, health plan representatives, and other entities and stakeholders that it deems appropriate, to convene a Task Force on PBM Reporting to determine what information related to pharmaceutical costs, if any, it should require to be reported by health plans or their contracted PBMs, in addition to reporting required in existing law.
In response, all 50 states having enacted at least one PBM-related law between 2017 and 2023. The GAO reviewed states’ regulation of PBMs, many of which are similar to the provisions of this bill. These laws include pharmacy reimbursement, transparency, through licensing and reporting, and pharmacy network and access requirements. One of the lessons learned includes providing regulators with broad regulatory authority was more effective than enacting specific statutory provisions as doing so allowed regulators to address emerging issues without new legislation, according to regulators from one state. Some regulators also stressed the need for robust enforcement of PBM laws and effective penalties to enforce them.
- SUPPORT. The California Pharmacists Association, California Chronic Care Coalition, San Francisco AIDS Foundation, and Los Angeles LGBT Center, cosponsors, write that while the initial purpose of PBMs was to negotiate contracts on behalf of their clients (health plans), there is now an inherent conflict of interest and lack of transparency in how they operate. PBMs are squarely in the middle of negotiating prices, demanding rebates, and driving formulary decisions—controlling virtually every aspect of prescription drug program. The self-dealing nature of PBMs is on full display when they steer patients to their company-owned mail-order, community and special pharmacies, all of which calls into question the ability of PBMs to fairly represent the employers, providers, and patients they purport to serve. The cosponsors write that the only healthcare entities that have seemingly avoided transparency and oversight are PBMs. By providing transparency and oversight of PBMs, the following harmful practices can be subject to scrutiny and, in some cases, prohibited:
- Rebate Pumping: PBMs favoring higher-cost drugs on a formulary because the PBM can negotiate a higher rebate, which PBMs retain as profit;
- Spread Pricing: PBMs charge the health plan a higher cost than what it pays to the pharmacy. This can lead to higher costs for the plan sponsor, which in turn can increase premiums and co-pays for patients;
- Claw-backs: After a prescription is filled, PBMs retroactively recoup the difference between a patient’s copay and the actual price of a drug when the copay amount is higher. The cosponsors write that it is important to note that the PBMs require a pharmacy to collect a copay from a patient that is set by the PBM. If the patient copay imposed by the PBM is higher than the ultimate reimbursement to the pharmacy, the PBM claws back the excess copay from the pharmacy, keeping it as a profit;
- Rebate retention: PBMs retain a portion of the drug manufacturer rebate as profit instead of returning full amount to the consumer or health plan; and,
- Patient Steering: PBMs require patients to transfer prescriptions to the PBM-owned mail-order or community pharmacies or the consumer faces higher copay amounts for their medications.
- SUPPORT IF AMENDED. The Association of Northern California Oncologists, the Medical Oncology Association of Southern California and the Association for Clinical Oncology request amendments to extend this bill’s protections for pharmacists from patient steering to physicians, in order to better enable California’s oncologists to provide the best care possible to California’s cancer patient population.
- OPPOSE UNLESS AMENDED. San Diego Regional Chamber of Commerce (SD Chamber) contends that this bill seeks to limit pharmacy network design by prohibiting health plans from using preferred pharmacies. When health plans use preferred pharmacies they obtain cost savings, which are then passed on to plan holders, including employers and employees, in the form of lower premiums or expanded benefits. Limiting pharmacy network design for health plans can drive up premiums and will simply increase revenue for a small number of pharmacies. Additionally, SD Chamber writes that restrictions on specialty network design can lead to diminished patient safety as plans could use unaccredited pharmacies that do not meet high standards for specialty drug storage and dispensing.
The California State Pipe Trades Council, California State Association of Electrical Workers and Western States Council of Sheet Metal Workers seek amendments to allow both spread pricing and pass-through contracts to be considered on the basis that health plans and health plan sponsors often ask for spread pricing contracts when issuing their request for proposals to compare different PBM payment models and determine which one best suits their needs.
- OPPOSITION. Various organizations representing the California Alliance for Prescription Affordability write that PBMs have proven to be the only entity helping to negotiate and drive prescription drug costs and this bill puts pharmacy profits ahead of California’s small businesses, their employees and families, and will make the postpandemic recovery that much more difficult, if not impossible, in the years ahead.
The Pharmaceutical Care Management Association (PCMA) writes that prohibiting employers and health plan sponsors from choosing how to compensate PBMs based on the savings they provide will encourage drug manufacturers to raise their prices. If plan sponsors are unable to incentivize lower costs, and are prohibited from encouraging PBMs to negotiate against drug manufacturers, ultimately, costs will increase. PCMA contends that banning performance-based contracts would cause an overall increase in health premiums in California. While PCMA is not opposed to licensure or to the overall policy objective of the state collecting and analyzing aggregated protected PBM data, PCMA wants to ensure the data is meaningful, useful, and practical. PCMA also notes that PBMs do not engage in the business of insurance and are third party administrators that do not take on financial risk like insurance companies and the result of this could cause CDI issuing regulations exempt from the Employee Retirement Income Security Act of 1974 (ERISA). PCMA concludes that this bill goes far beyond licensing and regulating of PBMs and will disrupt how health plans, employers, and unions choose to manage and pay for prescription drug benefits and will lead to higher costs for payers and patients in California.
- RELATED LEGISLATION. AB 2180 (Weber) would have required a health plan, health insurance policy, or PBM that administers pharmacy benefits for a health plan or health insurer to apply any amounts paid by the enrollee, insured, or a third-party patient assistance program for prescription drugs toward the enrollee’s or insured’s cost-sharing requirement, and would have only applied those requirements with respect to enrollees or insureds who have a chronic disease or terminal illness. AB 2180 was held in the Assembly Appropriations Committee.
- PREVIOUS LEGISLATION.
- AB 913 (Petrie-Norris) of 2023 would have required the BoP to license and regulate PBMs that manage the prescription drug coverage provided by a health plan or health insurer, except as specified. Would have set forth various duties of PBMs, including requirements to file a report with the BoP. AB 913 was never heard in the Assembly Business and Professions Committee.
- SB 873 (Bradford) of 2023 would have required an enrollee’s or insured’s defined cost sharing for each prescription drug to be calculated at the point of sale based on a price that is reduced by an amount equal to 90% of all rebates received, or to be received, in connection with the dispensing or administration of the drug. SB 873 was held in the Assembly Appropriations Committee.
- AB 948 (Berman), Chapter 820, Statutes of 2023, makes permanent existing law that prohibit the copayment, coinsurance, or any other form of cost sharing for a covered outpatient prescription drug for an individual prescription from exceeding $250 for a supply of up to 30 days or $500 for bronze products, except as specified; and, requires a non-grandfathered individual or small group plan contract or insurance policy to use specified definitions for each tier of a drug formulary. Prohibits a copayment or percentage coinsurance from exceeding 50% of the cost to the plan and require a plan or insurer to ensure that the enrollee or insured is subject to the lowest cost sharing that would be applied, whether or not both the generic equivalent and the brand name drug are on the formulary, if there is a generic equivalent to a brand name drug. Deletes biologics from the tier four definition in existing law.
- AB 524 (Skinner) of 2021 would have prohibited a health plan, a health insurer, or the agent thereof from engaging in patient steering, as specified. Would have defined “patient steering” to mean communicating to an enrollee or insured that they are required to have a prescription dispensed at, or pharmacy services provided by, a particular pharmacy, as specified, or offering group health care coverage contracts or policies that include provisions that limit access to only pharmacy providers that are owned or operated by the health care service plan, health insurer, or agent thereof. Governor Newsom vetoed AB 524 stating in part:
“While offering consumers a choice in pharmacies within their health plan or insurer networks is a worthwhile goal, the bill lacks clarity in key areas which may render it subject to misinterpretation or a lack of enforceability. It is unclear what business relationships between health plans, insurers, and their agents are intended to be affected because the bill does not define "agent" or "corporate affiliate." Furthermore, it is unclear what it means to "limit an enrollees' (or insureds') access" to certain pharmacy providers.
It is necessary to define these terms and concepts so appropriate oversight and enforcement may occur, particularly in light of the complexity of the contracting arrangements and benefit designs at issue. Finally, it is important to ensure that efforts to address these concerns do not have the unintended consequence of interfering with the ability of health plans and insurers to coordinate care and contain pharmaceutical costs for California's consumers.”
- AB 1803 (Committee on Health), Chapter 114, Statutes of 2019, requires a pharmacy to inform a customer at the point of sale for a covered prescription drug whether the retail price is lower than the applicable cost-sharing amount for the prescription drug, except as specified, and, if the customer pays the retail price, requires the pharmacy to submit the claim to the customer’s health plan or health insurer beginning January 1, 2020.
- AB 315 requires PBMs to register with the DMHC, to exercise good faith and fair dealing, and to disclose, upon a purchaser's request, information with respect to prescription product benefits, as specified.
- SB 17 requires health plans and insurers that offer commercial products and file rate information with the DMHC or CDI to annually report specific information related to the costs of covered prescription drugs.
- DOUBLE REFERRED. This bill is double-referred; upon passage of this Committee, this bill will be referred to the Assembly Judiciary Committee.
- AMENDMENTS. As this bill moves forward, the author has agreed to the following amendments:
- The following technical amendments:
- At INS § 17000(r): Does not include
either ofthe following: - At INS § 17010(c)(4)(B): nolo contendere; and,
- At INS § 17050(d)(2): The amount of savings, rebates, or other fees charged, realized, or collected by, or generated based on the activity of, the PBM, that is retained by the pharmacy benefit manager;
- At INS § 17000(r): Does not include
- The following substantive amendment:
- At INS § 17045: A pharmacy benefit manager shall not require more than
onetwo accreditation from an independent accrediting organization for pharmacists and pharmacies to dispense specialty drugs and shall make every effort to ensure that enhanced standards are not imposed to dispense specialty drugs beyond those related to the safety and competency necessary to comply with requirements for dispensing specified medications and providing optimal patient care.
- At INS § 17045: A pharmacy benefit manager shall not require more than
- The following technical amendments:
- POLICY COMMENTS.
- Regulatory Oversight of Health Insurance in California. In California, regulation and oversight of health insurance is split between two state departments – DMHC and CDI. According to data from the California Health Care Foundation, as of 2022, DMHC enrollees represent 13.2 million commercial lives whereas CDI insureds represent 0.8 million lives.
- Existing regulatory authority. One of the threshold issues for this bill is whether or not CDI is the appropriate state regulator given existing law requiring PBM registration under the DMHC. The Legislature should consider whether existing law should be expanded to include not just licensure and oversight of health plans by DMHC, but to third-party entities, like PBMs, that contract with health plans.
- Costs to implement this bill. While this bill establishes a PBM Account with fees to fund CDI’s duties in relation to responsibilities under this bill, the Senate Appropriations Committee notes a significant fiscal impact ranging in the high hundreds of thousands to low millions of dollars for CDI to license PBMs, as described above. It is unknown whether or not CDI will have the capacity to handle this expansion given the significant resources required by this bill.
- Regulatory Oversight of Health Insurance in California. In California, regulation and oversight of health insurance is split between two state departments – DMHC and CDI. According to data from the California Health Care Foundation, as of 2022, DMHC enrollees represent 13.2 million commercial lives whereas CDI insureds represent 0.8 million lives.
Should this bill be amended to require PBM licensure by DMHC considering the number of lives covered by the DMHC versus CDI and the potential expansion of existing law?
- Broad Regulatory Authority. Every arrangement that PBMs make with manufacturers, employers, and insurers is secret and proprietary, and these arrangements can make it difficult to examine PBM contracts. A regulatory framework, as established in this bill, will authorize the state to examine the kinds of deals PBMs are making. One of the lessons learned from the GAO report cited above, is that providing broad authority allows regulators the flexibility to address emerging issues and to avoid potential unintended consequences to consumers.
- Prescription Drug Pricing. From a consumer perspective and as the Congressional Committee on Oversight and Accountability noted, the focus of the pharmaceutical marketplace should be on the patient. Greater transparency is needed to determine the impact PBMs tactics are having on patients. This bill can be strengthened by allowing the regulator to study the contract terms between PBMs and their clients to understand the actual costs of pharmaceuticals to health plans and their enrollees prior to implementing some of the prohibitions codified in this bill.
- PBM Reimbursement. As drafted, this bill sets forth PBM reimbursement methods, specifically prohibiting spread pricing and allowing for passthrough payments. While this bill allows for PBM performance bonuses, it is unclear how this provision can be interpreted given the number of prohibitions and definitions in this bill. As noted by the opposition, health plans or purchasers ask for options to compare different PBM payment models to determine which one best suits their needs. One of the goals of the Office of Health Care Affordability is to promote high-value health system performance and promote the shift from fee-for-service payments to alternative payment models that provide financial incentives for equitable, high-quality, and cost-efficient care. Can this bill be interpreted to limit the options available to purchasers and the financial incentives for PBMs to negotiate lower prescription drug prices for their clients?
- Broad Regulatory Authority. Every arrangement that PBMs make with manufacturers, employers, and insurers is secret and proprietary, and these arrangements can make it difficult to examine PBM contracts. A regulatory framework, as established in this bill, will authorize the state to examine the kinds of deals PBMs are making. One of the lessons learned from the GAO report cited above, is that providing broad authority allows regulators the flexibility to address emerging issues and to avoid potential unintended consequences to consumers.
Without a broader regulatory approach, it is unclear whether this bill will reduce overall pharmaceutical spending. The Legislature may need to consider which reforms, along with changes to PBM reimbursement, will bring value to the health care system.
REGISTERED SUPPORT / OPPOSITION:
Support
California Pharmacists Association (cosponsors)
California Chronic Care Coalition (cosponsors)
San Francisco AIDS Foundation (cosponsors)
Los Angeles LGBT Center (cosponsors)
Insurance Commissioner Ricardo Lara / California Department of Insurance
AIDS Healthcare Foundation
Alliance for Patient Access
ALS Association; the
American Diabetes Association
Axis Advocacy
Biocom California
California Farmworker Foundation
California Health Collaborative
California Life Sciences
California Medical Association
California Society of Health System Pharmacists
California State Association of Psychiatrists (CSAP)
Cystic Fibrosis Research, INC. (CFRI)
Hemophilia Council of California
International Bipolar Foundation
International Foundation for Autoimmune & Autoinflammatory Arthritis
National Association of Chain Drug Stores
National Community Pharmacists Association (UNREG)
National Multiple Sclerosis Society
National Psoriasis Foundation
North East Medical Services
Pharmaceutical Research and Manufacturers of America
San Francisco Marin Medical Society
Spondylitis Association of America
United Nurses Associations of California/Union of Health Care Professionals
Opposition
Abate-a-weed
America's Health Insurance Plans (AHIP)
American GI Forum Foundation
American Muslims for Coalition for Change
Angel's Foundation
Association of California Life & Health Insurance Companies
Bell Gardens Chamber of Commerce
Black Business Association
Brea Chamber of Commerce
California Alliance for Prescription Affordability (CAPA)
California Association of Health Plans
California Clothing Recylcers
California Delivery Association
California El Salvadoran Chamber of Commerce
California Hispanic Chamber of Commerce
California Muslim Action Network
California State Association of Electrical Workers
California State Pipe Trades Council
Cerna Home Care
CJ Basso & Associates
Coalition for Small and Disabled Veteran Businesses
Coalition of California Chambers Orange County
Community Church Oakland
Corinthian Baptist Church
Crisp Catering
Cypress Chamber of Commerce
Defisal Foundation
Dublin Chamber of Commerce
Energías Del Corazón Foundation
Ephesian Missionary Baptist Church
Ethnos Church
Evergreen Missionary Baptist Church
Faith Action for All
First Union Baptist Church
Flasher Barricade Association
Gary Mckinsey Strategies
Granite Bay Benefits
King Courier
Latin Business Association
Law Offices of James E. Mahoney, Jr.
Los Angeles Civil Rights Association
M&l Brothers Foundation
Marina Chamber of Commerce
Martinez Communications
Menifee Bicycles
Mount Gilead Baptist Church
Orange County Hispanic Chamber of Commerce
Pharmaceutical Care Management Association
Pro Small Biz CA
Professional Small Business Services, INC.
Proyecto 555 Foundation
Sal's Mexican Restaurant
San Juan Capistrano Chamber of Commerce
Seabreeze Books & Charts
Shalom International
Slavic-American Chamber of Commerce
Spaces Renewed
Sperantia
Strategies for Your Success
The Row LA - the Church Without Walls
Tournament Advisors LLC
Vournas Coffee Trading Company
Western Pacific Roofing Company
Western States Council Sheet Metal, Air, Rail and Transportation
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 966 |
THIRD READING
Bill No: SB 966
Author: Wiener (D)
Amended: 4/29/24
Vote: 21
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 12-0, 4/15/24
AYES: Ashby, Nguyen, Alvarado-Gil, Archuleta, Becker, Dodd, Eggman, Glazer, Menjivar, Roth, Smallwood-Cuevas, Wilk
NO VOTE RECORDED: Niello
SENATE HEALTH COMMITTEE: 11-0, 4/24/24
AYES: Roth, Nguyen, Glazer, Gonzalez, Grove, Hurtado, Limón, Menjivar, Rubio, Smallwood-Cuevas, Wiener
SENATE APPROPRIATIONS COMMITTEE: 7-0, 5/16/24
AYES: Caballero, Jones, Ashby, Becker, Bradford, Seyarto, Wahab
SUBJECT: Pharmacy benefits
SOURCE: California Pharmacist Association
California Chronic Care Coalition
Los Angeles LGBT Center
San Francisco AIDS Foundation
DIGEST:
Establishes a licensing requirement for pharmacy benefit managers (PBMs) at the California Department of Insurance, and several contracting and compensation requirements and prohibitions affecting PBMs, health plans and insurers, pharmacists and pharmacies. Creates duties and obligations on PBMs, legal remedies for health plans, and insurers, as well as penalties and unfair competition declarations for violations of this bill.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Requires a PBM to disclose specified information to purchasers, upon request, including, but not limited to, the aggregate wholesale acquisition costs for each therapeutic category of drugs containing three or more drugs, as specified; and, the aggregate amount of rebates received by therapeutic category of drugs containing three or more drugs, including any utilization discounts received from the manufacturer or labeler.[BPC §4441]
This bill:
- Requires CDI to license and regulate PBMs on and after January 1, 2026 that provide services in this state. Requires, on or before April 1, 2027 and annually thereafter, a PBM to file with CDI a report that contains information required in existing law. Requires CDI to publish a report, by August 1, 2027 and annually thereafter, containing aggregate data and to exclude information that would cause financial, competitive, or proprietary harm to a PBM.
- Requires on or before October 1, 2025, and annually, a PBM to report, among other items, a list of the 50 costliest drugs, the 50 most frequently prescribed drugs, and the 50 highest revenue-producing drugs, grouped by generic, brand, specialty, and other. Requires CDI to compile the information into a report for the public and the Legislature due on or before January 1, 2026, and annually, that details the PBM impacts on drug costs.
- Deems the specific reports from the PBMs described above confidential and not disclosable under the California Public Records Act. Specifies that nothing prevents the Attorney General from investigating, prosecuting, defining any legitimate claim or cause of action, or to use the reports in any court proceeding of law.
- Prohibits a PBM from denying a contract pharmacy the opportunity to participate in a PBM network as preferred participation status if the pharmacy is willing to accept the same terms and conditions that the PBM has established for other pharmacies as a condition of preferred network participation status.
- Prohibits a contract issued, amended, or renewed on or after January 1, 2025, between a retail pharmacy and PBM from prohibiting the retail pharmacy from delivering a prescription drug by mail or common carrier to a patient or personal representative on request by the patient if the request is made prior to delivery, or, delivering a prescription to a patient or personal representative by an employee or contact or the retail pharmacy. Prohibits the retail pharmacy from charging the PBM for the delivery except as otherwise provided in the contract. Specifies that this does not prohibit the use of remote pharmacies, secure locker systems, or other types of pick up stations if permitted by law. Requires contracts to be open for inspection by CDI.
- Prohibits a PBM from requiring more than two accreditations from an independent accrediting organization for pharmacists and pharmacies that apply to be in a specialty network and to make every effort to ensure that enhanced standards are not imposed for participation in a specialty network beyond those related to the safety and competency necessary to comply with requirements for dispensing specified medications and providing optimal patient care.
- Prohibits a PBM from deriving income from services provided to health plans and insurers for services provided, except for income derived from a PBM fee. Requires the amount of fees to be set forth in the agreement between the PBM and the plan or insurer. Prohibits the fee from directly or indirectly being based or contingent upon, acquisition cost or any other price metric of a drug, the amount of savings, rebates, or other fees charged, realized, or collected by or generated based on the activity of the PBM, or the amount of premiums, deductibles, or other cost-sharing or fees charged, realized or collected from patients or other persons on behalf of patients.
- Prohibits spread pricing commencing January 1, 2025 for new and renewed contracts. Makes existing spread pricing terms void after January 1, 2028.
- Prohibits, when there is a subsequent amendment or renewal of a preexisting health plan or health insurer and PBM contract beginning January 1, 2025, from authorizing spread pricing, and prohibits any contracts or policies executed on or after January 1, 2025 from authorizing spread pricing.
- Authorizes health plans and insurers to pay performance bonuses to PBMs, and makes compensation arrangements open for inspection by CDI. Prohibits a PBM from reversing and resubmitting the claim of a contract pharmacy without prior and proper notification to the contract pharmacy, without just cause or attempting to first reconcile the claim, more than 90 days after the claim was affirmatively adjudicated. Prohibits a pharmacy or pharmacist from being charged a fee to process a claim electronically, and prohibits retaliation against a pharmacist or pharmacy for exercising rights or remedies under this bill, including terminating or refusing to renew a contract, increased audits, and failing to promptly pay money owed.
- Prohibits a PBM from unreasonably obstructing or interfering with a patient’s right to timely access to a prescription drug or device, except as permitted under existing law. Establishes enforcement authority and legal remedies associated with violations of this bill.
- Makes this bill’s provisions severable, if any provisions are held invalid.
COMMENTS:
Author’s statement. According to the author:
This bill reins in the worst abuses by PBMs. This legislation will protect consumers, provide transparency on prescription drug prices, and improve our healthcare system by ensuring that PBMs are being appropriately regulated. Vertical integration and a lack of oversight have allowed some PBMs’ to engage in unfair business practices that undermine healthcare access and drive up the cost of prescription drugs. By raising fees and lowering reimbursement rates, PBMs are making it hard for many independent pharmacies to stock vital medications, and forcing many of them to close. The complete lack of oversight has also allowed some PBMs to steer patients toward pharmacies they own, pocket large portions of the rebates they negotiate with drug manufacturers, and make misleading statements to customers. This bill fills that regulatory gap by requiring that all PBMs be licensed and disclose basic information regarding their business practices to the licensing entity.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee:
- Unknown likely significant fiscal impact ranging in the high hundreds of thousands to low millions of dollars for CDI to license PBMs (Insurance Fund and Pharmacy Benefit Manager Fund). CDI would likely require Insurance Fund or other fund support until it establishes and collects fee revenue sufficient to support the ongoing administration and enforcement operations of the PBM licensure program. Costs to CDI will likely include additional staff resources to develop regulations, establish the licensing framework, provide additional consumer service support to address complaints received from the public and the Board of Pharmacy, and to intake information from PBMs and publish required reports. There will also likely be additional enforcement and legal costs to ensure compliance with licensure requirements and prohibitions. Other costs may include informational technology resources to build infrastructure to support licensing or complaint intake systems. PBM license fee revenue may offset CDI’s costs. It is unknown at what level fees would need to be set for CDI to recoup its administrative and enforcement costs.
- DMHC reports ongoing annual costs of approximately $51,000 beginning in Fiscal Year 2025-26 to its Office of Financial Review for additional workload related to revising reporting templates, reviewing health plan filings, and compiling data for annual reporting and compliance requirements (Managed Care Fund).
- Unknown, potentially significant workload cost pressures to the courts to adjudicate cases brought by the Attorney General against PBMs engaged in specified prohibited activities and practices (Trial Court Trust Fund, General Fund).
SUPPORT: (Verified 4/30/24)
California Pharmacists Association (cosponsor)
California Chronic Care Coalition (cosponsor)
Los Angeles LGBT Center (cosponsor)
San Francisco AIDS Foundation (cosponsor)
AIDS Healthcare Foundation
Alliance for Patient Access
Alliance for Transparent and Affordable Prescriptions
ALS Association
American Diabetes Association
American GI Forum Education Foundation
APLA Health
California Association of Joint Powers Authorities
California Department of Insurance, Commissioner Ricardo Lara
California Health Collaborative
California Life Sciences
California Manufacturers & Technology Association
California Medical Association
California State Board of Pharmacy
Carrie’s Touch
Cystic Fibrosis Research, INC.
Hemophilia Council of California
Indian Pharmacists Association
Looms for Lupus
National Association of Chain Drug Stores
National Community Pharmacists Association
National Multiple Sclerosis Society
National Psoriasis Foundation
Neuropathy Action Foundation
North East Medical Services
Osteopathic Physicians and Surgeons of California
Pharmaceutical Research and Manufacturers of America
San Francisco Marin Medical Society
Spondylitis Association of America
The Partnership for Safe Medicines
United Nurses Association of California/Union of Health Care Professionals
Two individuals
OPPOSITION: (Verified 4/30/24)
America’s Health Insurance Plans
American GI Forum Foundation
Angel’s Foundation
Association of California Life and Health Insurance Companies
California Alliance for Prescription Affordability
California Association of Health Plans
California Chamber of Commerce (unless amended)
California Ecuadorian Chamber of Commerce
California El Salvadoran Chambers of Commerce
California Filipino Chamber of Commerce
California Guatemalan Chamber of Commerce
California Hispanic Chambers of Commerce
California Muslim Action Network
California Nicaraguan Chamber of Commerce
California Teamsters Public Affairs Council
Californians for Lower Drug Costs
Defisal Foundation
Energías del Corazón Foundation
Ethnos Church
Faith Action for All
Health Access California (unless amended)
Los Angeles Civil Rights Association
Pharmaceutical Care Management Association
Proyecto 555 Foundation
San Diego Regional Chamber of Commerce (unless amended)
Shalom International Outreach
Sperantia Foundation
St. Jude’s Hospital Foundation
The Community Church
The Council for Citizens Against Government Waste
The Row LA
Tournament Advisors LLC
US-Mexican Chamber of Commerce
Three individuals
ARGUMENTS IN SUPPORT: The California Pharmacist Association (co-sponsor) writes:
PBMs are squarely in the middle of negotiating prices, demanding rebates, and driving formulary decisions. Their unfair business practices have become more pervasive as vertical integration has increased. Some PBMs own their own pharmacy chains and mail order pharmacies, creating potential conflicts of interest. Studies have shown that patients are more likely to adhere to their medication regimens when they have a close relationship with their pharmacist. Most of the states have cracked down on PBM abuses, recognizing that community pharmacy is key to the healthcare system. In addition to owning pharmacies, in many cases, health plans and PBMs are now one in the same. In recent years, the largest PBMs merged with large health insurers. CVS acquired Aetna Inc., Express Scripts was acquired by Cigna, and OptumRx was already affiliated with United Healthcare. While there may be some efficiencies, vertical integration can create conflicts of interest that prioritize the financial interests of the integrated company over patient care. The California Board of Pharmacy writes that it has received public comments and complaints from consumers and health care providers stemming from actions by PBMs. Such complaints range in the types of medications involved from maintenance medications (such as the treatment of high blood pressure) to specialty medications (generally high-cost medications used to treat complex, chronic conditions). Investigations have revealed that the root cause of some delays in access, for example, stems from mandates established by PBM. Regrettably at this time the Board lacks jurisdiction and cannot take any meaningful action for the patient nor can the Board evaluate the system and regulate for systemic changes to address the root causes of such delays, thereby preventing future harm.
ARGUMENTS IN OPPOSITION: Pharmaceutical Care Management Association (PCMA) writes:
While ostensibly seeking to bring PBMs under state agency oversight, several provisions in the bill blatantly promote independent retail pharmacies under the guise of regulating PBMs. This legislation does nothing to lower costs for patients; it simply seeks to financially promote one industry over another with no consumer benefit. California Teamsters writes that many private sector unions partner with PBMs to create quality, affordable prescription drug benefit plans that work best for their members. Legislation that restricts the way they work with PBMs to lower the cost of care will result in increased health care costs to their Trust, and their members. America’s Health Insurance Plans, the Association of California Life and Health Insurance Companies, and the California Association of Health plans have many questions regarding the implementation, cost, and oversight of adding CDI as a regulator of PBMs. They also write that the current performance-based model incentivizes PBMs based on rebates and discounts, leading to lower prices for consumers. By removing the existing incentive structure, this bill would likely lead to health plans paying significantly more to manufacturers and pharmacies due to the loss of rebates and discounts, causing a significant increase in health insurance premiums that are passed onto patients.
Health Access California writes that additional technical amendments may be needed to completely address “any willing provider” concerns and to align the language of this bill with the two existing bodies of law on regulation of health insurance coverage, the Knox-Keene Act for health care service plans and the Insurance Code for policies of health insurance. They remain troubled by the provisions that appear to allow any pharmacy to provide specialty drugs. They seek amendments to clarify formularies are required to provide the lowest cost sharing for a brand name drug if there is a clinically equivalent generic drug. Health Access also seeks disclosure to purchasers of any fees received by PBMs from drug manufacturers, including the amount and purpose of those fees, even if unrelated to a specific drug. With respect to the revised fiduciary duty, because three or four major PBMs are part of health plans, they seek technical amendments to clarify that the duty is to the carrier responsible for coverage of the enrollee and subscriber, in the language of Knox-Keene, or the insured and policy-holder, in the language of the Insurance Code, rather than to the health plan that owns or is owned by the PBM. The San Diego Regional Chamber of Commerce writes that they have concerns with this bill’s restrictions on accreditation standards for specialty pharmacies they believe this bill would limit a health plan’s ability to require specialty pharmacies to meet more than two specialty accreditations. They indicate it would also negatively impact a plan sponsor’s ability to assess performance metrics (including customer service, drug therapy management, and patient adherence standards) for specialty pharmacies when creating a specialty network. These restrictions on specialty network design can lead to diminished patient safety as plans could use unaccredited pharmacies that do not meet high standards for specialty drug storage and dispensing.
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
5/17/24 13:32:25
**** END ****
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anna Caballero, Chair
2023 - 2024 Regular Session
SB 966 (Wiener) - Pharmacy benefits
Version: April 29, 2024 | Policy Vote: B., P. & E.D. 12 - 0, HEALTH 11 - 0 |
Urgency: No | Mandate: Yes |
Hearing Date: May 13, 2024 | Consultant: Janelle Miyashiro |
Bill Summary:
SB 966 requires pharmacy benefit managers (PBMs) to obtain and maintain a license from the California Department of Insurance (CDI) to operate as a PBM in the state; establishes various PBM reporting requirements; and prohibits PBMs from specified activities and contracting practices, subject to CDI enforcement and penalties.
Fiscal Impact:
- Unknown likely significant fiscal impact ranging in the high hundreds of thousands to low millions of dollars for CDI to license PBMs (Insurance Fund and Pharmacy Benefit Manager Fund). CDI would likely require Insurance Fund or other fund support until it establishes and collects fee revenue sufficient to support the ongoing administration and enforcement operations of the PBM licensure program.
Costs to CDI will likely include additional staff resources to develop regulations, establish the licensing framework, provide additional consumer service support to address complaints received from the public and the Board of Pharmacy, and to intake information from PBMs and publish required reports. There will also likely be additional enforcement and legal costs to ensure compliance with licensure requirements and prohibitions. Other costs may include IT resources to build infrastructure to support licensing or complaint intake systems. PBM license fee revenue may offset CDI’s costs. It is unknown at what level fees would need to be set for CDI to recoup its administrative and enforcement costs.
- The Department of Managed Health Care (DMHC) reports ongoing annual costs of approximately $51,000 beginning in Fiscal Year 2025-26 to its Office of Financial Review for additional workload related to revising reporting templates, reviewing health plan filings, and compiling data for annual reporting and compliance requirements (Managed Care Fund).
- Unknown, potentially significant workload cost pressures to the courts to adjudicate cases brought by the Attorney General (AG) against PBMs engaged in specified prohibited activities and practices (Trial Court Trust Fund, General Fund).
Background:
PBMs have been around since the early 1970s. Initially, PBMs’ functions were limited—they served as fiscal and administrative intermediaries between health plans, plan members, and pharmacies. What remains the same of PBMs, both in the past and currently, is their role as claims processor. Claims processing requires a pharmacy to contact a PBM to verify that a consumer has coverage for a requested prescription, determine whether the customer’s plan covers the drug, and how much copay is required. Once the prescription is filled, the pharmacy transmits patient details—the health plan number, the physician’s prescription, and the drug price—to the PBM. The PBM responds by approving or disapproving the transaction, and then forwards the reimbursement from the health plan to the retail pharmacy.
Nearly every health plan, whether sponsored by an employer, a union, Medicare, or self-purchased, employs a PBM, and PBMs’ functions have evolved over time from merely claims processing to include managing their clients’ entire pharmacy benefit. The functions offered to clients may now include:
- Negotiating prices for drugs, including discounts, rebates, and other concessions, with pharmaceutical manufacturers.
- Conducting drug-utilization reviews (i.e., compiling information regarding the projected volume of plan members who use a given drug).
- Disease management (i.e., managing the chronic conditions of high-risk, high-cost patients).
- Determining the composition of pharmacy and wholesaler networks.
- Running mail order and affiliated specialty pharmacies.
- Creating and managing formularies.
PBMs contract with pharmacies to create networks for their clients based on clients’ needs and state laws, which may include geographic retail requirements and limitations on mail-order pharmacies. Because nearly every individual with a pharmacy benefit must interact with a PBM, it follows that joining PBMs’ pharmacy networks is more than good business practice—it is essential for pharmacies’ survival. Pharmacies’ revenues from drug dispensing are primarily derived from health plans’ reimbursement for the drug’s cost, a dispensing fee, and a patient’s copay.
Contracts for inclusion in PBMs’ pharmacy networks are extensive and frequently updated. Common provisions include basic inventory requirements, professional codes of conduct, reimbursement amounts, reimbursement criteria, and applicable federal and state laws. Most contracts offered by PBMs to retail pharmacies are fairly boilerplate, meaning they consist of standardized terms and conditions that are routinely repeated with different parties. Disputes and grievances between PBMs and pharmacies are typically resolved through PBMs’ in-house dispute committees or by mandatory arbitration. Pharmacies are also subject to periodic, routine audits from PBMs during which time a pharmacy’s accounts are reviewed to reconcile reimbursements, fees, and ensure compliance with the contract terms.
While large pharmacies deal with PBMs directly, smaller pharmacies may contract with a pharmacy services administrative organization (PSAO) for leverage. A PSAO can represent the pharmacy in PBM contract negotiations and manage drug reimbursement claims, among other administrative offerings. PSAOs charge pharmacies fees for their services, and do not get any reimbursements from PBMs or other contract affiliates.
Proposed Law:
- Prohibits a health care service plan contract or a health insurance policy issued, amended, or renewed after January 1, 2025 from calculating an enrollee’s cost sharing at an amount that exceeds the actual rate paid for the prescription drug.
- Beginning January 1, 2025, prohibits new and preexisting contracts between a licensed PBM and a health care service plan or health insurer to authorize spread pricing.
- Requires health service plans and health insurers to annually report to regulators the following additional information about all covered drugs for each specified reporting category specified under current law:
- The aggregate wholesale acquisition costs from a pharmaceutical manufacturer or labeler for each drug.
- The aggregate amount of rebates received by the PBM for each drug.
- Any administrative fees received from the pharmaceutical manufacturer or labeler.
- The aggregate of payments, or the equivalent economic benefit, made by the PBM to pharmacies owned or controlled by the PBM for each drug.
- The aggregate of payments made by the PBM to pharmacies not owned or collected by the PBM for each drug.
- Tasks CDI with licensing and regulating PBMs.
- Requires CDI to adopt necessary regulations, and authorizes CDI to adopt emergency regulations until January 1, 2028.
- Establishes application requirements.
- Establishes license renewal requirements.
- Authorizes CDI to charge initial license and renewal application fees in an amount sufficient to fund the department’s regulatory duties. Establishes the Pharmacy Benefit Manager Fund in the State Treasury for CDI to use for costs related to the licensing and regulation of PBMs.
- Establishes enforcement mechanisms for CDI to refuse to issue a PBM a license and to deny, suspend, or revoke the license of a PBM, as specified.
- Authorizes CDI to examine or audit any PBM’s books and records to determine a PBM’s compliance with licensure requirements.
- Establishes penalties for PBMs who violate licensing requirements and prohibitions. Establishes the Pharmacy Benefit Manager Fines and Penalties Fund in the State Treasury.
- After January 1, 2026, requires a PBM to obtain and maintain a license from CDI to operate as a PBM in the state.
- Provides that a PBM license is valid for two years and is nontransferable.
- Establishes various reporting requirements for PBMs to submit information to CDI, and requires CDI to publish information it receives on its website and submit associated reports to the Legislature.
- Prohibits a PBM from imposing any requirements, conditions, or exclusions that discriminate, as specified, against a nonaffiliated pharmacy in connection with dispensing drugs.
- Provides that nothing precludes a PBM or purchaser of PBM services from establishing a network of contracting or participating pharmacies.
- Prohibits a PBM from:
- Requiring an enrollee or insured to use only an affiliated pharmacy that is a retail pharmacy if there are nonaffiliated pharmacies in the network.
- Financially inducing an enrollee, insured, or prescriber to transfer a prescription only to a retail affiliated pharmacy if there are nonaffiliated pharmacies in the network.
- Requiring a retail nonaffiliated pharmacy to transfer a prescription to a retail affiliated pharmacy if there are nonaffiliated pharmacies in the network.
- Unreasonably restricting an enrollee or insured from using a particular contracted retail pharmacy for the purpose of receiving pharmacist services covered by the enrollee’s or insured’s contract or policy.
- Communicating to an enrollee verbally, electronically, or in writing that the enrollee is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other pharmacies that have the ability to dispense the medication or provide the services and are also in network.
- Denying a contract pharmacy the opportunity to participate in PBM network as preferred participation status if the pharmacy is willing to accept the same terms and conditions that the PBM has established for other pharmacies as a condition of preferred network participation status.
- Requiring more than two accreditations from an independent accrediting organization for pharmacists and pharmacies that apply to be in a specialty network.
- Reversing and resubmitting the claim of a contract pharmacy unless certain conditions are met.
- Directly or indirectly charging or holding a pharmacist or pharmacy responsible for a fee related to a claim or reduce the amount of the claim at the time of the claim’s adjudication or after the claim is adjudicated.
- Charging a pharmacy or pharmacist a fee to process electronic claims.
- Retaliating against a pharmacist or pharmacy, as specified.
- Unreasonably obstructing or interfering with a patient’s right to timely access a prescription drug or device that has been legally prescribed for that patient at a contract pharmacy of their choice.
- Making, disseminating, or causing or permitting the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
- Prohibits a PBM from deriving income from PBM services provided to an insurer or health plan in this state except for income derived from PBM fees for services provided. Provides that the amount of any PBM fees shall be set forth in the agreement between the PBM and the insurer or health plan. Prohibits PBM fees from being directly or indirectly based on or contingent upon specified metrics.
- Authorizes a health care service plan or insurer from paying performance bonuses to a PBM.
- Requires compensation arrangements be open for CDI inspection.
- Provides that a contract issued, amended, or renewed after January 1, 2025 between a retail pharmacy and a PBM shall not prohibit the retail pharmacy from offering specified ancillary services.
- Provides that termination of a contract between a pharmacy and PBM does not release the PBM from the obligation to make a payment due to the pharmacy, as specified.
- Authorizes CDI to investigate referrals provided by the California Board of Pharmacy.
- Voids spread pricing terms in contracts between a PBM and a health care service plan or health insurer after January 1, 2028.
- After January 1, 2025, prohibits PBMs from entering into, amending, enforcing, renewing contracts with manufacturers that expressly or implicitly restrict, or implements implicit or express exclusivity for, those manufacturers’ drugs, medical devices, or other products.
- After January 1, 2025, prohibits PBMs entering into, amending, enforcing, renewing contracts with pharmacies or pharmacy administrative services organizations who do business in California that restrict or express exclusivity on, nonaffiliated pharmacies’ ability to contract with employers, insurers, and health care service plans.
- Establishes definitions.
- Makes other technical changes.
Related Legislation:
AB 913 (Petrie-Norris, 2024) would task the California State Board of Pharmacy with licensing and regulating PBMs. AB 913 died, pending a hearing in the Assembly Business and Professions Committee.
Staff Comments: It is unknown how many actions would be filed as a result of this bill. It generally costs about $8,300 to operate a courtroom for one eight-hour day. While the superior courts are not funded on a workload basis, an increase in workload could result in delayed court services and would put pressure on the General Fund to increase the amount appropriated to backfill for trial court operations. For illustrative purposes, the Governor’s 2024-25 state budget proposes $83.1 million ongoing General Fund to continue to backfill the Trial Court Trust Fund for expected revenue declines.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Richard Roth, Chair
BILL NO: SB 966
AUTHOR: | Wiener | ||
VERSION: | April 18, 2024 | ||
HEARING DATE: | April 24, 2024 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Pharmacy benefits
SUMMARY:
Establishes a licensing requirement for pharmacy benefit managers (PBMs) at the California Department of Insurance, and several contracting and compensation requirements and prohibitions affecting PBMs, health plans and insurers, pharmacists and pharmacies. Creates duties and obligations on PBMs, legal remedies for enrollees, insureds, health plans, insurers, and providers, as well as penalties and unfair competition declarations for violations of this bill.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Establishes authority for DMHC to enforce the following provisions of law related to PBMs:
- Requirements on health plans to disclose to a contracted pharmacy provider or its contracting agent, specified prescription drug information including the telephone number pharmacy providers may call for assistance and information necessary to process a pharmacy claim;
- Prohibition on a plan from including in a contract with a pharmacy provider or its contracting agent, a provision that prohibits the provider from informing a patient or a less costly alternative to a prescribed medication;
- Requirements on health plans that contract with PBMs to require the PBM to register with DMHC, exercise good faith and fair dealing in the performance of its contractual duties, comply with laws described in 5) - 8) below, and inform pharmacists of their right to complain to DMHC about unfair payment patterns and the health care provider’s bill of rights;
- Requirements that a PBM notify a health plan in writing of any activity, policy, or practice that directly or indirectly presents a conflict of interest with the discharge of its duty to the health plan to exercise good faith and fair dealing in the performance of its contractual duties. [HSC §1385.005]
- Requires a PBM to register with DMHC and complete an application, as specified. Prohibits the registration from being transferred. Allows DMHC to set a registration fee that does not exceed reasonable costs. [HSC §1385.005]
- Requires failure of a plan to comply with 2) above to constitute grounds for disciplinary action, and allows DMHC to investigate and take enforcement actions against a plan that fails to comply. Requires DMHC to periodically evaluate contracts between health plans and PBMs to determine if any audit, evaluation, or enforcement actions should be undertaken by DMHC. [HSC §1385.006]
- Establishes requirements for nongrandfathered health plans and health insurance policies that cover outpatient prescription drugs. [HSC §1342.7 and INS §10123.193]
- Requires a plan or insurer that provides essential health benefits to allow an enrollee or insured to access prescription drug benefits at an in-network retail pharmacy unless the prescription drug is subject to restricted distribution by the United States Food and Drug Administration (FDA) or requires special handling, provider coordination, or patient education that cannot be provided by a retail pharmacy. Permits a nongrandfathered individual or small group health plan contract or insurance policy to charge an enrollee or insured different cost-sharing for obtaining a covered drug at a retail pharmacy, but requires all cost-sharing to count toward the annual limitation on cost-sharing. [HSC §1367.42 and INS §10123.201]
- Establishes a pilot project to assess the impact of health plan and PBM prohibitions on the dispensing of certain amounts of prescription drugs by network retail pharmacies. Applies the provisions to pharmacy providers located in the counties of Riverside and Sonoma. Prohibits a health plan from, or permitting any delegated PBMs to prohibit, a pharmacy provider from dispensing a particular amount of a prescribed medication if the plan or PBM allows that amount to be dispensed through a pharmacy owned or controlled by the plan or PBM, unless the prescription drug is subject to restricted distribution by the FDA or requires special handling, provider coordination, or patient education that cannot be provided by a retail pharmacy. Requires health plans subject to this pilot to report annually to DMHC information and data relating to changes, if any, to costs and utilization of prescription drugs attributable to the prohibition of contract terms. Requires DMHC to summarize data received and provide the summary to the Governor and health policy committees of the Legislature. [HSC §1368.6]
- Requires contracts between a pharmacy and a carrier (health plan or insurer) or a PBM to provide pharmacy services to beneficiaries of a health benefit plan (any plan that provides, arranges, pays for, or reimburses the cost of health benefits) to comply with specified requirements regarding pharmacy audits. [BPC §4430 et. seq.]
- Prohibits the law on audits of pharmacy benefits from being construed to suggest or imply that the Department of Consumer Affairs or the California State Board of Pharmacy has any jurisdiction or authority over that law. [BPC §4439]
- Requires a PBM that reimburses a contracting pharmacy for a drug on a maximum allowable cost basis to comply with specified contracting requirements. [BPC §4440]
- Requires a PBM to disclose specified information to purchasers, upon request, including:
- The aggregate wholesale acquisition costs for each therapeutic category of drugs containing three or more drugs, as specified;
- The aggregate amount of rebates received by therapeutic category of drugs containing three or more drugs, including any utilization discounts received from the manufacturer or labeler;
- Any administrative fees received from the manufacturer or labeler;
- Whether the PBM has a contract, agreement, or other arrangement to exclusively dispense or provide a drug to a purchaser’s employees, insured, or enrollees, and the application of all consideration or economic benefits collected or received per the arrangement;
- Prescription drug utilization information of purchaser’s enrollees or insured that is not specific to any individual enrollee or insured;
- The aggregate of payments, or the equivalent economic benefit to pharmacies owned or controlled by the PBM;
- The aggregate of payments made by the PBM to pharmacies not owned or collected by the PBM; and,
- The aggregate amount of the fees imposed on, or collected from, network pharmacies or other assessments against network pharmacies, and the application of those amounts collected pursuant to contract with the purchaser. [BPC §4441]
This bill:
Licensing and reporting by CDI
- Requires CDI to license and regulate PBMs that provide services in this state. Requires submission of an application, organizational and governing documents, and information as to persons beneficially interested in or in management or with control over the PBM. Requires licensure renewal every two years and prohibits licensure transfer. Requires payment of an unspecified licensing fee.
- Requires, on or before April 1, 2027 and annually thereafter, a PBM to file with CDI a report that contains information required in 11) above of existing law from the preceding calendar year. Deems this report confidential and not disclosable under the California Public Records Act. Specifies that nothing prevents the Attorney General from investigating, prosecuting, defining any legitimate claim or cause of action, or to use the reports in any court proceeding of law. Requires CDI to publish a report, by August 1, 2027 and annually thereafter, containing aggregate data and to exclude information that would cause financial, competitive, or proprietary harm to a PBM.
Nonaffiliated pharmacies
- Defines a “nonaffiliated pharmacy” as a contract pharmacy that directly or indirectly, through one or more intermediaries, does not control, is not controlled by, and is not under common control with a PBM.
- Prohibits discrimination against nonaffiliated pharmacies in connection with dispensing drugs, including terms or conditions that apply only to nonaffiliated pharmacies, and refusing to contract with or terminating a contract with on the basis that the pharmacy is nonaffiliated, or for reasons other than those that apply equally to affiliated pharmacies, and, retaliation.
- Requires pharmacies affiliated with a PBM to disclose that an enrollee or insured is not obligated to use the affiliated pharmacy. Defines an “affiliated pharmacy” as a contract pharmacy that directly, or indirectly through on or more intermediaries, controls, is controlled by, or is under common control with, a PBM.
- Prohibits requirements that enrollee or insureds use only an affiliated pharmacy that is a retail pharmacy, financial inducement of an enrollee or insured to transfer a prescription to a retail affiliated pharmacy, requirements on retail nonaffiliated pharmacies to transfer a prescription to a retail affiliated pharmacy, unreasonable restrictions of pharmacist services covered by the enrollee or insureds plan, and communications that an enrollee or insured is required to have a prescription dispensed at, or pharmacist services provided by affiliated pharmacies.
- Allows a plan or agent to offer financial incentives, such as reduced copays, to use particular pharmacies.
Retail pharmacies mail order
- Prohibits a contract issued, amended, or renewed on or after January 1, 2025, between a retail pharmacy and PBM from prohibiting the retail pharmacy from delivering a prescription drug by mail or common carrier to a patient or personal representative on request by the patient if the request is made prior to delivery, or, delivering a prescription to a patient or personal representative by an employee or contact or the retail pharmacy. Prohibits the retail pharmacy from charging the PBM for the delivery except as otherwise provided in the contract. Specifies that this does not prohibit the use of remote pharmacies, secure locker systems, or other types of pick up stations if permitted by law.
Specialty pharmacy
- Prohibits a PBM from requiring more than two accreditations from an independent accrediting organization for pharmacists and pharmacies that apply to be in a specialty network and to make every effort to ensure that enhanced standards are not imposed for participation in a specialty network beyond those related to the safety and competency necessary to comply with requirements for dispensing specified medication.
PBM compensation
- Prohibits a PBM from deriving income from services provided to health plans and insurers, except for income derived from a PBM fee. Requires the amount of fees to be set forth in the agreement between the PBM and the plan or insurer. Prohibits the fee from directly or indirectly being based or contingent upon, acquisition cost or any other price metric of a drug, the amount of savings, rebates, or other fees charged, realized, or collected by or generated based on the activity of the PBM, or the amount of premiums, deductibles, or other cost-sharing or fees charged, realized or collected from patients or other persons on behalf of patients.
- Prohibits spread pricing commencing January 1, 2025 for new and renewed contracts. Makes existing spread pricing terms void after January 1, 2028.
- Prohibits, when there is a subsequent amendment or renewal of a preexisting health plan or health insurer and PBM contract beginning January 1, 2025, from authorizing spread pricing, and prohibits any contracts or policies executed on or after January 1, 2025 from authorizing spread pricing.
Pharmacy/pharmacist
- Prohibits a PBM from reversing and resubmitting the claim of a contract pharmacy without prior and proper notification to the contract pharmacy, without just cause or attempting to first reconcile the claim, more than 90 days after the claim was affirmatively adjudicated.
- Prohibits charging or holding a pharmacist or pharmacy responsible for a fee related to a claim or reducing the amount of the claim at the time of the claim’s adjudication or after the claim is adjudicated.
- Allows reduction of a claim if an audit and review indicates criminal wrongdoing, willful misrepresentation, fraud, or abuse; or, an investigation indicates that the pharmacy is or has committed criminal wrongdoing, willful misrepresentation, fraud or abuse.
- Prohibits a pharmacy or pharmacist from being charged a fee to process a claim electronically.
- Requires a PBM to honor payment obligations when a contract is terminated with a pharmacy.
- Prohibits retaliation against a pharmacist or pharmacy for exercising rights or remedies under this bill, including terminating or refusing to renew a contract, increased audits, and failing to promptly pay money owed.
Exclusive contracting
- Prohibits, notwithstanding any other law, a PBM from entering, amending, enforcing or renewing a contract with a manufacturer on or after January 1, 2025 that expressly or implicitly restricts, or implements implicit or express exclusivity for those manufacturers’ drugs, medical device, or other products.
- Prohibits, notwithstanding any other law, a PBM from entering, amending enforcing, or renewing a contract on or after January 1, 2025 with pharmacies or pharmacy administrative services organizations that expressly or implicitly restrict or impose implicit or express exclusivity on, nonaffiliated pharmacies; ability to relate to unaffiliated pharmacies’ ability to contract with employers, insurers, and health plans.
Miscellaneous
- Prohibits a PBM from unreasonably obstructing or interfering with a patient’s right to timely access to a prescription drug or device, except as permitted under existing law.
- Prohibits a PBM from making, disseminating, or causing or permitting the use of untrue, deceptive, or misleading information.
- Prohibits the authority of the Attorney General to maintain or restore competitive markets and prosecute state and federal antitrust and unfair competition violations from being narrowed, abrogated, or otherwise altered by this bill.
- Makes this bill’s provisions severable, if any provisions are held invalid.
Enforcement
- Allows CDI to refuse, revoke, deny, suspend a PBM license or issue a cease and desist order for cause and after a hearing, as specified. Allows fines not exceeding $20,000 per month until violations are remedied.
- Allows CDI to examine or audit a PBM’s books and records for compliance. Makes data confidential and not disclosable under the California Public Records Act. Allows disclosure to the Attorney General to investigate, prosecute, defend or use in a court proceeding, or for competition purposes.
- Requires CDI to establish a retention schedule for records.
Duty and other legal obligations
- Establishes a duty and obligation on a PBM to enrollees, insureds, health plans, insurers, providers, and makes the duty or obligation to the enrollee or insured and any other party, primary where there is a conflict.
- Makes an enrollee or insured entitled to legal or equitable relief for injury or loss. Makes a PBM liable for restitution to any enrollee or insured harmed by violations and subject to specified penalties.
- Establishes other requirements for the Attorney General to be entitled to injunctive relief and remedies and unfair competition violations.
- Makes remedies or penalties cumulative to each other and to the remedies or penalties available under all other laws of this state.
Enrollee/Insured Cost-sharing
- Requires a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, that provides prescription drug coverage, to calculate an enrollee’s cost-sharing amount, including deductible and coinsurance, as applicable, based exclusively on its negotiated rate for the drug. Allows deduction of rebates or any other discounts it receives, from the negotiated rate for a prescription drug from which cost-sharing amounts are calculated.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, this bill reins in the worst abuses by PBMs. This legislation will protect consumers, provide transparency on prescription drug prices, and improve our healthcare system by ensuring that PBMs are being appropriately regulated. Vertical integration and a lack of oversight have allowed some PBMs’ to engage in unfair business practices that undermine healthcare access and drive up the cost of prescription drugs. By raising fees and lowering reimbursement rates, PBMs are making it hard for many independent pharmacies to stock vital medications, and forcing many of them to close. The complete lack of oversight has also allowed some PBMs to steer patients toward pharmacies they own, pocket large portions of the rebates they negotiate with drug manufacturers, and make misleading statements to customers. This bill fills that regulatory gap by requiring that all PBMs be licensed and disclose basic information regarding their business practices to the licensing entity.
- Federal Trade Commission (FTC). Beginning in June 2022, the FTC has been investigating PBMs and their impact on the accessibility and affordability of prescription drugs. As part of this process, the FTC has issued a compulsory order to group purchasing organizations that negotiate drug rebates on behalf of PBMs. Previously, the FTC issued compulsory orders on the six largest PBMs. The inquiry intends to shed light on fees and clawbacks on unaffiliated pharmacies, steering patient towards PBM-owned pharmacies, unfair auditing of pharmacies, opaque pharmacy reimbursement methods, and negotiating rebates and fees that skew formulary incentives and impact costs for payers and patients.
- PBM registration. Existing law requires a PBM to register with DMHC. The law defines a PBM as a person, business, or other entity that, pursuant to a contract with a health plan, manages the prescription drug coverage provided by the health plan. This includes, but is not limited to, the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to prescription drug coverage, contracting with network pharmacies, and controlling the cost of covered prescription drugs. DMHC reviews the PBM Registration Application upon receipt of a flat filing fee of $3,500, and bills the PBM for time spent reviewing the PBM’s responses and changes requested by DMHC at a variable hourly rate, depending on the reviewer’s classification (up to $500/hour). The fees to review an initial PBM Registration Application are capped at $4,000.
- U.S. Governmental Accounting Office (GAO) report. In April 2024, the GAO publicly released a report on state regulation of PBMs in five states (Arkansas, California, Louisiana, Maine, and New York). For their study, GAO reviewed state laws and interviewed state regulators as well as a variety of stakeholders, including state pharmacy associations and state health plan associations in each of the five states, and four national organizations representing interests of PBMs, patients, employers, and drug manufacturers. The GAO findings include:
- Fiduciary Duty. Four of the five states (California, Louisiana, Maine, and New York) enacted laws to impose a duty of care on PBMs. The laws varied from imposing a fiduciary duty—that is, a requirement to act in the best interest of the health plan or other entity to which the duty is owed—to what state regulators described as “lesser” standards, such as a requirement to act in “good faith and fair dealing.” California currently has the good faith and fair dealing standard. According to the GAO, stakeholders disagree on to whom the fiduciary duty should be owed. This bill establishes a PBM duty to health plans, patients, and providers.
- Drug pricing. The five states enacted a variety of laws relating to drug pricing and pharmacy payments, such as laws limiting PBMs' use of manufacturer rebates and their ability to pay pharmacies less than they charge health plans—a practice referred to as “spread pricing.” Stakeholders had mixed reaction to more regulation in the areas of rebates, spread pricing, payment adjustments, pharmacy reimbursement, and maximum allowable costs. More stakeholder agreement was identified on regulation of rebates and spread pricing.
- Transparency. To increase the transparency of PBM operations, the five states enacted laws that require PBMs to be licensed by or registered with the state, or both, and to report certain information such as drug pricing, fees charged, and the amounts of rebates received and retained. All stakeholder groups were in support of more transparency.
- Networks and access. The five states also enacted laws regarding pharmacy networks and patient access. Examples include laws prohibiting discrimination against unaffiliated pharmacies and limiting patient co-pays charged by PBMs. Health plans and PBMs were not supportive of this regulation.
- Effective regulation. Regulators in four states said that providing regulators with broad regulatory authority was more effective than enacting specific statutory provisions. Doing so allowed regulators to address emerging issues without new legislation, according to regulators from one state. Two regulators also indicated that substantial penalties and sufficient resources were key to strong enforcement. Regulators from two states identified ambiguous or fragmented authority over different aspects of PBM activities as factors that limited their authority to enforce PBM laws. Regulators from one state said that their department is charged with collecting high-level information from PBMs through the registration process, but that the state law does not give the department direct oversight authority over PBMs. Further, the regulators said they only have jurisdiction over enrollee-facing practices—such as requirements pertaining to drug formularies or the adequacy of pharmacy networks—but not over PBMs’ dealings with pharmacies or health plans. One regulator indicated that having a record of penalties imposed by state regulators can prevent PBMs from obtaining federal contracts.
- Self-insured plans. Three state regulators expressed their desire to have more information on PBMs serving self-insured plans, similar to the transparency that fully insured plans must demonstrate in their states. Regulators in these three states described how concerns regarding Employee Retirement Income Security Act of 1974 (ERISA) preemption of state regulation of self-insured plans affected the enactment or enforcement of PBM laws in their states and resulted in less transparency for PBMs serving self-insured plans.
- ERISA Preemption. According to a National Association of Insurance Commissioners white paper on PBMs, issues of ERISA preemption are evolving. Based on a Pharmaceutical Care Management Association (PCMA) challenge of a state law in Rutledge v. PCMA, the U.S. Supreme Court concluded that ERISA is primarily concerned with preempting laws that require benefit plans be structured in a certain way but requirements that may increase costs or alter incentives for ERISA plans would not be preempted. State laws connected with or referencing ERISA plans could trigger preemption. In this case, related to pharmacy reimbursement, the court held that ERISA did not preempt the law. In another case, PCMA v. Wehbi, an appeals court stopped short of saying PBM regulation cannot be preempted but found that laws prohibiting PBMs from engaging in deceptive and anti-competitive practices did not meet the “connection with” standard. In PCMA v. Mulready, related to a right to pharmacy act, a U.S. District court held that the state law is not preempted by ERISA, but some of the law’s provisions are preempted by Medicare laws.
- PBM Task Force recommendations. AB 315 (Wood, Chapter 905, Statutes of 2018) requires DMHC to convene a Task Force on Pharmacy Benefit Management Reporting to determine “what information related to pharmaceutical costs, if any, DMHC should require to be reported by health plans or their contracted PBMs.” In order to increase transparency and understand how PBMs impact the cost of prescription drugs, the Task Force recommends requiring PBMs to report data related to PBM services provided for commercial health plans directly to the DMHC. PBMs would be required to report drug-specific data as well as aggregated information on PBMs, including revenue and expense information. At the drug level, the Task Force recommends requiring PBMs to report:
- A list of the 100 most costly drugs, the 100 most frequently prescribed drugs, and the 100 highest revenue-producing drugs, grouped by generic, brand, specialty, and other.
- For each drug that falls into the above categories:
- The pharmacy type used to fill the drug prescription, such as integrated, chain, independent, specialty, and mail order pharmacies; and,
- Pricing and rebate information, including the amount of rebate the PBM receives from the manufacturer, the amount of rebate the PBM passes to the health plan, the amount the health plan pays the PBM, and the amount the PBM pays the pharmacy.
At an aggregated level, the Task Force recommends gathering information on PBM including revenue and expense information, to determine PBM market impact and the value PBMs provide to consumers. This information would include reporting on:
- The health plans with which the PBM contracts, the scope of services provided to the health plan, and the number of enrollees served by the PBM.
- PBM revenue, including revenue from manufacturers, health plans, pharmacies and other revenue.
- PBM expenses, including payments to pharmacies, claims processing, special programs, administration, and other expenses.
- Pilot Project. The pilot project findings focus on the six plans with dispensing prohibitions in Riverside and Sonoma counties, in two categories: total prescriptions and impacted prescriptions. Impacted drugs are a subset of the total prescriptions and are prescriptions that were greater than a 30-day supply filled by a non-owned or non-controlled pharmacy. The most commonly dispensed prescription drugs were generic drugs for maintenance of chronic conditions, such as high cholesterol and hypothyroidism. These drugs are frequently dispensed in 90-day supplies. The total prescription cost for the six health plans was approximately $170.7 million, of which 9.1%, (approximately $15.6 million) was attributed to the impacted drugs. The total cost difference for impacted drugs that switched from being dispensed at a health plan, PBM owned or controlled pharmacy, to a non-owned or non-controlled pharmacy was 1.9% ($3.2 million). Given that costs were reduced during the pilot project, it appears that the average costs paid to non-owned or non-controlled pharmacies were lower than those paid to health plans or PBM owned or controlled pharmacies. DMHC notes that the public health emergency related to the COVID-19 pandemic occurred not long after the start of the pilot project and likely impacted the number of prescriptions filled at network pharmacies, particularly in the first year.
- Double referral. This bill passed out of the Senate Committee on Business Professions and Economic Development on April 15, 2024 on a vote of 12-0.
- Prior legislation. SB 524 (Skinner of 2021) would have prohibited a health plan or a health insurer from engaging in specified activities that limit enrollees’ or insureds’ access to pharmacies that are part of the plan’s or insurer’s network, except when special handling or clinical requirements are necessary, and, permits the use of financial incentives at network pharmacies. This bill was vetoed by Governor Newsom, who stated:
This bill would prohibit patient steering to certain pharmacies by health plans, health insurers, and their agents, as specified.
While offering consumers a choice in pharmacies within their health plan or insurer networks is a worthwhile goal, the bill lacks clarity in key areas which may render it subject to misinterpretation or a lack of enforceability. It is unclear what business relationships between health plans, insurers, and their agents are intended to be affected because the bill does not define "agent" or "corporate affiliate." Furthermore, it is unclear what it means to "limit an enrollees' (or insureds') access" to certain pharmacy providers.
It is necessary to define these terms and concepts so appropriate oversight and enforcement may occur, particularly in light of the complexity of the contracting arrangements and benefit designs at issue. Finally, it is important to ensure that efforts to address these concerns do not have the unintended consequence of interfering with the ability of health plans and insurers to coordinate care and contain pharmaceutical costs for California's consumers.
AB 315 (Wood, Chapter 905, Statutes of 2018) places various requirements on PBMs, including to register with DMHC, exercise good faith and fair dealing, and disclose, upon a purchaser’s request, information with respect to prescription product benefits specific to the purchaser for all retail, mail order, specialty, and compounded prescription products. AB 315 requires DMHC to convene a Task Force on Pharmacy Benefit Management Reporting to determine what information related to pharmaceutical costs, if any, it should require to be reported by health plans or their contracted PBMs. AB 315 establishes a pilot project in Riverside and Sonoma Counties to assess the impact of contract provisions that prohibit the dispensing of certain amounts of prescription drugs by network retail pharmacies.
SB 17 (Hernandez, Chapter 603, Statutes of 2017) required health plans and insurers that offer commercial products and file rate information with the DMHC or CDI to annually report specific information related to the costs of covered prescription drugs. Requires DMHC and CDI to compile specified information into a consumer-friendly report that demonstrates the overall impact of drug costs on health care premiums. Requires drug manufacturers to notify specified purchasers, in writing at least 90 days prior to the planned effective date, if it is increasing the wholesale acquisition cost (WAC) of a prescription drug by specified amounts. Requires drug manufacturers to notify the Department of Health Care Information and Access three days after federal FDA approval when introducing a new drug to market at a WAC that exceeds the Medicare Part D specialty drug threshold. Requires drug manufacturers to provide specified information to HCAI related to the drug’s price.
- Support. The California Pharmacist Association, a cosponsor, writes PBMs are squarely in the middle of negotiating prices, demanding rebates, and driving formulary decisions. Their unfair business practices have become more pervasive as vertical integration has increased. Some PBMs own their own pharmacy chains and mail order pharmacies, creating potential conflicts of interest. They may prioritize their own pharmacies in network contracts or steer patients towards them, regardless of whether another pharmacy might offer better service or prices. Community pharmacists often develop personal relationships with their patients, understanding their unique healthcare needs and providing personalized advice. This level of care and attention can be lost when patients are forced to rely on larger chain pharmacies or mail-order services. Studies have shown that patients are more likely to adhere to their medication regimens when they have a close relationship with their pharmacist. Most of the states have cracked down on PBM abuses, recognizing that community pharmacy is key to the healthcare system. The closure of community pharmacies can have broader public health implications, as it may lead to poorer health outcomes for affected populations. Without easy access to medications and healthcare services, patients may delay filling prescriptions, skip doses, or forgo necessary treatments altogether, exacerbating their health conditions. In addition to owning pharmacies, in many cases, health plans and PBMs are now one in the same. In recent years, the largest PBMs merged with large health insurers. CVS acquired Aetna Inc., Express Scripts was acquired by Cigna, and OptumRx was already affiliated with United Healthcare. While there may be some efficiencies, vertical integration can create conflicts of interest that prioritize the financial interests of the integrated company over patient care. The National Multiple Sclerosis Society writes PBMs play a powerful role in determining what access people with MS have to their disease modifying treatments (DMTs) and symptom management medications. PBMs can determine which medications are covered by payers, which tier those medications are on, and where consumers must get certain prescriptions filled (e.g., a specialty or mail order pharmacy). As the costs for these medications have increased, health plans and PBMs employ increasingly strict utilization management practices, like prior authorization and step therapy, to minimize the use and cost liability for these therapies. These practices present significant hurdles for prescribers and cause real delays and barriers for people living with MS in accessing medications that they and their providers decide are right for them. In addition, PBMs often place generic drugs and biosimilars in higher formulary tiers alongside brand medications, thus negating the cost savings to the health system and the patient. We have seen this practice in the MS space as MS generics are often covered as specialty medications and as a result sit on a higher cost-sharing tier than most regular generic medications; this results in higher out of pocket costs for people with MS. Likewise, a PBM may prefer a higher cost drug because it will increase their revenue so, despite lower cost alternatives being available, a higher cost product receives favorable formulary placement. We believe that the choice of therapy for people with MS should be between the patient and their healthcare provider, with the enrollee’s health being the top priority. The California Board of Pharmacy writes that it has received public comments and complaints from consumers and health care providers stemming from actions by PBMs. Such complaints range in the types of medications involved from maintenance medications (such as the treatment of high blood pressure) to specialty medications (generally high-cost medications used to treat complex, chronic conditions). Investigations have revealed that the root cause of some delays in access, for example, stems from mandates established by PBM. Regrettably at this time the Board lacks jurisdiction and cannot take any meaningful action for the patient nor can the Board evaluate the system and regulate for systemic changes to address the root causes of such delays, thereby preventing future harm.
- Opposition. PCMA writes while ostensibly seeking to bring PBMs under state agency oversight, several provisions in the bill blatantly promote independent retail pharmacies under the guise of regulating PBMs. Allowing any pharmacy to participate in a network without agreeing to a PBM’s terms and conditions (e.g., reimbursement rates) isn’t regulating PBMs, it’s increasing pharmacy profits. This legislation does nothing to lower costs for patients; it simply seeks to financially promote one industry over another with no consumer benefit. California Teamsters writes that many private sector unions partner with PBMs to create quality, affordable prescription drug benefit plans that work best for their members. Legislation that restricts the way they work with PBMs to lower the cost of care will result in increased health care costs to their Trust, and their members.
- Oppose unless amended. Health Access California writes that this bill eliminates any incentive to negotiate over drug prices, functionally eliminating the role of the PBM. It prohibits any fee based directly or indirectly on the acquisition cost, amount of savings or rebates, amount of premiums/deductibles/cost-sharing as well as spread pricing, which is defined as any time a PBM charges a private payer a price different from the price charged to a pharmacy or pharmacist. The PBM is limited to a management fee that cannot be related to the amount of savings they generate. Provisions related to this prohibition are proposed in the Business and Professions Code, the Knox-Keene Act and the Insurance Code. Health Access proposes that the provisions on basing fees directly or indirectly on costs be deleted and that the provision on spread pricing be revised to prohibit a PBM from charging a consumer, health plan, insurer or other third-party payer more for a drug than the PBM paid the pharmacy. The current language eliminates any pricing in which the price is different, even if the purchaser or consumer pays less, not more. Health Access also has serious questions about the provisions that prohibit drug manufacturers from entering into exclusive arrangements with PBMs and the implications of those provisions for pricing, and they oppose those provisions that constitute “any willing provider” provisions as contrary to longstanding California policy permitting health plans, insurers and other payers to rely on networks of providers. The California Chamber of Commerce believes Sections 17035 and 17040 disrupt the pharmacy network model and limit an employer’s ability to build out preferred networks. These provisions limit financial incentives and take away an employer’s ability to design a benefit for their employees. While we are mindful of the important role all pharmacies play in their communities, diminishing preferred networks and preferred delivery models, such as mail order for specialty drugs, will impact the economies of scale and increase health care prices for the consumer.
- Policy comments. The committee may wish to adopt amendments to address the following policy concerns:
- Regulator. While this bill has assigned licensing authority to CDI, there are still questions about whether or not CDI is best suited for this task compared to DMHC, which currently registers PBMs. At present, neither department has indicated a willingness to license PBMs. The author and sponsors are encouraged to continue to explore which entity is best suited for this responsibility.
- Regulations. Whichever department ends up with oversight responsibilities of PBMs, the regulator will need to establish rules and regulations rapidly, and at the same time, with stakeholder input. This bill should be amended to initially allow for regulations to be adopted on an emergency basis.
- Consumer protections. Health care consumers’ access to, and affordability of, medically necessary drugs, devices, and services should be the primary focus of any PBM regulation. As such, this bill should be amended to ensure consumers benefit from low cost-sharing and are provided with a mechanism to submit complaints about PBMs. This bill should also authorize the regulator to investigate complaints referred by the Board of Pharmacy.
- Networks. Provider networks are foundational to managed care. This bill should be amended to clarify that pharmacy provider networks are permitted under any licensing framework. Any in network pharmacy wishing to be considered preferred should be required to meet the same terms and conditions that apply to other preferred pharmacies.
- Transparency. Recommendations from the AB 315 Task Force to promote more transparency in the health care system around the role of PBMs have never been enacted. This bill should be amended to incorporate those recommendations.
- Compensation. Spread pricing seems to contribute to the mystery of PBM motivations. This bill limits PBM compensation to a fee-based on service compensation model. Some have raised concerns that eliminating spread pricing will reduce incentives for PBMs to negotiate low drug prices for purchasers. This bill should continue to ban spread pricing but also allow for performance based compensation arrangements that are more transparent and open to inspection by the regulator.
- Fiduciary duty. This bill establishes a fiduciary duty of the PBM to consumers, purchasers, and providers. It is unclear how a duty can be owed to all of these stakeholders. This should be narrowed so that the duty is owed to the purchaser of the PBM services. Plan sponsors should owe a duty to their members, enrollees or insureds.
- Amendments. The author and sponsor have requested the committee adopt a number of amendments.
- Revise the definition of spread pricing.
- Delay licensure requirement after January 1, 2026.
- Authorize CDI to establish fees and establish a fund for deposit of the fees.
- Add the AB 315 Task Force recommendations to the reporting requirements of PBMs, plans, and insurers.
- Require PBMs to reimburse its network pharmacies for the ingredient component of the pharmacies’ services at a reasonable amount to ensure that the network pharmacies are able to acquire the drug.
- Replace the accreditation requires and with the following:
(a)A pharmacy benefit manager may only require pharmacist or pharmacy accreditation standards or recertification requirements that are related to the safety and competency necessary to meet the United States Food and Drug Administration’s limited distribution requirements for dispensing any drug that, on a drug-by-drug basis, requires extraordinary special handling, provider coordination, or clinical care or monitoring when such extraordinary requirements cannot be met by a retail pharmacy.
(b) For purposes of this paragraph, drugs requiring extraordinary special handling are limited to drugs that are subject to a risk evaluation and mitigation strategy approved by the United States Food and Drug Administration and that:
(c) For participation in a specialty network, a pharmacy benefit manager may not require a pharmacy to meet requirements for participation beyond those necessary to demonstrate the pharmacy’s ability to dispense the drug in accordance with the United States Food and Drug Administration’s approved manufacturer labeling.
- Revise the clawback provisions as follows:
(d) A pharmacy benefit manager shall not directly or indirectly, including indirectly through a pharmacy services administrative organization, charge or hold a pharmacist or pharmacy responsible for a fee related to a claim or reduce the amount of the reimbursement or payment of a claim, or aggregate of claims, through aggregated effective rate, direct or indirect remuneration, quality assurance program or otherwise, at, or after, the time of the claim’s adjudication or after the claim is adjudicated.
- Add the following language to the audit requirements: Each pharmacy benefit manager shall pay to the department all expenses for such examinations and audits. Funds shall be deposited to the pharmacy benefit manager licensure fund.
- Allow the remedies and penalties provided in this bill to apply to violations of SB 786 (Portantino, Chapter 414, Statutes of 2023) related to 340B Covered Entities.
- Add the following language to the audit requirements: Each pharmacy benefit manager shall pay to the department all expenses for such examinations and audits. Funds shall be deposited to the pharmacy benefit manager licensure fund.
SUPPORT AND OPPOSITION:
Support: California Pharmacist Association (cosponsor)
California Chronic Care Coalition (cosponsor)
AIDS Healthcare Foundation
APLA Health
California Association of Joint Powers Authorities
California Health Collaborative
California Life Sciences
California Manufacturers & Technology Association
California Medical Association
California State Board of Pharmacy
Cystic Fibrosis Research, INC.
National Association of Chain Drug Stores
National Community Pharmacists Association
National Multiple Sclerosis Society
National Psoriasis Foundation
North East Medical Services
Pharmaceutical Research and Manufacturers of America
San Francisco Marin Medical Society
Oppose: America’s Health Insurance Plans
American GI Forum Foundation
Association of California Life and Health Insurance Companies
California Association of Health Plans
California Chamber of Commerce (unless amended)
Californians for Lower Drug Costs
California El Salvadoran Chambers of Commerce
California Hispanic Chambers of Commerce
California Teamsters Public Affairs Council
Defisal Foundation
Health Access California (unless amended)
Pharmaceutical Care Management Association
Shalom International Outreach
Sperantia Foundation
The Community Church
The Council for Citizens Against Government Waste
The Row LA
Three individuals
-- END --
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Angelique Ashby, Chair
2023 - 2024 Regular
Bill No: SB 966 Hearing Date: April 15, 2024
Author: | Wiener | ||
Version: |
| ||
Urgency: | Fiscal: | ||
Consultant: | |||
Subject: Pharmacy benefits
SUMMARY:
Requires the Board of Pharmacy (Board) to license and regulate Pharmacy Benefit Managers (PBMs), mandates that a PBM which provides services in the state be licensed by the Board, and prohibits a PBM from various activities, subject to Board enforcement and penalties for violating prohibitions.
NOTE:
This measure is double-referred to the Senate Committee on Health, second.
Existing law:
- The Pharmacy Law, provides for the licensure and regulation of pharmacies, pharmacists and wholesalers of dangerous drugs or devices by the Board of Pharmacy. (Business and Professions Code (BPC) § 4000 et seq.)
- Provides for the licensure and regulation of health care service plans (health plans) by the Department of Managed Health Care (DMHC) and the regulation of health insurers by the Department of Insurance (CDI). (Health and Safety Code (HSC) § 1340 et seq.; California Insurance Code § 740 et seq.)
- Requires a health plan to disclose specified prescription drug information to a contracted pharmacy or its contracting agent as well as a phone number pharmacy providers may call for assistance and information to process a pharmacy claim. Prohibits a health plan from including a provision in a contract with a pharmacy provider or contracting agent that prohibits the provider from informing a patient of a less costly alternative to a prescription medication. (HSC § 1385.003)
- Requires PBMs, if the PBM contracts with a health plan for prescription drug coverage, to comply with the requirements for health plans in 3) above, to register with DMHC, provide DMHC specified information about the PBM and PBM’s operations, to exercise good faith and fair dealing in the performance of contractual duties to a health care service plan, to comply with provisions related to pharmacy audits, to inform pharmacists of their right to submit complaints about the PBM, and to notify a health care service plan of activities that present a conflict of interest that interferes with the PBM’s contractual duties. (HSC § 1385.004)
- Specifies that failure by a health plan to comply with PBM contractual requirements constitutes grounds for disciplinary action. Requires the Director of DMHC, as appropriate, to investigate and take enforcement action against a health plan that fails to comply with these requirements and to periodically evaluate contracts between health plans and PBMs to determine if any audit, evaluation, or enforcement actions should be undertaken by DMHC. (HSC §1385.006)
- Establishes various standards in the Pharmacy Law for entities conducting pharmacy audits, including but not limited to a prohibition on entities from receiving payment or other consideration tied to the amount claimed or actual amount recovered from the pharmacy that is the subject of the audit. (BPC § 4433)
- Requires a PBM to quarterly disclose, upon the request of a purchaser, for all retail, mail order, specialty, and compounded products, specified information about aggregate acquisition costs, aggregate amounts of rebates received by the PBM, administrative fees received from a pharmaceutical manufacturer or labeler, aggregate payments made to both pharmacies owned and not owned by the PBM, prescription drug utilization information for the purchaser's enrollees or insureds, aggregate fees on network pharmacies, and PBM contracts with a pharmaceutical manufacturer to exclusively dispense or provide a drug to a purchaser's employees or enrollees. (BPC § 4441)
This bill:
- Requires the Board to license and regulate PBMs and mandates that a PBM which provides services in the state be licensed by the Board, renewed every two years. Requires a PBM to provide specified information to the Board in an application about the PBM’s management, control, and services, as well as a document in which the PBM confirms that its business practices and each ongoing contract comply with the law. Authorizes the Board to refuse to issue a PBM license if the PBM or individual responsible for PBM conduct has had a certificate of authority or license denied or revoked in another state. Authorizes the Board to examine or audit PBM records to determine compliance.
- Provides the Board broad enforcement authority for PBMs and cease and desist authority for unlicensed PBMs. Authorizes PBM operations to continue, if a PBM license is suspended or restricted, for up to 60 days or longer if the Board determines operation is in the beneficial interests of enrollees and insureds. Subjects a suspended or restricted licensed PBM to a Board-determined fine each month of up to $20,000 until the PBM remedies the violation.
- Requires the Board to compile an annual report (excluding information that causes financial, competitive, or proprietary harm to a PBM) comprised of information that PBMs would be required to provide the Board in a mandated annual report on or before April 1, 2027. Information includes that which registered PBMs already, pursuant to current law, provide quarterly to purchasers upon request for all retail, mail order, specialty, and compounded prescription drugs.
- Makes various definitions to support this new Board license type and regulatory work, including but not limited to:
- “PBM” means a person, business, or other entity that, either directly or indirectly, manages the prescription drug coverage, including, but not limited to, the following: clinical or other formulary or preferred drug list development or management; the processing and payment of claims for prescription drugs, the negotiation or administration of rebates, discounts, payment differentials, or other incentives for the inclusion of particular prescription drugs in a particular category or to promote the purchase of particular prescription drugs; the performance of drug utilization review; the processing of drug prior authorization requests; the adjudication of appeals or grievances related to prescription drug coverage; contracting with pharmacies; and controlling the cost of covered prescription drugs. Provides an exemption from the definition of PBM for a health plan that is part of a fully integrated delivery system in which enrollees primarily use pharmacies that are entirely owned and operated by the health care service plan as well as a contract that employers, insurers, or groups of employers or insurers enter into with a pharmacy, group of pharmacies, or pharmacy benefit network to provide medicines and medical supplies to injured workers.
- “Affiliated pharmacy” means a contract pharmacy that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a PBM and “nonaffiliated pharmacy” means a contract pharmacy that directly, or indirectly through one or more intermediaries, does not control, is not controlled by, and is not under common control with, a pharmacy benefit manager. The bill requires an affiliated pharmacy to disclose to an enrollee or insured, before a prescription is dispensed, that the enrollee or insured is not obligated to use the affiliated pharmacy.
- Prohibits a PBM from:
- Imposing terms or conditions applied to nonaffiliated pharmacies based on their status as a nonaffiliated pharmacy.
- Refusing to contract with or terminating a contract with a nonaffiliated pharmacy on the basis that the pharmacy is a nonaffiliated pharmacy or for reasons other than those that apply equally to affiliated pharmacies.
- Retaliating against a nonaffiliated pharmacy based on its exercise of any right or remedy authorized by this law.
- Requiring an enrollee or insured to use only an affiliated pharmacy that is a retail pharmacy.
- Financially inducing an enrollee, insured, or prescriber to transfer a prescription only to a retail affiliated pharmacy.
- Requiring a retail nonaffiliated pharmacy to transfer a prescription to a retail affiliated pharmacy.
- Unreasonably restricting an enrollee or insured from using a particular retail pharmacy for the purposes of receiving pharmacist services covered by the enrollee’s or insured’s contract or policy.
- Communicating to an enrollee verbally, electronically, or in writing that the enrollee is required to have a prescription dispensed at, or pharmacy services provided by, a particular affiliated pharmacy or pharmacies if there are other pharmacies that have the ability to dispense the medication or provide the services.
- Prohibiting a retail pharmacy from offering prescription delivery by mail or common carrier, or by an employee or contractor of the retail pharmacy.
- Requiring pharmacist or pharmacy accreditation standards or recertification requirements inconsistent with, more stringent than, or in addition to federal and state requirements to obtain reimbursement for a covered drug.
- Deriving income from PBM services provided to an insurer or health plan in California except for income derived from a pharmacy benefit management fee.
- Reversing and resubmitting a contract pharmacy claim without notifying the contract pharmacy, without attempting to reconcile the claim with the pharmacy, and more than 90 days after the claim was adjudicated.
- Directly or indirectly, including indirectly through a pharmacy services administrative organization, charge or hold a pharmacist or pharmacy responsible for a fee related to a claim or reduce the amount of the claim at the time of the claim’s adjudication or after the claim is adjudicated.
- Charging a pharmacy or pharmacist a fee to process a claim electronically.
- Retaliating against a pharmacist or pharmacy by terminating or refusing to renew a contract; subjecting the pharmacist or pharmacy to increased audits; or failing to promptly pay the pharmacist or pharmacy money based on the pharmacist’s or pharmacy’s exercise of a right or remedy.
- Unreasonably obstructing or interfering with a patient’s right to timely access a prescription drug or device that has been legally prescribed for that patient at a pharmacy of their choice, except as permitted under existing law.
- Making, disseminating, or causing or permitting the use of an advertisement, promotion, solicitation, representation, proposal, or offer that is known to be, or reasonably should be known to be, untrue, deceptive, or misleading.
- Conducting spread pricing in California beginning January 1, 2025 but if a preexisting contract between a PBM and a health care service plan or health insurer authorizes spread pricing, any subsequent amendment or renewal of that contract shall not contain that authorization and any such spread pricing terms shall be void after January 1, 2028.
- Entering into, amending, enforcing, or renewing a contract on or after January 1, 2025, with manufacturers who do business in California that expressly or implicitly restrict, or implements implicit or express exclusivity for, those manufacturers’ drugs, medical devices, or other products. Entering into, amending, enforcing, or renewing a contract on or after January 1, 2025, with pharmacies or pharmacy administrative services organizations who do business in California that expressly or implicitly restrict, or impose implicit or express exclusivity on, nonaffiliated pharmacies’ ability to contract with employers, insurers, and health care service plans.
- Provides that any person that violates these requirements is subject to an injunction and liable for a civil penalty of not less than $1,000 or more than $7,500 for each violation which shall be assessed and recovered in a civil action brought in the name of the people of the State of California by the Attorney General.
- Specifies that a PBM that violates provisions of 3) and 5) is, in addition to any other penalty provided by law, liable for restitution to any enrollee or insured harmed by the violation and is subject to a penalty not exceeding the greater of up to $1,000 for the first violation and $2,500 for each subsequent violation or the aggregate economic gross receipts attributable to all violations.
- Specifies that a violation of 5) a)-h) and j) above is an act of unfair competition.
- Authorizes any person or trade association to institute a civil action for violations of this bill to recover civil penalties not less than $100 or more than $2,500 for each violation or for injunctive or declaratory relief or for any other relief the court deems proper. Requires the court, in assessing the amount of civil penalties, to consider any one or more of the relevant circumstances presented by any of the parties to the case, including, but not limited to, the nature and seriousness of the misconduct, the number of violations, the persistence of the misconduct, the length of time over which the misconduct occurred, the willfulness of the defendant’s misconduct, and the defendant’s assets, liabilities, and net worth. Specifies that the remedies or penalties provided are cumulative to each other and to the remedies or penalties available under all other laws of this state.
- Requires a health plan contract and health insurance policy that provides prescription drug coverage to calculate an enrollee’s cost-sharing amount, including deductible and coinsurance, as applicable, based exclusively on its negotiated rate for the prescription drug. This subdivision does not prevent a health care service plan from deducting rebates, as that term is defined by Section 4445 of the Business and Professions Code, or any other discounts it receives, from the negotiated rate for a prescription drug from which cost-sharing amounts are calculated.
FISCAL EFFECT:
Unknown. This bill is keyed fiscal by Legislative Counsel.
COMMENTS:
- Purpose. The The California Pharmacists Association (CPhA), California Chronic Care Coalition, California Legislative LGBTQ Caucus, Los Angeles LGBT Center, and San Francisco AIDS Foundation are the Sponsors of this bill. According to the Author:
“PBMs are a significant part of the pharmacy delivery system, but they operate out of reach of California regulators. Initially created to in the 1960s to process pharmacy claims, push generic drugs to lower costs and develop pharmacy networks, PBM practices have evolved in ways to allow them to abuse their market power to prioritize their profits over patient care. This is evident in their patient steering practices in which they confuse consumers by wrongly communicating to them that their current independent pharmacy is not in network and that they can only receive their medication from a pharmacy that is either owned or under the control of the PBM. This type of self-dealing that increases their bottom line as the expense of patient choice is not permitted for other professions and is expressly prohibited in the Business and Professions statutes for physicians.
Additionally, the state currently lacks a mechanism to require and enforce transparency requirements on PBMs. This is extremely important as there is no way to determine whether health care payors and consumers are benefiting from drug rebates.
PBMs also engage in anticompetitive practices that make it exceedingly difficult to operate independent chains and community pharmacies. PBMs’ administrative fee collection and vendor contracting entity fees have increased exponentially — from “nearly zero in 2018 to greater than 1.7 billion in 2022.”
These unfair business practices have caused many independent pharmacies to close and driven up lowered reimbursement rates for certain drugs so significantly that many independent pharmacies can no longer afford to stock them. The result is a significant lack of access for patients.
California’s lack of direct oversight of PBMs makes it difficult, if not impossible, for the state to ensure that their ever-evolving activities are driven by patient concerns and not profit motives.”
- PBMs. PBMs have been around since the early 1970s. Initially, PBMs’ functions were limited -- they served as fiscal and administrative intermediaries between health plans, plan members, and pharmacies. What remains the same of PBMs, both in the past and currently, is their role as claims processor. Claims processing requires a pharmacy to contact a PBM to verify that a consumer has coverage for a requested prescription, determine whether the customer’s plan covers the drug, and how much copay is required. Once the prescription is filled, the pharmacy transmits patient details -- the health plan number, the physician’s prescription, and the drug price -- to the PBM. The PBM responds by approving or disapproving the transaction, and then forwards the reimbursement from the health plan to the retail pharmacy.
Nearly every health plan, whether sponsored by an employer, a union, Medicare, or self-purchased, employs a PBM, and PBMs’ functions have evolved over time from merely claims processing to include managing their clients’ entire pharmacy benefit. The functions offered to clients may now include:
- Negotiating prices for drugs, including discounts, rebates, and other concessions, with pharmaceutical manufacturers;
- Conducting drug-utilization reviews (i.e., compiling information regarding the projected volume of plan members who use a given drug);
- Disease management (i.e., managing the chronic conditions of high-risk, high-cost patients);
- Determining the composition of pharmacy and wholesaler networks;
- Running mail-order and affiliated specialty pharmacies; and,
Creating and managing formularies.
PBMs contract with pharmacies to create networks for their clients based on clients’ needs and state laws, which may include geographic retail requirements and limitations on mail-order pharmacies. Because nearly every individual with a pharmacy benefit must interact with a PBM, it follows that joining PBMs’ pharmacy networks is more than good business practice -- it is essential for pharmacies’ survival. Pharmacies’ revenues from drug dispensing are primarily derived from health plans’ reimbursement for the drug’s cost, a dispensing fee, and a patient’s copay.
Contracts for inclusion in PBMs’ pharmacy networks are extensive and frequently-updated. Common provisions include basic inventory requirements, professional codes of conduct, reimbursement amounts, reimbursement criteria, and applicable federal and state laws. Most contracts offered by PBMs to retail pharmacies are fairly boilerplate, meaning they consist of standardized terms and conditions that are routinely repeated with different parties. Disputes and grievances between PBMs and pharmacies are typically resolved through PBMs’ in-house dispute committees or by mandatory arbitration. Pharmacies are also subject to periodic, routine audits from PBMs during which time a pharmacy’s accounts are reviewed to reconcile reimbursements, fees, and ensure compliance with the contract terms.
While large pharmacies deal with PBMs directly, smaller pharmacies may contract with a pharmacy services administrative organization (PSAO) for leverage. A PSAO can represent the pharmacy in PBM contract negotiations and manage drug reimbursement claims, among other administrative offerings. PSAOs charge pharmacies fees for their services, and do not get any reimbursements from PBMs or other contract affiliates.
According to a 2005 Federal Trade Commission (FTC) report on PBMs and mail-order pharmacies, many health plan sponsors offer their members prescription drug insurance and hire PBMs to manage these pharmacy benefits on their behalf. As part of the management of these benefits, PBMs assemble networks of retail and mail-order pharmacies so that the plan sponsor’s members can fill prescriptions easily and in multiple locations.
AB 315 (Wood, Chapter 905, Statutes of 2018) required PBMs to register with DMHC and to disclose, upon a purchaser’s request, information with respect to prescription product benefits. The law also required DMHC to convene a Task Force on PBM Reporting to determine what information related to pharmaceutical costs, if any, DMHC should require to be reported by health care service plans or their contracted PBMs. AB 315 also established a pilot project in Riverside and Sonoma Counties to assess the impact of health plan and PBM prohibitions that prohibit the dispensing of certain amounts of prescription drugs by network retail pharmacies.
The Task Force on PBM Reporting issued a report to the Legislature in 2020 which outlined a series of recommendations aimed at increasing transparency and understanding how PBMs impact the cost of prescription drugs. The report noted that presentations and public comments made to the Task Force stressed the need for additional PBM transparency to help understand what is driving prescription drug cost increases and determine how consumers can be better protected. The Task Force discussed the need for PBM data at the drug level to determine whether and how PBMs impact specific drug prices. It was suggested PBMs may target specific drugs for posttransaction fees and may steer consumers who are prescribed high-cost drugs to the PBM’s integrated pharmacy. The Task Force also discussed the need for information on PBM revenue and expenses, as this information is opaque not only to the consumer, but also to the health plans, pharmacies, and manufacturers with which the PBM works. The report recommends, at the drug level, requiring PBMs to report to DMHC:
- A list of the 100 most costly drugs, the 100 most frequently prescribed drugs, and the 100 highest revenue-producing drugs, grouped by generic, brand, specialty, and other.
- For each drug that falls into the above categories: The pharmacy type used to fill the drug prescription, such as integrated, chain, independent, specialty, and mail order pharmacies. Pricing and rebate information, including the amount of rebate the PBM receives from the manufacturer, the amount of rebate the PBM passes to the health plan, the amount the health plan pays the PBM, and the amount the PBM pays the pharmacy.
The report recommends, at an aggregated level, gathering information on PBMs, including revenue and expense information, to determine PBM market impact and the value PBMs provide to consumers by requiring PBMs to report:
- The health plans with which the PBM contracts, the scope of services provided to the health plan, and the number of enrollees served by the PBM.
- PBM revenue, including revenue from manufacturers, health plans, pharmacies, and other revenue.
- PBM expenses, including payments to pharmacies, claims processing, special programs, administration, and other expenses.
States have increasingly moved to require PBMs to be licensed or registered with a CDI-type insurance regulatory entity or Insurance Commissioner. PBMs historically argued that various state laws could not apply to them due to federal preemption under the Employee Retirement Income Security Act of 1974 (ERISA). However, a recent United States Supreme Court ruling provides clarity on this subject. In 2015, Arkansas passed a law barring PBMs from setting the price they pay independent drug stores for medicines obtained for their contracted health insurers’ customers. Arkansas and other states have held PBMs responsible for independent pharmacies and drug stores losing money on the medicines they dispense. In challenging the 2015 Arkansas law, PBMs argued that this law did not apply to them due to federal preemption under ERISA. The Supreme Court upheld the Arkansas state law, stating that, as a general rule, ERISA does not preempt “state rate regulations that merely increase costs or alter incentives for ERISA plans without forcing plans to adopt any particular scheme of substantive coverage.” At least 25 states require licensure, while almost all other than 3 and the District of Columbia, require certification or registration in order to operate in that state.
- Sunrise Questionnaire Response. Rules of the Senate Committee on Business, Professions, and Economic Development (Rule No. 6, Setting and Hearing of Bills) specify that “Prior to hearing any bill or other measure that proposes to create a new state licensing agency or a new category of licensed or regulated professional, the Author or sponsor of the legislation shall develop a plan for the establishment and operation of the agency or creation of the new licensed category in accordance with the requirements of Government Code Section 9148 et seq. The plan shall include the completion of an occupational regulation proposal review worksheet titled the ‘Sunrise Questionnaire’ by the Author or sponsor of the legislation.”
The Author and sponsors provided this information to the Committee (PBM Sunrise Response) on March 12, 2024.
In response to the questions related to public demand for a regulatory standard and the nature and severity of the harm a lack of licensure may result in, the responses in the PBM Sunrise Response state that “…there has been significant consumer demand for regulatory standards. In this case, consumers include both the patients who ultimately are provided direct services from the PBMs, but also the providers (physicians, oncologists, pharmacists) who have a direct relationship with those patients and are interested in ensuring that they are provided their medication timely and cost-effectively… “Consumers are regularly being harmed by the actions of the PBMs utilizing anticompetitive and non-transparent practices to reduce access and increase the price of drugs.”
The PBM Sunrise Response states the following as examples of consumer harm necessitating licensure:
- Patient-provider interference and lack of patient choice: To maximize profits, PBMs have engaged in the practice of “patient steering” in which they confuse consumers by wrongly communicating to them that their current pharmacy is not in network (even though it is) and that they can only receive their medication from a pharmacy that is either owned or under the control of the PBM. This type of self-dealing disrupts the provider-patient relationship for financial – and not clinical – reasons that are not in the best interests of the consumer. Because of this, this type of self-dealing is expressly prohibited in the Business and Professions statutes for physicians.
- Diminished patient access: PBM payment reductions have resulted in closures of community pharmacies, which ultimately harms patients by reducing/restricting their choice and limiting competition. Payment reductions have resulted from charging an insurance plan a different amount than it reimburses the pharmacy and clawing back reimbursement payments. In many cases, pharmacies are reimbursed at below cost for certain drugs, resulting in declining revenue for pharmacies and ultimately lack of access to the medication either because it is no longer stocked, or the pharmacy is closed.
- Increased Costs due to the Lack of Transparency. Changes in the PBM business model have created perverse incentives that contribute to the high cost of prescription medications – costs that are borne by all healthcare consumers and payors.
- Rebate Pumping: PBMs engage in “rebate pumping” where newer, higher cost drugs that pay larger rebates – which they pocket – are placed on formularies even though they may not be the best drug on a therapeutic class. This is a serious conflict of interest as PBMs should act to lower plans’ costs but often act to maximize their profits.
- Spread Pricing: PBMs engage in “spread pricing,” in which they charge the plans higher costs than what is paid to the pharmacy for dispensing medication. This practice leads to higher costs for the plans which can increase premiums and copays for patients.
- Overpromotion of PBM Owned Mail Order and Specialty Pharmacies: PBMs promote the use of their own mail order and specialty pharmacy services on the premise that they are more cost-effective but there is no evidence to support those claims and the over promotion of the services can increase plan costs in the following ways: PBMs benefit twice from these arrangements: first from the regular PBM administration fee and the drug sale; Average rebate earnings on mail order dispenses is 250% of that on community pharmacy dispenses; PBM mail order facilities can influence the dispense by contacting the prescriber to switch the prescription from a generic or nonpreferred brand to preferred name brand to earn greater spreads and rebates; PBMs often use a higher Maximum Allowable Cost (MAC) pricing for mail order to charge payors and the lower MAC used by community pharmacies to pay manufacturers to maximize the spread which they keep.
The Sunrise Questionnaire asks why marketplace factors will not be as effective as governmental regulation in ensuring public welfare. In response, the PBM Sunrise Response states that “Outside of action being taken by the State Attorney General, licensure that grants PBMs the ability to operate in California is the only way to ensure they operate in the best interest of consumers and payors. Because they currently operate outside of the state’s direct regulatory control, they are able to evade investigation and punishment for their unfair and anti-consumer business practices. The evolution of the PBM business model over the last 30 years demonstrates that they stay one step ahead of competitors and the regulators. The evolution has led to mass consolidation and vertical integration in the industry – both of which have given PBMs enormous market strength – and has created distorted the incentives for them to act in the best interests of consumer and payors. The big three PBMs (Caremark, Express Scripts, and Optum Rx) are monopolies that exert control over 80 percent of consumers lives with little to no state oversight.
The market share of the “Big Three” is in the billions of dollars annually and is such that huge fines (usually in the hundreds of thousands of dollars) have been levied against them in recent years when malfeasance has been discovered. This is usually done through settlements with State Attorneys General. This is why pending federal legislation proposes to fine PBMs $10,000 per day for violating the law…Because they are currently unregulated and face limited consequences for any malfeasance (unintentional or intentional), PBMs routinely make decisions that are in their best interest and neither the patients they serve nor the clients with whom they contract. They make large business decisions that have the potential to harm consumers and community pharmacies.”
- Licensure, Recognition and Regulation. According to a 2002 article featured in the Yale Journal of Regulation, to protect the public from potentially harmful health services rendered by unqualified people, each state has enacted licensing laws, or practice acts. The article noted that typically, these laws do three things: (1) They define the practice of the profession in question; (2) they limit that practice to people who satisfactorily complete a specified training regime and pass an examination; and (3) they restrict to license holders both the use of the professional title or credentials and the performance of the defined practice functions.
According to “A Theory of Regulation: A Platform for State Regulatory Reform”, 5:2 CAL. REG. L. REP. 3 (Spring 1985), “Government should regulate a particular trade or profession only after an honest assessment of the marketplace and any flaws which present a threat of irreparable harm, or prevent normal marketplace functioning from driving out incompetent, dishonest, or impaired practitioners. The article outlines that “licensing is one form of regulation but should be reserved for trades and professions in which incompetence is likely to cause irreparable harm — that is, harm for which money cannot compensate. If there is likely irreparable harm, then a prior restraint- type barrier to entry (licensing) which addresses and prevents that precise harm should be imposed; additionally, the licensing agency should set industrywide standards of conduct and ethics, and police violations of those standards through a vigorous enforcement program”. According to the article, in the absence of probable irreparable harm, numerous regulatory alternatives to licensing exist, including the posting of a bond to ensure a fund to compensate injured consumers, a certification program which has the effect of disclosing information to consumers about the qualifications of a practitioner and protects the use of a title or a permit program, as some examples.
A practice act along with licensure typically confers the exclusive right to practice a given profession on practitioners who meet specified criteria related to education, experience, and examination, and often is embodied in a statutory licensing act (i.e., those who are not licensed cannot lawfully practice the profession). A practice act is the highest and most restrictive form of professional regulation, and is intended to avert severe harm to the public health, safety or welfare that could be caused by unlicensed practitioners.
A title act and a certification or registration program, on the other hand, often reserves the use of a particular professional (named) designation to practitioners who have demonstrated specified education, experience or other criteria such as certification by another organization. A title act typically does not restrict the practice of a profession or occupation and allows others to practice within that profession; it merely differentiates between practitioners who meet the specified criteria, and are authorized by law to represent themselves accordingly, (usually by a specified title) and those who do not. Some title acts also include a state certification or registration program, or reliance on a national certification or registration program, so that those who use the specified title, and hold themselves out to the public, have been certified or registered by a state created or national entity as having met the specified requirements. This entity may also regulate to some extent the activities of the particular profession by setting standards for the profession to follow, and to also provide oversight of the practice of the profession by reporting unfair business practices or violations of the law and either denying or revoking a certification or registration if necessary.
This bill proposes licensure for PBMs but, rather than establish minimum standards to meet licensure requirements, instead mandates licensure for all PBMs as defined and establishes prohibitions on licensees, rather than establishing practice privileges.
- Arguments in Support. Supporters write that PBMs favor branded medications that are financially incentivized by manufacture rebates and state that although generics are the majority (90%) of US prescriptions, they account for only 3% of US health care spending. Supporters are concerned about the lack of transparency as to how rebates are paid to payors, if at all, and believe this bill will ensure drug rebates will be passed on to the payers instead of increasing the current PBM monopoly’s bottom line. Supporters note that with soaring healthcare costs, there is increasing scrutiny on providers, hospitals, manufacturers and insurance companies. The only healthcare entities that have seemingly avoided transparency and oversight are PBMs. According to supporters, this bill will help Californians better access the medications that they need - thus increasing adherence for patients living with chronic conditions. Supporters cite a study showing that the share of PBM profits from fees (which are tied to the list price of a medicine) has quadrupled in the last 10 years and note that due to PBM exclusion of products with lower list prices and basing patient costs on list price instead of net price, patients face a higher financial burden for their prescription drugs. Supporters cite the prohibited activities in this bill as a big step forward and one that will help patients in California.
- Arguments in Opposition. The Pharmaceutical Care Management Association (PCMA) writes that several provisions of this bill promote independent retail pharmacies under the guise of regulating PBMs and that it does nothing to lower costs for patients but simply seeks to financially promote one industry over another with no consumer benefit. The organization notes that mail order facilities affiliated with a PBM is already required to be licensed and regulated by the Board and that giving pharmacists regulatory authority over non-pharmacy contractual partners sets a dangerous precedent. PCMA is concerned that the bill would allow any pharmacy to participate in the PBM’s network, regardless of quality and without having to agree to the PBM’s terms and conditions. According to PCMA, prohibiting employers and health plan sponsors from choosing how to compensate PBMs based on the savings they provide will encourage drug manufacturers to raise their pieces and that banning performance-based contracts would cause an increase in health insurance premiums of up to $26.6 billion. PCMA also notes that spread pricing enables health plans and employers to better manage their total drug spend with greater certainty. The organization is also concerned about the inclusion of a private right of action for any harm caused, which does not conform to existing enforcement authority for pharmacies and pharmacists. PCMA states that there have been no reports that PBMs are failing to comply with the requirements of AB 315 are concerned that the bill’s sponsors “are convinced PBMs are to blame for any and all market challenges.”
According to Health Access California, PBMs “engage in a variety of behaviors that inure to the benefit of the PBM, not the consumer. California law has taken some steps to improve consumer protections, and we would support more. Additionally, the vertical integration of the three major PBMs with national insurers raises serious questions about transparency as well as the benefit to consumers and other purchasers.” The organization writes that the bill should be amended: “We propose that the provisions on basing fees directly or indirectly on costs be deleted and that the provision on spread pricing be revised to prohibit a PBM from charging a consumer, health plan, insurer or other third-party payer more for a drug than the PBM paid the pharmacy. The current language in SB 966 eliminates any pricing in which the price is different, even if the purchaser or consumer pays less, not more.
We also have serious questions about the provisions that prohibit drug manufacturers from entering into exclusive arrangements with pharmacy benefit managers and the implications of those provisions for pricing.” The organization is also concerned about licensure by the Board of Pharmacy: “We support the regulation of PBMs to prevent unscrupulous behavior but question the need for licensure. We ask whether sufficient regulation of the behavior of PBMs can be achieved without licensure…Most other states that have regulated PBMs have done so through the department that regulates health insurance: the California state agency that regulates over 95% of state-regulated health coverage is the Department of Managed Health Care which already registers PBMs but does not have clear enforcement authority.” Health Access California also opposes “provisions that constitute ‘any willing provider’ provisions as contrary to longstanding California policy permitting health plans, insurers and other payers to rely on networks of providers.” The group is also concerned about “provisions that appear to allow any pharmacy to provide specialty drugs, especially if those medications require special handling or storage.”
The Utilization Review Accreditation Commission (URAC) writes that this bill “…goes beyond traditional PBM regulation and restricts a critical quality component in pharmacy accreditation that has been a longstanding tool for driving quality improvement and patient safety…It serves only to weaken existing patient safety protections and quality improvement initiatives that benefit all Californians.” The organization notes that prohibits the use of accreditation standards in contracts between PBMs and pharmacy providers would effectively prohibit payers from using the accreditation process to implement any quality standards or safety programs for pharmacies beyond the basic requirements for licensure from the California State Board of Pharmacy. They state that “URAC accreditation builds on the foundational oversight of Boards of Pharmacy by adding a far more comprehensive review of a pharmacy’s ability to deliver quality services and care management to patients receiving complex, expensive medications in a consistent and reliable manner. Unlike minimum licensure standards, URAC accreditation validates the operations and care management provided by pharmacies based on quality standards defined by national best practices. This differs from Boards of Pharmacy that focus on a much more limited scope of issues addressing licensure and the environment in which the pharmacy is dispensing drugs. Board of Pharmacy licensure standards on their own are insufficient to deliver high-quality care required for those seeking to serve patients prescribed specialty medications. The gap that exists between accreditation and minimum licensure represents meaningful steps that result in improved quality and safety.” According to URAC, removing this language would be a meaningful step toward ensuring that S.B. 966 does not exceed the scope of appropriate PBM regulation or inadvertently jeopardize patient safety and the quality of pharmacies in California.
- Policy Comments, Questions, and Suggested Amendments.
Different definitions of PBMs. PBMs are already defined in the Health and Safety Code (for purposes of registration with DMHC for those PBMs that contract with a health plan) and defined in the Business and Professions Code (relate to standards for entities conducting pharmacy audits.) This same Business and Professions Code definition used to define a PBM for purposes of prohibitions on imposing any requirements, conditions, or exclusions that discriminate against certain clinics, certain disease program grantees, and certain hospitals. This bill proposes a separate definition for PBMs for purposes of licensure by the Board. The Author should continue refining the definition of PBMs in order to provide clarity, uniformity, and to avoid confusion, particularly if the goal is to create another regulatory pathway for these industry players.
Task Force on PBM Reporting recommendations and outlines for disclosures. The PBM Sunrise Response cites lack of transparency and the negative impacts of not having data as one of the rationales for PBM licensure. The Task Force on PBM Reporting was required to determine the information related to pharmaceutical costs, if any, DMHC should require to be reported by health care service plans or their contracted PBMs. As the Task Force report notes, eight task force members (representing pharmacies, health plans, consumers, and non-profit organizations), heard presentations from a variety of sources (including DMHC staff, the California Office of Statewide Health Planning and Development, the Pharmaceutical Care Management Association), the California Association of Health Plans, the California Pharmacists Association, and representatives from pharmacies and life sciences). The report states that “The presentations and public comments made to the Task Force stressed the need for additional PBM transparency to help understand what is driving prescription drug cost increases and determine how consumers can be better protected…The Task Force also discussed the need for information on PBM revenue and expenses, as this information is opaque not only to the consumer, but also to the health plans, pharmacies, and manufacturers with which the PBM works. Gathering data on the sources of revenue and expenses will help demonstrate the value PBMs bring to the marketplace...” If transparency is a goal, it seems logical to reflect the work of the very entity aimed at determining what information would increase transparency by following the recommendations of the Task Force on PBM Reporting. Moving forward, the Author should enhance reporting on drug specific information and aggregated information, including on, revenue and costs pursuant to the Task Force recommendations.
Specialty pharmacies. This bill prohibits a PBM from requiring “pharmacist or pharmacy accreditation standards or recertification requirements inconsistent with, more stringent than, or in addition to federal and state requirements to obtain reimbursement for a covered drug.” Accreditation establishes certain measures of quality and concerns have been raised about the limitations this language may pose on the use of particularly accredited specialty pharmacies. Certain drugs and patient populations may require different handling and different standards and as such, the bill should be amended to ensure that pharmacies and pharmacists are not required to be included in a network if they do not meet specified requirements, when requirements are necessary.
Civil action. In addition to establishing a robust enforcement framework and penalties for violating the provisions of licensure, most significantly for engaging in prohibited activities, this bill authorizes “any person or trade association” to institute a civil action for violations of this bill. A private right of action allows a private person or persons to enforce their rights under a particular statute. Express rights explicitly outline in statute how a person or persons can enforce their rights in court, and against whom. The question as to whether a private right of action should exist in a statute is a common one in the Legislature, about which proponents often argue explicitly providing these statutory rights expands access to justice for private citizens, and opponents are concerned about creating unnecessary lawsuits that will backlog courts and create additional, unnecessary expenses for individuals or business owners. In this case, it is unclear why private civil action authority is necessary, particularly since the Author and Sponsors believe that a lack of state-level government enforcement against PBMs is necessary and at the heart of this bill. The bill should be amended to strike the authority for any person or trade association to bring a civil action against a licensed PBM.
Licensure by the Board of Pharmacy. Licensing laws exist to protect the public from potentially harmful services rendered by unqualified businesses and individuals. The intent of licensure is not to punish good actors or impose punitive requirements on businesses and individuals but rather to establish a baseline of licensee quality and competency and corresponding enforcement provisions for consequences of violating the regulatory framework.
Pharmacists’ livelihoods and responsibility to patients are certainly impacted by PBM activities, processes, and decisions, however the regulation of PBMs through licensure and enforcement by the Board of Pharmacy, comprised of a majority of pharmacists, poses a number of challenges. In 2010, the Federal Trade Commission (FTC) brought an administrative complaint against the North Carolina State Board of Dental Examiners for exclusion of non-dentists from the practice of teeth whitening. The FTC alleged that the Board’s decision was an uncompetitive and unfair method of competition under the Federal Trade Commission Act. This opened the Board to lawsuits and substantial damages from affected parties.
The Board was composed of 6 licensed, practicing dentists and 2 public members. The practice of teeth whitening was not addressed in the North Carolina Dental Practice Act.
Boards like the Board of Pharmacy are semiautonomous bodies whose members are appointed by the Governor and the Legislature. Although most of the non-healing arts boards have statutory authority for a public majority allotment in their makeup, most healing arts and non-healing arts boards are comprised of a majority of members representing the profession. North Carolina State Board of Dental Examiners v. FTC placed limitations on the immunity of regulatory boards controlled by active market participants. This is because individuals who are directly affected by their own rulemaking may not be able to detect their biases, purposefully or inadvertently placing their benefit over those of the public. Or, as the Supreme Court stated, “Dual allegiances are not always apparent to an actor.”
There are questions as to whether PBM practices at their core constitute the practice of pharmacy and thus should be regulated by the Board of Pharmacy, as well as whether licensure by the Board will result in meaningful oversight and accountability as the Author and Sponsors say is necessary for this category of marketplace players. The Board notes that the definition of PBM contained in this bill specifically references “drug utilization review” and that clinical service, among other activities of a PBM, is an example of PBMs being directly involved in patient care issues and the practice of pharmacy. Certain PBMs may also own and control mail-order or other pharmacies. However, those pharmacies already have to be licensed as a separate entity by the Board and in accordance with Pharmacy Law requirements for pharmacies. The majority of characteristics of a PBM, as defined in current law, or proposed to be defined in this bill, include coverage and payer-related activities. While these certainly impact patient care and the effective delivery of pharmacy services, there are more appropriate agencies in the state to oversee PBM activities and enforce provisions of PBM contracts. The heart of the Board’s enforcement program are pharmacy inspectors, who the Board notes are registered pharmacists. Enforcement of complex PBM activities by pharmacists who may be impacted, financially and otherwise, by those very PBMs may not be appropriate, and, coupled with the significant amount of resources and time for formal investigations and discipline by the Board, the bill should be amended to strike the Board of Pharmacy as the regulatory entity for PBMs and for now, replace it with CDI. While CDI may be an appropriate entity for licensure, based on the precedent in other states for a CDI-like entities to oversee PBMs, moving forward, discussions should continue to ensure that any additional state-level regulation of PBMs balances the expertise of state agencies in this space, reflects existing frameworks that may be effectively built upon, and establishes a clearly defined fee structure.
SUPPORT AND OPPOSITION:
Support:
AIDS Healthcare Foundation
APLA Health
California Association of Joint Powers Authorities
California Chronic Care Coalition
California Legislative LGBTQ Caucus
California Life Sciences
California Medical Association
California Pharmacists Association
California State Board of Pharmacy
Los Angeles LGBT Center
National Association of Chain Drug Stores
National Community Pharmacists Association
National Multiple Sclerosis Society
National Psoriasis Foundation
Pharmaceutical Research and Manufacturers of America
San Francisco AIDS Foundation
Opposition:
Abate-a-weed
America's Health Insurance Plans (AHIP)
Association of California Life & Health Insurance Companies
California Alliance for Prescription Affordability (CAPA)
California Association of Health Plans
California Chamber of Commerce
California Clothing Recylcers
California Hispanic Chamber of Commerce
California Hispanic Chambers of Commerce
California Teamsters Public Affairs Council
Californians for Lower Drug Costs
Coalition for Small and Disabled Veteran Businesses
Crisp Catering
Cypress Chamber of Commerce
Flasher Barricade Association
Granite Bay Benefits
Health Access California
Marina Chamber of Commerce
Menifee Bicycles
Orange County Hispanic Chamber of Commerce
Pharmaceutical Care Management Association
Professional Small Business Services, INC.
Sal’s Mexican Restaurant
Seabreeze Books & Charts
Slavic-American Chamber of Commerce
Strategies for Your Success
Pharmaceutical Care Management Association
URAC
Numerous Individuals and Business Owners
-- END --
Discussed in Hearing
Senate Floor
Assembly Floor
Assembly Standing Committee on Judiciary
Assembly Standing Committee on Health
Senate Floor
Senate Standing Committee on Health
Senate Standing Committee on Business, Professions and Economic Development
Bill Author
Bill Co-Author(s):